
==== Front
Br J PharmacolBr. J. Pharmacol10.1111/(ISSN)1476-5381BPHBritish Journal of Pharmacology0007-11881476-5381John Wiley and Sons Inc. Hoboken 2665043910.1111/bph.13348BPH1334810.1111/bph.13348The Concise Guide to PHARMACOLOGY 2015/16The Concise Guide to PHARMACOLOGY 2015/16The Concise Guide to PHARMACOLOGY 2015/16: G
protein‐coupled receptors The Concise Guide to PHARMACOLOGY
2015/16: G protein‐coupled receptorsAlexander Stephen PH 
1
Davenport Anthony P 
2
Kelly Eamonn 
3
Marrion Neil 
3
Peters John A 
4
Benson Helen E 
5
Faccenda Elena 
5
Pawson Adam J 
5
Sharman Joanna L 
5
Southan Christopher 
5
Davies Jamie A 
5
CGTP Collaborators 
1 
School of
Biomedical Sciences
University of Nottingham Medical School
Nottingham
NG7 2UH
UK

2 
Clinical
Pharmacology Unit
University of Cambridge
Cambridge
CB2 0QQ
UK

3 
School of
Physiology and Pharmacology
University of Bristol
Bristol
BS8 1TD
UK

4 
Neuroscience
Division, Medical Education Institute, Ninewells Hospital and Medical
School
University of Dundee
Dundee
DD1 9SY
UK

5 
Centre for
Integrative Physiology
University of Edinburgh
Edinburgh
EH8 9XD
UK
12 2015 09 12 2015 09 12 2015 172 24 10.1111/bph.v172.24The Concise Guide to PHARMACOLOGY 2015/16.This issue was published by Wiley with financial contributions from the British
Pharmacological Society, the International Union of Basic and Clinical Pharmacology, the
Wellcome Trust (099156/Z/12/Z]), which supports the website and the University of
Edinburgh, who host the guidetopharmacology.org
website.5744 5869 © 2015 The Authors. British
Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of The
British Pharmacological Society.This is an open access article under the terms of the Creative Commons Attribution License, which
permits use, distribution and reproduction in any medium, provided the original
work is properly cited.The Concise Guide to PHARMACOLOGY 2015/16
provides concise overviews of the key properties of over 1750 human drug targets with
their pharmacology, plus links to an open access knowledgebase of drug targets and
their ligands (www.guidetopharmacology.org),
which provides more detailed views of target and ligand properties. The full contents
can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.13348/full. G
protein‐coupled receptors are one of the eight major pharmacological targets into
which the Guide is divided, with the others being: ligand‐gated ion channels,
voltage‐gated ion channels, other ion channels, nuclear hormone receptors, catalytic
receptors, enzymes and transporters. These are presented with nomenclature guidance
and summary information on the best available pharmacological tools, alongside key
references and suggestions for further reading. The Concise Guide is published in
landscape format in order to facilitate comparison of related targets. It is a
condensed version of material contemporary to late 2015, which is presented in
greater detail and constantly updated on the website www.guidetopharmacology.org, superseding data
presented in the previous Guides to Receptors & Channels and the Concise Guide to
PHARMACOLOGY 2013/14. It is produced in conjunction with NC‐IUPHAR and provides the
official IUPHAR classification and nomenclature for human drug targets, where
appropriate. It consolidates information previously curated and displayed separately
in IUPHAR‐DB and GRAC and provides a permanent, citable, point‐in‐time record that
will survive database updates.

 source-schema-version-number2.0component-idbph13348header-idbph13348-hdr-0001cover-dateDecember 2015details-of-publishers-convertorConverter:WILEY_ML3GV2_TO_NLMPMC version:4.9.8 mode:remove_FC
converted:28.11.2016


Alexander , S. PH. 
, 
Davenport , A. P. 
, 
Kelly , E. 
, 
Marrion , N. 
, 
Peters , J. A. 
, 
Benson , H. E. 
, 
Faccenda , E. 
, 
Pawson , A. J. 
, 
Sharman , J. L. 
, 
Southan , C. 
, 
Davies , J. A. 
, and CGTP
Collaborators  (2015 ) The
Concise Guide to PHARMACOLOGY 2015/16: G protein‐coupled
receptors . British Journal of
Pharmacology , doi: 10.1111/bph.13348.
==== Body
Conflict of interest
The authors state that there are no conflicts
of interest to declare.

Overview
G protein‐coupled receptors (GPCRs) are the
largest class of membrane proteins in the human genome. The term "7TM receptor" is
commonly used interchangeably with "GPCR", although there are some receptors with
seven transmembrane domains that do not signal through G proteins. GPCRs share a
common architecture, each consisting of a single polypeptide with an extracellular
N‐terminus, an intracellular C‐terminus and seven hydrophobic transmembrane domains
(TM1‐TM7) linked by three extracellular loops (ECL1‐ECL3) and three intracellular
loops (ICL1‐ICL3). About 800 GPCRs have been identified in man, of which about half
have sensory functions, mediating olfaction ( 400), taste (33), light perception (10)
and pheromone signalling (5) [1309]. The remaining  350
non‐sensory GPCRs mediate intersignalling by ligands that range in size from small
molecules to peptide to large proteins; they are the targets for the majority of
drugs in clinical usage [1451, 1560], although only a minority
of these receptors are exploited therapeutically. The first classification scheme to
be proposed for GPCRs [984] divided them, on the basic
of sequence homology, into six classes. These classes and their prototype members
were as follows: Class A(rhodopsin‐like), Class B (secretin
receptor family), Class C (metabotropic glutamate), Class
D(fungal mating pheromone receptors), Class E (cyclic AMP receptors) and
Class F (frizzled/smoothened). Of these, classes D and E are not
found in vertebrates. An alternative classification scheme "GRAFS" [1666] divides vertebrate GPCRs
into five classes, overlapping with the A‐F nomenclature, viz:


Glutamate family (class C), which includes metabotropic glutamate
receptors, a calcium‐sensing receptor and GABAB receptors, as well as
three taste type 1 receptors [class C list] and a family of
pheromone receptors (V2 receptors) that are abundant in rodents but absent in man
[1309].


Rhodopsin family (class A), which includes receptors for a wide variety
of small molecules, neurotransmitters, peptides and hormones, together with olfactory
receptors, visual pigments, taste type 2 receptors and five pheromone receptors (V1
receptors). [Class A list]


Adhesion family GPCRs are phylogenetically related to class B receptors,
from which they differ by possessing large extracellular N‐termini that are
autoproteolytically cleaved from their 7TM domains at a conserved "GPCR proteolysis
site" (GPS) which lies within a much larger ( 320 residue) "GPCR
autoproteolysis‐inducing" (GAIN) domain, an evolutionary ancient mofif also found in
polycystic kidney disease 1 (PKD1)‐like proteins, which has been suggested to be both
required and sufficient for autoproteolysis [1538]. [Adhesion family list].


Frizzled family (class F) consists of 10 Frizzled proteins (FZD(1‐10))
and Smoothened (SMO). [Frizzled family list]. The FZDs
are activated by secreted lipoglycoproteins of the WNT family, whereas SMO is
indirectly activated by the Hedgehog (HH) family of proteins acting on the
transmembrane protein Patched (PTCH).


Secretin family (class B), encoded by 15 genes in humans. The ligands
for receptors in this family are polypeptide hormones of 27‐141 amino‐acid residues;
nine of the mammalian receptors respond to ligands that are structurally related to
one another (glucagon, glucagon‐like peptides (GLP‐1, GLP‐2), glucose‐dependent
insulinotropic polypeptide (GIP), secretin, vasoactive intestinal peptide (VIP),
pituitary adenylate cyclase‐activating polypeptide (PACAP) and
growth‐hormone‐releasing hormone (GHRH) [703].

GPCR families


Family
	
Class A
	
Class B (Secretin)
	
Class C (Glutamate)
	
Adhesion
	
Frizzled
	

Receptors with known ligands
	197a
	15	12	0	11	

Orphans
	87 (54)a
	‐	8 (1)a
	26 (6)a
	0	

Sensory (olfaction)
	390b,c
	‐	‐	‐	‐	

Sensory (vision)
	10d opsins	‐	‐	‐	‐	

Sensory (taste)
	30c taste 2	‐	3c taste 1	‐	‐	

Sensory (pheromone)
	5c vomeronasal 1	‐	‐	‐	‐	

Total
	719	15	22	33	11	




aNumbers in brackets refer to orphan receptors for which an endogenous
ligand has been proposed in at least one publication, see [396]; b[1443]; c[1309]; d[1866].

Much of our current understanding of the
structure and function of GPCRs is the result of pioneering work on the visual
pigment rhodopsin and on the β
2 adrenoceptor, the latter culminating in the award of the 2012 Nobel
Prize in chemistry to Robert Lefkowitz and Brian Kobilka [975, 1073].

Family structure

5746 Orphan and other 7TM
receptors



5746 Class A Orphans



5756 Class C Orphans



5756 Taste 1 receptors



5757 Taste 2 receptors



5758 Other 7TM proteins



5759 5‐Hydroxytryptamine
receptors



5764 Acetylcholine receptors
(muscarinic)



5766 Adenosine receptors



5768 Adhesion Class GPCRs



5770 Adrenoceptors



5774 Angiotensin receptors



5775 Apelin receptor



5777 Bile acid receptor



5778 Bombesin receptors



5780 Bradykinin receptors



5781 Calcitonin receptors



5783 Calcium‐sensing receptors



5784 Cannabinoid receptors



5785 Chemerin receptor



5785 Chemokine receptors



5791 Cholecystokinin receptors



5792 Class Frizzled GPCRs



5793 Complement peptide receptors



5795 Corticotropin‐releasing factor
receptors



5796 Dopamine receptors



5798 Endothelin receptors



5799 G protein‐coupled estrogen
receptor



5800 Formylpeptide receptors



5801 Free fatty acid receptors



5803 GABAB receptors



5805 Galanin receptors



5806 Ghrelin receptor



5807 Glucagon receptor family



5809 Glycoprotein hormone
receptors



5810 Gonadotrophin‐releasing hormone
receptors



5811 GPR18, GPR55 and GPR119



5812 Histamine receptors



5814 Hydroxycarboxylic acid
receptors



5815 Kisspeptin receptor



5816 Leukotriene receptors



5818 Lysophospholipid (LPA)
receptors



5819 Lysophospholipid (S1P)
receptors



5820 Melanin‐concentrating hormone
receptors



5821 Melanocortin receptors



5822 Melatonin receptors



5823 Metabotropic glutamate
receptors



5826 Motilin receptor



5827 Neuromedin U receptors



5828 Neuropeptide FF/neuropeptide AF
receptors



5829 Neuropeptide S receptor



5829 Neuropeptide W/neuropeptide B
receptors



5830 Neuropeptide Y receptors



5832 Neurotensin receptors



5833 Opioid receptors



5835 Orexin receptors



5836 Oxoglutarate receptor



5836 P2Y receptors



5838 Parathyroid hormone
receptors



5839 Platelet‐activating factor
receptor



5840 Prokineticin receptors



5841 Prolactin‐releasing peptide
receptor



5842 Prostanoid receptors



5844 Proteinase‐activated
receptors



5846 QRFP receptor



5846 Relaxin family peptide
receptors



5848 Somatostatin receptors



5850 Succinate receptor



5850 Tachykinin receptors



5852 Thyrotropin‐releasing hormone
receptors



5852 Trace amine receptor



5854 Urotensin receptor



5854 Vasopressin and oxytocin
receptors



5856 VIP and PACAP receptors



Orphan and other 7TM receptors


Class A Orphans

Overview
Table 1 lists a number of putative GPCRs identified by
NC‐IUPHAR[530], for which preliminary evidence for an endogenous ligand has been
published, or for which there exists a potential link to a disease, or disorder.
These GPCRs have recently been reviewed in detail [396]. The GPCRs in Table 1 are all Class A,
rhodopsin‐like GPCRs. Class A orphan GPCRs not listed in Table 1 are putative GPCRs with
as‐yet unidentified endogenous ligands.

Table 1 Class A orphan GPCRs with putative endogenous ligands


GPR1
	
GPR3
	
GPR4
	
GPR6
	
GPR12
	
GPR15
	
GPR17
	
GPR20
	

GPR22
	
GPR26
	
GPR31
	
GPR34
	
GPR35
	
GPR37
	
GPR39
	
GPR50
	

GPR63
	
GRP65
	
GPR68
	
GPR75
	
GPR84
	
GPR87
	
GPR88
	
GPR132
	

GPR149
	
GPR161
	
GPR183
	
LGR4
	
LGR5
	
LGR6
	
MAS1
	
MRGPRD
	

MRGPRX1
	
MRGPRX2
	
P2RY10
	
TAAR2
					
In addition the orphan receptors GPR18, GPR55 and GPR119 which are reported to respond to endogenous agents analogous to the
endogenous cannabinoid ligands have been grouped together (GPR18, GPR55 and GPR119).


Nomenclature	
GPR1
	
GPR3
	
GPR4
	
GPR6
	
HGNC, UniProt	
GPR1, P46091
	
GPR3, P46089
	
GPR4, P46093
	
GPR6, P46095
	
Endogenous
ligand	–	–	Protons	–	
Endogenous
agonists	
chemerin
(RARRES2, Q99969)
(pK
d 8.3) [95]	–	–	–	
Agonists	–	
diphenyleneiodonium
chloride (pEC50 6) [2091]	–	–	
Comments	Reported to act as
a co‐receptor for HIV [1724]. See
review [396] for
discussion of pairing with chemerin.	
sphingosine
1‐phosphate was reported to be an endogenous agonist
[1921], but this
finding was not replicated in subsequent studies [2093]. Reported
to activate adenylyl cyclase constitutively through Gs
[466]. Gene
disruption results in premature ovarian ageing [1063], reduced
β‐amyloid deposition [1868] and
hypersensitivity to thermal pain [1615] in mice.
First small molecule inverse agonist [860] and
agonists identified [2091].	An initial report
suggesting activation by lysophosphatidylcholine and sphingosylphosphorylcholine [2131] has been
retracted [2148]. GPR4,
GPR65, GPR68 and GPR132 are now thought to function as proton‐sensing
receptors detecting acidic pH [396, 1704]. Gene
disruption is associated with increased perinatal mortality and
impaired vascular proliferation [2085]. Negative
allosteric modulators of GPR4 have been reported [1889].	An initial report
that sphingosine
1‐phosphate (S1P) was a high‐affinity ligand
(EC50 value of 39nM) [815, 1921] was not
repeated by arrestin PathHunter[TM] assays [1785, 2093]. Reported
to activate adenylyl cyclase constitutively through Gs and
to be located intracellularly [1453].
GPR6‐deficient mice showed reduced striatal cyclic AMP production
in vitro and selected alterations in instrumental
conditioning in vivo. [1134].	




Nomenclature	
GPR12
	
GPR15
	
GPR17
	
GPR19
	
HGNC, UniProt	
GPR12, P47775
	
GPR15, P49685
	
GPR17, Q13304
	
GPR19, Q15760
	
Endogenous
agonists	–	–	
UDP‐glucose
(pEC50 5.9–9.5) [130, 344], LTC4 (pEC50 7.8–9.5) [344], UDP‐galactose
(pEC50 6–8.9) [130, 344], uridine
diphosphate (pEC50 6–8.8) [130, 344], LTD4 (pEC50 8.1–8.4) [344]	–	
Comments	Reports that
sphingosine
1‐phosphate is a ligand of GPR12 [814, 1921] have not
been replicated in arrestin‐based assays [1785, 2093]. Gene
disruption results in dyslipidemia and obesity [154].	Reported to act as
a co‐receptor for HIV [462]. In an
infection‐induced colitis model, Gpr15 knockout mice
were more prone to tissue damage and inflammatory cytokine expression
[945].	Reported to be a
dual leukotriene and uridine
diphosphate receptor [344]. Another
group instead proposed that GPR17 functions as a negative regulator of
the CysLT1 receptor response to leukotriene D4
(LTD4). For further discussion, see [396]. Reported
to antagonize CysLT1 receptor signalling in
vivoand in vitro [1175]. See
reviews [250] and
[396].	–	




Nomenclature	
GPR20
	
GPR21
	
GPR22
	
GPR25
	
GPR26
	
HGNC, UniProt	
GPR20, Q99678
	
GPR21, Q99679
	
GPR22, Q99680
	
GPR25, O00155
	
GPR26, Q8NDV2
	
Comments	Reported to inhibit
adenylyl cyclase constitutively through Gi/o [708]. GPR20
deficient mice exhibit hyperactivity characterised by increased total
distance travelled in an open field test [207].	
Gpr21 knockout mice were resistant to diet‐induced
obesity, exhibiting an increase in glucose tolerance and insulin
sensitivity, as well as a modest lean phenotype [1448].	Gene disruption
results in increased severity of functional decompensation following
aortic banding [10]. Identified
as a susceptibility locus for osteoarthritis [494, 929, 1935].	–	Has been reported
to activate adenylyl cyclase constitutively through Gs
[880].
Gpr26 knockout mice show increased levels of
anxiety and depression‐like behaviours [2117].	




Nomenclature	
GPR27
	
GPR31
	
GPR32
	
GPR33
	
GPR34
	
HGNC, UniProt	
GPR27, Q9NS67
	
GPR31, O00270
	
GPR32, O75388
	
GPR33, Q49SQ1
	
GPR34, Q9UPC5
	
Rank order of
potency	–	–	
resolvin
D1>LXA4
	–	–	
Endogenous
agonists	–	
12S‐HETE
(Selective) (pEC50 9.6) [665] –
Mouse	
resolvin D1
(pEC50 11.1) [1006], LXA4 (pEC50 9.7) [1006]	–	
lysophosphatidylserine (Selective) (pEC50
6.6–6.9) [960, 1817]	
Labelled
ligands	–	–	
[3H]resolvin
D1 (Agonist) (pK
d 9.7) [1006]	–	–	
Comments	Knockdown of Gpr27
reduces endogenous mouse insulin promotor activity and
glucose‐stimulated insulin secretion [1012].	See [396] for
discussion of pairing.	
resolvin D1 has
been demonstrated to activate GPR32 in two publications [316, 1006]. The
pairing was not replicated in a recent study based on arrestin
recruitment [1785].
GPR32 is a pseudogene in mice and rats. See
reviews [250] and
[396].	
GPR33 is a pseudogene in most individuals, containing
a premature stop codon within the coding sequence of the second
intracellular loop [1621].	Lysophosphatidylserine has been reported to be a ligand of GPR34 in
several publications, but the pairing was not replicated in a recent
study based on arrestin recruitment [1785]. Fails to
respond to a variety of lipid‐derived agents [2093]. Gene
disruption results in an enhanced immune response [1102].
Characterization of agonists at this receptor is discussed in
[819] and
[396].	




Nomenclature	
GPR35
	
GPR37
	
GPR37L1
	
GPR39
	
GPR42
	
HGNC, UniProt	
GPR35, Q9HC97
	
GPR37, O15354
	
GPR37L1, O60883
	
GPR39, O43194
	
GPR42, O15529
	
Endogenous
agonists	
2‐oleoyl‐LPA
(pEC50 7.3–7.5) [1436], kynurenic acid
(pEC50 3.9–4.4) [1785, 1980]	–	–	
Zn2+ [775]	–	
Agonists	–	
neuropeptide head
activator (pEC50 8–8.5) [1578]	–	
compound 1 [PMID:
24900608] (pEC50 4.9–7.2) [166]	–	
Comments	Several studies
have shown that kynurenic acid is an agonist of GPR35 but it remains
controversial whether the proposed endogenous ligand reaches
sufficient tissue concentrations to activate the receptor [1015]. 2‐oleoyl‐LPA has
also been proposed as an endogenous ligand [1436] but these
results were not replicated in an arrestin assay [1785]. The
phosphodiesterase inhibitor zaprinast
[1863] has become
widely used as a surrogate agonist to investigate GPR35 pharmacology
and signalling [1863]. GPR35 is
also activated by the pharmaceutical adjunct pamoic acid
[2124]. See
reviews [396] and
[429].	Reported to
associate and regulate the dopamine transporter [1207] and to be
a substrate for parkin [1205]. Gene
disruption results in altered striatal signalling [1206]. The
peptides prosaptide and prosaposin are proposed as endogenous ligands
for GPR37 and GPR37L1 [1264].	The peptides
prosaptide and prosaposin are proposed as endogenous ligands for GPR37
and GPR37L1 [1264].	Zn2+ has
been reported to be a potent and efficacious agonist of human, mouse
and rat GPR39 [2089]. obestatin
(GHRL, Q9UBU3), a
fragment from the ghrelin precursor, was reported initially as an
endogenous ligand, but subsequent studies failed to reproduce these
findings. GPR39 has been reported to be
down‐regulated in adipose tissue in obesity‐related diabetes
[273]. Gene
disruption results in obesity and altered adipocyte metabolism
[1497]. Reviewed
in [396].	–	




Nomenclature	
GPR45
	
GPR50
	
GPR52
	
GPR61
	
HGNC, UniProt	
GPR45, Q9Y5Y3
	
GPR50, Q13585
	
GPR52, Q9Y2T5
	
GPR61, Q9BZJ8
	
Comments	–	GPR50 is
structurally related to MT1 and MT2 melatonin
receptors, with which it heterodimerises constitutively and
specifically [1089].
Gpr50 knockout mice display abnormal
thermoregulation and are much more likely than wild‐type mice to enter
fasting‐induced torpor [111].	First small
molecule agonist reported [1703].	GPR61 deficient
mice exhibit obesity associated with hyperphagia [1363]. Although
no endogenous ligands have been identified, 5‐(nonyloxy)tryptamine has
been reported to be a low affinity inverse agonist [1852].	




Nomenclature	
GPR62
	
GPR63
	
GPR65
	
GPR68
	
GPR75
	
HGNC, UniProt	
GPR62, Q9BZJ7
	
GPR63, Q9BZJ6
	
GPR65, Q8IYL9
	
GPR68, Q15743
	
GPR75, O95800
	
Endogenous
ligand	–	–	Protons	Protons	–	
Comments	–	
sphingosine
1‐phosphate and dioleoylphosphatidic
acid have been reported to be low affinity agonists for
GPR63 [1394] but this
finding was not replicated in an arrestin‐based assay [2093].	GPR4, GPR65, GPR68
and GPR132 are now thought to function as proton‐sensing receptors
detecting acidic pH [396, 1704]. Reported
to activate adenylyl cyclase; gene disruption leads to reduced
eosinophilia in models of allergic airway disease [1000].	GPR68 was
previously identified as a receptor for sphingosylphosphorylcholine (SPC) [2068], but the
original publication has been retracted [2067]. GPR4,
GPR65, GPR68 and GPR132 are now thought to function as proton‐sensing
receptors detecting acidic pH [396, 1704]. A family
of 3,5‐disubstituted isoxazoles were identified as agonists of GPR68
[1617].	
CCL5 (CCL5, P13501) was
reported to be an agonist of GPR75 [816], but the
pairing could not be repeated in an arrestin assay [1785].	




Nomenclature	
GPR78
	
GPR79
	
GPR82
	
GPR83
	
GPR84
	
HGNC, UniProt	
GPR78, Q96P69
	
GPR79, –	
GPR82, Q96P67
	
GPR83, Q9NYM4
	
GPR84, Q9NQS5
	
Agonists	–	–	–	
Zn2+ (pEC50 5) [1351] –
Mouse	
decanoic acid
(pEC50 5–5.4) [1785, 1981], undecanoic acid
(pEC50 5.1) [1981], lauric acid
(pEC50 5) [1981]	
Comments	GPR78 has been
reported to be constitutively active, coupled to elevated cAMP
production [880].	–	Mice with
Gpr82 knockout have a lower body weight and body
fat content associated with reduced food intake, decreased serum
triglyceride levels, as well as higher insulin sensitivity and glucose
tolerance [479].	One isoform has
been implicated in the induction of CD4(+) CD25(+) regulatory T cells
(Tregs) during inflammatory immune responses [696]. The
extracellular N‐terminal domain is reported as an intramolecular
inverse agonist [1352].	Medium chain free
fatty acids with carbon chain lengths of 9‐14 activate GPR84
[1828, 1981]. A
surrogate ligand for GPR84, 6‐n‐octylaminouracil has also been proposed [1828]. See
review [396] for
discussion of classification. Mutational analysis and molecular
modelling of GPR84 has been reported [1397].	




Nomenclature	
GPR85
	
GPR87
	
GPR88
	
GPR101
	
HGNC, UniProt	
GPR85, P60893
	
GPR87, Q9BY21
	
GPR88, Q9GZN0
	
GPR101, Q96P66
	
Endogenous
agonists	–	
LPA
(pEC50 7.4) [1344, 1836]	–	–	
Agonists	–	–	
compound 2 [PMID:
24793972] (pEC50 6.2) [868]	–	
Comments	Proposed to
regulate hippocampal neurogenesis in the adult, as well as
neurogenesis‐dependent learning and memory [303].	–	Gene disruption
results in altered striatal signalling [1137]. Small
molecule agonists have been reported [147].	Mutations in GPR101
have been linked to gigantism and acromegaly [1906].	




Nomenclature	
GPR132
	
GPR135
	
GPR139
	
GPR141
	
GPR142
	
HGNC, UniProt	
GPR132, Q9UNW8
	
GPR135, Q8IZ08
	
GPR139, Q6DWJ6
	
GPR141, Q7Z602
	
GPR142, Q7Z601
	
Endogenous
ligand	Protons	–	–	–	–	
Agonists	–	–	
compound 1a [PMID:
24900311] (pEC50 7.4) [1721]	–	–	
Comments	GPR4, GPR65, GPR68
and GPR132 are now thought to function as proton‐sensing receptors
detecting acidic pH [396, 1704]. Reported
to respond to lysophosphatidylcholine [891], but later
retracted [2038].	–	Peptide agonists
have been reported [828].	–	Small molecule
agonists have been reported [1890, 2106].	




Nomenclature	
GPR146
	
GPR148
	
GPR149
	
GPR150
	
GPR151
	
HGNC, UniProt	
GPR146, Q96CH1
	
GPR148, Q8TDV2
	
GPR149, Q86SP6
	
GPR150, Q8NGU9
	
GPR151, Q8TDV0
	
Comments	Yosten et
al. demonstrated inhibition of proinsulin
C‐peptide (INS, P01308)‐induced
stimulation of cFos expression folllowing knockdown of GPR146 in KATO
III cells, suggesting proinsulin C‐peptide as an endogenous ligand of
the receptor [2103].	–	
Gpr149 knockout mice displayed increased fertility
and enhanced ovulation, with increased levels of FSH receptor and
cyclin D2 mRNA levels [463].	–	GPR151 responded to
galanin with an EC50 value of 2 μM,
suggesting that the endogenous ligand shares structural features with
galanin
(GAL, P22466)
[813].	




Nomenclature	
GPR152
	
GPR153
	
GPR160
	
GPR161
	
GPR162
	
HGNC, UniProt	
GPR152, Q8TDT2
	
GPR153, Q6NV75
	
GPR160, Q9UJ42
	
GPR161, Q8N6U8
	
GPR162, Q16538
	
Comments	–	–	–	A C‐terminal
truncation (deletion) mutation in Gpr161 causes congenital cataracts
and neural tube defects in the vacuolated lens (vl) mouse mutant
[1226]. The
mutated receptor is associated with cataract, spina bifida and white
belly spot phenotypes in mice [994]. Gene
disruption is associated with a failure of asymmetric embryonic
development in zebrafish [1085].	–	




Nomenclature	
GPR171
	
GPR173
	
GPR174
	
GPR176
	
GPR182
	
HGNC, UniProt	
GPR171, O14626
	
GPR173, Q9NS66
	
GPR174, Q9BXC1
	
GPR176, Q14439
	
GPR182, O15218
	
Endogenous
agonists	–	–	
lysophosphatidylserine (pEC50 7.1)
[825]	–	–	
Comments	GPR171 has been
shown to be activated by the endogenous peptide BigLEN {Mouse}.
This receptor‐peptide interaction is believed to be involved in
regulating feeding and metabolism responses [621].	–	See [819] which
discusses characterization of agonists at this receptor.	–	Rat GPR182 was
first proposed as the adrenomedullin receptor [904]. However,
it was later reported that rat and human GPR182 did not respond to
adrenomedullin [927] and GPR182
is not currently considered to be a genuine adrenomedullin receptor
[722].	




Nomenclature	
GPR183
	
LGR4
	
LGR5
	
LGR6
	
MAS1
	
HGNC, UniProt	
GPR183, P32249
	
LGR4, Q9BXB1
	
LGR5, O75473
	
LGR6, Q9HBX8
	
MAS1, P04201
	
Endogenous
agonists	
7α,25‐dihydroxycholesterol (Selective)
(pEC50 8.1–9.8) [694, 1125], 7α,27‐dihydroxycholesterol (Selective)
(pEC50 8.9) [1125], 7β,
25‐dihydroxycholesterol (Selective) (pEC50
8.7) [1125], 7β,
27‐dihydroxycholesterol (Selective) (pEC50
7.3) [1125]	
R‐spondin‐2
(RSPO2, Q6UXX9)
(pEC50 12.5) [266], R‐spondin‐1
(RSPO1, Q2MKA7)
(pEC50 10.7) [266], R‐spondin‐3
(RSPO3, Q9BXY4)
(pEC50 10.7) [266], R‐spondin‐4
(RSPO4, Q2I0M5)
(pEC50 10.1) [266]	
R‐spondin‐2
(RSPO2, Q6UXX9)
(pEC50 12) [266], R‐spondin‐1
(RSPO1, Q2MKA7)
(pEC50 11.1) [266], R‐spondin‐3
(RSPO3, Q9BXY4)
(pEC50 11) [266], R‐spondin‐4
(RSPO4, Q2I0M5)
(pEC50 9.4) [266]	
R‐spondin‐1
(RSPO1, Q2MKA7)
[266, 2140], R‐spondin‐2
(RSPO2, Q6UXX9)
[266, 2140], R‐spondin‐3
(RSPO3, Q9BXY4)
[266, 2140], R‐spondin‐4
(RSPO4, Q2I0M5)
[266, 2140]	–	
Agonists	–	–	–	–	
angiotensin‐(1‐7) (AGT, P01019)
(pK
i 7.3) [612] –
Mouse	
Comments	Two independent
publications have shown that 7α,25‐dihydroxycholesterol is an
agonist of GPR183 and have demonstrated by mass spectrometry that this
oxysterol is present endogenously in tissues [694, 1125].
Gpr183‐deficient mice show a reduction in the early antibody response
to a T‐dependent antigen. GPR183‐deficient B cells fail to migrate to
the outer follicle and instead stay in the follicle centre [923, 1488].	LGR4 does not
couple to heterotrimeric G proteins or recruit arrestins when
stimulated by the R‐spondins, indicating a unique mechanism of action.
R‐spondins bind to LGR4, which specifically associates with Frizzled
and LDL receptor‐related proteins (LRPs) that are activated by the
extracellular Wnt molecules and then trigger canonical Wnt signalling
to increase gene expression [266, 1612, 2140]. Gene
disruption leads to multiple developmental disorders [869, 1154, 1781, 2005].	The four R‐spondins
can bind to LGR4, LGR5, and LGR6, which specifically associate with
Frizzled and LDL receptor‐related proteins (LRPs), proteins that are
activated by extracellular Wnt molecules and which then trigger
canonical Wnt signalling to increase gene expression [266, 2140].	–	–	




Nomenclature	
MAS1L
	
MRGPRD
	
MRGPRE
	
MRGPRF
	
MRGPRG
	
HGNC, UniProt	
MAS1L, P35410
	
MRGPRD, Q8TDS7
	
MRGPRE, Q86SM8
	
MRGPRF, Q96AM1
	
MRGPRG, Q86SM5
	
Endogenous
agonists	–	
β‐alanine (pEC50 4.8)
[1729, 1785]	–	–	–	
Comments	–	An endogenous
peptide with a high degree of sequence similarity to angiotensin‐(1‐7) (AGT, P01019),
alamandine
(AGT), was shown to promote NO release in MRGPRD‐transfected
cells. The binding of alamandine to MRGPRD to was shown to be blocked
by D‐Pro7‐angiotensin‐(1‐7), β‐alanine and PD123319
[1045]. Genetic
ablation of MRGPRD+ neurons of adult mice decreased behavioural
sensitivity to mechanical stimuli but not to thermal stimuli
[278]. See
reviews [396] and
[1779].	See reviews
[396] and
[1779].	MRGPRF has been
reported to respond to stimulation by angiotensin metabolites
[589]. See
reviews [396] and
[1779].	See reviews
[396] and
[1779].	




Nomenclature	
MRGPRX1
	
MRGPRX2
	
MRGPRX3
	
MRGPRX4
	
HGNC, UniProt	
MRGPRX1, Q96LB2
	
MRGPRX2, Q96LB1
	
MRGPRX3, Q96LB0
	
MRGPRX4, Q96LA9
	
Endogenous
agonists	
bovine adrenal medulla
peptide 8‐22 (PENK, P01210)
(Selective) (pEC50 5.3–7.8) [299, 1080, 1785]	
PAMP‐20
(ADM, P35318)
(Selective) [899]	–	–	
Agonists	–	
cortistatin‐14
{Mouse, Rat} (pEC50 6.9–7.6) [899, 1594, 1785]	–	–	
Selective
agonists	–	
PAMP‐12 (human)
(pEC50 7.2–7.7) [899]	–	–	
Comments	Reported to mediate
the sensation of itch [1131, 1739]. Reports
that bovine adrenal medulla
peptide 8‐22 (PENK, P01210) was the
most potent of a series of proenkephalin A‐derived peptides as an
agonist of MRGPRX1 in assays of calcium mobilisation and radioligand
binding [1080] were
replicated in an independent study using an arrestin recruitment assay
[1785]. See
reviews [396] and
[1779].	A diverse range of
substances has been reported to be agonists of MRGPRX2, with
cortistatin 14 the highest potency agonist in assays of calcium
mobilisation [1594], also
confirmed in an independent study using an arrestin recruitment assay
[1785]. See
reviews [396] and
[1779].	–	See reviews
[396] and
[1779].	




Nomenclature	
OPN3
	
OPN4
	
OPN5
	
P2RY8
	
HGNC, UniProt	
OPN3, Q9H1Y3
	
OPN4, Q9UHM6
	
OPN5, Q6U736
	
P2RY8, Q86VZ1
	
Comments	–	–	Evidence indicates
OPN5 triggers a UV‐sensitive Gi‐mediated signalling pathway
in mammalian tissues [982].	–	




Nomenclature	
P2RY10
	
TAAR2
	
TAAR3
	
TAAR4P
	
HGNC, UniProt	
P2RY10, O00398
	
TAAR2, Q9P1P5
	
TAAR3, Q9P1P4
	
TAAR4P, –	
Rank order of
potency	–	
β‐phenylethylamine>tryptamine
[185]	–	–	
Endogenous
agonists	
sphingosine
1‐phosphate (Selective) (pEC50 7.3)
[1344], LPA (Selective)
(pEC50 6.9) [1344]	–	–	–	
Comments	–	Probable pseudogene
in 10‐15% of Asians due to a polymorphism (rs8192646) producing a
premature stop codon at amino acid 168 [396].	
TAAR3 is thought to be a pseudogene in man though
functional in rodents [396].	Pseudogene in man
but functional in rodents [396].	




Nomenclature	
TAAR5
	
TAAR6
	
TAAR8
	
TAAR9
	
HGNC, UniProt	
TAAR5, O14804
	
TAAR6, Q96RI8
	
TAAR8, Q969N4
	
TAAR9, Q96RI9
	
Comments	Trimethylamine is
reported as an agonist [1974] and
3‐iodothyronamine an inverse agonist [426].	–	–	
TAAR9 appears to be functional in most individuals
but has a polymorphic premature stop codon at amino acid 61
(rs2842899) with an allele frequency of 10‐30% in different
populations [1944].	




Class C Orphans


Nomenclature	
GPR156
	
GPR158
	
GPR179
	
GPRC5A
	
GPRC5B
	
GPRC5C
	
GPRC5D
	
HGNC, UniProt	
GPR156, Q8NFN8
	
GPR158, Q5T848
	
GPR179, Q6PRD1
	
GPRC5A, Q8NFJ5
	
GPRC5B, Q9NZH0
	
GPRC5C, Q9NQ84
	
GPRC5D, Q9NZD1
	




Taste 1 receptors

Overview
Whilst the taste of acid and salty foods appear
to be sensed by regulation of ion channel activity, bitter, sweet and umami tastes
are sensed by specialised GPCR. Two classes of taste GPCR have been identified, T1R
and T2R, which are similar in sequence and structure to Class C and Class A GPCR,
respectively. Activation of taste receptors appears to involve gustducin‐
(Gαt3) and Gα14‐mediated signalling, although
the precise mechanisms remain obscure. Gene disruption studies suggest the
involvement of PLCβ2 [2122], TRPM5 [2122] and IP3 [764] receptors in post‐receptor
signalling of taste receptors. Although predominantly associated with the oral
cavity, taste receptors are also located elsewhere, including further down the
gastrointestinal system, in the lungs and in the brain.


Sweet/Umami

T1R3 acts as an obligate partner in T1R1/T1R3
and T1R2/T1R3 heterodimers, which sense umami or sweet, respectively. T1R1/T1R3
heterodimers respond to L‐glutamic acid and may be
positively allosterically modulated by 5'‐nucleoside monophosphates, such as
5'‐GMP[1096]. T1R2/T1R3 heterodimers
respond to sugars, such as sucrose, and artificial
sweeteners, such as saccharin[1376].


Nomenclature	
TAS1R1
	
TAS1R2
	
TAS1R3
	
HGNC, UniProt	
TAS1R1, Q7RTX1
	
TAS1R2, Q8TE23
	
TAS1R3, Q7RTX0
	




Taste 2 receptors


Bitter

The composition and stoichiometry of bitter
taste receptors is not yet established. Bitter receptors appear to separate into two
groups, with very restricted ligand specificity or much broader responsiveness. For
example, T2R5 responded to cycloheximide, but not 10 other
bitter compounds [287], while T2R14 responded to
at least eight different bitter tastants, including (‐)‐α‐thujone
and picrotoxinin[119].

Specialist database BitterDB contains additional information on bitter
compounds and receptors [2023].


Nomenclature	
TAS2R1
	
TAS2R3
	
TAS2R4
	
TAS2R5
	
TAS2R7
	
TAS2R8
	
HGNC, UniProt	
TAS2R1, Q9NYW7
	
TAS2R3, Q9NYW6
	
TAS2R4, Q9NYW5
	
TAS2R5, Q9NYW4
	
TAS2R7, Q9NYW3
	
TAS2R8, Q9NYW2
	




Nomenclature	
TAS2R9
	
TAS2R10
	
TAS2R13
	
TAS2R14
	
TAS2R16
	
TAS2R19
	
HGNC, UniProt	
TAS2R9, Q9NYW1
	
TAS2R10, Q9NYW0
	
TAS2R13, Q9NYV9
	
TAS2R14, Q9NYV8
	
TAS2R16, Q9NYV7
	
TAS2R19, P59542
	




Nomenclature	
TAS2R20
	
TAS2R30
	
TAS2R31
	
TAS2R38
	
TAS2R39
	
TAS2R40
	
HGNC, UniProt	
TAS2R20, P59543
	
TAS2R30, P59541
	
TAS2R31, P59538
	
TAS2R38, P59533
	
TAS2R39, P59534
	
TAS2R40, P59535
	




Nomenclature	
TAS2R41
	
TAS2R42
	
TAS2R43
	
TAS2R45
	
TAS2R46
	
TAS2R50
	
TAS2R60
	
HGNC, UniProt	
TAS2R41, P59536
	
TAS2R42, Q7RTR8
	
TAS2R43, P59537
	
TAS2R45, P59539
	
TAS2R46, P59540
	
TAS2R50, P59544
	
TAS2R60, P59551
	




Other 7TM proteins


Nomenclature	
GPR107
	
GPR137
	
OR51E1
	
TPRA1
	
GPR143
	
GPR157
	
HGNC, UniProt	
GPR107, Q5VW38
	
GPR137, Q96N19
	
OR51E1, Q8TCB6
	
TPRA1, Q86W33
	
GPR143, P51810
	
GPR157, Q5UAW9
	
Endogenous
agonists	–	–	–	–	
levodopa [1141]	–	
Comments	GPR107 is a member of
the LUSTR family of proteins found in both plants and animals, having
similar topology to Gprotein‐coupled receptors [461]	–	OR51E1 is a putative
olfactory receptor.	TPRA1 shows no
homology to known G protein‐coupled receptors.	Loss‐of‐function
mutations underlie ocular albinism type 1 [103].	GPR157 has ambiguous
sequence similarities to several different GPCR families (class A, class
B and the slime mould cyclic AMP receptor). Because of its distant
relationship to other GPCRs, it cannot be readily classified.	




5‐Hydroxytryptamine receptors

Overview
5‐HT receptors (nomenclature as agreed by
the NC‐IUPHAR Subcommittee on 5‐HT
receptors [
789
] and subsequently revised [
707
]) are, with the exception of the ionotropic 5‐HT3 class,
GPCR receptors where the endogenous agonist is 5‐hydroxytryptamine. The
diversity of metabotropic 5‐HT receptors is increased by alternative splicing that
produces isoforms of the 5‐HT2A (non‐functional), 5‐HT2C
(non‐functional), 5‐HT4, 5‐HT6 (non‐functional) and
5‐HT7 receptors. Unique amongst the GPCRs, RNA editing produces
5‐HT2C receptor isoforms that differ in function, such as efficiency
and specificity of coupling to Gq/11 and also pharmacology [164, 2011]. Most 5‐HT receptors
(except 5‐ht 1e and 5‐ht 5a/5b) play specific roles mediating
functional responses in different tissues (reviewed by [1554, 1957].


Nomenclature	
5‐HT1A
receptor
	
5‐HT1B
receptor
	
5‐HT1D
receptor
	
5‐ht1e
receptor
	
5‐HT1F
receptor
	
HGNC, UniProt	
HTR1A, P08908
	
HTR1B, P28222
	
HTR1D, P28221
	
HTR1E, P28566
	
HTR1F, P30939
	
Agonists	
U92016A
(pK
i 9.7) [1240], vilazodone
(Partial agonist) (pK
i 9.7) [402], vortioxetine
(Partial agonist) (pK
i 7.8) [90]	
L‐694,247
(pK
i 9.2) [637], naratriptan
(Partial agonist) (pK
i 8.1) [1365], eletriptan
(pK
i 8) [1365], frovatriptan
(pK
i 8) [2069], zolmitriptan
(Partial agonist) (pK
i 7.7) [1365], vortioxetine
(Partial agonist) (pK
i 7.5) [90], rizatriptan
(Partial agonist) (pK
i 6.9) [1365]	
dihydroergotamine (pK
i 9.2–9.9) [684, 1084, 1091], ergotamine
(pK
i 9.1) [616], L‐694,247
(pK
i 9) [2052], naratriptan
(pK
i 8.4–9) [432, 1365, 1577], zolmitriptan
(pK
i 8.9) [1365], frovatriptan
(pK
i 8.4) [2069], rizatriptan
(pK
i 7.9) [1365]	
BRL‐54443
(pK
i 8.7) [227]	
BRL‐54443
(pK
i 8.9) [227], eletriptan
(pK
i 8) [1365], sumatriptan
(pK
i 7.2–7.9) [11, 12, 1365, 1968]	
Selective
agonists	
8‐OH‐DPAT
(pK
i 8.4–9.4) [406, 685, 896, 1079, 1280, 1386, 1388, 1389], NLX‐101
(pK
i 8.6) [1387]	
CP94253
(pK
i 8.7) [976]	
PNU109291
(pK
i 9.1) [483] – Gorilla,
eletriptan
(pK
i 8.9) [1365]	–	
lasmiditan
(pK
i 8.7) [1375], LY334370
(pK
i 8.7) [1968], 5‐BODMT
(pK
i 8.4) [966], LY344864
(pK
i 8.2) [1502]	
Antagonists	
(S)‐UH 301
(pK
i 7.9) [1386]	–	–	–	–	
Selective
antagonists	
WAY‐100635
(pK
i 7.9–9.2) [1386, 1388], robalzotan
(pK
i 9.2) [872]	
SB 224289
(Inverse agonist) (pK
i 8.2–8.6) [583, 1384, 1696], SB236057
(Inverse agonist) (pK
i 8.2) [1272], GR‐55562
(pK
B 7.4) [791]	
SB 714786
(pK
i 9.1) [1987]	–	–	
Nomenclature	
5‐HT1A
receptor
	
5‐HT1B
receptor
	
5‐HT1D
receptor
	
5‐ht1e
receptor
	
5‐HT1F
receptor
	
Labelled
ligands	
[3H]robalzotan (Antagonist)
(pK
d 9.8) [861], [3H]WAY100635 (Antagonist)
(pK
d 9.5) [933], [3H]8‐OH‐DPAT (Agonist) (pK
d 6–9.4) [156, 896, 1385, 1388], [3H]NLX‐112 (Agonist) (pK
d 8.9) [748], [11C]WAY100635 (Antagonist) [1915], p‐[18F]MPPF (Antagonist) [368]	
[3H]N‐methyl‐AZ10419369 (Agonist, Partial
agonist) (pK
d 9.4) [1182], [3H]GR
125,743 (Selective Antagonist) (pK
d 8.6–9.2) [637, 2061], [3H]alniditan (Agonist) (pK
d 8.6–9) [1084], [125I]GTI (Agonist) (pK
d 8.9) [193, 232] – Rat,
[3H]eletriptan (Agonist, Partial agonist)
(pK
d 8.5) [1365], [3H]sumatriptan (Agonist, Partial agonist)
(pK
d 8) [1365], [11C]AZ10419369 (Agonist, Partial agonist)
[1950]	
[3H]eletriptan (Agonist)
(pK
d 9.1) [1365], [3H]alniditan (Agonist) (pK
d 8.8–8.9) [1084], [125I]GTI (Selective Agonist)
(pK
d 8.9) [193, 232] – Rat,
[3H]GR
125,743 (Selective Antagonist) (pK
d 8.6) [2061], [3H]sumatriptan (Agonist)
(pK
d 8.2) [1365]	
[3H]5‐HT (Agonist) (pK
d 8.1–8.2) [1237, 1463]	
[3H]LY334370 (Agonist) (pK
d 9.4) [1968], [125I]LSD (Agonist) (pK
d 9) [44] – Mouse	
Comments	–	Wang et
al. (2013) report X‐ray structures which reveal the
binding modality of ergotamine and
dihydroergotamine to the 5‐HT1B receptor in
comparison with the structure of the 5‐HT2B receptor
[1978].	–	–	–	




Nomenclature	
5‐HT2A
receptor
	
5‐HT2B
receptor
	
5‐HT2C
receptor
	
5‐HT4
receptor
	
HGNC, UniProt	
HTR2A, P28223
	
HTR2B, P41595
	
HTR2C, P28335
	
HTR4, Q13639
	
Agonists	
DOI
(pK
i 7.4–9.2) [204, 1374, 1755]	
methysergide
(Partial agonist) (pK
i 8–9.4) [970, 1605, 1969], DOI
(pK
i 7.6–7.7) [1025, 1374, 1659]	
DOI
(pK
i 7.2–8.6) [465, 1374, 1659], Ro 60‐0175
(pK
i 7.7–8.2) [953, 970]	
cisapride
(Partial agonist) (pK
i 6.4–7.4) [77, 128, 597, 1266, 1267, 1941]	
Selective
agonists	–	
BW723C86
(pK
i 7.3–8.6) [108, 970, 1659], Ro 60‐0175
(pK
i 8.3) [970]	
WAY‐163909
(pK
i 6.7–8) [454], lorcaserin
(pK
i 7.8) [1878]	
TD‐8954
(pK
i 9.4) [1250], ML 10302
(Partial agonist) (pK
i 7.9–9) [136, 160, 1266, 1267, 1268], RS67506
(pEC50 8.8) [731] – Rat,
relenopride
(Partial agonist) (pK
i 8.3) [607], velusetrag
(pK
i 7.7) [1139, 1763], BIMU 8
(pK
i 7.3) [347]	
Antagonists	
risperidone
(Inverse agonist) (pK
i 9.3–10) [986, 1008, 1675], mianserin
(pK
i 7.7–9.6) [970, 1001, 1280], ziprasidone
(pK
i 8.8–9.5) [986, 1008, 1675, 1711], volinanserin
(pIC50 6.5–9.3) [970, 1142, 1568], blonanserin
(pK
i 9.1) [1421], clozapine
(Inverse agonist) (pK
i 7.6–9) [970, 1008, 1277, 1675, 1943], olanzapine
(pK
i 8.6–8.9) [986, 1008, 1675, 1711], nefazodone
(pK
i 8.2) [1698], chlorpromazine
(Inverse agonist) (pK
i 8.1) [1008], loxapine
(Inverse agonist) (pK
i 8.1) [1008], trifluoperazine
(pK
i 7.9) [1008], pimozide
(pK
i 7.1–7.7) [986, 1008], trazodone
(pK
i 7.4) [970], haloperidol
(pK
i 6.7–7.3) [1008, 1277, 1675, 1711, 1943], mesoridazine
(pK
i 7.3) [326], mirtazapine
(pK
i 7.2) [513], mirtazapine
(pK
i 7.2) [513], quetiapine
(pK
i 6.4–7) [986, 1008], molindone
(pK
i 6.5) [1008]	
mianserin
(pK
i 7.9–8.8) [180, 970, 1969]	
mianserin
(Inverse agonist) (pK
i 8.3–9.2) [524, 970, 1280], methysergide
(pK
i 8.6–9.1) [465, 970], ziprasidone
(Inverse agonist) (pK
i 7.9–9) [743, 1008, 1711], olanzapine
(Inverse agonist) (pK
i 8.1–8.4) [743, 1008, 1711], loxapine
(Inverse agonist) (pK
i 7.8–8) [743, 1008], mirtazapine
(pK
i 7.4) [513], mirtazapine
(pK
i 7.4) [513], trazodone
(pK
i 6.6) [970], trifluoperazine
(pK
i 6.4) [1008], agomelatine
(pK
i 6.2) [1276]	–	
Selective
antagonists	
ketanserin
(pK
i 8.1–9.7) [234, 970, 1559], pimavanserin
(Inverse agonist) (pK
i 9.3) [572, 1943]	
BF‐1
(pK
i 10.1) [1671], RS‐127445
(pK
i 9–9.5) [180, 970], EGIS‐7625
(pK
i 9) [1001]	
FR260010
(pK
i 9) [700], SB 242084
(pK
i 8.2–9) [928, 970], RS‐102221
(pK
i 8.3–8.4) [181, 970]	
RS 100235
(pK
i 8.7–12.2) [347, 1589], SB 204070
(pK
i 9.8–10.4) [128, 1266, 1267, 1941], GR 113808
(pK
i 9.3–10.3) [77, 128, 160, 347, 1267, 1589, 1941]	
Labelled
ligands	
[3H]fananserin (Antagonist)
(pK
d 9.9) [1188] – Rat,
[3H]ketanserin (Antagonist)
(pK
d 8.6–9.7) [970, 1559], [11C]volinanserin (Antagonist) [676], [18F]altanserin (Antagonist) [1601]	
[3H]LSD (Agonist) (pK
d 8.7) [1559], [3H]5‐HT (Agonist) (pK
d 8.1) [1967] – Rat,
[3H]mesulergine (Antagonist, Inverse
agonist) (pK
d 7.9) [970], [125I]DOI (Agonist) (pK
d 7.7–7.6)	
[125I]DOI (Agonist) (pK
d 8.7–9) [524], [3H]mesulergine (Antagonist, Inverse
agonist) (pK
d 9.3–8.7) [524, 1559], [3H]LSD (Agonist)	
[123I]SB
207710 (Antagonist) (pK
d 10.1) [228] – Pig, [3H]GR
113808 (Antagonist) (pK
d 10.3–9.7) [77, 128, 1268, 1941], [3H]RS
57639 (Selective Antagonist) (pK
d 9.7) [179] – Guinea
pig, [11C]SB207145 (Antagonist)
(pK
d 8.6) [1169]	
Comments	–	LSD (lysergic acid)
and ergotamine show
a strong preference for arrestin recruitment over G protein coupling
at the 5‐HT2B receptor, with no such preference evident at
5‐HT1B receptors, and they also antagonise
5‐HT7A receptors [1963]. DHE
(dihydroergocryptine), pergolide and
cabergoline also
show significant preference for arrestin recruitment over G protein
coupling at 5‐HT2B receptors [1963].	The serotonin
antagonist mesulergine was
key to the discovery of the 5‐HT2C receptor [1479].	–	




Nomenclature	
5‐ht5a
receptor
	
5‐ht5b
receptor
	
5‐HT6
receptor
	
5‐HT7
receptor
	
HGNC, UniProt	
HTR5A, P47898
	
HTR5BP, –	
HTR6, P50406
	
HTR7, P34969
	
Selective
agonists	–	–	
WAY‐181187
(pK
i 8.7) [1663], E6801 (Partial
agonist) (pK
i 8.7) [769], WAY‐208466
(pK
i 8.3) [135], EMD‐386088
(pIC50 8.1) [1228]	
LP‐12
(pK
i 9.9) [1082], LP‐44
(pK
i 9.7) [1082], LP‐211
(pK
i 9.2) [1083] – Rat,
AS‐19
(pK
i 9.2) [947], E55888
(pK
i 8.6) [206]	
Antagonists	–	–	–	
lurasidone
(pK
i 9.3) [829], pimozide
(pK
i 9.3) [1604] – Rat,
vortioxetine
(pK
i 6.3) [90]	
Selective
antagonists	
SB 699551
(pK
i 8.2) [366]	–	
SB399885
(pK
i 9) [763], SB 271046
(pK
i 8.9) [224], cerlapirdine
(pK
i 8.9) [358], SB357134
(pK
i 8.5) [225], Ro 63‐0563
(pK
i 7.9–8.4) [168, 1754]	
SB269970
(pK
i 8.6–8.9) [1874], SB656104
(pK
i 8.7) [531], DR‐4004
(pK
i 8.7) [615, 938], JNJ‐18038683
(pK
i 8.2) [177], SB 258719
(Inverse agonist) (pK
i 7.5) [1875]	
Labelled
ligands	
[125I]LSD (Agonist) (pK
d 9.7) [636], [3H]5‐CT (Agonist) (pK
d 8.6) [636]	
[125I]LSD (Agonist) (pK
d 9.3) [1227] – Mouse,
[3H]5‐CT (Agonist) [1965] –
Mouse	
[11C]GSK215083 (Antagonist)
(pK
i 9.8) [1462], [125I]SB258585 (Selective Antagonist)
(pK
d 9) [763], [3H]LSD (Agonist) (pK
d 8.7) [167], [3H]Ro
63‐0563 (Antagonist) (pK
d 8.3) [168], [3H]5‐CT (Agonist)	
[3H]5‐CT (Agonist) (pK
d 9.4) [1874], [3H]5‐HT (Agonist) (pK
d 8.1–9) [93, 1793], [3H]SB269970 (Selective Antagonist)
(pK
d 8.9) [1874], [3H]LSD (Agonist) (pK
d 8.5–8.6) [1793]	



Comments
Tabulated p
K
i and K
D values refer to binding to human 5‐HT receptors unless indicated
otherwise. The nomenclature of 5‐HT1B/5‐HT1D receptors has been
revised [707]. Only the non‐rodent form
of the receptor was previously called 5‐HT1D: the human 5‐HT1B
receptor (tabulated) displays a different pharmacology to the rodent forms of the
receptor due to Thr335 of the human sequence being replaced by Asn in rodent
receptors. NAS181 is a selective
antagonist of the rodent 5‐HT1B receptor. Fananserin and ketanserin bind with high
affinity to dopamine D4 and histamine H1 receptors respectively, and
ketanserin is a potent
α1 adrenoceptor antagonist, in addition to blocking
5‐HT2A receptors. The human 5‐ht5A receptor has been claimed
to couple to several signal transduction pathways when stably expressed in C6 glioma
cells [1404]. The human orthologue of
the mouse 5‐ht5b receptor is non‐functional due to interruption of the
gene by stop codons. The 5‐ht1e receptor appears not to have been cloned
from mouse, or rat, impeding definition of its function. In addition to the receptors
listed in the table, an 'orphan' receptor, unofficially termed 5‐HT1P, has
been described [600].

Further Reading
Bockaert J et al. (2011)
5‐HT(4) receptors, a place in the sun: act two. Curr Opin Pharmacol
11: 87‐93 [PMID:21342787]


Codony X et al. (2011) 5‐HT(6)
receptor and cognition. Curr Opin Pharmacol
11: 94‐100 [PMID:21330210]


Hartig PR et al. (1996)
Alignment of receptor nomenclature with the human genome: classification of 5‐HT1B
and 5‐HT1D receptor subtypes. Trends Pharmacol. Sci.
17: 103‐5 [PMID:8936345]


Hayes DJ et al. (2011) 5‐HT
receptors and reward‐related behaviour: a review. Neurosci Biobehav
Rev
35: 1419‐49 [PMID:21402098]


Hoyer D et al. (1994)
International Union of Pharmacology classification of receptors for
5‐hydroxytryptamine (Serotonin). Pharmacol. Rev.
46: 157‐203 [PMID:7938165]


Leopoldo M et al. (2011)
Serotonin 5‐HT7 receptor agents: Structure‐activity relationships and potential
therapeutic applications in central nervous system disorders. Pharmacol.
Ther.
129: 120‐48 [PMID:20923682]


Meltzer HY et al. (2011) The
role of serotonin receptors in the action of atypical antipsychotic drugs.
Curr Opin Pharmacol
11: 59‐67 [PMID:21420906]


Roberts AJ et al. (2012) The
5‐HT(7) receptor in learning and memory. Hippocampus
22: 762‐71 [PMID:21484935]


Sargent BJ et al. (2011)
Targeting 5‐HT receptors for the treatment of obesity. Curr Opin
Pharmacol
11: 52‐8 [PMID:21330209]



Acetylcholine receptors
(muscarinic)

Overview
Muscarinic acetylcholine receptors
(nomenclature as agreed by the NC‐IUPHAR Subcommittee on Muscarinic Acetylcholine Receptors
[
275
]) are GPCRs of the Class A, rhodopsin‐like family where the endogenous
agonist is acetylcholine. In addition to
the agents listed in the table, AC‐42, its structural analogues
AC‐260584 and 77‐LH‐28‐1, N‐desmethylclozapine, TBPB and LuAE51090 have been described
as functionally selective agonists of the M1 receptor subtype
via binding in a mode distinct from that utilized by
non‐selective agonists [71, 878, 1040, 1041, 1232, 1635, 1786, 1787, 1825]. There are two
pharmacologically characterised allosteric sites on muscarinic receptors, one defined
by it binding gallamine, strychnine and brucine, and the other defined
by the binding of KT 5720, WIN 62,577, WIN 51,708 and staurosporine[1052, 1053].


Nomenclature	
M1
receptor
	
M2
receptor
	
HGNC, UniProt	
CHRM1, P11229
	
CHRM2, P08172
	
Agonists	
carbachol
(pK
i 3.2–5.3) [334, 846, 2040], pilocarpine
(Partial agonist) (pK
i 5.1) [846], bethanechol
(pK
i 4) [846]	
bethanechol
(pK
i 4) [846]	
Antagonists	
glycopyrrolate
(pIC50 9.9) [1801], umeclidinium
(pK
i 9.8) [1035, 1632], AE9C90CB
(pK
i 9.7) [1749], propantheline
(pK
i 9.7) [797], atropine
(pK
i 8.5–9.6) [334, 552, 759, 797, 1486, 1762], tiotropium
(pK
i 9.6) [428], 4‐DAMP
(pK
i 9.2) [458], dicyclomine
(pK
i 9.1) [68], scopolamine
(pK
i 9) [797], trihexyphenidyl
(pK
i 8.9) [68], tripitramine
(pK
i 8.8) [1176], UH‐AH 37
(pK
i 8.6–8.7) [609, 2012], tolterodine
(pK
i 8.5–8.7) [609, 1749], oxybutynin
(pK
i 8.6) [410, 818, 1749], darifenacin
(pK
i 7.5–8.3) [609, 730, 759, 818, 1749], pirenzepine
(pK
i 7.8–8.3) [238, 458, 730, 797, 875, 2012], solifenacin
(pK
i 7.6) [818, 1749], AFDX384
(pK
i 7.5) [458], AQ‐RA 741
(pK
i 7.2–7.5) [458, 609], methoctramine
(pK
i 6.6–7.3) [458, 493, 730, 1762], himbacine
(pK
i 6.7–7.1) [458, 875, 1286], muscarinic toxin
3 (pK
i 7.1) [875], otenzepad
(pK
d 6.2) [493]	
tiotropium
(pK
i 9.9) [428], umeclidinium
(pK
i 9.8) [1035, 1632], propantheline
(pK
i 9.5) [797], glycopyrrolate
(Full agonist) (pIC50 9.3) [1801], atropine
(pK
i 7.8–9.2) [238, 310, 759, 797, 1002, 1373, 1486], AE9C90CB
(pK
i 8.6) [1749], tolterodine
(Inverse agonist) (pK
i 8.4–8.6) [609, 1373, 1749], AQ‐RA 741
(pK
i 8.4) [458, 609], himbacine
(pK
i 7.9–8.4) [458, 875, 1002, 1286], methoctramine
(pK
i 7.3–8.4) [238, 458, 493, 730, 1002, 1373], 4‐DAMP
(pK
i 8.3) [1002], AFDX384
(pK
i 8.2) [458], biperiden
(pK
d 8.2) [173], oxybutynin
(pK
i 7.7–8.1) [818, 1749], darifenacin
(Inverse agonist) (pK
i 7–7.6) [609, 730, 759, 818, 1373, 1749], UH‐AH 37
(pK
i 7.3–7.4) [609, 2012], otenzepad
(pK
i 6.7–7.2) [238, 1002], solifenacin
(pK
i 6.9–7.1) [818, 1749], pirenzepine
(pK
i 6–6.7) [238, 458, 730, 797, 875, 1002, 1373, 2012], VU0255035
(pK
i 6.2) [1717], muscarinic toxin
3 (pK
i<6) [875], guanylpirenzepine (pK
i 5.3) [1966] – Rat,
muscarinic toxin
7 (pK
i<5) [1414]	
Selective
antagonists	
biperiden
(pK
d 9.3) [173], VU0255035
(pK
i 7.8) [1717], guanylpirenzepine (pK
i 7.3–7.6) [23, 1966] – Rat	
tripitramine
(pK
i 9.6) [1176]	
Allosteric
modulators	
muscarinic toxin
7 (Negative) (pK
i 11–11.1) [1414], benzoquinazolinone
12 (Positive) (pK
B 6.6) [4], KT 5720
(Positive) (pK
d 6.4) [1052], brucine
(Positive) (pK
d 4.5–5.8) [846, 1051], BQCA (Positive)
(pK
B 4–4.8) [4, 5, 261, 1161], VU0029767
(Positive) [1208], VU0090157
(Positive) [1208]	
W‐84 (Negative)
(pK
d 6–7.5) [1299, 1908], C7/3‐phth (Negative) (pK
d 7.1) [335], alcuronium
(Negative) (pK
d 6.1–6.9) [846, 1908], gallamine
(Negative) (pK
d 5.9–6.3) [348, 1049], LY2119620
(Positive) (pK
d 5.7) [383, 1010], LY2033298
(Positive) (pK
d 4.4) [1933]	
Labelled
ligands	
[3H]QNB (Antagonist) (pK
d 10.6–10.8) [336, 1486], Cy3B‐telenzepine
(Antagonist) (pK
d 10.5) [742], [3H]N‐methyl
scopolamine (Antagonist) (pK
d 9.4–10.3) [280, 334, 336, 759, 846, 847, 875, 932, 1049], [3H](+)telenzepine (Antagonist)
(pK
i 9.4) [500] – Rat,
Alexa‐488‐telenzepine (Antagonist) (pK
d 9.3) [742], [3H]pirenzepine (Antagonist)
(pK
d 7.9) [1995], BODIPY‐pirenzepine (Antagonist) (pK
i 7) [820], [11C]butylthio‐TZTP (Agonist) [504], [11C]xanomeline (Agonist) [504], [18F](R,R)‐quinuclidinyl‐4‐fluoromethyl‐benzilate
(Antagonist) [935] – Rat	
[3H]QNB (Antagonist) (pK
d 10.1–10.6) [1486], Cy3B‐telenzepine
(Antagonist) (pK
i 10.4) [1380], [3H]tiotropium (Antagonist)
(pK
d 10.3) [1632], [3H]N‐methyl
scopolamine (Antagonist) (pK
d 9.3–9.9) [280, 310, 759, 846, 847, 875, 932, 1049, 1985], Alexa‐488‐telenzepine (Antagonist) (pK
i 8.8) [1380], [3H]acetylcholine (Agonist)
(pK
d 8.8) [1050], [3H]oxotremorine‐M (Agonist)
(pK
d 8.7) [137], [3H]dimethyl‐W84 (Allosteric modulator,
Positive) (pK
d 8.5) [1908], [18F]FP‐TZTP (Agonist) [845] –
Mouse	




Nomenclature	
M3
receptor
	
M4
receptor
	
M5
receptor
	
HGNC, UniProt	
CHRM3, P20309
	
CHRM4, P08173
	
CHRM5, P08912
	
Agonists	
pilocarpine
(Partial agonist) (pK
i 5.1) [846], carbachol
(pK
i 4–4.4) [310, 846, 2040], bethanechol
(pK
i 4.2) [846]	
pilocarpine
(Partial agonist) (pK
i 5.2) [846], carbachol
(pK
i 4.3–4.9) [846, 2040], bethanechol
(pK
i 4) [846]	
pilocarpine
(Partial agonist) (pK
i 5) [639], carbachol
(pK
i 4.9) [2040]	
Antagonists	
tiotropium
(pK
i 9.5–11.1) [428, 442], umeclidinium
(pK
i 10.2) [1035, 1632], propantheline
(pK
i 10) [797], AE9C90CB
(pK
i 9.9) [1749], atropine
(pK
i 8.9–9.8) [238, 442, 759, 797, 1486, 1762], ipratropium
(pK
i 9.3–9.8) [442, 759], aclidinium
(pIC50 9.8) [1530], clidinium
(pK
i 9.6) [442], glycopyrrolate
(pIC50 9.6) [1801], 4‐DAMP
(pK
i 9.3) [458], darifenacin
(pK
i 8.6–9.1) [609, 730, 759, 818, 1749], dicyclomine
(pK
i 9) [68], oxybutynin
(pK
i 8.8–8.9) [410, 818, 1749], tolterodine
(pK
i 8.4–8.5) [609, 1749], biperiden
(pK
d 8.4) [173], UH‐AH 37
(pK
i 8.1–8.2) [609, 2012], solifenacin
(pK
i 7.7–8) [818, 1749], tropicamide
(pK
i 7.5) [68], AQ‐RA 741
(pK
i 7.2–7.3) [458, 609], AFDX384
(pK
i 7.2) [458], himbacine
(pK
i 6.9–7.2) [458, 875, 1286], methoctramine
(pK
i 6.1–6.9) [238, 458, 493, 730, 1762], tripitramine
(pK
i 6.8) [1288], pirenzepine
(pK
i 6.5–6.8) [238, 458, 730, 797, 875, 2012], guanylpirenzepine (pK
i 6.2) [1966] – Rat,
VU0255035
(pK
i 6.1) [1717], otenzepad
(pK
i 6.1) [238], muscarinic toxin
3 (pK
i<6) [875], muscarinic toxin
7 (pK
i<5) [1414]	
umeclidinium
(pK
i 10.3) [1632], glycopyrrolate
(pIC50 9.8) [1801], AE9C90CB
(pK
i 9.5) [1749], 4‐DAMP
(pK
i 8.9) [458], oxybutynin
(pK
i 8.7) [1749], biperiden
(pK
d 8.6) [173], UH‐AH 37
(pK
i 8.3–8.4) [609, 2012], tolterodine
(pK
i 8.3–8.4) [609, 1749], AQ‐RA 741
(pK
i 7.8–8.2) [458, 609], himbacine
(pK
i 7.9–8.2) [458, 875, 1286], darifenacin
(pK
i 7.3–8.1) [609, 730, 759, 1749], AFDX384
(pK
i 8) [458], tripitramine
(pK
i 7.9) [1288], pirenzepine
(pK
i 7–7.6) [458, 730, 797, 875, 2012], methoctramine
(pK
i 6.6–7.5) [238, 458, 493, 730], otenzepad
(pK
d 7) [493], solifenacin
(pK
i 6.8) [1749], guanylpirenzepine (pK
i 6.2) [1966] – Rat,
VU0255035
(pK
i 5.9) [1717], muscarinic toxin
7 (pK
i<5) [1414]	
umeclidinium
(pK
i 9.9) [1632], glycopyrrolate
(pIC50 9.7) [1801], AE9C90CB
(pK
i 9.5) [1749], 4‐DAMP
(pK
i 9) [458], tolterodine
(pK
i 8.5–8.8) [609, 1749], darifenacin
(pK
i 7.9–8.6) [609, 730, 759, 1749], UH‐AH 37
(pK
i 8.3) [609, 2012], biperiden
(pK
d 8.2) [173], oxybutynin
(pK
i 7.9) [1749], AQ‐RA 741
(pK
i 6.1–7.8) [458, 609], tripitramine
(pK
i 7.5) [1176], methoctramine
(pK
i 6.3–7.2) [238, 458, 493, 730], solifenacin
(pK
i 7.2) [1749], pirenzepine
(pK
i 6.8–7.1) [730, 875, 2012], guanylpirenzepine (pK
d 6.8) [514] – Unknown,
himbacine
(pK
i 5.4–6.5) [458, 875, 1286], AFDX384
(pK
i 6.3) [458], muscarinic toxin
3 (pK
i<6) [875], otenzepad
(pK
i 5.6) [238], muscarinic toxin
7 (pK
i<5) [1414]	
Selective
antagonists	–	–	
ML381
(pK
i 6.3) [593]	
Allosteric
modulators	
WIN 62,577
(Positive) (pK
d 5.1) [1053], N‐chloromethyl‐brucine (Positive) (pK
d 3.3) [1051]	
muscarinic toxin
3 (Negative) (pK
i 8.7) [875, 1444], LY2119620
(Positive) (pK
d 5.7) [383], thiochrome
(Positive) (pK
d 4) [1050], LY2033298
(Positive) [286], VU0152099
(Positive) [201], VU0152100
(Positive) [201]	
ML380 (Positive)
(pEC50 6.7) [595]	
Selective
allosteric modulators	–	–	
ML375 (Negative)
(pIC50 6.5) [594]	
Labelled
ligands	
[3H]tiotropium (Antagonist)
(pK
d 10.7) [1632], [3H]QNB (Antagonist) (pK
d 10.4) [1486], [3H]N‐methyl
scopolamine (Antagonist) (pK
d 9.7–10.2) [280, 310, 759, 797, 846, 875, 932, 1049], [3H]darifenacin (Antagonist)
(pK
d 9.5) [1762]	
[3H]QNB (Antagonist) (pK
d 9.7–10.5) [336, 1486], [3H]N‐methyl
scopolamine (Antagonist) (pK
d 9.9–10.2) [280, 310, 336, 759, 846, 875, 932, 1049, 1444, 1985], [3H]acetylcholine (Agonist)
(pK
d 8.2) [1050]	
[3H]QNB (Antagonist) (pK
d 10.2–10.7), [3H]N‐methyl
scopolamine (Antagonist) (pK
d 9.3–9.7) [280, 310, 759, 875, 932, 1985]	



Comments

LY2033298 and BQCA have also been shown to
directly activate the M4 and M1 receptors, respectively, via an
allosteric site [1059, 1060, 1366, 1367]. The allosteric site for
gallamine and strychnine on M2
receptors can be labelled by [3H]dimethyl‐W84[1908]. McN‐A‐343 is a functionally
selective partial agonist that appears to interact in a bitopic mode with both the
orthosteric and an allosteric site on the M2 muscarinic receptor
[1934]. THRX160209, hybrid 1 and hybrid
2, are multivalent (bitopic) ligands that also achieve selectivity for M2
receptors by binding both to the orthosteric and a nearby allosteric site [52, 1796].

Although numerous ligands for muscarinic
acetylcholine receptors have been described, relatively few selective antagonists
have been described, so it is common to assess the rank order of affinity of a number
of antagonists of limited selectivity (e.g.
4‐DAMP, darifenacin, pirenzepine) in order to
identify the involvement of particular subtypes. It should be noted that the measured
affinities of antagonists (and agonists) in radioligand binding studies are sensitive
to ionic strength and can increase over 10‐fold at low ionic strength compared to its
value at physiological ionic strengths [151].

Further Reading
Caulfield MP et al. (1998)
International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine
receptors. Pharmacol. Rev.
50: 279‐290 [PMID:9647869]


Eglen RM. (2012) Overview of muscarinic
receptor subtypes. Handb Exp Pharmacol 3‐28 [PMID:22222692]


Gregory KJ et al. (2007)
Allosteric modulation of muscarinic acetylcholine receptors. Curr
Neuropharmacol
5: 157‐67 [PMID:19305798]


Kruse AC et al. (2014)
Muscarinic acetylcholine receptors: novel opportunities for drug development.
Nat Rev Drug Discov
13: 549‐60 [PMID:24903776]


Leach K et al. (2012)
Structure‐function studies of muscarinic acetylcholine receptors. Handb Exp
Pharmacol 29‐48 [PMID:22222693]


Valant C et al. (2012) The
best of both worlds? Bitopic orthosteric/allosteric ligands of g protein‐coupled
receptors. Annu. Rev. Pharmacol. Toxicol.
52: 153‐78 [PMID:21910627]



Adenosine receptors

Overview
Adenosine receptors (nomenclature as
agreed by the NC‐IUPHAR
Subcommittee on Adenosine Receptors [
541
]) are activated by the endogenous ligand adenosine(potentially inosine also at A3
receptors). Crystal structures for the antagonist‐bound and agonist‐bound
A2A adenosine receptors have been described [835, 2065].


Nomenclature	
A1
receptor
	
A2A
receptor
	
A2B
receptor
	
A3
receptor
	
HGNC, UniProt	
ADORA1, P30542
	
ADORA2A, P29274
	
ADORA2B, P29275
	
ADORA3, P0DMS8
	
Agonists	
cyclopentyladenosine (pK
i 6.5–9.4) [388, 570, 736, 839, 870, 1592, 2141]	–	–	–	
(Sub)family‐selective agonists	
NECA
(pK
i 5.3–8.2) [570, 870, 1592, 1903, 2077]	
NECA
(pK
i 6.9–8.7) [189, 427, 570, 943, 1021, 2077]	
NECA
(pK
i 5.7–6.9) [146, 189, 862, 1113, 1798, 1945, 2077]	
NECA
(pK
i 7.5–8.4) [189, 570, 840, 1634, 1946, 2077]	
Selective
agonists	
5‐Cl‐5‐deoxy‐(±)‐ENBA (pK
i 9.3) [536], GR79236
(pK
i 8.5) [839] – Rat,
CCPA
(pK
i 7.7–8.1) [839, 1419]	
apadenoson
(pK
i 9.3) [1481], UK‐432,097
(pK
i 8.3) [2065], CGS 21680
(pK
i 6.7–8.1) [189, 427, 570, 839, 943, 968, 1021, 1419], regadenoson
(pK
i 6.5) [839]	
BAY 60‐6583
(pK
i 8–8.5) [460]	
IB‐MECA
(pK
i 8.7–9.2) [511, 561, 968, 1946], Cl‐IB‐MECA
(pK
i 8–8.9) [202, 840, 941], MRS5698
(pK
i 8.5) [1898]	
Antagonists	
caffeine
(pK
i 4.3–5) [6, 409, 838]	
SCH 58261
(pK
i 8.3–9.2) [427, 1021, 1445], theophylline
(pK
i 5.2–5.8) [427, 838,
968, 1945], caffeine
(pK
i 4.6–5.6) [6, 838,
1021]	
theophylline
(pK
i 4.1–5) [141, 511, 944, 1945], caffeine
(pK
i 4.5–5) [141, 188, 944]	
caffeine
(pK
i 4.9) [838]	
(Sub)family‐selective antagonists	
CGS 15943
(pK
i 8.5) [1445], xanthine amine
congener (pK
d 7.5) [536]	
CGS 15943
(pK
i 7.7–9.4) [427, 943, 968, 1445], xanthine amine
congener (pK
i 8.4–9) [427, 968]	
xanthine amine
congener (pK
i 6.9–8.8) [146, 862, 863, 968, 1113, 1798], CGS 15943
(pK
i 6–8.1) [65, 862, 863, 968, 1445, 1798]	
CGS 15943
(pK
i 7–7.9) [949, 968, 1445, 1946], xanthine amine
congener (pK
i 7–7.4) [968, 1634, 1946]	
Selective
antagonists	
PSB36
(pK
i 9.9) [6] – Rat,
DPCPX
(pK
i 7.4–9.2) [826, 1419, 1592, 2015, 2141], derenofylline
(pK
i 9) [897], WRC‐0571
(pK
i 8.8) [1210]	
SCH442416
(pK
i 8.4–10.3) [1728, 1891], ZM‐241385
(pK
i 8.8–9.1) [1445]	
PSB‐0788
(pK
i 9.4) [188], PSB603
(pK
i 9.3) [188], MRS1754
(pK
i 8.8) [862, 948], PSB1115
(pK
i 7.3) [723]	
MRS1220
(pK
i 8.2–9.2) [840, 949, 1818, 2090], VUF5574
(pK
i 8.4) [2143], MRS1523
(pK
i 7.7) [1092], MRS1191
(pK
i 7.5) [840, 866, 1097]	
Labelled
ligands	
[3H]CCPA (Agonist) (pK
d 9.2) [968, 1592], [3H]DPCPX (Antagonist) (pK
d 8.4–9.2) [388, 511, 968, 1445, 1592, 1903]	
[3H]ZM
241385 (Antagonist) (pK
d 8.7–9.1) [36, 569], [3H]CGS
21680 (Agonist) (pK
d 7.7–7.8) [852, 1976]	
[3H]MRS1754 (Antagonist)
(pK
d 8.8) [862]	
[125I]AB‐MECA (Agonist) (pK
d 9–9.1) [1445, 1946]	



Comments
Adenosine inhibits many intracellular
ATP‐utilising enzymes, including adenylyl cyclase (P‐site). A pseudogene exists for
the A2B adenosine receptor (ADORA2BP1) with 79% identity to the A2B adenosine receptor cDNA coding
sequence, but which is unable to encode a functional receptor [841]. DPCPX also exhibits antagonism
at A2B receptors (pK
i ca. 7,[34, 968]). Antagonists at
A3 receptors exhibit marked species differences, such that only
MRS1523 and MRS1191 are selective at the
rat A3 receptor. In the absence of other adenosine receptors, [3H]DPCPX and
[3H]ZM 241385 can
also be used to label A2B receptors (KD
ca. 30 and 60 nM respectively). [125I]AB‐MECA also
binds to A1 receptors [968]. [3H]CGS 21680 is
relatively selective for A2A receptors, but may also bind to other sites
in cerebral cortex [384, 871]. [3H]NECA binds to
other non‐receptor elements, which also recognise adenosine [1143]. XAC‐BY630 has been described as
a fluorescent antagonist for labelling A1 adenosine receptors in living
cells, although activity at other adenosine receptors was not examined [212].

Further Reading
Fredholm BB et al. (2011)
International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and
classification of adenosine receptors–an update. Pharmacol. Rev.
63: 1‐34 [PMID:21303899]


Göblyös A et al. (2011)
Allosteric modulation of adenosine receptors. Biochim. Biophys. Acta
1808: 1309‐18 [PMID:20599682]


Headrick JP et al. (2011)
Adenosine and its receptors in the heart: regulation, retaliation and adaptation.
Biochim. Biophys. Acta
1808: 1413‐28 [PMID:21094127]


Lasley RD. (2011) Adenosine receptors and
membrane microdomains. Biochim. Biophys. Acta
1808: 1284‐9 [PMID:20888790]


Mundell S et al. (2011)
Adenosine receptor desensitization and trafficking. Biochim. Biophys.
Acta
1808: 1319‐28 [PMID:20550943]


Ponnoth DS et al. (2011)
Adenosine receptors and vascular inflammation. Biochim. Biophys.
Acta
1808: 1429‐34 [PMID:20832387]


Wei CJ et al. (2011) Normal
and abnormal functions of adenosine receptors in the central nervous system revealed
by genetic knockout studies. Biochim. Biophys. Acta
1808: 1358‐79 [PMID:21185258]



Adhesion Class GPCRs

Overview
Adhesion GPCRs are structurally identified on
the basis of a large extracellular region, similar to the Class B GPCR, but which is
linked to the 7TM region by a "stalk" motif containing a GPCR proteolytic site. The
N‐terminus often shares structural homology with proteins such as lectins and
immunoglobulins, leading to the term adhesion GPCR [543, 2097]. The nomenclature
of these receptors was revised in 2015 as recommended by NC‐IUPHAR and the Adhesion GPCR Consortium [683].


Nomenclature	
ADGRA1
	
ADGRA2
	
ADGRA3
	
ADGRB1
	
ADGRB2
	
HGNC, UniProt	
ADGRA1, Q86SQ6
	
ADGRA2, Q96PE1
	
ADGRA3, Q8IWK6
	
ADGRB1, O14514
	
ADGRB2, O60241
	
Endogenous
agonists	–	–	–	
phosphatidylserine [1461]	–	
Comments	–	–	–	ADGRB1 is reported
to respond to phosphatidylserine [1461].	–	




Nomenclature	
ADGRB3
	
CELSR1
	
CELSR2
	
CELSR3
	
ADGRD1
	
HGNC, UniProt	
ADGRB3, O60242
	
CELSR1, Q9NYQ6
	
CELSR2, Q9HCU4
	
CELSR3, Q9NYQ7
	
ADGRD1, Q6QNK2
	




Nomenclature	
ADGRD2
	
ADGRE1
	
ADGRE2
	
ADGRE3
	
ADGRE4P
	
HGNC, UniProt	
ADGRD2, Q7Z7M1
	
ADGRE1, Q14246
	
ADGRE2, Q9UHX3
	
ADGRE3, Q9BY15
	
ADGRE4P, Q86SQ3
	




Nomenclature	
ADGRE5
	
ADGRF1
	
ADGRF2
	
ADGRF3
	
ADGRF4
	
HGNC, UniProt	
ADGRE5, P48960
	
ADGRF1, Q5T601
	
ADGRF2, Q8IZF7
	
ADGRF3, Q8IZF5
	
ADGRF4, Q8IZF3
	




Nomenclature	
ADGRF5
	
ADGRG1
	
ADGRG2
	
ADGRG3
	
ADGRG4
	
HGNC, UniProt	
ADGRF5, Q8IZF2
	
ADGRG1, Q9Y653
	
ADGRG2, Q8IZP9
	
ADGRG3, Q86Y34
	
ADGRG4, Q8IZF6
	
Comments	–	Reported to bind
tissue transglutaminase 2 [2066] and
collagen, which activates the G12/13 pathway [1155].	–	–	–	




Nomenclature	
ADGRG5
	
ADGRG6
	
ADGRG7
	
ADGRL1
	
HGNC, UniProt	
ADGRG5, Q8IZF4
	
ADGRG6, Q86SQ4
	
ADGRG7, Q96K78
	
ADGRL1, O94910
	




Nomenclature	
ADGRL2
	
ADGRL3
	
ADGRL4
	
ADGRV1
	
HGNC, UniProt	
ADGRL2, O95490
	
ADGRL3, Q9HAR2
	
ADGRL4, Q9HBW9
	
ADGRV1, Q8WXG9
	
Comments	–	–	–	Loss‐of‐function
mutations are associated with Usher syndrome, a sensory deficit
disorder [843].	




Adrenoceptors

Overview

Adrenoceptors, α1


α
1‐Adrenoceptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on Adrenoceptors
[
248
], see also [
752
]) are activated by the endogenous agonists (‐)‐adrenaline and (‐)‐noradrenaline with equal
potency. Phenylephrine, methoxamine and cirazoline are agonists
selective for α
1‐adrenoceptors relative to α
2‐adrenoceptors, while prazosin (8.5‐10.5) and
corynanthine(6.5‐7.5) are
antagonists considered selective for α
1‐adrenoceptors relative to α
2‐adrenoceptors. [3H]prazosin(0.25
nM) and [125I]HEAT(0.1
nM; also known as BE2254) are relatively selective radioligands. The
α
1A‐adrenoceptor antagonist S(+)‐niguldipine also has
high affinity for L‐type Ca2+ channels. The conotoxin rho‐TIA acts as a negative
allosteric modulator at the α
1B‐adrenoceptor [1716], while the snake toxin
ρ‐Da1a acts as a selective non‐competitive
antagonist at the α
1A‐adrenoceptor [1236, 1548]. Fluorescent
derivatives of prazosin (Bodipy PL‐prazosin‐QAPB) are increasingly used to examine
cellular localisation of α
1‐adrenoceptors. The vasoconstrictor effects of selective
α1‐adrenoceptor agonists have led to their use as nasal
decongestants; antagonists are used to treat hypertension (doxazosin, prazosin) and benign
prostatic hyperplasia (alfuzosin, tamsulosin). The combined
α
1‐ and β
2‐adrenoceptor antagonist carvedilol is widely used to
treat congestive heart failure, although the contribution of α
1‐adrenoceptor blockade to the therapeutic effect is unclear. Several
anti‐depressants and anti‐psychotic drugs possess α
1‐adrenoceptor blocking properties that are believed to contribute to
side effects such as orthostatic hypotension and extrapyramidal effects.


Nomenclature	
α1A‐adrenoceptor
	
α1B‐adrenoceptor
	
α1D‐adrenoceptor
	
HGNC,
UniProt	
ADRA1A, P35348
	
ADRA1B, P35368
	
ADRA1D, P25100
	
Endogenous
agonists	–	–	
(‐)‐adrenaline (pK
i 7.2) [1722]	
Agonists	
oxymetazoline
(pK
i 8–8.2) [780,
1420,
1722,
1862],
phenylephrine
(pK
i 5.2–5.4) [1862],
methoxamine
(pK
i 5–5.2) [1722,
1862]	
phenylephrine
(pIC50 6.3–7.5) [532,
1289]	–	
Selective
agonists	
A61603
(pIC50 7.8–8.4) [532,
969],
dabuzalgron
(pK
i 7.4) [162]	–	–	
Antagonists	
prazosin
(Inverse agonist) (pK
i 9–9.9) [289,
389,
532,
1722,
2029],
doxazosin
(pK
i 9.3) [689], terazosin
(pK
i 8.7) [1263],
phentolamine
(pK
i 8.6) [1722],
alfuzosin
(pK
i 8.1) [750]	
prazosin
(Inverse agonist) (pK
i 9.6–9.9) [532,
1722,
2029],
tamsulosin
(Inverse agonist) (pK
i 9.5–9.7) [532,
1722,
2029],
doxazosin
(pK
i 9.1) [689], alfuzosin
(pK
i 8.6) [751],
terazosin
(pK
i 8.6) [1263],
phentolamine
(pK
i 7.5) [1722]	
prazosin
(Inverse agonist) (pK
i 9.5–10.2) [532,
1722,
2029],
tamsulosin
(pK
i 9.8–10.2) [532,
1722,
2029],
doxazosin
(pK
i 9.1) [689], terazosin
(pK
i 9.1) [1263],
alfuzosin
(pK
i 8.4) [750],
dapiprazole
(pK
i 8.4) [68], phentolamine
(Inverse agonist) (pK
i 8.2) [1722],
RS‐100329
(pK
i 7.9) [2029],
labetalol
(pK
i 6.6) [68]	
Selective
antagonists	
tamsulosin
(pK
i 10–10.7) [289,
389,
532,
1722,
2029],
silodosin
(pK
i 10.4) [1722],
S(+)‐niguldipine (pK
i 9.1–10) [532,
1722],
RS‐100329
(pK
i 9.6) [2029],
SNAP5089
(pK
i 8.8–9.4) [750,
1081,
2014],
ρ‐Da1a (pK
i 9.2–9.3) [1236,
1548],
RS‐17053
(pK
i 9.2–9.3) [289,
389,
529,
532]	
Rec 15/2615
(pK
i 9.5) [1867],
L‐765314
(pK
i 7.7) [1470],
AH 11110
(pK
i 7.5) [1652]	
BMY‐7378
(pK
i 8.7–9.1) [268,
2102]	




Adrenoceptors, α2


α
2‐Adrenoceptors (nomenclature as agreed by NC‐IUPHAR Subcommittee on
Adrenoceptors; [
248
]) are activated by endogenous agonists with a relative potency of
(‐)‐adrenaline>(‐)‐noradrenaline. Brimonidine and talipexole are agonists
selective for α
2‐adrenoceptors relative to α
1‐adrenoceptors, rauwolscine and yohimbine are antagonists
selective for α
2‐adrenoceptors relative to α
1‐adrenoceptors. [3H]rauwolscine(1
nM), [3H]brimonidine(5
nM) and [3H]RX821002(0.5
nM and 0.1 nM at α
2C) are relatively selective radioligands. There is species variation
in the pharmacology of the α
2A‐adrenoceptor; for example, yohimbine, rauwolscine and oxymetazoline have an
 20‐fold higher affinity for the human α
2A‐adrenoceptor compared to the rat, mouse and bovine receptor. These
α
2A orthologues are sometimes referred to as α
2D‐adrenoceptors. Multiple mutations of α
2‐adrenoceptors have been described, some of which are associated with
alterations in function. Presynaptic α
2‐adrenoceptors are widespread in the nervous system and regulate many
functions, hence the multiplicity of actions. The effects of classical (not
subtype selective) α
2‐adrenoceptor agonists such as clonidine, guanabenz and brimonidine on central
baroreflex control (hypotension and bradycardia), as well as their ability to
induce hypnotic effects and analgesia, and their ability to modulate seizure
activity and platelet aggregation are mediated by α
2A‐adrenoceptors. Clonidine has been used as
an anti‐hypertensive and also to counteract opioid withdrawal. Actions on
imidazoline recognition sites may contribute to the pharmacological effects of
clonidine. α
2‐Adrenoceptor agonists such as dexmedetomidine have been
widely used as sedatives and analgesics in veterinary medicine (also xylazine) and are now used
frequently in humans. Dexmedetomidine also has analgesic, sympatholytic and
anxiolytic properties but is notable for the production of sedation without
respiratory depression. α
2‐Adrenoceptor antagonists are relatively little used therapeutically
although yohimbine has been used to
treat erectile dysfunction and several anti‐depressants (e.g. Mirtazapine) that block
α
2‐adrenoceptors may work through this mechanism. The roles of
α
2B and α
2C‐adrenoceptors are less clear but the α
2B subtype appears to be involved in neurotransmission in the spinal
cord and α
2C in regulating catecholamine release from adrenal chromaffin
cells.


Nomenclature	
α2A‐adrenoceptor
	
α2B‐adrenoceptor
	
α2C‐adrenoceptor
	
HGNC,
UniProt	
ADRA2A, P08913
	
ADRA2B, P18089
	
ADRA2C, P18825
	
Endogenous
agonists	
(‐)‐adrenaline (pK
i 5.6–8.3) [854,
1503]	
(‐)‐noradrenaline (Partial agonist)
(pK
i 5.6–9.1) [854,
1484,
1503]	
(‐)‐noradrenaline (pK
i 5.9–8.7) [854,
1484,
1503]	
Agonists	
dexmedetomidine (Partial agonist)
(pK
i 7.6–9.6) [854,
1163,
1484,
1503],
clonidine
(Partial agonist) (pK
i 7.2–9.2) [854,
1484,
1503],
brimonidine
(pK
i 6.7–8.7) [854,
1163,
1484,
1503],
apraclonidine
(pK
i 8.5) [1343],
guanabenz
(pIC50 7.4) [68], guanfacine
(Partial agonist) (pK
i 7.1–7.3) [854,
1165]	
dexmedetomidine (pK
i 7.5–9.7) [854,
1163,
1484,
1503],
clonidine
(Partial agonist) (pK
i 6.7–9.5) [854,
1484,
1503],
brimonidine
(Partial agonist) (pK
i 6–8.3) [854,
1484,
1503],
guanabenz
(pIC50 6.8) [68], guanfacine
(pK
i 5.8–6.5) [854]	
dexmedetomidine (pK
i 7–9.3) [854,
1484,
1503],
brimonidine
(Partial agonist) (pK
i 5.7–7.6) [854,
1163,
1484,
1503],
apraclonidine
(pK
i 7.5) [1343],
guanfacine
(Partial agonist) (pK
i 5.4–6.2) [854],
guanabenz
(pIC50 6) [68]	
Selective
agonists	
oxymetazoline
(Partial agonist) (pK
i 8–8.6) [854,
1163,
1922]	–	–	
Antagonists	
yohimbine
(pK
i 8.5–9.5) [247,
416,
1922],
WB 4101
(pK
i 8.4–9.4) [247,
416,
1922],
spiroxatrine
(pK
i 9) [1922],
mirtazapine
(pK
i 7.7) [513],
tolazoline
(pK
i 5.4) [854]	
yohimbine
(pK
i 8.4–9.2) [247,
416,
1922]	
yohimbine
(pK
i 7.9–8.9) [247,
416,
1922],
phenoxybenzamine (pK
i 8.5) [2002],
tolazoline
(pK
i 5.5) [854]	
Selective
antagonists	
BRL 44408
(pK
i 8.2–8.8) [1922,
2104]	
imiloxan
(pK
i 7.3) [1269] –
Rat	
JP1302
(pK
B 7.8) [1631]	
Labelled
ligands	–	–	
[3H]MK‐912 (Antagonist)
(pK
d 10.1) [1922]	




Adrenoceptors, β


β‐Adrenoceptors (nomenclature as agreed by the NC‐IUPHAR Subcommittee on
Adrenoceptors, [
248
]) are activated by the endogenous agonists (‐)‐adrenaline and (‐)‐noradrenaline. Isoprenaline is a synthetic
agonist selective for β‐adrenoceptors relative to
α
1‐ and α
2‐adrenoceptors, while for β
1 and β
2 adrenoceptors, propranolol(pKi8.2‐9.2) and cyanopindolol(pKi
10.0‐11.0) are relatively selective antagonists. (‐)‐noradrenaline, xamoterol and (‐)‐Ro 363 are agonists that
show selectivity for β
1‐ relative to β
2‐adrenoceptors. Pharmacological differences exist between human and
mouse β
3‐adrenoceptors, and the 'rodent selective' agonists BRL 37344 and CL316243 have low efficacy
at the human β
3‐adrenoceptor whereas CGP 12177 and L 755507 activate human
β
3‐adrenoceptors [1649]. β
3‐Adrenoceptors are relatively resistant to blockade by propranolol(pKi5.8‐7.0), but can be blocked by high
concentrations of bupranolol(pKi8.65 [1650]). SR59230A has reasonably high
affinity at β
3‐adrenoceptors [1197], but does not
discriminate well between the three β‐adrenoceptor subtypes
[262] and has been reported
to have lower affinity for the β
3‐adrenoceptor in some circumstances [913]. L‐748337 is the most
selective antagonist for β
3 adrenoceptors. [125I]‐cyanopindolol,
[125I]‐hydroxybenzylpindolol and [3H]‐alprenolol are high affinity
radioligands widely used to label β
1‐ and β
2‐adrenoceptors and β
3‐adrenoceptors can be labelled with higher concentrations (nM) of
[125I]‐cyanopindolol in the presence of appropriate concentrations
of β
1‐ and β
2‐adrenoceptor antagonists. [3H]L‐748337 is a
β
3‐selective radioligand. Fluorescent ligands such as
BODIPY‐TMR‐CGP12177 are also increasingly being used to track
β‐adrenoceptors at the cellular level [86]. Somewhat selective
β
1‐adrenoceptor selective agonists (denopamine, dobutamine) are used
short‐term to treat cardiogenic shock but, in the longer term, reduce survival.
β
1‐Adrenoceptor‐preferring antagonists are used to treat hypertension
(atenolol, betaxolol, bisoprolol, metoprolol and nebivolol), cardiac
arrhythmias (atenolol, bisoprolol,
esmolol) and cardiac failure
(metoprolol, nebivolol).
Cardiac failure is also succesfully treated with carvedilol which blocks both
β
1‐ and β
2‐adrenoceptors, as well as α
1‐adrenoceptors. β
2‐Adrenoceptor‐selective agonists are powerful bronchodilators widely
used to treat respiratory disorders. There are both short (salbutamol, terbutaline) and long acting
drugs (formoterol, salmeterol). Although many
first generation β‐adrenoceptor antagonists (propranolol) block both
β
1‐ and β
2‐adrenoceptors there are no β
2‐adrenoceptor‐selective antagonists used therapeutically. The
β
3‐adrenoceptor agonist mirabegron is used to
control overactive bladder syndrome.


Nomenclature	
β1‐adrenoceptor
	
β2‐adrenoceptor
	
β3‐adrenoceptor
	
HGNC,
UniProt	
ADRB1, P08588
	
ADRB2, P07550
	
ADRB3, P13945
	
Rank order of
potency	
(‐)‐noradrenaline>(‐)‐adrenaline
	
(‐)‐adrenaline>(‐)‐noradrenaline
	
(‐)‐noradrenaline = (‐)‐adrenaline
	
Endogenous
agonists	
noradrenaline
(pK
i 6) [549]	–	–	
Agonists	
pindolol
(Partial agonist) (pK
i 9.3) [1011],
isoprenaline
(pK
i 6.6–7) [549,
1651],
dobutamine
(Partial agonist) (pK
i 5.5) [831]	
pindolol
(Partial agonist) (pK
i 9.4) [1011],
arformoterol
(pK
i 8.6) [37],
isoprenaline
(pK
i 6.4) [1651],
dobutamine
(Partial agonist) (pK
i 6.2) [1100],
ephedrine
(Partial agonist) (pK
i 5.6) [851]	
carazolol
(pK
i 8.7) [1256]	
Selective
agonists	
(‐)‐Ro 363
(pK
i 8) [1301],
xamoterol
(Partial agonist) (pK
i 7) [831],
denopamine
(Partial agonist) (pK
i 5.8) [831,
1830]	
formoterol
(pEC50 10.1) [81],
salmeterol
(pEC50 9.9) [81],
zinterol
(pEC50 9.5) [81],
vilanterol
(pEC50 9.4) [1534],
procaterol
(pEC50 8.4) [81],
indacaterol
(pK
i 7.8) [107],
fenoterol
(pK
i 6.9) [55],
salbutamol
(Partial agonist) (pK
i 5.8–6.1) [83, 831],
terbutaline
(Partial agonist) (pK
i 5.6) [83],
orciprenaline
(pK
d 5.3) [1784]	
L 755507
(pEC50 10.1) [81],
L742791
(pEC50 8.8) [2000],
mirabegron
(pEC50 7.7) [1849],
CGP 12177
(Partial agonist) (pK
i 6.1–7.3) [159,
1144,
1256,
1301],
SB251023
(pEC50 7.1) [810] – Mouse,
BRL 37344
(pK
i 6.4–7) [159,
431,
768,
1256],
CL316243
(pK
i 5.2) [2080]	
Antagonists	
carvedilol
(pK
i 9.5) [262],
bupranolol
(pK
i 7.3–9) [262,
1144],
levobunolol
(pK
i 8.4) [68], labetalol
(pK
i 8.2) [68], metoprolol
(pK
i 7–7.6) [83, 262,
768,
1144],
esmolol
(pK
i 6.9) [68], nadolol
(pK
i 6.9) [262],
practolol
(pK
i 6.1–6.8) [83, 1144],
propafenone
(pK
i 6.7) [68], sotalol
(pK
i 6.1) [68]	
carvedilol
(pK
i 9.4–9.9) [83, 262],
timolol
(pK
i 9.7) [83],
propranolol
(pK
i 9.1–9.5) [83, 86, 831,
1144],
levobunolol
(pK
i 9.3) [68], bupranolol
(pK
i 8.3–9.1) [262,
1144],
alprenolol
(pK
i 9) [83],
nadolol
(pK
i 7–8.6) [83, 262],
labetalol
(pK
i 8) [68], propafenone
(pK
i 7.4) [68], sotalol
(pK
i 6.5) [68]	
carvedilol
(pK
i 9.4) [262],
bupranolol
(pK
i 6.8–7.3) [159,
262,
1144,
1256],
propranolol
(pK
i 6.3–7.2) [1144,
1517],
levobunolol
(pK
i 6.8) [1517]	
Selective
antagonists	
CGP 20712A
(pK
i 8.5–9.2) [83, 262,
1144],
levobetaxolol
(pK
i 9.1) [1715],
betaxolol
(pK
i 8.8) [1144],
nebivolol
(pIC50 8.1–8.7) [1476] –
Rabbit, atenolol
(pK
i 6.7–7.6) [83, 886,
1144],
acebutolol
(pK
i 6.4) [68]	
ICI 118551
(Inverse agonist) (pK
i 9.2–9.5) [83, 86, 1144]	
L‐748337
(pK
i 8.4) [262],
SR59230A
(pK
i 6.9–8.4) [262,
405,
768],
L748328
(pK
i 8.4) [262]	
Labelled
ligands	
[125I]ICYP (Selective Antagonist)
(pK
d 10.4–11.3) [831,
1144,
1651]	
[125I]ICYP (Antagonist)
(pK
d 11.1) [1144,
1651]	
[125I]ICYP (Agonist, Partial agonist)
(pK
d 9.2–9.8) [1144,
1301,
1517,
1651,
1806]	
Comments	The agonists
indicated have less than two orders of magnitude selectivity
[81].	–	Agonist
SB251023 has
a pEC50 of 6.9 for the splice variant of the mouse
β
3 receptor, β
3b [810].	



Comments

Adrenoceptors, α1

The clone originally called the
α
1C‐adrenoceptor corresponds to the pharmacologically defined
α
1A‐adrenoceptor [752]. Some tissues possess
α
1A‐adrenoceptors (termed α
1L‐adrenoceptors [532, 1329]) that display
relatively low affinity in functional and binding assays for prazosin(pKi< 9) indicative of different receptor states or locations.
α
1A‐adrenoceptor C‐terminal splice variants form homo‐ and heterodimers,
but fail to generate a functional α
1L‐adrenoceptor [1557]. α
1D‐Adrenoceptors form heterodimers with α
1B‐ or β
2‐adrenoceptors that show increased cell‐surface expression [1917]. Recombinant
α
1D‐adrenoceptors have been shown in some heterologous systems to be
mainly located intracellularly but cell‐surface localization is attained by
truncation of the N‐terminus, or by co‐expression of α
1B‐ or β
2‐adrenoceptors to form heterodimers [670, 1917]. In smooth muscle of
native blood vessels all three α
1‐adrenoceptor subtypes are located on the surface and intracellularly
[1260, 1261].

Signalling is predominantly via
Gq/11 but α
1‐adrenoceptors also couple to Gi/o, Gs and
G12/13. Several ligands activating α
1A‐adrenoceptors display ligand directed signalling bias relative to
noradrenaline. For example, oxymetazoline is a full
agonist for extracellular acidification rate (ECAR) and a partial agonist for
Ca2+ release but does not stimulate cAMP production. Phenylephrine is biased
toward ECAR versus Ca2+ release or cAMP accumulation but not between
Ca2+ release and cAMP accumulation [495]. There are also
differences between subtypes in coupling efficiency to different pathways‐
e.g. in some systems coupling efficiency to Ca2+
signalling is α
1A>α
1B>α
1D, but for MAP kinase signalling is α
1D>α
1A>α
1B. In vascular smooth muscle, the potency of agonists is related to
the predominant subtype, α
1D‐ conveying greater agonist sensitivity than α
1A‐adrenoceptors [526].


Adrenoceptors, α2


ARC‐239(pKi 8.0)
and prazosin(pKi 7.5)
show selectivity for α
2B‐ and α
2C‐adrenoceptors over α
2A‐adrenoceptors.Oxymetazoline is a reduced
efficacy agonist and is one of many α
2‐adrenoceptor agonists that are imidazolines or closely related
compounds. Other binding sites for imidazolines, distinct from α
2‐adrenoceptors, and structurally distinct from the 7TM adrenoceptors,
have been identified and classified as I1, I2 and
I3sites [390]; catecholamines have a
low affinity, while rilmenidine and moxonidine are selective ligands for these
sites, evoking hypotensive effects in vivo.
I1‐imidazoline receptors are involved in central inhibition of
sympathetic tone, I2‐imidazoline receptors are an allosteric binding
site on monoamine oxidase B, and I3‐imidazoline receptors regulate
insulin secretion from pancreatic β‐cells. α
2A‐adrenoceptor stimulation reduces insulin secretion from
β‐islets [2083], with a polymorphism
in the 5'‐UTR of the ADRA2A gene being associated with increased receptor
expression in β‐islets and heightened susceptibility to
diabetes [1599].


α
2A‐ and α
2C‐adrenoceptors form homodimers [1758]. Heterodimers between
α
2A‐ and either the α
2c‐adrenoceptor or μ opioid peptide receptor exhibit
altered signalling and trafficking properties compared to the individual receptors
[1758, 1858, 1956]. Signalling by
α
2‐adrenoceptors is primarily via Gi/o, however the
α
2A‐adrenoceptor also couples to Gs[459]. Imidazoline compounds
display bias relative to each other at the α
2A‐adrenoceptor when assayed by [35S] GTPγS
binding compared to inhibition of cAMP accumulation [1477]. The noradrenaline
reuptake inhibitor desipramine acts directly on the α
2A‐adrenoceptor, promoting internalisation via
recruitment of arrestin without activating G proteins [371].


Adrenoceptors, β

Radioligand binding with [125I]ICYP can be
used to define β
1‐ or β
2‐adrenoceptors when conducted in the presence of a 'saturating'
concentration of either a β
1‐ or β
2‐adrenoceptor‐selective antagonist. [3H]CGP12177 or
[3H]dihydroalprenolol can be used in place of [125I]ICYP.
Binding of a fluorescent analogue of CGP 12177 to
β
2‐adrenoceptors in living cells has been described [84]. [125I]ICYP at
higher (nM) concentrations can be used to label β
3‐adrenoceptors in systems where there are few if any other
β‐adrenoceptor subtypes. Pharmacological differences exist
between human and mouse β
3‐adrenoceptors, and the 'rodent selective' agonists BRL 37344 and CL316243 are partial
agonists at the human β
3‐adrenoceptor whereas CGP 12177 and L 755507 activate human
β3‐adrenoceptors with greater potency [1650]. The
β
3‐adrenoceptor has an intron in the coding region, but splice variants
have only been described for the mouse [496], where the isoforms
display different signalling characteristics [810]. There are 3
β‐adrenoceptors in turkey (termed the tβ,
tβ3c and tβ4c) that have a pharmacology that
differs from the human β‐adrenoceptors [82]. Numerous polymorphisms
have been described for the three β‐adrenoceptors; some are
associated with alterations in agonist‐evoked signalling and trafficking, altered
susceptibility to disease and/or altered responses to pharmacotherapy [1103].

All β‐adrenoceptors couple
to Gs(activating adenylyl cyclase and elevating cAMP levels), but it is
also clear that they activate other G proteins such as Gi and many
other G protein‐independent signalling pathways, including arrestin‐mediated
signalling, which may in turn lead to activation of MAP kinases. Many antagonists
at β
1‐ and β
2‐adrenoceptors are agonists at β
3‐adrenoceptors (CL316243, CGP 12177 and carazolol). Many
‘antagonists’ that block agonist‐stimulated cAMP accumulation, for example
carvedilol and bucindolol,
are able to activate MAP kinase pathways [85, 497, 559, 560, 1649, 1650] and thus display
'protean agonism'. Bupranolol appears to act as
a neutral antagonist in most systems so far examined. Agonists also display biased
signalling at the β
2‐adrenoceptor via Gs or arrestins [443].

The X‐ray crystal structures have been
described of the agonist bound [1988] and antagonist bound
forms of the β
1‐ [1989], agonist‐bound
[313] and antagonist‐bound
forms of the β
2‐adrenoceptor [1561, 1598], as well as a fully
active agonist‐bound, Gs protein‐coupled β
2‐adrenoceptor [1562]. Carvedilol and bucindolol
bind to an extended site of the β
1‐adrenoceptor involving contacts in TM2, 3, and 7 and extracellular
loop 2 that may facilitate coupling to arrestins [1989]. Compounds displaying
arrestin‐biased signalling at the β
2‐adrenoceptor also have a greater effect on the conformation of TM7,
whereas full agonists for Gs coupling promote movement of TM5 and TM6
[1127]. Recent studies using
NMR spectroscopy have demonstrated significant conformational flexibility in the
β
2‐adrenoceptor which is stabilized by both agonist and G proteins
highlighting the dynamic nature of interactions with both ligand and downstream
signalling partners [946, 1199, 1413]. Such flexibility will
likely have consequences for our understanding of biased agonism, and for the
future therapeutic exploitation of this phenomenon.

Further Reading
Baker JG et al. (2011)
Evolution of β‐blockers: from anti‐anginal drugs to ligand‐directed
signalling. Trends Pharmacol. Sci.
32: 227‐34 [PMID:21429598]


Bylund DB et al. (1994)
International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol.
Rev.
46: 121‐136 [PMID:7938162]


Cazzola M et al. (2011)
β(2) ‐adrenoceptor agonists: current and future direction.
Br. J. Pharmacol.
163: 4‐17 [PMID:21232045]


Daly CJ et al. (2011)
Previously unsuspected widespread cellular and tissue distribution of
β‐adrenoceptors and its relevance to drug action. Trends
Pharmacol. Sci.
32: 219‐26 [PMID:21429599]


Evans BA et al. (2010)
Ligand‐directed signalling at beta‐adrenoceptors. Br. J. Pharmacol.
159: 1022‐38 [PMID:20132209]


Gilsbach R et al. (2012) Are
the pharmacology and physiology of α_2 adrenoceptors determined by
α_2‐heteroreceptors and autoreceptors respectively? Br.
J. Pharmacol.
165: 90‐102 [PMID:21658028]


Jensen BC et al. (2011)
Alpha‐1‐adrenergic receptors: targets for agonist drugs to treat heart failure.
J. Mol. Cell. Cardiol.
51: 518‐28 [PMID:21118696]


Kobilka BK. (2011) Structural insights into
adrenergic receptor function and pharmacology. Trends Pharmacol.
Sci.
32: 213‐8 [PMID:21414670]


Langer SZ. (2015)
α2‐Adrenoceptors in the treatment of major neuropsychiatric
disorders. Trends Pharmacol. Sci.
36: 196‐202 [PMID:25771972]


McGrath JC. (2015) Localization of
α‐adrenoceptors: JR Vane Medal Lecture. Br. J.
Pharmacol.
172: 1179‐94 [PMID:25377869]


Michel MC et al. (2011) Are
there functional β_3‐adrenoceptors in the human heart? Br.
J. Pharmacol.
162: 817‐22 [PMID:20735409]


Michel MC et al. (2011)
β‐adrenoceptor agonist effects in experimental models of bladder
dysfunction. Pharmacol. Ther.
131: 40‐9 [PMID:21510978]


Michel MC et al. (2015)
Selectivity of pharmacological tools: implications for use in cell physiology. A
review in the theme: Cell signaling: proteins, pathways and mechanisms. Am.
J. Physiol., Cell Physiol.
308: C505‐20 [PMID:25631871]


Nishimune A et al. (2012)
Phenotype pharmacology of lower urinary tract α(1)‐adrenoceptors.
Br. J. Pharmacol.
165: 1226‐34 [PMID:21745191]


Vasudevan NT et al. (2011)
Regulation of β‐adrenergic receptor function: an emphasis on
receptor resensitization. Cell Cycle
10: 3684‐91 [PMID:22041711]


Walker JK et al. (2011) New
perspectives regarding β(2) ‐adrenoceptor ligands in the treatment
of asthma. Br. J. Pharmacol.
163: 18‐28 [PMID:21175591]
Angiotensin receptors



Angiotensin receptors

Overview
The actions of angiotensin II (AGT, P01019) (Ang II) are mediated
by AT1 and AT2 receptors (nomenclature as agreed by the
NC‐IUPHAR Subcommittee on
Angiotensin Receptors [
2137
]), which have around 30% sequence similarity. Endogenous ligands are
angiotensin II(AGT, P01019) and angiotensin III(AGT, P01019) (Ang III), while
angiotensin I(AGT, P01019) is weakly active in
some systems.


Nomenclature	
AT1
receptor
	
AT2
receptor
	
HGNC, UniProt	
AGTR1, P30556
	
AGTR2, P50052
	
Selective
agonists	
L‐162,313
(pIC50 7.8–7.9) [1490]	
CGP42112
(pIC50 9.6) [190], [p‐aminoPhe6]ang
II (pK
d 9.1–9.4) [1789, 2139] –
Rat	
Antagonists	
telmisartan
(pIC50 8.4) [1241], olmesartan
(pIC50 8.1) [981]	–	
Selective
antagonists	
candesartan
(pIC50 9.5–9.7) [1942], EXP3174
(pIC50 7.4–9.5) [1887, 1942], eprosartan
(pIC50 8.4–8.8) [464], irbesartan
(pIC50 8.7–8.8) [1942], losartan
(pIC50 7.4–8.7) [1887, 2139],
valsartan
(pIC50 8.6) [2138], azilsartan
(pIC50 8.1–8.1) [1551, 1844]	
PD123177
(pIC50 8.5–9.5) [291, 321, 450] – Rat,
EMA401
(pIC50 8.5–9.3) [518, 1582, 1767], PD123319
(pK
d 8.7–9.2) [449, 2025, 2139]	
Labelled
ligands	
[3H]A81988 (Antagonist) (pK
d 9.2) [690] – Rat,
[3H]L158809 (Antagonist)
(pK
d 9.2) [305] – Rat,
[3H]eprosartan (Antagonist)
(pK
d 9.1) [21] – Rat,
[3H]valsartan (Antagonist) (pIC50
8.8–9) [1954], [125I]EXP985 (Antagonist)
(pK
d 8.8) [322] – Rat,
[3H]losartan (Antagonist)
(pK
d 8.2) [294] – Rat	
[125I]CGP42112 (Agonist)
(pK
d 10.6) [2017, 2018, 2139]	



Comments
AT1 receptors are predominantly
coupled to Gq/11, however they are also linked to arrestin recruitment and
stimulate G protein‐independent arrestin signalling [1156]. Most species express a
single AGTR1 gene, but two related agtr1a and
agtr1b receptor genes are expressed in rodents. The
AT2 receptor counteracts several of the growth responses initiated by
the AT1 receptors. The AT2 receptor is much less abundant than
the AT1 receptor in adult tissues and is upregulated in pathological
conditions. AT1 receptor antagonists bearing substituted 4‐phenylquinoline
moieties have been synthesized, which bind to AT1 receptors with nanomolar
affinity and are slightly more potent than losartan in functional studies
[264]. The antagonist activity
of CGP42112 at the AT2
receptor has also been reported [2147].

The AT1 and bradykinin B2 receptors
have been proposed to form a heterodimeric complex [3].

There is also evidence for an AT4
receptor that specifically binds angiotensin IV (AGT, P01019) and is located in the
brain and kidney. An additional putative endogenous ligand for the AT4
receptor has been described (LVV‐hemorphin(HBB, P68871), a globin decapeptide)
[1296].

Further Reading
Ellis B et al. (2012) Evidence
for a functional intracellular angiotensin system in the proximal tubule of the
kidney. Am. J. Physiol. Regul. Integr. Comp. Physiol.
302: R494‐509 [PMID:22170616]


Karnik SS et al. (2015)
International Union of Pharmacology. LXXXIX. Angiotensin Receptors: Interpreters of
pathophysiological angiotensinergic stimuli. Pharmacological Reviews


MacKenzie A. (2011) Endothelium‐derived
vasoactive agents, AT1 receptors and inflammation. Pharmacol. Ther.
131: 187‐203 [PMID:21115037]


Patel BM et al. (2012)
Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases.
Eur. J. Pharmacol.
697: 1‐12 [PMID:23041273]


Putnam K et al. (2012) The
renin‐angiotensin system: a target of and contributor to dyslipidemias, altered
glucose homeostasis, and hypertension of the metabolic syndrome. Am. J.
Physiol. Heart Circ. Physiol.
302: H1219‐30 [PMID:22227126]


Sevá Pessôa B et al. (2013)
Key developments in renin‐angiotensin‐aldosterone system inhibition. Nat Rev
Nephrol
9: 26‐36 [PMID:23165302]


Zhang H et al. (2015)
Structure of the Angiotensin receptor revealed by serial femtosecond crystallography.
Cell
161: 833‐44 [PMID:25913193]


de Gasparo M et al. (2000)
International Union of Pharmacology. XXIII. The angiotensin II receptors.
Pharmacol. Rev.
52: 415‐472 [PMID:10977869]



Apelin receptor

Overview
The apelin receptor (nomenclature as
agreed by the NC‐IUPHAR
Subcommittee on the apelin receptor [
1510
]) responds to apelin, a 36 amino‐acid peptide derived initially from
bovine stomach. Apelin‐36(APLN, Q9ULZ1), apelin‐13(APLN, Q9ULZ1) and [Pyr1]apelin‐13(APLN, Q9ULZ1) are the predominant
endogenous ligands which are cleaved from a 77 amino‐acid precursor peptide
(APLN, Q9ULZ1) by a so far
unidentified enzymatic pathway [1864]. A second family of
peptides discovered independently and named Elabela [323] or Toddler, that has
little sequence similarity to apelin, has been proposed as a second endogenous apelin
receptor ligand [1475].


Nomenclature	
apelin receptor
	
HGNC, UniProt	
APLNR, P35414
	
Rank order of
potency	
[Pyr1]apelin‐13 (APLN, Q9ULZ1)
≥apelin‐13
(APLN, Q9ULZ1)
>apelin‐36
(APLN, Q9ULZ1)
[503, 1864]	
Endogenous
agonists	
apelin‐13
(APLN, Q9ULZ1)
(Selective) (pIC50 8.8–9.5) [503, 785, 1254], apelin receptor early
endogenous ligand (APELA, P0DMC3)
(Selective) (pK
d 9.3) [412], apelin‐17
(APLN, Q9ULZ1)
(Selective) (pIC50 7.9–9) [468, 1254], [Pyr1]apelin‐13 (APLN, Q9ULZ1)
(Selective) (pIC50 7–8.8) [918, 1254], Elabela/Toddler‐21 (APELA, P0DMC3)
(pIC50 8.7) [2086], Elabela/Toddler‐32 (APELA, P0DMC3)
(pIC50 8.7) [2086], apelin‐36
(APLN, Q9ULZ1)
(Selective) (pIC50 8.2–8.6) [503, 785, 918, 1254], Elabela/Toddler‐11 (APELA, P0DMC3)
(pIC50 7.2) [2086]	
Selective
agonists	
MM07 (Biased
agonist) (pEC50 9.5) [203]	
Antagonists	
MM54
(pK
i 8.2) [1166]	
Labelled
ligands	
[125I][Nle75,Tyr77]apelin‐36
(human) (Agonist) (pK
d 11.2) [918], [125I][Glp65Nle75,Tyr77]apelin‐13
(Agonist) (pK
d 10.7) [785], [125I](Pyr1)apelin‐13
(Agonist) (pK
d 9.5) [911], [125I]apelin‐13 (Agonist)
(pK
d 9.2) [503], [3H](Pyr1)[Met(0)11]‐apelin‐13
(Agonist) (pK
d 8.6) [1254]	



Comments
Potency order determined for heterologously
expressed human apelin receptor (pD
2 values range from 9.5 to 8.6). The apelin receptor may also act as a
co‐receptor with CD4 for isolates of human immunodeficiency virus, with apelin
blocking this function [279]. A modified apelin‐13
peptide, apelin‐13(F13A) was reported to
block the hypotensive response to apelin in rat in vivo[1067], however, this peptide
exhibits agonist activity in HEK293 cells stably expressing the recombinant apelin
receptor [503].

Further Reading
Chandrasekaran B et al. (2008)
The role of apelin in cardiovascular function and heart failure. Eur. J.
Heart Fail.
10: 725‐32 [PMID:18583184]


Cheng B et al. (2012)
Neuroprotection of apelin and its signaling pathway. Peptides
37: 171‐3 [PMID:22820556]


Davenport AP et al. (2007)
Apelins. In Encyclopedic Reference of Molecular Pharmacology Edited
by Offermanns S, Rosenthal W: Springer: 201‐206

Japp AG et al. (2008) The
apelin‐APJ system in heart failure: pathophysiologic relevance and therapeutic
potential. Biochem. Pharmacol.
75: 1882‐92 [PMID:18272138]


Langelaan DN et al. (2009)
Structural insight into G‐protein coupled receptor binding by apelin.
Biochemistry
48: 537‐48 [PMID:19123778]


O'Carroll AM et al. (2013) The
apelin receptor APJ: journey from an orphan to a multifaceted regulator of
homeostasis. J. Endocrinol.
219: R13‐35 [PMID:23943882]


Pitkin SL et al. (2010)
International Union of Basic and Clinical Pharmacology. LXXIV. Apelin receptor
nomenclature, distribution, pharmacology, and function. Pharmacol.
Rev.
62: 331‐42 [PMID:20605969]


Yang P et al. (2015) Apelin,
Elabela/Toddler, and biased agonists as novel therapeutic agents in the
cardiovascular system. Trends Pharmacol. Sci.
[PMID:26143239]



Bile acid receptor

Overview
The bile acid receptor (GPBA) responds to bile
acids produced during the liver metabolism of cholesterol. Selective agonists
are promising drugs for the treatment of metabolic disorders, such as type II
diabetes, obesity and atherosclerosis.


Nomenclature	
GPBA receptor
	
HGNC, UniProt	
GPBAR1, Q8TDU6
	
Rank order of
potency	
lithocholic
acid>deoxycholic
acid>chenodeoxycholic
acid, cholic acid
(Unknown) [917, 1214]	
Selective
agonists	
betulinic acid
(pEC50 6) [590], oleanolic acid
(pEC50 5.7) [1648]	



Comments
The triterpenoid natural product betulinic acid has also been
reported to inhibit inflammatory signalling through the NFκB pathway
[1842]. Disruption of GPBA
expression is reported to protect from cholesterol gallstone formation [1951]. A new series of
5‐phenoxy‐1,3‐dimethyl‐1H‐pyrazole‐4‐carboxamides have been reported as highly potent
agonists [1138].

Further Reading
Duboc H et al. (2014) The bile
acid TGR5 membrane receptor: from basic research to clinical application. Dig
Liver Dis
46: 302‐12 [PMID:24411485]


Fiorucci S et al. (2010) Bile
acid‐activated receptors in the treatment of dyslipidemia and related disorders.
Prog. Lipid Res.
49: 171‐85 [PMID:19932133]


Fiorucci S et al. (2009)
Bile‐acid‐activated receptors: targeting TGR5 and farnesoid‐X‐receptor in lipid and
glucose disorders. Trends Pharmacol. Sci.
30: 570‐80 [PMID:19758712]


Keitel V et al. (2012)
Perspective: TGR5 (Gpbar‐1) in liver physiology and disease. Clin Res Hepatol
Gastroenterol
36: 412‐9 [PMID:22521118]


Lefebvre P et al. (2009) Role
of bile acids and bile acid receptors in metabolic regulation. Physiol.
Rev.
89: 147‐91 [PMID:19126757]


Lieu T et al. (2014) GPBA: a
GPCR for bile acids and an emerging therapeutic target for disorders of digestion and
sensation. Br. J. Pharmacol.
171: 1156‐66 [PMID:24111923]


Pols TW et al. (2011) The bile
acid membrane receptor TGR5 as an emerging target in metabolism and inflammation.
J. Hepatol.
54: 1263‐72 [PMID:21145931]


Tiwari A et al. (2009) TGR5:
an emerging bile acid G‐protein‐coupled receptor target for the potential treatment
of metabolic disorders. Drug Discov. Today
14: 523‐30 [PMID:19429513]



Bombesin receptors

Overview
Bombesin receptors (nomenclature
recommended by the NC‐IUPHAR Subcommittee on bombesin receptors, [
857
]) are activated by the endogenous ligands gastrin‐releasing
peptide(GRP, P07492) (GRP), neuromedin B(NMB, P08949) (NMB) and GRP‐(18‐27)(GRP, P07492) (previously named
neuromedin C). Bombesin is a tetradecapeptide,
originally derived from amphibians, and is an agonist at BB1 and
BB2 receptors. These receptors couple primarily to the Gq/11
family of G proteins (but see also [857]). Each of these receptors
is widely distributed in the CNS and peripheral tissues [625, 857, 1556, 1642]. Activation of
BB1 and BB2 receptors causes a wide range of physiological
actions, including the stimulation of normal and neoplastic tissue growth,
smooth‐muscle contraction, appetite and feeding behavior, secretion and many central
nervous system effects [857, 858, 859, 1185, 1317, 1556]. A physiological role for
the BB3 receptor has yet to be fully defined although recently studies
using receptor knockout mice and newly described agonists/antagonists suggest an
important role in glucose and insulin regulation, metabolic homeostasis, feeding and
other CNS behaviors and growth of normal/neoplastic tissues [625, 1186, 1430].


Nomenclature	
BB1
receptor
	
BB2
receptor
	
BB3
receptor
	
HGNC, UniProt	
NMBR, P28336
	
GRPR, P30550
	
BRS3, P32247
	
Endogenous
agonists	
neuromedin B
(NMB, P08949)
(Selective) (pK
i 8.1–10.3) [857, 1556, 1919]	
neuromedin C
(pIC50 9.9) [1919], gastrin releasing
peptide(14‐27) (human) (Selective) (pIC50
9.7–9.8) [1919]	–	
Selective
agonists	–	–	
compound 8a [PMID:
24900283] (pIC50 8.9) [1129], compound 9g [PMID:
24412111] (pEC50 8.8) [1220], MK‐7725
(pIC50 8.5) [324], MK‐5046
(pK
i 7.7–8.4) [1321, 1689], [D‐Tyr6,Apa‐4Cl11,Phe13,Nle14]bombesin‐(6‐14)
(pK
i 8.1) [1202], compound 17c [PMID:
25497965] (pEC50 7.9) [1219], compound 9f [PMID:
24412111] (pEC50 7.8) [1220], bag‐1
(pIC50 7.7) [659], compound 22e [PMID:
20167483] (pIC50 7.6) [727], bag‐2
(pIC50 7) [659]	
Antagonists	
D‐Nal‐Cys‐Tyr‐D‐Trp‐Lys‐Val‐Cys‐Nal‐NH2 (pIC50 6.2–6.6) [624]	–	–	
Selective
antagonists	
PD 176252
(pIC50 9.3–9.8) [624], PD 168368
(pIC50 9.3–9.6) [624], dNal‐cyc(Cys‐Tyr‐dTrp‐Orn‐Val)‐Nal‐NH2
	
[D‐Phe6,
Leu13,
Cpa14,ψ13‐14]bombesin‐(6‐14)
(pK
i 9.8) [624], JMV641
(pIC50 9.3) [1892] – Mouse,
[(3‐Ph‐Pr6),
His7,D‐Ala11,D‐Pro13,ψ13‐14),Phe14]
bombesin‐(6‐14) (pIC50 9.2) [624, 1062], [D‐Tpi6,
Leu13ψ(CH2NH)‐Leu14]bombesin‐(6‐14)
(pIC50 8.9) [624], Ac‐GRP‐(20‐26)‐methylester (pIC50 8.7)
[624], JMV594
(pIC50 8.7–8.7) [1133, 1892] –
Mouse	
bantag‐1
(pIC50 8.6–8.7) [659, 1321], ML‐18
(pIC50 5.3) [1316]	
Labelled
ligands	
[125I]BH‐NMB
(human, mouse, rat) (Agonist), [125I][Tyr4]bombesin
(Agonist)	
[125I][D‐Tyr6]bombesin‐(6‐13)‐methyl
ester (Selective Antagonist) (pK
d 9.3) [1201] – Mouse,
[125I][Tyr4]bombesin (Agonist)
(pK
d 8.2) [131], [125I]GRP
(human) (Agonist)	
[3H]bag‐2 (Agonist) (pK
d 8.6) [659] – Mouse,
[125I][D‐Tyr6,β‐Ala11,Phe13,Nle14]bombesin‐(6‐14)
(Agonist) (pK
d 8–8.4) [1203, 1321]	



Comments
All three subtypes may be activated by
[D‐Phe6,β‐Ala11,Phe13,Nle14]bombesin‐(6‐14)[1203]. [D‐Tyr6,Apa‐4Cl11,Phe13,Nle14]bombesin‐(6‐14)
has more than 200‐fold selectivity for BB3 receptors over BB1
and BB2[1202].

Further Reading
Gonzalez N et al. (2008)
Bombesin‐related peptides and their receptors: recent advances in their role in
physiology and disease states. Curr Opin Endocrinol Diabetes Obes
15: 58‐64 [PMID:18185064]


González N et al. (2015)
Bombesin receptor subtype 3 as a potential target for obesity and diabetes.
Expert Opin. Ther. Targets 1‐18 [PMID:26066663]


Jensen RT et al. (2008)
International Union of Pharmacology. LXVIII. Mammalian bombesin receptors:
nomenclature, distribution, pharmacology, signaling, and functions in normal and
disease states. Pharmacol. Rev.
60: 1‐42 [PMID:18055507]


Jensen RT et al. (2013)
Bombesin‐Related Peptides. In Handbook of Biologically Active Peptides. 2nd
Revised edition. Edited by Kastin AJ: Elsevier: 1188‐1196 [ISBN:
9780123850959]

Jensen RT et al. (2013)
Bombesin Peptides (Cancer). In Handbook of Biologically Active Peptides. 2nd
Revised edition. Edited by Kastin AJ: Elsevier: 506‐511 [ISBN:
9780123850959]

Ladenheim EE.. (2013) Bombesin. In
Handbook of Biologically Active Peptides. 2nd Revised edition. Edited by
Kastin AJ: Elsevier: 1064‐1070 [ISBN: 9780123850959]

Majumdar ID et al. (2011)
Biology of mammalian bombesin‐like peptides and their receptors. Curr Opin
Endocrinol Diabetes Obes
18: 68‐74 [PMID:21042212]


Moody TW et al. (2015)
Neuropeptides as lung cancer growth factors. Peptides
[PMID:25836991]


Ramos‐Álvarez I et al. (2015)
Insights into bombesin receptors and ligands: Highlighting recent advances.
Peptides
[PMID:25976083]


Roesler R et al. (2012)
Gastrin‐releasing peptide receptors in the central nervous system: role in brain
function and as a drug target. Front Endocrinol (Lausanne)
3: 159 [PMID:23251133]


Sun YG et al. (2009) Cellular
basis of itch sensation. Science
325: 1531‐4 [PMID:19661382]



Bradykinin receptors

Overview
Bradykinin (or kinin) receptors
(nomenclature as agreed by the NC‐IUPHAR subcommittee on Bradykinin (kinin) Receptors [
1072
]) are activated by the endogenous peptides bradykinin(KNG1, P01042) (BK), [des‐Arg9]bradykinin(KNG1, P01042), Lys‐BK (kallidin(KNG1, P01042)), [des‐Arg10]kallidin(KNG1, P01042), T‐kinin(KNG1, P01042) (Ile‐Ser‐BK), [Hyp3]bradykinin(KNG1, P01042) and Lys‐[Hyp3]‐bradykinin(KNG1, P01042). The variation in
affinity or inactivity of B2 receptor antagonists could reflect the
existence of species homologues of B2 receptors.


Nomenclature	
B1
receptor
	
B2
receptor
	
HGNC, UniProt	
BDKRB1, P46663
	
BDKRB2, P30411
	
Rank order of
potency	
[des‐Arg10]kallidin (KNG1, P01042)
>[des‐Arg9]bradykinin (KNG1, P01042) =
kallidin
(KNG1, P01042)
>bradykinin
(KNG1, P01042)	
kallidin
(KNG1, P01042)
>bradykinin
(KNG1, P01042)
≫[des‐Arg9]bradykinin (KNG1, P01042),
[des‐Arg10]kallidin (KNG1, P01042)	
Endogenous
agonists	
[des‐Arg10]kallidin (KNG1, P01042)
(Selective) (pK
i 9.6–10) [69, 104, 876]	–	
Selective
agonists	
[Sar,D‐Phe8,des‐Arg9]bradykinin
(pK
i 5.7) [876]	
[Hyp3,Tyr(Me)8]BK, [Phe8,ψ(CH2‐NH)Arg9]BK
	
Antagonists	
[Leu9,des‐Arg10]kallidin
(pK
i 9.1–9.3) [69, 104]	–	
Selective
antagonists	
B‐9958
(pK
i 9.2–10.3) [596, 1570], R‐914
(pA2 8.6) [617], R‐715
(pA2 8.5) [618]	
icatibant
(pK
i 10.2) [39], FR173657
(pA2 8.2) [1593], anatibant
(pK
i 8.2) [1537]	
Labelled
ligands	
[125I]Hpp‐desArg10HOE140
(pK
d 10), [3H]Lys‐[des‐Arg9]BK (Agonist)
(pK
d 9.4), [3H]Lys‐[Leu8][des‐Arg9]BK
(Antagonist)	
[3H]BK (human,
mouse, rat) (Agonist) (pK
d 9.4) [2034] – Mouse,
[3H]NPC17731 (Antagonist)
(pK
d 9.1–9.4) [2119, 2120], [125I][Tyr8]bradykinin
(Agonist)	



Further Reading
Campos MM et al. (2006)
Non‐peptide antagonists for kinin B1 receptors: new insights into their therapeutic
potential for the management of inflammation and pain. Trends Pharmacol.
Sci.
27: 646‐51 [PMID:17056130]


Duchene J et al. (2009) The
kinin B(1) receptor and inflammation: new therapeutic target for cardiovascular
disease. Curr Opin Pharmacol
9: 125‐31 [PMID:19124274]


Marceau F et al. (2004)
Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug
Discov
3: 845‐52 [PMID:15459675]


Paquet JL et al. (1999)
Pharmacological characterization of the bradykinin B2 receptor: inter‐species
variability and dissociation between binding and functional responses. Br. J.
Pharmacol.
126: 1083‐90 [PMID:10204994]


Thornton E et al. (2010) Kinin
receptor antagonists as potential neuroprotective agents in central nervous system
injury. Molecules
15: 6598‐618 [PMID:20877247]



Calcitonin receptors

Overview
This receptor family comprises a group of
receptors for the calcitonin/CGRP family of peptides. The calcitonin (CT), amylin
(AMY), calcitonin gene‐related peptide (CGRP) and adrenomedullin (AM) receptors
(nomenclature as agreed by the NC‐IUPHAR Subcommittee on CGRP, AM, AMY, and CT receptors [
721
,
1528
]) are generated by the genes CALCR (which codes for the CT receptor (CTR)) and CALCRL(which codes for the calcitonin receptor‐like receptor, CLR, previously
known as CRLR). Their function and pharmacology are altered in the presence of RAMPs
(receptor activity‐modifying proteins), which are single TM domain proteins of
ca. 130 amino acids, identified as a family of three members;
RAMP1, RAMP2 and RAMP3. There are splice variants of CTR; these in turn produce
variants of the AMY receptor [1528], some of which can be
potently activated by CGRP. The endogenous agonists are the peptides calcitonin(CALCA, P01258), α‐CGRP(CALCA, P06881) (formerly known as
CGRP‐I), β‐CGRP(CALCB, P10092) (formerly known as
CGRP‐II), amylin(IAPP, P10997) (occasionally called
islet‐amyloid polypeptide, diabetes‐associated polypeptide), adrenomedullin(ADM, P35318) and adrenomedullin 2/intermedin
(ADM2, Q7Z4H4). There are species
differences in peptide sequences, particularly for the CTs. CTR‐stimulating peptide {Pig}
(CRSP) is another member of the family with selectivity for the CTR but it is not
expressed in humans [907]. Olcegepant (also known as
BIBN4096BS, pKi 10.5) and telcagepant(also known as
MK0974, pKi 9) are the most selective antagonists available, having
a high selectivity for CGRP receptors, with a particular preference for those of
primate origin.

CLR by itself binds no known endogenous ligand,
but in the presence of RAMPs it gives receptors for CGRP, adrenomedullin and
adrenomedullin 2/intermedin.


Nomenclature	
CT receptor
	
AMY1
receptor
	
AMY2
receptor
	
AMY3
receptor
	
HGNC, UniProt	
CALCR, P30988
	–	–	–	
Subunits	–	
RAMP1 (Accessory
protein), CT receptor
	
CT receptor,
RAMP2 (Accessory
protein)	
CT receptor,
RAMP3 (Accessory
protein)	
Rank order of
potency	
calcitonin
(salmon)≥calcitonin
(CALCA, P01258)
≥amylin
(IAPP, P10997),
α‐CGRP (CALCA, P06881)
>adrenomedullin
(ADM, P35318),
adrenomedullin
2/intermedin (ADM2, Q7Z4H4)	
calcitonin
(salmon)≥amylin
(IAPP, P10997)
≥α‐CGRP (CALCA, P06881)
>adrenomedullin
2/intermedin (ADM2, Q7Z4H4)
≥calcitonin
(CALCA, P01258)
>adrenomedullin
(ADM, P35318)	Poorly defined	
calcitonin
(salmon)≥amylin
(IAPP, P10997)
>α‐CGRP (CALCA, P06881)
≥adrenomedullin
2/intermedin (ADM2, Q7Z4H4)
≥calcitonin
(CALCA, P01258)
>adrenomedullin
(ADM, P35318)	
Endogenous
agonists	
calcitonin
(CALCA, P01258)
(Selective) (pEC50 9–11.2) [32, 58, 718, 1027, 1087, 1341]	
amylin
(IAPP, P10997)
(pEC50 9–9.7) [610]	
amylin
(IAPP, P10997)
(pEC50 8.3–9.1) [610]	
amylin
(IAPP, P10997)
(pEC50 8.9–9.6) [610]	
Labelled
ligands	
[125I]CT
(human) (Agonist) (pK
d 9–10), [125I]CT
(salmon) (Agonist) (pK
d 10)	
[125I]BH‐AMY
(rat, mouse) (Agonist) (pK
d 9–10)	
[125I]BH‐AMY
(rat, mouse) (Agonist) (pK
d 9–10)	
[125I]BH‐AMY
(rat, mouse) (Agonist) (pK
d 9–10)	




Nomenclature	
calcitonin receptor‐like
receptor
	
CGRP receptor
	
AM1
receptor
	
AM2
receptor
	
HGNC, UniProt	
CALCRL, Q16602
	–	–	–	
Subunits	–	
calcitonin receptor‐like
receptor, RAMP1 (Accessory
protein)	
calcitonin receptor‐like
receptor, RAMP2 (Accessory
protein)	
calcitonin receptor‐like
receptor, RAMP3 (Accessory
protein)	
Rank order of
potency	–	
α‐CGRP (CALCA, P06881)
>adrenomedullin
(ADM, P35318)
≥adrenomedullin
2/intermedin (ADM2, Q7Z4H4)
>amylin
(IAPP, P10997)
≥calcitonin
(salmon)
	
adrenomedullin
(ADM, P35318)
>adrenomedullin
2/intermedin (ADM2, Q7Z4H4)
>α‐CGRP (CALCA, P06881),
amylin
(IAPP, P10997)
>calcitonin
(salmon)
	
adrenomedullin
(ADM, P35318)
≥adrenomedullin
2/intermedin (ADM2, Q7Z4H4)
≥α‐CGRP (CALCA, P06881)
>amylin
(IAPP, P10997)
>calcitonin
(salmon)
	
Endogenous
agonists	–	
β‐CGRP (CALCB, P10092)
(pK
i 9.9–11) [20, 1251], α‐CGRP (CALCA, P06881)
(pK
i 9.7–10) [20, 1251]	
adrenomedullin
(ADM, P35318)
(pK
i 8.3–9.2) [20, 1251]	
adrenomedullin
(ADM, P35318)
(pK
i 8.3–9) [20, 539]	
Antagonists	–	
olcegepant
(pK
i 10.2–10.7) [435, 719, 720, 1194], telcagepant
(pK
i 9.1) [1633]	–	–	
Selective
antagonists	–	–	
AM‐(22‐52)
(human) (pK
i 7–7.8) [20, 720, 1251]	–	
Labelled
ligands	–	
[125I]αCGRP (human)
(Agonist) (pK
d 10), [125I]αCGRP (mouse, rat)
(Agonist)	
[125I]AM
(rat) (Agonist) (pK
d 10–9)	
[125I]AM
(rat) (Agonist) (pK
d 9–10)	



Comments
It is important to note that a complication
with the interpretation of pharmacological studies with AMY receptors in transfected
cells is that most of this work has likely used a mixed population of receptors,
encompassing RAMP‐coupled CTR as well as CTR alone. This means that although in
binding assays human calcitonin(CALCA, P01258) has low affinity for
125I‐AMY binding sites, cells transfected with CTR and RAMPs can
display potent CT functional responses. Transfection of human CTR with any RAMP can
generate receptors with a high affinity for both salmon CT and AMY and varying
affinity for different antagonists [337, 718, 719]. The major human CTR
splice variant (hCT(a), which does not contain an insert) with RAMP1
(i.e. the AMY1(a) receptor) has a high affinity for
CGRP, unlike hCT(a)‐RAMP3 (i.e. AMY3(a)
receptor) [337, 718]. However, the AMY receptor
phenotype is RAMP‐type, splice variant and cell‐line‐dependent [1886]. In particular, CGRP is a
more potent agonist than amylin(IAPP, P10997) at increasing cAMP at
the delta 47 hCT(a) receptor, when transfected with RAMP1 (to give the corresponding
AMY1(a) receptor) in Cos 7 cells [1543].

The ligands described represent the best
available but their selectivity is limited. For example, adrenomedullin has
appreciable affinity for CGRP receptors. CGRP can show significant cross‐reactivity
at AMY receptors and AM2 receptors. Adrenomedullin 2/intermedin also has
high affinity for the AM2 receptor [779]. CGRP‐(8‐37) acts as an
antagonist of CGRP (pKi 8) and inhibits some AM and AMY
responses (pKi 6‐7). It is weak at CT receptors. Salmon
CT‐(8‐32) is an antagonist at both AMY and CT receptors. AC187, a salmon CT analogue, is
also an antagonist at AMY and CT receptors. Human AM‐(22‐52) has some selectivity
towards AM receptors, but with modest potency (pKi  7),
limiting its use [720]. AM‐(22‐52) is slightly
more effective at AM1 than AM2 receptors but this difference is
not sufficient for this peptide to be a useful discriminator of the AM receptor
subtypes. Olcegepant shows the greatest
selectivity between receptors but still has significant affinity for AMY1
receptors [1973].

Ligand responsiveness at CT and AMY receptors
can be affected by receptor splice variation and can depend on the pathway being
measured. Particularly for AMY receptors, relative potency can vary with the type and
level of RAMP present and can be influenced by other factors such as G proteins
[1324, 1886].

Gs is a prominent route for effector
coupling for CLR and CTR but other pathways (e.g. Ca2+,
ERK, Akt), and G proteins can be activated [1972]. There is evidence that
CGRP‐RCP (a 148 amino‐acid hydrophilic protein, ASL(P04424) is important for the
coupling of CLR to adenylyl cyclase [498]. [125I]‐Salmon
CT is the most common radioligand for CT receptors but it has high affinity for AMY
receptors and is also poorly reversible. [125I]‐Tyr0‐CGRP is
widely used as a radioligand for CGRP receptors.

Some early literature distinguished between
CGRP1 and CGRP2 receptors. It is now clear that the complex of CALCRL and
RAMP1 represents the CGRP1 subtype and is now known simply as the CGRP receptor [721]. The
CGRP2 receptor is now considered to have arisen from the actions of CGRP at
AM2 and AMY receptors. This term should not be used [721].

Further Reading
Barwell J et al. (2012)
Calcitonin and calcitonin receptor‐like receptors: common themes with family B GPCRs?
Br. J. Pharmacol.
166: 51‐65 [PMID:21649645]


Booe JM et al. (2015)
Structural Basis for Receptor Activity‐Modifying Protein‐Dependent Selective Peptide
Recognition by a G Protein‐Coupled Receptor. Mol. Cell
[PMID:25982113]


Hay DL et al. (2008)
International Union of Pharmacology. LXIX. Status of the calcitonin gene‐related
peptide subtype 2 receptor. Pharmacol. Rev.
60: 143‐5 [PMID:18552275]


Hong Y et al. (2011) The
pharmacology of Adrenomedullin 2/Intermedin. Br J Pharmacol
[PMID:21658025]


Moore EL et al. (2011)
Targeting a Family B GPCR/RAMP Receptor Complex: CGRP Receptor Antagonists and
Migraine. Br J Pharmacol
[PMID:21871019]


Poyner DR et al. (2002)
International Union of Pharmacology. XXXII. The mammalian calcitonin gene‐related
peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol
Rev.
54: 233‐246 [PMID:12037140]


Russo AF. (2015) Calcitonin gene‐related
peptide (CGRP): a new target for migraine. Annu. Rev. Pharmacol.
Toxicol.
55: 533‐52 [PMID:25340934]



Calcium‐sensing receptors

Overview
The calcium‐sensing receptor (CaS,
provisional nomenclature as recommended by NC‐IUPHAR[
530
]) responds to extracellular calcium and magnesium in the millimolar
range and to gadolinium and some polycations in the micromolar range [229]. The sensitivity of CaS to
primary agonists can be increased by aromatic L‐amino acids [362] and also by elevated
extracellular pH [1544] or decreased
extracellular ionic strength [1545]. This receptor bears no
sequence or structural relation to the plant calcium receptor, also called CaS.


Nomenclature	
CaS receptor
	
GPRC6 receptor
	
HGNC, UniProt	
CASR, P41180
	
GPRC6A, Q5T6X5
	
Amino‐acid rank
order of potency	
L‐phenylalanine,
L‐tryptophan,
L‐histidine>L‐alanine>L‐serine,
L‐proline,
L‐glutamic
acid>L‐aspartic acid
(not L‐lysine, L‐arginine, L‐leucine and L‐isoleucine) [362]	–	
Cation rank order
of potency	
Gd3+>Ca2+>Mg2+ [229]	–	
Polyamine rank
order of potency	
spermine>spermidine>putrescine
[1546]	–	
Allosteric
modulators	
AC265347
(Positive) (pEC50 7.6–8.1) [1160], NPS 2143
(Negative) (pIC50 7.1–7.4) [1377, 2087], cinacalcet
(Positive) (pEC50 7.3) [1378], calindol
(Positive) (pEC50 6.5) [1499], calindol
(Positive) (pK
d 6–6.5) [930], tecalcet
(Positive) (pK
d 6.5) [1379], calhex 231
(Negative) (pIC50 6.4) [1500]	–	
Comments	2‐benzylpyrrolidine
derivatives of NPS 2143 are also negative allosteric modulators of the
calcium sensing receptor [2087]. etelcalcetide is
a novel peptide agonist of the receptor [1975].	GPRC6 is a related
Gq‐coupled receptor which responds to basic amino acids
[2004].	



Comments
Positive allosteric modulators of CaS are
termed Type II calcimimetics and can suppress parathyroid hormone (PTH(PTH, P01270)) secretion [1379]. Negative allosteric
modulators are called calcilytics and can act to increase PTH(PTH, P01270) secretion [1377].

The central role of CaS in the maintenance of
extracellular calcium homeostasis is seen most clearly in patients with
loss‐of‐function CaS mutations who develop familial hypocalciuric hypercalcaemia
(heterozygous mutation) or neonatal severe hyperparathyroidism (homozygous mutation)
and in CaS null mice [293, 765], which exhibit similar
increases in PTH secretion and blood Ca2+ levels. A gain‐of‐function mutation in the CaS gene is associated with
autosomal dominant hypocalcaemia.

Further Reading
Breitwieser GE. (2012) Minireview: the intimate
link between calcium sensing receptor trafficking and signaling: implications for
disorders of calcium homeostasis. Mol. Endocrinol.
26: 1482‐95 [PMID:22745192]


Brown EM. (2013) Role of the calcium‐sensing
receptor in extracellular calcium homeostasis. Best Pract. Res. Clin.
Endocrinol. Metab.
27: 333‐43 [PMID:23856263]


Conigrave AD et al. (2013)
Calcium‐sensing receptor (CaSR): pharmacological properties and signaling pathways.
Best Pract. Res. Clin. Endocrinol. Metab.
27: 315‐31 [PMID:23856262]


Magno AL et al. (2011) The
calcium‐sensing receptor: a molecular perspective. Endocr. Rev.
32: 3‐30 [PMID:20729338]


Nemeth EF et al. (2013)
Calcimimetic and calcilytic drugs for treating bone and mineral‐related disorders.
Best Pract. Res. Clin. Endocrinol. Metab.
27: 373‐84 [PMID:23856266]


Wellendorph P et al. (2004)
Molecular cloning, expression, and sequence analysis of GPRC6A, a novel family C
G‐protein‐coupled receptor. Gene
335: 37‐46 [PMID:15194188]


Yarova PL et al. (2015)
Calcium‐sensing receptor antagonists abrogate airway hyperresponsiveness and
inflammation in allergic asthma. Sci Transl Med
7: 284ra60 [PMID:25904744]



Cannabinoid receptors

Overview
Cannabinoid receptors (nomenclature as
agreed by the NC‐IUPHAR
Subcommittee on Cannabinoid Receptors [
1494
]) are activated by endogenous ligands that include
N‐arachidonoylethanolamine (anandamide), N‐homo‐γ‐linolenoylethanolamine, N‐docosatetra‐7,10,13,16‐enoylethanolamine and 2‐arachidonoylglycerol. Potency
determinations of endogenous agonists at these receptors are complicated by the
possibility of differential susceptibility of endogenous ligands to enzymatic
conversion [35].


Nomenclature	
CB1
receptor
	
CB2
receptor
	
HGNC, UniProt	
CNR1, P21554
	
CNR2, P34972
	
(Sub)family‐selective agonists	
HU‐210
(pK
i 9.1–10.2) [509, 1733], CP55940
(pK
i 8.3–9.2) [509, 1602, 1733], WIN55212‐2
(pK
i 6.9–8.7) [509, 1730, 1733], Δ9‐tetrahydrocannabinol (Partial agonist)
(pK
i 7.3–7.4) [509, 1733]	
HU‐210
(pK
i 9.3–9.8) [509, 1579, 1733], WIN55212‐2
(pK
i 8.4–9.6) [509, 1730, 1733], CP55940
(pK
i 8.6–9.2) [509, 1602, 1733], Δ9‐tetrahydrocannabinol (Partial agonist)
(pK
i 7.1–7.5) [106, 509, 1579, 1733]	
Selective
agonists	
arachidonyl‐2‐chloroethylamide (pK
i 8.9) [755] – Rat,
arachidonylcyclopropylamide (pK
i 8.7) [755] – Rat,
O‐1812
(pK
i 8.5) [420] – Rat,
R‐(+)‐methanandamide
(pK
i 7.7) [931] – Rat	
JWH‐133
(pK
i 8.5) [804, 1493], L‐759,633
(pK
i 7.7–8.2) [576, 1602], AM1241
(pK
i 8.1) [2088], L‐759,656
(pK
i 7.7–7.9) [576, 1602], HU‐308
(pK
i 7.6) [699]	
Selective
antagonists	
rimonabant
(pK
i 7.9–8.7) [508, 509, 1586, 1613, 1733], AM251
(pK
i 8.1) [1038] – Rat,
AM281
(pK
i 7.9) [1037] – Rat,
LY320135
(pK
i 6.9) [508]	
SR144528
(pK
i 8.3–9.2) [1587, 1602], AM‐630
(pK
i 7.5) [1602]	
Labelled
ligands	
[3H]rimonabant (Antagonist)
(pK
d 8.9–10) [205, 761, 889, 1498, 1588, 1742, 1873] – Rat	–	



Comments
Both CB1 and CB2
receptors may be labelled with [3H]CP55940(0.5 nM;
[1733]) and [3H]WIN55212‐2(2‐2.4
nM; [1756, 1783]). Anandamide is also an agonist
at vanilloid receptors (TRPV1) and PPARs[1418, 2135]. There is evidence for an
allosteric site on the CB1 receptor [1532]. All of the compounds
listed as antagonists behave as inverse agonists in some bioassay systems [1494]. Moreover, GPR18, GPR55 and GPR119,
although showing little structural similarity to CB1 and
CB2receptors, respond to endogenous agents that are structurally similar
to the endogenous cannabinoid ligands [1494].

Further Reading
Alexander SP et al. (2007) The
complications of promiscuity: endocannabinoid action and metabolism. Br. J.
Pharmacol.
152: 602‐23 [PMID:17876303]


Di Marzo V et al. (2007)
Endocannabinoids and the regulation of their levels in health and disease.
Curr. Opin. Lipidol.
18: 129‐40 [PMID:17353660]


Howlett AC et al. (2011)
Endocannabinoid tone versus constitutive activity of cannabinoid receptors.
Br. J. Pharmacol.
163: 1329‐43 [PMID:21545414]


McPartland JM et al. (2007)
Meta‐analysis of cannabinoid ligand binding affinity and receptor distribution:
interspecies differences. Br. J. Pharmacol.
152: 583‐93 [PMID:17641667]


Mechoulam R et al. (2013) The
endocannabinoid system and the brain. Annu Rev Psychol
64: 21‐47 [PMID:22804774]


O'Sullivan SE. (2007) Cannabinoids go nuclear:
evidence for activation of peroxisome proliferator‐activated receptors. Br.
J. Pharmacol.
152: 576‐82 [PMID:17704824]


Pertwee RG et al. (2010)
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors
and their ligands: beyond CB_1 and CB_2. Pharmacol. Rev.
62: 588‐631 [PMID:21079038]


Ross RA. (2011)
L‐α‐lysophosphatidylinositol meets GPR55: a deadly relationship.
Trends Pharmacol. Sci.
32: 265‐9 [PMID:21367464]



Chemerin receptor

Overview
The chemerin receptor (nomenclature as
recommended by NC‐IUPHAR[
396
]) is activated by chemerin [1148, 1253, 2108] and the lipid‐derived,
anti‐inflammatory ligand resolvin E1 (RvE1), which is
the result of sequential metabolism of EPA by aspirin‐modified
cyclooxygenase and lipoxygenase [56, 57]. In addition, two GPCRs for
resolvin D1 (RvD1) have been
identified, FPR2/ALX, the lipoxin A4 receptor, and GPR32, an orphan
receptor [1006].


Nomenclature	
chemerin
receptor
	
HGNC, UniProt	
CMKLR1, Q99788
	
Rank order of
potency	
resolvin
E1>chemerin C‐terminal
peptide>18R‐HEPE>EPA [56]	
Selective
agonists	
resolvin E1
	
Labelled
ligands	
[3H]resolvin
E1 (Agonist) (pK
d 8) [56, 57]	




Chemokine receptors

Overview
Chemokine receptors (nomenclature as
agreed by the NC‐IUPHAR
Subcommittee on Chemokine Receptors [
78
,
1346
,
1347
]) comprise a large subfamily of 7TM proteins that bind one or more
chemokines, a large family of small cytokines typically possessing chemotactic
activity for leukocytes. Chemokine receptors can be divided by function into two main
groups: G protein‐coupled chemokine receptors, which mediate leukocyte trafficking,
and “Atypical chemokine receptors”, which may signal through non‐G protein‐coupled
mechanisms and act as chemokine scavengers to downregulate inflammation or shape
chemokine gradients [78].

Chemokines in turn can be divided by structure
into four subclasses by the number and arrangement of conserved cysteines. CC (also
known as β‐chemokines; n= 28), CXC (also known as
α‐chemokines; n= 17) and CX3C
(n= 1) chemokines all have four conserved cysteines, with zero,
one and three amino acids separating the first two cysteines respectively. C
chemokines (n= 2) have only the second and fourth cysteines found in
other chemokines. Chemokines can also be classified by function into homeostatic and
inflammatory subgroups. Most chemokine receptors are able to bind multiple
high‐affinity chemokine ligands, but the ligands for a given receptor are almost
always restricted to the same structural subclass. Most chemokines bind to more than
one receptor subtype. Receptors for inflammatory chemokines are typically highly
promiscuous with regard to ligand specificity, and may lack a selective endogenous
ligand. G protein‐coupled chemokine receptors are named acccording to the class of
chemokines bound, whereas ACKR is the root acronym for atypical chemokine receptors
[79]. Listed are those human
agonists with EC50 values <50 nM in either Ca2+ flux or
chemotaxis assays at human recombinant G protein‐coupled chemokine receptors
expressed in mammalian cell lines. There can be substantial cross‐species differences
in the sequences of both chemokines and chemokine receptors, and in the pharmacology
and biology of chemokine receptors. Endogenous and microbial non‐chemokine ligands
have also been identified for chemokine receptors. Many chemokine receptors function
as HIV co‐receptors, but CCR5 is the only one demonstrated to play an essential role
in HIV/AIDS pathogenesis. The tables include both standard chemokine receptor names
[2101] and the most commonly
used aliases. Numerical data quoted are typically pK
i or pIC50 values from radioligand binding to heterologously
expressed receptors.


Nomenclature	
CCR1
	
CCR2
	
CCR3
	
HGNC, UniProt	
CCR1, P32246
	
CCR2, P41597
	
CCR3, P51677
	
Endogenous
agonists	
CCL3 (CCL3, P10147)
(pK
i 7.8–10.2) [328, 357, 747, 2134], CCL23 (CCL23, P55773)
(Selective) (pK
i 8.9) [328], CCL5 (CCL5, P13501)
(pK
i 6.8–8.2) [357, 747], CCL7 (CCL7, P80098)
(pK
i 8.1) [328, 667], CCL15 (CCL15, Q16663)
(Selective) (pIC50 7.9) [373], CCL14 (CCL14, Q16627)
(pK
i 7.4) [328], CCL13 (CCL13, Q99616),
CCL8 (CCL8, P80075)	
CCL2 (CCL2, P13500)
(pIC50 9.3–10.2) [373, 1159, 1291, 1465, 1920], CCL13 (CCL13, Q99616)
(pIC50 8.6–8.7) [1159, 1920], CCL7 (CCL7, P80098)
(pIC50 8.4–8.7) [373, 1159, 1920], CCL11 (CCL11, P51671) (Partial
agonist) (pIC50 7.1–7.7) [1159, 1465], CCL16 (CCL16, O15467)	
CCL13 (CCL13, Q99616)
(pIC50 8.7–10.3) [1332, 1920], CCL24 (CCL24, O00175)
(Selective) (pIC50 8–9.4) [1332, 1465], CCL5 (CCL5, P13501)
(pK
i 8.5–9.3) [391], CCL7 (CCL7, P80098)
(pK
i 8.6–9.2) [391], CCL11 (CCL11, P51671)
(Selective) (pIC50 8.7–9) [452, 961, 1332, 1625, 1920], CCL26 (CCL26, Q9Y258)
(Selective) (pIC50 7.9–8.9) [961, 1332, 1465], CCL15 (CCL15, Q16663)
(pIC50 8.6) [373], CCL28 (CCL28, Q9NRJ3),
CCL8 (CCL8, P80075)	
Agonists	–	–	
CCL11 {Mouse}
(pK
i 9.5–10) [391]	
Endogenous
antagonists	
CCL4 (CCL4, P13236)
(Selective) (pK
i 7.1–7.8) [328, 357]	
CCL26 (CCL26, Q9Y258)
(Selective) (pIC50 8.5) [1465]	
CXCL10
(CXCL10, P02778)
(Selective), CXCL11
(CXCL11, O14625)
(Selective), CXCL9 (CXCL9, Q07325)
(Selective)	
Antagonists	–	–	–	
Selective
antagonists	
BX 471
(pK
i 8.2–9) [1098], compound 2b‐1 [PMID:
12614873] (pIC50 8.7) [1368], CP‐481,715
(pK
d 8) [614], UCB35625
(pIC50 8) [1625]	
GSK Compound 34
(pK
i 7.6)	
banyu (I)
(Inverse agonist) (pK
i 8.5) [1977], SB328437
(pK
i 8.4), BMS compound 87b
(pK
i 8.1) [1964]	
Antibodies	–	–	–	
Labelled
ligands	
[125I]CCL7
(human) (Agonist) (pK
d 9.2) [127], [125I]CCL3
(human) (Agonist) (pK
d 8–8.8) [127, 623, 1646], [125I]CCL5
(human) (Agonist) (pK
d 8.2) [1646]	
[125I]CCL2
(human) (Agonist), [125I]CCL7
(human) (Agonist)	
[125I]CCL11
(human) (Antagonist) (pK
d 8.3) [1977], [125I]CCL5
(human) (Agonist), [125I]CCL7
(human) (Agonist)	




Nomenclature	
CCR4
	
CCR5
	
HGNC, UniProt	
CCR4, P51679
	
CCR5, P51681
	
Endogenous
agonists	
CCL22 (CCL22, O00626)
(Selective) (pIC50 9.2) [822], CCL17 (CCL17, Q92583)
(Selective) (pIC50 8.7) [822]	
CCL5 (CCL5, P13501)
(pK
i 9.2–9.7) [75, 1364, 1611], CCL4 (CCL4, P13236)
(Selective) (pK
i 9.4–9.6) [1364, 1611], CCL8 (CCL8, P80075)
(pK
i 9.3) [1611], CCL3 (CCL3, P10147)
(pK
i 8–8.9) [1364, 1611, 2134], CCL11 (CCL11, P51671)
(pIC50 7.7) [157], CCL2 (CCL2, P13500)
(pK
i 7.5) [1364], CCL14 (CCL14, Q16627)
(pK
i 7.2) [1364], CCL16 (CCL16, O15467)	
Agonists	
vMIP‐III
	
R5‐HIV‐1 gp120
	
Endogenous
antagonists	–	
CCL7 (CCL7, P80098)
(Selective) (pK
i 7.5) [1364]	
Antagonists	–	
vicriviroc
(pK
i 9.1) [1805], ancriviroc
(pK
i 7.8–8.7) [1173, 1455, 1805]	
Selective
antagonists	–	
E913
(pIC50 8.7) [1174], aplaviroc
(pK
i 8.5) [1173], maraviroc
(pIC50 8.1) [1364], TAK‐779
(pK
i 7.5) [1173], MRK‐1 [1023] – Rat	
Antibodies	
mogamulizumab
(Inhibition) [51, 1731]	–	
Labelled
ligands	
[125I]CCL17
(human) (Agonist), [125I]CCL27
(human) (Agonist)	
[125I]CCL4
(human) (Agonist) (pK
d 9.6) [1364], [125I]CCL3
(human) (Agonist), [125I]CCL5
(human) (Agonist), [125I]CCL8
(human) (Agonist)	




Nomenclature	
CCR6
	
CCR7
	
CCR8
	
CCR9
	
CCR10
	
HGNC, UniProt	
CCR6, P51684
	
CCR7, P32248
	
CCR8, P51685
	
CCR9, P51686
	
CCR10, P46092
	
Endogenous
agonists	
CCL20 (CCL20, P78556)
(pIC50 7.9–8.5) [18, 74, 1526], beta‐defensin 4A
(DEFB4A
DEFB4B, O15263)
(Selective) [2081]	
CCL21 (CCL21, O00585)
(Selective) (pIC50 9.3) [2099], CCL19 (CCL19, Q99731)
(Selective) (pIC50 7.7–9, median 8.6) [1449, 2098, 2099]	
CCL1 (CCL1, P22362)
(Selective) (pIC50 8.5–9.8) [387, 710, 824], CCL8 {Mouse} –
Mouse	
CCL25 (CCL25, O15444)
(Selective)	
CCL27 (CCL27, Q9Y4X3)
(Selective), CCL28 (CCL28, Q9NRJ3)
(Selective)	
Agonists	–	–	
vMIP‐I
(pIC50 8.9–9.9) [387, 824]	–	–	
Selective
antagonists	–	–	
vMCC‐I
(pIC50 9.4) [387]	–	–	
Labelled
ligands	
[125I]CCL20
(human) (Agonist) (pK
d∼10) [641]	
[125I]CCL19
(human) (Agonist), [125I]CCL21
(human) (Agonist) [856]	
[125I]CCL1
(human) (Agonist) (pK
d 8.9–9.7) [824, 1597]	
[125I]CCL25
(human) (Agonist)	–	




Nomenclature	
CXCR1
	
CXCR2
	
CXCR3
	
HGNC, UniProt	
CXCR1, P25024
	
CXCR2, P25025
	
CXCR3, P49682
	
Endogenous
agonists	
CXCL8 (CXCL8, P10145)
(pK
i 8.8–9.5) [142, 675, 1068, 2032, 2049], CXCL6 (CXCL6, P80162)
(pK
i 7) [2053]	
CXCL1 (CXCL1, P09341)
(Selective) (pK
i 8.4–9.7) [675, 1068, 2049], CXCL8 (CXCL8, P10145)
(pK
i 8.8–9.5) [142, 675, 1068, 2032, 2049], CXCL7 (PPBP, P02775)
(Selective) (pIC50 6.3–9.3) [16], CXCL3 (CXCL3, P19876)
(Selective) (pIC50 7.8–9.2) [16], CXCL2 (CXCL2, P19875)
(Selective) (pIC50 7–9.1) [16], CXCL5 (CXCL5, P42830)
(Selective) (pIC50 6.9–9) [16], CXCL6 (CXCL6, P80162)
(pK
d 7) [2053]	
CXCL11
(CXCL11, O14625)
(Selective) (pK
i 10.4–10.5) [734], CXCL10
(CXCL10, P02778)
(Selective) (pK
i 7.8–9.8) [734, 2006], CXCL9 (CXCL9, Q07325)
(Selective) (pK
i 7.3–8.3) [734, 2006]	
Agonists	
vCXCL1
(pIC50 7.4) [1158], HIV‐1 matrix protein
p17 (pK
d 5.7) [602]	
vCXCL1
(pIC50 8.2) [1158], HIV‐1 matrix protein
p17 (pK
d 6.9) [602]	–	
Selective
agonists	–	–	–	
Endogenous
antagonists	–	–	
CCL11 (CCL11, P51671)
(Selective) (pK
i 7.2) [2006], CCL7 (CCL7, P80098)
(Selective) (pK
i 6.6) [2006]	
Antagonists	–	–	–	
Selective
antagonists	–	
navarixin
(pIC50 10.3) [78, 456], danirixin
(pIC50 7.9) [1285], SB 225002
(pIC50 7.7) [2016], elubirixin
(pIC50 7.7) [78], SX‐517
(pIC50 7.2) [1172]	–	
Allosteric
modulators	
reparixin
(Negative) (pIC50 9) [142]	
reparixin
(Negative) (pIC50 6.4) [142]	–	
Labelled
ligands	
[125I]CXCL8
(human) (Agonist) (pK
d 8.9–9.6) [675, 1584]	
[125I]CXCL8
(human) (Agonist) (pK
d 9–9.4) [675, 1584], [125I]CXCL1
(human) (Agonist), [125I]CXCL5
(human) (Agonist), [125I]CXCL7
(human) (Agonist)	
[125I]CXCL10
(human) (Agonist), [125I]CXCL11
(human) (Agonist)	
Comments	Reports on the
expression of native CXCR1 by mouse leukocytes are not conclusive.
There are reports on the existence of mouse Cxcr1 and
on Cxcr1 knockout mice, but the distinct function of
the gene and of its knockout phenotype are unclear [118, 351, 1297, 1628, 1794].	–	–	




Nomenclature	
CXCR4
	
CXCR5
	
CXCR6
	
HGNC, UniProt	
CXCR4, P61073
	
CXCR5, P32302
	
CXCR6, O00574
	
Endogenous
agonists	
CXCL12α (CXCL12, P48061)
(Selective) (pK
d 7.7–8.2) [746, 1136], CXCL12β (CXCL12, P48061)
(Selective) (pK
d 7.9) [746]	
CXCL13
(CXCL13, O43927)
(Selective) (pK
d 7.3) [97]	
CXCL16
(CXCL16, Q9H2A7)
(Selective) (pK
d 9) [2026]	
Agonists	–	–		
Selective
agonists	
ALX40‐4C
(Partial agonist) (pIC50 6.1) [2121], X4‐HIV‐1 gp120
	–		
Endogenous
antagonists	–	–		
Antagonists	
plerixafor
(pK
i 7) [2121]	–		
Selective
antagonists	
T134
(pIC50 8.4) [1856], AMD070
(pIC50 7.9) [1750], HIV‐Tat
	–		
Allosteric
modulators	–	–		
Labelled
ligands	
[125I]CXCL12α (human)
(Agonist) (pK
d 8.1–8.4) [421, 746]	
[125I]CXCL13
(mouse) (Agonist) [222] –
Mouse	
[125I]CXCL16
(human) (Agonist)	
Comments	–	–	–	




Nomenclature	
CX3CR1
	
XCR1
	
ACKR1
	
ACKR2
	
HGNC, UniProt	
CX3CR1, P49238
	
XCR1, P46094
	
ACKR1, Q16570
	
ACKR2, O00590
	
Endogenous
ligands	–	–	
CXCL5 (CXCL5, P42830),
CXCL6 (CXCL6, P80162),
CXCL8 (CXCL8, P10145),
CXCL11
(CXCL11, O14625),
CCL2 (CCL2, P13500),
CCL5 (CCL5, P13501),
CCL7 (CCL7, P80098),
CCL11 (CCL11, P51671),
CCL14 (CCL14, Q16627),
CCL17 (CCL17, Q92583)	
CCL2 (CCL2, P13500),
CCL3 (CCL3, P10147),
CCL4 (CCL4, P13236),
CCL5 (CCL5, P13501),
CCL7 (CCL7, P80098),
CCL8 (CCL8, P80075),
CCL11 (CCL11, P51671),
CCL13 (CCL13, Q99616),
CCL14 (CCL14, Q16627),
CCL17 (CCL17, Q92583),
CCL22 (CCL22, O00626)	
Endogenous
agonists	
CX3CL1 (CX3CL1, P78423)
(Selective) (pIC50 8.9) [577]	
XCL1 (XCL1, P47992)
(Selective), XCL2 (XCL2, Q9UBD3)
(Selective)	–	–	
Labelled
ligands	
[125I]CX3CL1 (human)
(Agonist)	–	–		
Comments	–	When fused with
secreted alkaline phophatase (SEAP), XCL1 functions as a probe at
XCR1	ACKR1 is used by
Plasmodium vivax and Plasmodium
knowlsei for entering erythrocytes.		




Nomenclature	
ACKR3
	
ACKR4
	
CCRL2
	
HGNC, UniProt	
ACKR3, P25106
	
ACKR4, Q9NPB9
	
CCRL2, O00421
	
Endogenous
ligands	–	–	
chemerin C‐terminal
peptide, CCL19 (CCL19, Q99731)
[95]	
Endogenous
agonists	
CXCL12α (CXCL12, P48061)
(pEC50 7.5–7.9) [640, 1785], CXCL11
(CXCL11, O14625),
adrenomedullin
{Mouse} [965] –
Mouse	
CCL19 (CCL19, Q99731)
(pK
i 8.4) [1997], CCL25 (CCL25, O15444)
(pK
i 7.6) [1997], CCL21 (CCL21, O00585)
(pK
i 6.9) [1997]	–	



Comments
Mouse Cxcr binds iodinated mouse KC (CXCL1{Mouse}) and mouse MIP‐2
(CXCL2{Mouse}) with high
affinity (mouse KC and MIP‐2 are homologues of human CXCL1(CXCL1, P09341), CXCL2(CXCL2, P19875) and CXCL3(CXCL3, P19876)), but shows low
affinity for human IL‐8 (CXCL8(CXCL8, P10145)).

Specific chemokine receptors facilitate cell
entry by microbes, such as ACKR1 for Plasmodium vivax, and CCR5 for
HIV‐1. Virally encoded chemokine receptors are known (e.g. US28, a
homologue of CCR1 from human cytomegalovirus and ORF74, which encodes a homolog of
CXCR2 in Herpesvirus saimiri and Herpesvirus‐68), but their role in
viral life cycles is not established. Viruses can exploit or subvert the chemokine
system by producing chemokine antagonists and scavengers.

The CC chemokine family (CCL1‐28) includes I309
(CCL1(CCL1, P22362)), MCP‐1 (CCL2(CCL2, P13500)),
MIP‐1α(CCL3(CCL3, P10147)),
MIP‐1β(CCL4(CCL4, P13236)), RANTES (CCL5(CCL5, P13501)), MCP‐3 (CCL7(CCL7, P80098)), MCP‐2 (CCL8(CCL8, P80075)), eotaxin (CCL11(CCL11, P51671)), MCP‐4 (CCL13(CCL13, Q99616)), HCC‐1 (CCL14(CCL14, Q16627)), Lkn‐1/HCC‐2
(CCL15(CCL15, Q16663)), TARC (CCL17(CCL17, Q92583)), ELC (CCL19(CCL19, Q99731)), LARC (CCL20(CCL20, P78556)), SLC (CCL21(CCL21, O00585)), MDC (CCL22(CCL22, O00626)), MPIF‐1 (CCL23(CCL23, P55773)), eotaxin‐2 (CCL24(CCL24, O00175)), TECK (CCL25(CCL25, O15444)), eotaxin (CCL26(CCL26, Q9Y258)), eskine/CTACK
(CCL27(CCL27, Q9Y4X3)) and MEC (CCL28(CCL28, Q9NRJ3)). The CXC chemokine
family (CXCL1‐17) includes GROα(CXCL1(CXCL1, P09341)),
GROβ(CXCL2(CXCL2, P19875)),
GROγ(CXCL3(CXCL3, P19876)), platelet factor 4
(CXCL4(PF4, P02776)), ENA78 (CXCL5(CXCL5, P42830)), GCP‐2 (CXCL6(CXCL6, P80162)), NAP‐2 (CXCL7(PPBP, P02775)), IL‐8 (CXCL8(CXCL8, P10145)), MIG (CXCL9(CXCL9, Q07325)), IP10 (CXCL10(CXCL10, P02778)), I‐TAC (CXCL11(CXCL11, O14625)), SDF‐1 (CXCL12,
i.e.
CXCL12α(CXCL12, P48061) and CXCL12β(CXCL12, P48061)), BLC (CXCL13(CXCL13, O43927)), BRAK (CXCL14(CXCL14, O95715)), mouse lungkine
(CXCL15 {Mouse}) SR‐PSOX
(CXCL16(CXCL16, Q9H2A7)) and CXCL17(CXCL17, Q6UXB2). The CX3C
chemokine (CX3CL1(CX3CL1, P78423)) is also known as
fractalkine (neurotactin in the mouse). Like CXCL16(CXCL16, Q9H2A7), and unlike other
chemokines, CX3CL1(CX3CL1, P78423) is multimodular
containing a chemokine domain, an elongated mucin‐like stalk, a transmembrane domain
and a cytoplasmic tail. Both plasma membrane‐associated and shed forms have been
identified. The C chemokine (XCL1(XCL1, P47992)) is also known as
lymphotactin.

Two chemokine receptor antagonists have now
been approved by the FDA: the CCR5 antagonist maraviroc (Pfizer) for
treatment of HIV/AIDS in patients with CCR5‐using strains; and the CXCR4 antagonist
plerixafor (Sanofi) for
hematopoietic stem cell mobilization with G‐CSF(CSF3, P09919) in patients undergoing
transplantation in the context of chemotherapy for lymphoma and multiple myeloma.

Further Reading
Bachelerie F et al. (2015) An
atypical addition to the chemokine receptor nomenclature: IUPHAR Review ~15~.
Br. J. Pharmacol.
[PMID:25958743]


Koelink PJ et al. (2012)
Targeting chemokine receptors in chronic inflammatory diseases: an extensive review.
Pharmacol. Ther.
133: 1‐18 [PMID:21839114]


Murphy PM. (2002) International Union of
Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacol.
Rev.
54: 227‐9 [PMID:12037138]


Murphy PM et al. (2000)
International Union of Pharmacology. XXII. Nomenclature for chemokine receptors.
Pharmacol. Rev.
52: 145‐176 [PMID:10699158]


Muñoz LM et al. (2011)
Receptor oligomerization: a pivotal mechanism for regulating chemokine function.
Pharmacol. Ther.
131: 351‐8 [PMID:21600920]


Scholten DJ et al. (2012)
Pharmacological modulation of chemokine receptor function. Br. J.
Pharmacol.
165: 1617‐43 [PMID:21699506]


Szpakowska M et al. (2012)
Function, diversity and therapeutic potential of the N‐terminal domain of human
chemokine receptors. Biochem. Pharmacol.
84: 1366‐80 [PMID:22935450]


White GE et al. (2013) CC
chemokine receptors and chronic inflammation–therapeutic opportunities and
pharmacological challenges. Pharmacol. Rev.
65: 47‐89 [PMID:23300131]



Cholecystokinin receptors

Overview
Cholecystokinin receptors (nomenclature
as agreed by the NC‐IUPHAR
Subcommittee on CCK receptors [
1403
]) are activated by the endogenous peptides cholecystokinin‐8 (CCK‐8(CCK, P06307)), CCK‐33(CCK, P06307), CCK‐58(CCK, P06307) and gastrin (gastrin‐17(GAST, P01350)). There are only two
distinct subtypes of CCK receptors, CCK1 and CCK2 receptors
[992, 1986], with some alternatively
spliced forms most often identified in neoplastic cells. The CCK receptor subtypes
are distinguished by their peptide selectivity, with the CCK1 receptor
requiring the carboxyl‐terminal heptapeptide‐amide that includes a sulfated tyrosine
for high affinity and potency, while the CCK2 receptor requires only the
carboxyl‐terminal tetrapeptide shared by both CCK and gastrin peptides. These
receptors have characteristic and distinct distributions, with both present in both
the central nervous system and peripheral tissues.


Nomenclature	
CCK1
receptor
	
CCK2
receptor
	
HGNC, UniProt	
CCKAR, P32238
	
CCKBR, P32239
	
Rank order of
potency	
CCK‐8 (CCK, P06307)
≫gastrin‐17
(GAST, P01350),
desulfated
cholecystokinin‐8>CCK‐4 (CCK, P06307)	
CCK‐8 (CCK, P06307)
≥gastrin‐17
(GAST, P01350),
desulfated
cholecystokinin‐8, CCK‐4 (CCK, P06307)	
Endogenous
agonists	–	
desulfated
cholecystokinin‐8 (pIC50 8.3–8.7) [1071], gastrin‐17
(GAST, P01350)
(Selective) (pIC50 8.3) [805] – Mouse,
CCK‐4 (CCK, P06307)
(pIC50 7.5) [832], desulfated
gastrin‐14 (GAST, P01350),
desulfated
gastrin‐17 (GAST, P01350),
desulfated
gastrin‐34 (GAST, P01350),
desulfated
gastrin‐71 (GAST, P01350),
gastrin‐14
(GAST, P01350),
gastrin‐34
(GAST, P01350),
gastrin‐71
(GAST, P01350)	
Selective
agonists	
A‐71623
(pIC50 8.4) [63] – Rat,
JMV180
(pIC50 8.3) [926], GW‐5823
(pIC50 7.6) [737]	
RB‐400
(pK
i 9.1) [123] – Rat,
PBC‐264
(pIC50 9.1) [844] – Rat	
Antagonists	
lintitript
(pIC50 8.3) [632]	–	
Selective
antagonists	
devazepide
(pIC50 9.7) [805] – Rat,
T‐0632
(pIC50 9.6) [1861] – Rat,
PD‐140548
(pIC50 8.6) [1748] – Rat,
lorglumide
(pIC50 6.7–8.2) [805, 834] – Rat	
YF‐476
(pIC50 9.7) [196, 1854], GV150013
(pIC50 9.4) [1930], L‐740093
(pIC50 9.2) [1398], YM‐022
(pIC50 9.2) [1398], JNJ‐26070109
(pIC50 8.5) [1336], L‐365260
(pIC50 8.4) [1071], RP73870
(pIC50 8) [1115] – Rat,
LY262691
(pIC50 7.5) [1561] – Rat	
Labelled
ligands	
[3H]devazepide (Antagonist)
(pK
d 9.7) [292], [125I]DTyr‐Gly‐[(Nle28,31)CCK‐26‐33
(Agonist) (pIC50 9) [1527]	
[3H]PD140376 (Antagonist)
(pK
i 9.7–10) [809] – Guinea
pig, [125I]PD142308 (Antagonist)
(pK
d 9.6) [781] – Guinea pig, [125I]DTyr‐Gly‐[(Nle28,31)CCK‐26‐33
(Agonist) (pIC50 9) [1527], [125I]gastrin (Agonist) (pIC50
9), [3H]gastrin (Agonist) (pIC50 9),
[3H]L365260 (Antagonist)
(pK
d 8.2–8.5) [1398], [125I]‐BDZ2 (Antagonist) (pK
i 8.4) [25]	



Comments
While a cancer‐specific CCK receptor has been
postulated to exist, which also might be responsive to incompletely processed forms
of CCK (Gly‐extended forms), this has never been isolated. An alternatively spliced
form of the CCK2 receptor in which intron 4 is retained, adding 69 amino
acids to the intracellular loop 3 (ICL3) region, has been described to be present
particularly in certain neoplasms where mRNA mis‐splicing has been commonly observed
[1764], but it is not clear that
this receptor splice form plays a special role in carcinogenesis. Another alternative
splicing event for the CCK2 receptor was reported [1782], with alternative donor
sites in exon 4 resulting in long (452 amino acids) and short (447 amino acids) forms
of the receptor differing by five residues in ICL3, however, no clear functional
differences have been observed.

Further Reading
Cawston EE et al. (2010)
Therapeutic potential for novel drugs targeting the type 1 cholecystokinin receptor.
Br. J. Pharmacol.
159: 1009‐21 [PMID:19922535]


Dockray GJ. (2009) Cholecystokinin and
gut‐brain signalling. Regul. Pept.
155: 6‐10 [PMID:19345244]


Dufresne M et al. (2006)
Cholecystokinin and gastrin receptors. Physiol. Rev.
86: 805‐47 [PMID:16816139]


Miller LJ et al. (2008)
Structural basis of cholecystokinin receptor binding and regulation.
Pharmacol. Ther.
119: 83‐95 [PMID:18558433]



Class Frizzled GPCRs

Overview
Receptors of the Class Frizzled (FZD,
nomenclature as agreed by the NC‐IUPHAR subcommittee on the Class Frizzled GPCRs [
1676
]), are GPCRs originally identified inDrosophila
[285], which are highly
conserved across species. FZDs are activated by WNTs, which are cysteine‐rich
lipoglycoproteins with fundamental functions in ontogeny and tissue homeostatis. FZD
signalling was initially divided into two pathways, being either dependent on the
accumulation of the transcription regulator β‐catenin(CTNNB1, P35222) or being
β‐catenin‐independent (often referred to as canonical
vs. non‐canonical WNT/FZD signalling, respectively). WNT
stimulation of FZDs can, in cooperation with the low density lipoprotein receptors
LRP5 (O75197) and LRP6(O75581), lead to the inhibition
of a constitutively active destruction complex, which results in the accumulation of
β‐catenin and subsequently its translocation to the nucleus.
β‐Catenin, in turn, modifies gene transcription by interacting
with TCF/LEF transcription factors. β‐Catenin‐independent FZD
signalling is far more complex with regard to the diversity of the activated
pathways. WNT/FZD signalling can lead to the activation of pertussis toxin‐sensitive
heterotrimeric G proteins [939], the elevation of
intracellular calcium [1757], activation of
cGMP‐specific PDE6 [17] and elevation of cAMP as
well as RAC‐1, JNK, Rho and Rho kinase signalling [695]. Furthermore, the
phosphoprotein Disheveled constitutes a key player in WNT/FZD signalling. As with
other GPCRs, members of the Frizzled family are functionally dependent on the
arrestin scaffolding protein for internalization [306], as well as for
β‐catenin‐dependent [235] and ‐independent
[236, 940] signalling. The pattern of
cell signalling is complicated by the presence of additional ligands, which can
enhance or inhibit FZD signalling (secreted Frizzled‐related proteins (sFRP),
Wnt‐inhibitory factor(WIF1, Q9Y5W5) (WIF), sclerostin(SOST, Q9BQB4) or Dickkopf (DKK)), as
well as modulatory (co)‐receptors with Ryk, ROR1, ROR2 and Kremen, which may also
function as independent signalling proteins.


Nomenclature	
FZD1
	
FZD2
	
FZD3
	
FZD4
	
FZD5
	
HGNC, UniProt	
FZD1, Q9UP38
	
FZD2, Q14332
	
FZD3, Q9NPG1
	
FZD4, Q9ULV1
	
FZD5, Q13467
	




Nomenclature	
FZD6
	
FZD7
	
FZD8
	
FZD9
	
FZD10
	
HGNC, UniProt	
FZD6, O60353
	
FZD7, O75084
	
FZD8, Q9H461
	
FZD9, O00144
	
FZD10, Q9ULW2
	




Nomenclature	
SMO
	
HGNC, UniProt	
SMO, Q99835
	
Antagonists	
saridegib
(pIC50 8.9) [1904], glasdegib
(pIC50 8.3) [1342], erismodegib
(pK
i 8.2) [1979]	
Selective
antagonists	
vismodegib
(pK
i 7.8) [1979]	



Comments
There is limited knowledge about WNT/FZD
specificity and which molecular entities determine the signalling outcome of a
specific WNT/FZD pair. Understanding of the coupling to G proteins is incomplete (see
[423]). There is also a scarcity
of information on basic pharmacological characteristics of FZDs, such as binding
constants, ligand specificity or concentration‐response relationships [937].


Ligands associated with FZD signalling



WNTs: Wnt‐1(WNT1, P04628), Wnt‐2(WNT2, P09544) (also known as
Int‐1‐related protein), Wnt‐2b(WNT2B, Q93097) (also known as WNT‐13),
Wnt‐3(WNT3, P56703) , Wnt‐3a(WNT3A, P56704), Wnt‐4(WNT4, P56705), Wnt‐5a(WNT5A, P41221) , Wnt‐5b(WNT5B, Q9H1J7), Wnt‐6(WNT6, Q9Y6F9), Wnt‐7a(WNT7A, O00755), Wnt‐7b(WNT7B, P56706), Wnt‐8a(WNT8A, Q9H1J5), Wnt‐8b(WNT8B, Q93098), Wnt‐9a(WNT9A, O14904) (also known as WNT‐14),
Wnt‐9b(WNT9B, O14905) (also known as WNT‐15
or WNT‐14b), Wnt‐10a(WNT10A, Q9GZT5), Wnt‐10b(WNT10B, O00744) (also known as WNT‐12),
Wnt‐11(WNT11, O96014) and Wnt‐16(WNT16, Q9UBV4).


Extracellular proteins that interact with FZDs:
norrin(NDP, Q00604), R‐spondin‐1(RSPO1, Q2MKA7), R‐spondin‐2(RSPO2, Q6UXX9) , R‐spondin‐3(RSPO3, Q9BXY4), R‐spondin‐4(RSPO4, Q2I0M5), sFRP‐1(SFRP1, Q8N474), sFRP‐2(SFRP2, Q96HF1), sFRP‐3(FRZB, Q92765), sFRP‐4(SFRP4, Q6FHJ7), sFRP‐5(SFRP5, Q6FHJ7).


Extracellular proteins that interact with WNTs or LRPs:
Dickkopf 1(DKK1, O94907), WIF1 (Q9Y5W5), sclerostin(SOST, Q9BQB4), kremen 1(KREMEN1, Q96MU8) and kremen 2 (KREMEN2, Q8NCW0)


Small exogenous ligands: Foxy‐5 [1835], Box‐5, UM206 [1031], and XWnt8 (P28026) also known as mini‐Wnt8.

Further Reading
Dijksterhuis JP et al. (2013)
WNT/Frizzled signaling: receptor‐ligand selectivity with focus on FZD‐G protein
signaling and its physiological relevance. Br J Pharmacol
[PMID:24032637]


King TD et al. (2012) The
Wnt/β‐catenin signaling pathway: a potential therapeutic target
in the treatment of triple negative breast cancer. J. Cell. Biochem.
113: 13‐8 [PMID:21898546]


King TD et al. (2012)
Frizzled7 as an emerging target for cancer therapy. Cell. Signal.
24: 846‐51 [PMID:22182510]


Koval A et al. (2011) Yellow
submarine of the Wnt/Frizzled signaling: submerging from the G protein harbor to the
targets. Biochem. Pharmacol.
82: 1311‐9 [PMID:21689640]


Schuijers J et al. (2012)
Adult mammalian stem cells: the role of Wnt, Lgr5 and R‐spondins. EMBO
J.
31: 2685‐96 [PMID:22617424]


Schulte G. (2010) International Union of Basic
and Clinical Pharmacology. LXXX. The class Frizzled receptors. Pharmacol.
Rev.
62: 632‐67 [PMID:21079039]


Schulte G et al. (2010)
beta‐Arrestins ‐ scaffolds and signalling elements essential for WNT/Frizzled
signalling pathways? Br. J. Pharmacol.
159: 1051‐8 [PMID:19888962]



Complement peptide receptors

Overview
Complement peptide receptors
(nomenclature as agreed by the NC‐IUPHAR subcommittee on Complement peptide receptors [
967
]) are activated by the endogenous  75 amino‐acid anaphylatoxin
polypeptides C3a(C3, P01024). C4a(C4A, P0C0L4) and C5a(C5, P01031), generated upon
stimulation of the complement cascade.


Nomenclature	
C3a receptor
	
C5a1
receptor
	
C5a2
receptor
	
HGNC, UniProt	
C3AR1, Q16581
	
C5AR1, P21730
	
C5AR2, Q9P296
	
Rank order of
potency	
C3a (C3, P01024)
>C5a (C5, P01031)
[41]	
C5a (C5, P01031),
C5a des‐Arg
(C5) >C3a (C3, P01024)
[41]	–	
Endogenous
agonists	–	
ribosomal protein
S19 (RPS19, P39019)
[2071]	–	
Agonists	
E7
(pEC50 8.7) [43], compound 21 [PMID:
25259874] (pEC50 7.7) [1571], SQ007‐5 (Partial
agonist) (pEC50 6.7) [124], Ac‐RHYPLWR
(pEC50 6) [672]	
N‐methyl‐Phe‐Lys‐Pro‐D‐Cha‐Cha‐D‐Arg‐CO2H
(pIC50 7.6) [916, 989]	–	
Antagonists	
SB290157
(pIC50 7.6) [40], compound 4 [PMID:
25259874] (pIC50 5.9) [1571]	
CHIPS
(pK
d 9) [1522], W54011
(pK
i 8.7) [1819], AcPhe‐Orn‐Pro‐D‐Cha‐Trp‐Arg (pIC50 7.9)
[2039], N‐methyl‐Phe‐Lys‐Pro‐D‐Cha‐Trp‐D‐Arg‐CO2H
(pIC50 7.2) [989]	–	
Labelled
ligands	
[125I]C3a
(human) (Agonist) (pK
d 8.4) [296]	
[125I]C5a
(human) (Agonist) (pK
d 8.7) [803]	
[125I]C5a
(human) (Agonist)	
Comments	–	–	Binds C5a
complement factor, but appears to lack G protein signalling and has
been termed a decoy receptor [1684].	



Comments

SB290157 has also been reported
to have agonist properties at the C3a receptor [1218]. The putative
chemoattractant receptor termed C5a2 (also known as GPR77, C5L2) binds
[125I]C5a with no clear signalling function, but has a putative role
opposing inflammatory responses [257, 568, 585]. Binding to this site may
be displaced with the rank order C5a des‐Arg(C5)>C5a(C5, P01031) [257, 1440] while there is
controversy over the ability of C3a(C3, P01024) and C3a des Arg(C3, P01024) to compete [778, 894, 895, 1440]. C5a2 appears
to lack G protein signalling and has been termed a decoy receptor [1684]. However, C5a2
does recruit arrestin after ligand binding, which might provide a signaling pathway
for this receptor [89, 1937], and forms heteromers
with C5a1. C5a, but not C5a‐des Arg, induces upregulation of heteromer
formation between complement C5a receptors C5aR and C5L2 [380]. There are also reports of
pro‐inflammatory activity of C5a2, mediated by HMGB1, but the signaling
pathway that underlies this is currently unclear (reviewed in [1095]).

Further Reading
Hajishengallis G. (2010) Complement and
periodontitis. Biochem. Pharmacol.
80: 1992‐2001 [PMID:20599785]


Klos A et al. (2013)
International Union of Pharmacology. LXXXVII. Complement peptide C5a, C4a, and C3a
receptors. Pharmacol. Rev.
65: 500‐43 [PMID:23383423]


Manthey HD et al. (2009)
Complement component 5a (C5a). Int. J. Biochem. Cell Biol.
41: 2114‐7 [PMID:19464229]


Monk PN et al. (2007)
Function, structure and therapeutic potential of complement C5a receptors.
Br. J. Pharmacol.
152: 429‐48 [PMID:17603557]


Sacks SH. (2010) Complement fragments C3a and
C5a: the salt and pepper of the immune response. Eur. J. Immunol.
40: 668‐70 [PMID:20186746]



Corticotropin‐releasing factor
receptors

Overview
Corticotropin‐releasing factor (CRF,
nomenclature as agreed by the NC‐IUPHAR subcommittee on Corticotropin‐releasing Factor Receptors
[
716
]) receptors are activated by the endogenous peptides corticotrophin‐releasing
hormone (CRH, P06850), a 41 amino‐acid
peptide, urocortin 1(UCN, P55089), 40 amino‐acids,
urocortin 2 (UCN2, Q96RP3), 38 amino‐acids and
urocortin 3 (UCN3, Q969E3), 38 amino‐acids.
CRF1 and CRF2 receptors are activated non‐selectively by
corticotrophin‐releasing
hormone (CRH, P06850) and urocortin 1 (UCN, P55089). Binding to CRF
receptors can be conducted using [125I]Tyr0‐CRF or [125I]Tyr0‐sauvagine with K
d values of 0.1‐0.4 nM. CRF1 and CRF2 receptors are
non‐selectively antagonized by α‐helical CRF, D‐Phe‐CRF‐(12‐41) and astressin.


Nomenclature	
CRF1
receptor
	
CRF2
receptor
	
HGNC, UniProt	
CRHR1, P34998
	
CRHR2, Q13324
	
Endogenous
agonists	–	
urocortin 2
(UCN2, Q96RP3)
(Selective) (pK
d 8.5–8.6) [392], urocortin 3
(UCN3, Q969E3)
(Selective) (pK
d 7.9–8) [392]	
Antagonists	
SSR125543A
(pK
i 8.7) [663]	–	
Selective
antagonists	
CP 154,526
(pIC50 9.3–10.4) [1153] – Rat,
DMP696
(pK
i 8.3–9) [726], NBI27914
(pK
i 8.3–9) [298], R121919
(pK
i 8.3–9) [2133], antalarmin
(pK
i 8.3–9) [2001], CP376395
(pIC50 8.3) [307] – Rat,
CRA1000
(pIC50 6.4–7.1) [284]	
antisauvagine
(pK
d 8.8–9.6) [394], K41498
(pK
i 9.2) [1048], K31440
(pK
i 8.7–8.8) [1622]	



Comments
A CRF binding protein has been identified
(CRHBP, P24387) to which both corticotrophin‐releasing
hormone(CRH, P06850) and urocortin 1(UCN, P55089) bind with high
affinities, which has been suggested to bind and inactivate circulating corticotrophin‐releasing
hormone(CRH, P06850) [1489].

Further Reading
Grammatopoulos DK. (2012) Insights into
mechanisms of corticotropin‐releasing hormone receptor signal transduction.
Br. J. Pharmacol.
166: 85‐97 [PMID:21883143]


Gysling K. (2012) Relevance of both type‐1 and
type‐2 corticotropin releasing factor receptors in stress‐induced relapse to cocaine
seeking behaviour. Biochem. Pharmacol.
83: 1‐5 [PMID:21843515]


Hauger RL et al. (2003)
International Union of Pharmacology. XXXVI. Current status of the nomenclature for
receptors for corticotropin‐releasing factor and their ligands. Pharmacol
Rev.
55: 21‐26 [PMID:12615952]


Valentino RJ et al. (2013)
Sex‐biased stress signaling: the corticotropin‐releasing factor receptor as a model.
Mol. Pharmacol.
83: 737‐45 [PMID:23239826]


Zhu H et al. (2011)
Corticotropin‐releasing factor family and its receptors: pro‐inflammatory or
anti‐inflammatory targets in the periphery? Inflamm. Res.
60: 715‐21 [PMID:21476084]



Dopamine receptors

Overview
Dopamine receptors (nomenclature as
agreed by the NC‐IUPHAR
Subcommittee on Dopamine Receptors [1677]) are commonly divided into
D1‐like (D1 and D5) and D2‐like
(D2, D3 and D4) families, where the endogenous
agonist is dopamine.


Nomenclature	
D1
receptor
	
D2
receptor
	
HGNC, UniProt	
DRD1, P21728
	
DRD2, P14416
	
Endogenous
agonists	
dopamine
(pK
i 4.3–5.6) [1823, 1884]	
dopamine
(pK
i 4.7–7.2) [245, 545, 1653]	
Agonists	
fenoldopam
(pK
i 6.5–7.9) [1884]	
rotigotine
(pK
i 10.2) [424], cabergoline
(Partial agonist) (pK
i 9–9.2) [1279], aripiprazole
(Partial agonist) (pK
i 9.1) [2111], bromocriptine
(pK
i 7.3–8.3) [545, 1279, 1653], MLS1547 (Biased
agonist) (pK
i 8.2) [544], ropinirole
(pK
i 8.1) [732], apomorphine
(Partial agonist) (pK
i 5.7–7.5) [245, 545, 1279, 1653, 1776], pramipexole
(pK
i 5.1–7.4) [1273, 1653], benzquinamide
(pK
i 5.4) [643]	
(Sub)family‐selective agonists	
A68930
(pEC50 6.8) [1381], SKF‐38393
(Partial agonist) (pK
i 6.2–6.8) [1823, 1884]	
quinpirole
(pK
i 4.9–7.7) [245, 1273, 1473, 1776, 1778, 1940]	
Selective
agonists	
SKF‐83959
(Biased agonist) (pEC50 9.7) [364], SKF‐81297
(pK
i 8.7) [46] – Rat	
sumanirole
(pK
i 8.1) [1239]	
Antagonists	
flupentixol
(pK
i 7–8.4) [1823, 1884]	
blonanserin
(pK
i 9.9) [1421], pipotiazine
(pK
i 9.7) [1777], perphenazine
(pK
i 8.9–9.6) [1008, 1691],
risperidone
(pK
i 9.4) [60], perospirone
(pK
i 9.2) [1692], trifluoperazine
(pK
i 8.9–9) [1008, 1693], asenapine
(pK
i 8.9) [1711], sertindole
(pK
i 8–8.9) [986, 1008, 1691],
fluphenazine
(pK
i 8.8) [1647], flupentixol
(pK
i 8.8) [545], pimozide
(pK
i 7–8.8) [545, 1776], olanzapine
(pK
i 8.7) [60], mesoridazine
(pK
i 8.7) [326], ziprasidone
(pK
i 8.6) [60], prochlorperazine
(pK
i 8.4) [68], loxapine
(pK
i 7.9–8.3) [1008, 1693], (‐)‐sulpiride
(pK
i 6.3–8) [545, 1776, 1860], amisulpride
(pK
i 7.9–8) [1195, 1776], metoclopramide
(pK
i 7.5) [1221] – Mouse,
quetiapine
(pK
i 7.2) [60], trans‐flupenthixol (pK
i 6.9) [545], clozapine
(pK
i 5.8–6.9) [545, 1164, 1711, 1776, 1860], promazine
(pK
i 6.5) [246]	
(Sub)family‐selective antagonists	
SCH‐23390
(pK
i 7.4–9.5) [1823, 1884], SKF‐83556
(pK
i 9.5) [1823], ecopipam
(pK
i 8.3) [1885]	
haloperidol
(pK
i 7.4–8.8) [545, 1164, 1273, 1776, 1885]	
Selective
antagonists	–	
L‐741,626
(pK
i 7.9–8.5) [655, 1020], domperidone
(pK
i 7.9–8.4) [545, 1776], raclopride
(pK
i 8) [1281], ML321
(pK
i 7) [2058, 2059]	
Labelled
ligands	
[3H]SCH‐23390 (Antagonist)
(pK
d 9.5) [2127]	
[3H]spiperone (Antagonist)
(pK
d 10.2) [239, 767, 2125] – Rat	
Labelled
ligands	
[125I]SCH23982 (Antagonist)
(pK
d 9.5) [408]	
[3H]raclopride (Antagonist)
(pK
d 8.9) [1028] – Rat	




Nomenclature	
D3
receptor
	
D4
receptor
	
D5
receptor
	
HGNC, UniProt	
DRD3, P35462
	
DRD4, P21917
	
DRD5, P21918
	
Endogenous
agonists	
dopamine
(pK
i 6.4–7.3) [245, 545, 1653, 1778]	
dopamine
(pK
i 7.6) [1940]	
dopamine
(pK
i 6.6) [1823]	
Agonists	
pramipexole
(pK
i 8.4–8.7) [1273, 1653], bromocriptine
(Partial agonist) (pK
i 7.1–8.2) [545, 1279, 1653], ropinirole
(pK
i 7.7) [732], apomorphine
(Partial agonist) (pK
i 6.1–7.6) [245, 545, 1279, 1653, 1776]	
apomorphine
(Partial agonist) (pK
i 8.4) [1279]	–	
(Sub)family‐selective agonists	
quinpirole
(pK
i 6.4–8) [245, 1273, 1281, 1473, 1653, 1776, 1778, 1940]	
quinpirole
(pK
i 7.5) [1279, 1473, 1940]	
A68930
(pEC50 6.6) [1381]	
Selective
agonists	
PD 128907
(pK
i 7.6–7.7) [1539, 1653]	
PD168,077
(Partial agonist) (pK
i 8.8) [995] – Rat,
A412997
(pK
i 8.1) [1319] – Rat,
A412997
(pK
i 8.1) [1319]	–	
Antagonists	
perospirone
(pK
i 9.6) [1776], sertindole
(pK
i 8–8.8) [60, 1675, 1691],
prochlorperazine
(pK
i 8.4) [68], (‐)‐sulpiride
(pK
i 6.7–7.7) [545, 1776, 1860], loxapine
(pK
i 7.7) [1691], domperidone
(pK
i 7.1–7.6) [545, 1776], promazine
(pK
i 6.8) [246]	
perospirone
(pK
i 10.1) [1694], sertindole
(pK
i 7.8–9.1) [246, 1691,
1693, 1694], sonepiprazole
(pK
i 8.9) [1668], loxapine
(pK
i 8.1) [1693]	–	
(Sub)family‐selective antagonists	
haloperidol
(pK
i 7.5–8.6) [545, 1711, 1776, 1885]	
haloperidol
(pK
i 8.7–8.8) [1033, 1711, 1885]	
SCH‐23390
(pK
i 7.5–9.5) [1823], SKF‐83556
(pK
i 9.4) [1823], ecopipam
(pK
i 8.3) [1823]	
Selective
antagonists	
S33084
(pK
i 9.6) [1278], nafadotride
(pK
i 9.5) [1654], PG01037
(pK
i 9.2) [656], NGB 2904
(pK
i 8.8) [2055], SB 277011‐A
(pK
i 8) [1569], (+)‐S‐14297
(pK
i 6.9–7.9) [1275, 1281]	
L745870
(pK
i 9.4) [1020], A‐381393
(pK
i 8.8) [1361], L741742
(pK
i 8.5) [1609], ML398
(pK
i 7.4) [138]	–	
Selective
allosteric modulators	
SB269652
(Negative) (pK
i∼9) [558]	–	–	
Labelled
ligands	–	
[3H]spiperone (Antagonist)
(pK
d 9.5) [749, 1940]	
[3H]SCH‐23390 (Antagonist)
(pK
d 9.2) [1580]	
Labelled
ligands	
[3H]spiperone (Antagonist)
(pK
d 9.9) [767, 2125] – Rat,
[3H]7‐OH‐DPAT (Agonist) (pK
d 9.6) [1581], [3H]PD128907 (Agonist) (pK
d 9) [27]	
[125I]L750667 (Antagonist)
(pK
d 9.8) [1473], [3H]NGD941 (Antagonist) (pK
d 8.3) [1533]	
[125I]SCH23982 (Antagonist)
(pK
d 9.1) – Unknown	



Comments
The selectivity of many of these agents is less
than two orders of magnitude. [3H]raclopride
exhibits similar high affinity for D2 and D3 receptors (low
affinity for D4), but has been used to label D2 receptors in
the presence of a D3‐selective antagonist. [3H]7‐OH‐DPAT has
similar affinity for D2 and D3 receptors, but labels only
D3 receptors in the absence of divalent cations. The pharmacological
profile of the D5 receptor is similar to, yet distinct from, that of the
D1 receptor. The splice variants of the D2 receptor are
commonly termed D2S and D2L (short and long). The
DRD4 gene encoding the D4 receptor is highly
polymorphic in humans, with allelic variations of the protein from amino acid 387 to
515.

Further Reading
Beaulieu JM et al. (2015)
Dopamine receptors ‐ IUPHAR Review 13. Br. J. Pharmacol.
172: 1‐23 [PMID:25671228]


Beaulieu JM et al. (2011) The
physiology, signaling, and pharmacology of dopamine receptors. Pharmacol.
Rev.
63: 182‐217 [PMID:21303898]


Cumming P. (2011) Absolute abundances and
affinity states of dopamine receptors in mammalian brain: A review.
Synapse
65: 892‐909 [PMID:21308799]


Maggio R et al. (2010)
Dopamine D2‐D3 receptor heteromers: pharmacological properties and therapeutic
significance. Curr Opin Pharmacol
10: 100‐7 [PMID:19896900]


Ptácek R et al. (2011)
Dopamine D4 receptor gene DRD4 and its association with psychiatric disorders.
Med. Sci. Monit.
17: RA215‐20 [PMID:21873960]


Schwartz J‐C et al.. (1998)
Dopamine Receptors. In The IUPHAR Compendium of Receptor Characterization and
Classification Edited by Girdlestone D: IUPHAR Media: 141‐151

Undieh AS. (2010) Pharmacology of signaling
induced by dopamine D(1)‐like receptor activation. Pharmacol. Ther.
128: 37‐60 [PMID:20547182]



Endothelin receptors

Overview
Endothelin receptors (nomenclature as
agreed by the NC‐IUPHAR
Subcommittee on Endothelin Receptors [
395
]) are activated by the endogenous 21 amino‐acid peptides endothelins
1‐3 (endothelin‐1(EDN1, P05305), endothelin‐2(EDN2, P20800) and endothelin‐3(EDN3, P14138)).


Nomenclature	
ETA
receptor
	
ETB
receptor
	
HGNC, UniProt	
EDNRA, P25101
	
EDNRB, P24530
	
Family selective
agonists	
endothelin‐1
(EDN1, P05305) =
endothelin‐2
(EDN2, P20800)
>endothelin‐3
(EDN3, P14138)
[1178]	
endothelin‐1
(EDN1, P05305) =
endothelin‐2
(EDN2, P20800),
endothelin‐3
(EDN3, P14138)	
Selective
agonists	–	
sarafotoxin S6c
(pK
d 8.8–9.8) [1016, 1616], BQ 3020
(pK
i 9.7) [1576], [Ala1,3,11,15]ET‐1 (pK
d 8.7–9.2) [1300], IRL 1620
(pK
i 8.7) [1991]	
(Sub)family‐selective antagonists	
SB209670
(pK
B 9.4) [474] – Rat,
TAK 044
(pA2 8.4) [1993] – Rat,
bosentan
(pA2 7.2) [354] – Rat	
SB209670
(pK
B 9.4) [474] – Rat,
TAK 044
(pA2 8.4) [1993] – Rat,
bosentan
(pK
i 7.1) [1349]	
Selective
antagonists	
atrasentan
(pA2 9.2–10.5) [1446], PD‐156707
(pK
d 9–9.8) [1180], macitentan
(pIC50 9.3) [174], sitaxsentan
(pA2 8) [2047], FR139317
(Inverse agonist) (pIC50 7.3–7.9) [1178], ambrisentan
(pIC50 7.7) [175], BQ123
(pA2 6.9–7.4) [1178], avosentan
(pIC50 7.3) [210], ambrisentan
(pA2 7.1) [175]	
A192621
(pK
d 8.1) [2145], BQ788
(pK
d 7.9–8) [1616], IRL 2500
(pK
d 7.2) [1616], Ro 46‐8443
(pIC50 7.2) [209]	
Labelled
ligands	
[125I]PD164333 (Antagonist)
(pK
d 9.6–9.8) [398], [3H]S0139 (Antagonist) (pK
d 9.2), [125I]PD151242 (Antagonist)
(pK
d 9–9.1) [399], [3H]BQ123 (Antagonist) (pK
d 8.5) [817]	
[125I]IRL1620 (Agonist) (pK
d 9.9–10.1) [1362], [125I]BQ3020 (Agonist) (pK
d 8.3–10) [702, 1300, 1495], [125I][Ala1,3,11,15]ET‐1
(Agonist) (pK
d 9.7) [1300]	



Comments
Splice variants of the ETA receptor
have been identified in rat pituitary cells; one of these, ETAR‐C13,
appeared to show loss of function with comparable plasma membrane expression to wild
type receptor [713]. Subtypes of the
ETB receptor have been proposed, although gene disruption studies in
mice suggest that only a single gene product exists [1295].

Further Reading
Clozel M et al. (2013)
Endothelin receptor antagonists. Handb Exp Pharmacol
218: 199‐227 [PMID:24092342]


Davenport AP. (2002) International Union of
Pharmacology. XXIX. Update on endothelin receptornomenclature. Pharmacol.
Rev.
54: 219‐226 [PMID:12037137]


Dhaun N et al. (2012)
Endothelin‐1 and the kidney–beyond BP. Br. J. Pharmacol.
167: 720‐31 [PMID:22670597]


Kohan DE et al. (2012)
Clinical trials with endothelin receptor antagonists: what went wrong and where can
we improve? Life Sci.
91: 528‐39 [PMID:22967485]


Kohan DE et al. (2011)
Regulation of blood pressure and salt homeostasis by endothelin. Physiol.
Rev.
91: 1‐77 [PMID:21248162]


Ling L et al. (2013)
Endothelin‐2, the forgotten isoform: emerging role in the cardiovascular system,
ovarian development, immunology and cancer. Br. J. Pharmacol.
168: 283‐95 [PMID:22118774]


Maguire JJ et al. (2014)
Endothelin@25 ‐ new agonists, antagonists, inhibitors and emerging research
frontiers: IUPHAR Review 12. Br. J. Pharmacol.
171: 5555‐72 [PMID:25131455]


Maguire JJ et al. (2015)
Endothelin Receptors and Their Antagonists. Semin. Nephrol.
35: 125‐136 [PMID:25966344]


Said N et al. (2012)
Permissive role of endothelin receptors in tumor metastasis. Life
Sci.
91: 522‐7 [PMID:22846215]


Speed JS et al. (2013)
Endothelin, kidney disease, and hypertension. Hypertension
61: 1142‐5 [PMID:23608655]



G protein‐coupled estrogen
receptor

Overview
The G protein‐coupled estrogen receptor (GPER,
nomenclature as agreed by the NC‐IUPHAR Subcommittee on the G protein‐coupled estrogen receptor
[
1536
]) was identified following observations of estrogen‐evoked cyclic AMP signalling in breast
cancer cells [61], which mirrored the
differential expression of an orphan 7‐transmembrane receptor GPR30 [265]. There are observations of
both cell‐surface and intracellular expression of the GPER receptor [1573, 1877].


Nomenclature	
GPER
	
HGNC, UniProt	
GPER1, Q99527
	
Selective
agonists	
G1
(pK
i 8) [176]	
Selective
antagonists	
G36
(pIC50 6.8–6.9) [414], G15
(pIC50 6.7) [413]	
Labelled
ligands	
[3H]17β‐estradiol
(Agonist) (pK
d 8.5–8.6) [1877]	



Comments
Antagonists at the nuclear estrogen receptor,
such as fulvestrant and tamoxifen[515], as well as the flavonoid
‘phytoestrogens’ genistein and quercetin[1177], are agonists at GPER
receptors.

Further Reading
Barton M et al. (2015)
Emerging roles of GPER in diabetes and atherosclerosis. Trends Endocrinol.
Metab.
26: 185‐92 [PMID:25767029]


Han G et al. (2013) GPER: a
novel target for non‐genomic estrogen action in the cardiovascular system.
Pharmacol. Res.
71: 53‐60 [PMID:23466742]


Lappano R et al. (2014) GPER
Function in Breast Cancer: An Overview. Front Endocrinol (Lausanne)
5: 66 [PMID:24834064]


Prossnitz ER et al. (2015)
International Union of Basic and Clinical Pharmacology. XCVII. G Protein‐Coupled
Estrogen Receptor and Its Pharmacologic Modulators. Pharmacol. Rev.
67: 505‐40 [PMID:26023144]


Prossnitz ER et al. (2014)
Estrogen biology: new insights into GPER function and clinical opportunities.
Mol. Cell. Endocrinol.
389: 71‐83 [PMID:24530924]



Formylpeptide receptors

Overview
The formylpeptide receptors
(nomenclature agreed by the NC‐IUPHAR Subcommittee on the formyl peptide receptor family
[
2092
]) respond to exogenous ligands such as the bacterial product fMet‐Leu‐Phe (fMLP) and
endogenous ligands such as annexin I(ANXA1, P04083) , cathepsin G(CTSG, P08311), amyloid
β42, serum amyloid A and spinorphin, derived from
β‐haemoglobin(HBB, P68871).


Nomenclature	
FPR1
	
FPR2/ALX
	
FPR3
	
HGNC, UniProt	
FPR1, P21462
	
FPR2, P25090
	
FPR3, P25089
	
Rank order of
potency	
fMet‐Leu‐Phe>cathepsin G
(CTSG, P08311)
>annexin I
(ANXA1, P04083)
[1058, 1821]	
LXA4=aspirin triggered lipoxin
A4=ATLa2>LTC4=LTD4≫15‐deoxy‐LXA4≫fMet‐Leu‐Phe
[352, 519, 521, 651, 1846]	–	
Endogenous
agonists	–	
LXA4 (Selective) (pEC50∼12) [1006], resolvin D1
(Selective) (pEC50∼11.9) [1006], aspirin triggered lipoxin
A4 (Selective)	
F2L (HEBP1, Q9NRV9)
(Selective) (pEC50 8–8.2) [1274]	
Agonists	
fMet‐Leu‐Phe
(pEC50 10.1–10.2) [546, 1734]	–	–	
Selective
agonists	–	
ATLa2 [662]	–	
Endogenous
antagonists	
spinorphin
(Selective) (pIC50 4.3) [1099, 1348]	–	–	
Antagonists	
t‐Boc‐FLFLF
(pK
i 6–6.5) [2008]	–	–	
Selective
antagonists	
cyclosporin H
(pK
i 6.1–7.1) [2008, 2078]	–	–	
Labelled
ligands	
[3H]fMet‐Leu‐Phe (Agonist)
(pK
d 7.6–9.3) [990]	
[3H]LXA4 (Agonist) (pK
d 9.2–9.3) [519, 520]	–	
Comments	A FITC‐conjugated
fMLP analogue has been used for binding to the mouse recombinant
receptor [724].	The agonist
activity of the lipid mediators described has been questioned
[697, 1513], which may
derive from batch‐to‐batch differences, partial agonism or biased
agonism. Recent results from Cooray et al. (2013)
[365] have
addressed this issue and the role of homodimers and heterodimers in
the intracellular signaling .	–	



Comments
Note that the data for FPR2/ALX are also
reproduced on the leukotriene receptor page.

Further Reading
Dorward DA et al. (2015) The
Role of Formylated Peptides and Formyl Peptide Receptor 1 in Governing Neutrophil
Function during Acute Inflammation. Am. J. Pathol.
185: 1172‐1184 [PMID:25791526]


Dufton N et al. (2010)
Therapeutic anti‐inflammatory potential of formyl‐peptide receptor agonists.
Pharmacol. Ther.
127: 175‐88 [PMID:20546777]


Liu M et al. (2012) G
protein‐coupled receptor FPR1 as a pharmacologic target in inflammation and human
glioblastoma. Int. Immunopharmacol.
14: 283‐8 [PMID:22863814]


Rabiet MJ et al. (2011)
N‐formyl peptide receptor 3 (FPR3) departs from the homologous FPR2/ALX receptor with
regard to the major processes governing chemoattractant receptor regulation,
expression at the cell surface, and phosphorylation. J. Biol. Chem.
286: 26718‐31 [PMID:21543323]


Yazid S et al. (2012)
Anti‐inflammatory drugs, eicosanoids and the annexin A1/FPR2 anti‐inflammatory
system. Prostaglandins Other Lipid Mediat.
98: 94‐100 [PMID:22123264]


Ye RD et al. (2009)
International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the
formyl peptide receptor (FPR) family. Pharmacol. Rev.
61: 119‐61 [PMID:19498085]



Free fatty acid receptors

Overview
Free fatty acid receptors (FFA,
nomenclature as agreed by the NC‐IUPHAR Subcommittee on free fatty acid receptors [
396
,
1803
]) are activated by free fatty acids. Long‐chain saturated and
unsaturated fatty acids (C14.0 (myristic acid), C16:0
(palmitic acid), C18:1
(oleic acid), C18:2 (linoleic acid), C18:3,
(α‐linolenic acid), C20:4 (arachidonic acid), C20:5,n‐3
(EPA), C22:6,n‐3 (docosahexaenoic acid)) activate
FFA1 [218, 833, 998] and FFA4 receptors
[757, 812, 1427], while short chain fatty
acids (C2 (acetic acid), C3 (propanoic acid), C4 (butyric acid) and C5 (pentanoic acid)) activate FFA2
[226, 1057, 1399] and FFA3 [226, 1057] receptors. In addition,
thiazolidinedione PPARγ agonists such as rosiglitazone activate FFA1
(pEC50 5.2; [999, 1768, 1802]) and small molecule
allosteric modulators, such as 4‐CMTB, have recently been
characterised for FFA2 [801, 1070, 1769].


Nomenclature	
FFA1 receptor
	
FFA2 receptor
	
FFA3 receptor
	
FFA4 receptor
	
GPR42
	
HGNC, UniProt	
FFAR1, O14842
	
FFAR2, O15552
	
FFAR3, O14843
	
FFAR4, Q5NUL3
	
GPR42, O15529
	
Endogenous
agonists	
docosahexaenoic
acid (pEC50 5.4–6) [218, 833]	–	–	
α‐linolenic acid (pEC50 5.5)
[1727]	–	
Agonists	
fasiglifam
(pEC50 7.1) [893, 1791, 1909]	–	–	–	–	
(Sub)family‐selective agonists	
α‐linolenic acid (pEC50
4.6–5.7) [218, 833, 998], oleic acid
(pEC50 3.9–5.7) [218, 833, 998], myristic acid
(pEC50 4.5–5.1) [218, 833, 998]	
propanoic acid
(pEC50 3–4.9) [226, 1057, 1399, 1670], acetic acid
(pEC50 3.1–4.6) [226, 1057, 1399, 1670], butyric acid
(pEC50 2.9–4.6) [226, 1057, 1399, 1670], trans‐2‐methylcrotonic acid
(pEC50 3.8) [1670], 1‐methylcyclopropanecarboxylic acid (pEC50
2.6) [1670]	
propanoic acid
(pEC50 3.9–5.7) [226, 1057, 1670, 2063], butyric acid
(pEC50 3.8–4.9) [226, 1057, 1670, 2063], 1‐methylcyclopropanecarboxylic acid (pEC50
3.9) [1670], acetic acid
(pEC50 2.8–3.9) [226, 1057, 1670, 2063]	
myristic acid
(pEC50 5.2) [1996], oleic acid
(pEC50 4.7) [1996]	–	
Selective
agonists	
AMG‐837
(pEC50 8.5) [1110], TUG‐770
(pEC50 8.2) [332], GW9508
(pEC50 7.3) [217], linoleic acid
(pEC50 4.4–5.7) [218, 833, 998]	
compound 1 [PMID:
23589301] (pEC50 7.1) [800] – Rat,
(S)‐4‐CMTB
(pEC50 6.4) [801, 1070]	–	
compound A [PMID
24997608] (pEC50 7.6) [1428], TUG‐891
(pEC50 7) [1727] – Unknown,
NCG21
(pEC50 5.9) [1829]	–	
Selective
antagonists	
GW1100
(pIC50 6) [217]	
GLPG0974
(pIC50 8.1) [1512], CATPB
(pIC50 6.5) [801]	–	–	–	
Comments	Antagonist
GW1100 has been
shown to reduce [35S]GTPγS binding in
FFAR1‐expressing cells [1802]. GW1100 is
also an oxytocin receptor antagonist [217]. TUG‐770
and GW9508 are both
approximately 100 fold selective for FFA1 over FFA4 [217, 332]. AMG‐837
and the related analogue AM6331 have been suggested to have an
allosteric mechanism of action at FFA1, with respect to the
orthosteric fatty acid binding site [1110, 2064].	–	Beta‐hydroxybutyrate has been reported to antagonise FFA3 responses
to short chain fatty acids [951]. A range of
FFA3 selective molecules with agonist and antagonist properties, but
which bind at sites distinct from the short chain fatty acid binding
site, have recently been described [799].	
compound A [PMID
24997608] exhibits more than 1000 fold selectivity
[1428], and
TUG‐891 50‐1000
fold selectivity for FFA4 over FFA1 [1727], dependent
on the assay. NGC21 exhibits approximately 15 fold selectivity for
FFA4 over FFA1 [1820].	–	



Comments
Short (361 amino acids) and long (377 amino
acids) splice variants of human FFA4 have been reported [1318], which differ by a 16
amino acid insertion in intracellular loop 3, and exhibit differences in
intracellular signalling properties in recombinant systems [1996]. The long FFA4 splice
variant has not been identified in other primates or rodents to date [757, 1318].


GPR42 was originally described as a pseudogene within the family (ENSFM00250000002583), but the
recent discovery of several polymorphisms suggests that some versions of GPR42 may be
functional [1101]. GPR84 is a structurally‐unrelated G protein‐coupled receptor which has been
found to respond to medium chain fatty acids [1981].

Further Reading
Mancini AD et al. (2013) The
fatty acid receptor FFA1/GPR40 a decade later: how much do we know? Trends
Endocrinol. Metab.
24: 398‐407 [PMID:23631851]


Maslowski KM et al. (2011)
Diet, gut microbiota and immune responses. Nat. Immunol.
12: 5‐9 [PMID:21169997]


Milligan G et al. (2009)
Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and
FFA3. Br. J. Pharmacol.
158: 146‐53 [PMID:19719777]


Reimann F et al. (2012)
G‐protein‐coupled receptors in intestinal chemosensation. Cell
Metab.
15: 421‐31 [PMID:22482725]


Stoddart LA et al. (2008)
International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, ‐2, and
‐3: pharmacology and pathophysiological functions. Pharmacol. Rev.
60: 405‐17 [PMID:19047536]


Talukdar S et al. (2011)
Targeting GPR120 and other fatty acid‐sensing GPCRs ameliorates insulin resistance
and inflammatory diseases. Trends Pharmacol. Sci.
32: 543‐50 [PMID:21663979]


Watterson KR et al. (2014)
Treatment of type 2 diabetes by free Fatty Acid receptor agonists. Front
Endocrinol (Lausanne)
5: 137 [PMID:25221541]



GABAB receptors

Overview
Functional GABAB receptors
(nomenclature as agreed by the NC‐IUPHAR Subcommittee on GABAB receptors [
194
,
1507
]) are formed from the heterodimerization of two similar 7TM subunits
termed GABAB1 and GABAB2[194, 478, 1506, 1507, 1926]. GABAB
receptors are widespread in the CNS and regulate both pre‐ and postsynaptic activity.
The GABAB1 subunit, when expressed alone, binds both antagonists and
agonists, but the affinity of the latter is generally 10‐100‐fold less than for the
native receptor. The GABAB1 subunit when expressed alone is not
transported to the cell membrane and is non‐functional. However, Richer et
al.. (2008) report that GABAB1 alone can control ERK/MAPK
pathway activity [1585]. Co‐expression of
GABAB1 and GABAB2 subunits allows transport of
GABAB1 to the cell surface and generates a functional receptor that can
couple to signal transduction pathways such as high‐voltage‐activated Ca2+
channels (Cav2.1, Cav2.2), or inwardly rectifying potassium
channels (Kir3) [144, 194, 195]. The
GABAB2subunit also determines the rate of internalisation of the dimeric
GABAB receptor [693]. The GABAB1
subunit harbours the GABA (orthosteric)‐binding site within an extracellular domain
(ECD) venus flytrap module (VTM), whereas the GABAB2 subunit mediates G
protein‐coupled signalling [194, 591, 592, 1506]. The two subunits
interact by direct allosteric coupling [1313], such that
GABAB2 increases the affinity of GABAB1 for agonists and
reciprocally GABAB1 facilitates the coupling of GABAB2 to G
proteins [591, 1013, 1506]. GABAB1 and
GABAB2 subunits assemble in a 1:1 stoichiometry by means of a
coiled‐coil interaction between α‐helices within their
carboxy‐termini that masks an endoplasmic reticulum retention motif (RXRR) within the
GABAB1 subunit but other domains of the proteins also contribute to
their heteromerization [144, 243, 1506]. Recent evidence
indicates that higher order assemblies of GABABreceptor comprising dimers
of heterodimers occur in recombinant expression systems and in vivo
and that such complexes exhibit negative functional cooperativity between
heterodimers [361, 1505]. Adding further
complexity, KCTD (potassium channel tetramerization proteins) 8, 12, 12b and 16
associate as tetramers with the carboxy terminus of the GABAB2 subunit to
impart altered signalling kinetics and agonist potency to the receptor complex
[102, 1680, 1914] and reviewed by
[1508]. Four isoforms of the
human GABAB1 subunit have been cloned. The predominant
GABAB1(a) and GABAB1(b) isoforms, which are most prevalent
in neonatal and adult brain tissue respectively, differ in their ECD sequences as a
result of the use of alternative transcription initiation sites.
GABAB1(a)‐containing heterodimers localise to distal axons and mediate
inhibition of glutamate release in the CA3‐CA1 terminals, and GABA release onto the
layer 5 pyramidal neurons, whereas GABAB1(b)‐containing receptors occur
within dendritic spines and mediate slow postsynaptic inhibition [1541, 1955]. Isoforms generated by
alternative splicing are GABAB1(c) that differs in the ECD, and
GABAB1(e), which is a truncated protein that can heterodimerize with
the GABAB2 subunit but does not constitute a functional receptor. Only the
1a and 1b variants are identified as components of native receptors [194]. Additional
GABAB1 subunit isoforms have been described in rodents and humans
[1065] and reviewed
by [144].


Nomenclature	
GABAB
receptor
	
Subunits	
kcdt12b
(Accessory protein), KCTD16
(Accessory protein), KCTD12
(Accessory protein), GABAB2, GABAB1, KCTD8 (Accessory
protein)	
Agonists	
CGP 44532
(pIC50 8.6) [551] – Rat, (‐)‐baclofen
(pIC50 8.5) [551] – Rat, 3‐APPA
(pK
i 5.2–7.2) [762], baclofen
(pK
i 4.3–6.2) [762, 2041], 3‐APMPA
(pK
i 5.1) [2041]	
Antagonists	
CGP 62349
(pK
i 8.5–8.9) [762, 2041], CGP 55845
(pK
i 7.8) [2041], SCH 50911
(pK
i 5.5–6) [762, 2041], CGP 35348
(pK
i 4.4) [2041], 2‐hydroxy‐saclofen (pIC50 4.1) [914] – Rat	
Labelled
ligands	
[3H]CGP
54626 (Antagonist) (pK
i 9.1) [879] – Rat,
[3H]CGP
62349 (Antagonist) (pK
d 9.1) [922] – Rat,
[125I]CGP
64213 (Antagonist) (pK
d 9) [563] – Rat,
[125I]CGP
71872 (Antagonist) (pK
d 9) [914] – Rat,
[3H](R)‐(‐)‐baclofen (Agonist)	



Subunits

Nomenclature	
GABAB1
	
GABAB2
	
HGNC, UniProt	
GABBR1, Q9UBS5
	
GABBR2, O75899
	



Comments
Potencies of agonists and antagonists listed in
the table, quantified as IC50 values for the inhibition of [3H]CGP27492 binding
to rat cerebral cortex membranes, are from [194, 550, 551]. Radioligand
K
D values relate to binding to rat brain membranes. CGP 71872 is a photoaffinity
ligand for the GABAB1 subunit [122]. CGP27492 (3‐APPA), CGP35024 (3‐APMPA) and CGP 44532 act as antagonists at
human GABAA
ρ1 receptors, with potencies in the low micromolar range [550]. In addition to the
ligands listed in the table, Ca2+ binds to the VTM of the GABAB1 subunit to act as a positive
allosteric modulator of GABA[563]. In cerebellar Purkinje
neurones, the interaction of Ca2+ with the GABAB receptor enhances the activity of
mGlu1, through functional cross‐talk involving G‐protein
Gβ
γ subunits [1590, 1837]. Synthetic positive
allosteric modulators with low, or no, intrinsic activity include CGP7930, GS39783, BHF‐177 and (+)‐BHFF[9, 144, 150, 550]. The site of action of
CGP7930 and GS39783 appears to be on the
heptahelical domain of the GABAB2 subunit [455, 1506]. In the presence of
CGP7930 or GS39783, CGP 35348 and 2‐hydroxy‐saclofen behave as
partial agonists [550]. A negative allosteric
modulator of GABAB activity has been reported [302]. Knock‐out of the
GABAB1 subunit in C57B mice causes the development of severe
tonic‐clonic convulsions that prove fatal within a month of birth, whereas GABAB1−/− BALB/c mice, although also displaying spontaneous epileptiform activity,
are viable. The phenotype of the latter animals additionally includes hyperalgesia,
hyperlocomotion (in a novel, but not familiar, environment), hyperdopaminergia,
memory impairment and behaviours indicative of anxiety [482, 1932]. A similar phenotype has
been found for GABAB2−/− BALB/c mice [582].

Further Reading
Bettler B et al. (2004)
Molecular structure and physiological functions of GABA(B) receptors.
Physiol. Rev.
84: 835‐67 [PMID:15269338]


Bowery NG et al. (2002)
International Union of Pharmacology. XXXIII. Mammalian gamma‐aminobutyricacid(B)
receptors: structure and function. Pharmacol Rev.
54: 247‐264 [PMID:12037141]


Froestl W. (2011) An historical perspective on
GABAergic drugs. Future Med Chem
3: 163‐75 [PMID:21428811]


Gassmann M et al. (2012)
Regulation of neuronal GABA(B) receptor functions by subunit composition.
Nat. Rev. Neurosci.
13: 380‐94 [PMID:22595784]


Marshall FH. (2005) Is the GABA B heterodimer a
good drug target? J. Mol. Neurosci.
26: 169‐76 [PMID:16012190]


Rondard P et al. (2011) The
complexity of their activation mechanism opens new possibilities for the modulation
of mGlu and GABAB class C G protein‐coupled receptors.
Neuropharmacology
60: 82‐92 [PMID:20713070]



Galanin receptors

Overview
Galanin receptors (provisional
nomenclature as recommended by NC‐IUPHAR[
530
]) are activated by the endogenous peptides galanin(GAL, P22466) and galanin‐like peptide(GALP, Q9UBC7). Human galanin(GAL, P22466) is a 30 amino‐acid
non‐amidated peptide [499]; in other species, it is
29 amino acids long and C‐terminally amidated. Amino acids 1‐14 of galanin are highly
conserved in mammals, birds, reptiles, amphibia and fish. Shorter peptide species
(e.g. human galanin‐1‐19 [139] and porcine galanin‐5‐29
[1740]) and N‐terminally
extended forms (e.g. N‐terminally seven and nine residue elongated
forms of porcine galanin [140, 1740]) have been reported.


Nomenclature	
GAL1
receptor
	
GAL2
receptor
	
GAL3
receptor
	
HGNC, UniProt	
GALR1, P47211
	
GALR2, O43603
	
GALR3, O60755
	
Rank order of
potency	
galanin
(GAL, P22466)
>galanin‐like
peptide (GALP, Q9UBC7)
[1433]	
galanin‐like
peptide (GALP, Q9UBC7)
≥galanin
(GAL, P22466)
[1433]	
galanin‐like
peptide (GALP, Q9UBC7)
>galanin
(GAL, P22466)
[1039]	
Agonists	–	
galanin(2‐29)
(rat/mouse) (pK
i 7.2–8.7) [1457, 1982, 1983, 1984] – Rat	–	
Selective
agonists	–	
[D‐Trp2]galanin‐(1‐29) (pK
i 8.1) [1765] – Rat	–	
Selective
antagonists	
2,3‐dihydro‐1,4‐dithiin‐1,1,4,4‐tetroxide
(pIC50 5.6) [1688]	
M871
(pK
i 7.9) [1780]	
SNAP 398299
(pK
i 8.3) [987, 988, 1833], SNAP 37889
(pK
i 7.8–7.8) [987, 988, 1833]	
Selective
allosteric modulators	–	
CYM2503
(Positive) (pEC50 9.2) [1147] – Rat	–	
Labelled
ligands	
[125I][Tyr26]galanin (human)
(Agonist) (pK
d 10.3) [525], [125I][Tyr26]galanin (human)
(Agonist) (pK
d 7.8) [525]	
[125I][Tyr26]galanin (human)
(Agonist) (pK
d 9.2) [1983] – Rat	
[125I][Tyr26]galanin (pig)
(Agonist) (pK
d 8.6) [187, 1766]	
Comments	–	The CYM2503 PAM
potentiates the anticonvulsant activity of endogenous galanin in mouse
seizure models [1147].	–	



Comments

galanin‐(1‐11) is a
high‐affinity agonist at GAL1/GAL2(pK
i 9), and galanin(2‐11) is selective for
GAL2 and GAL3 compared with GAL1[1146].
[125I]‐[Tyr26]galanin binds to all three subtypes with
K
d values generally reported to range from 0.05 to 1 nM, depending on the
assay conditions used [525, 1752, 1765, 1766, 1983]. Porcine galanin‐(3‐29)
does not bind to cloned GAL1, GAL2 or GAL3
receptors, but a receptor that is functionally activated by porcine galanin‐(3‐29)
has been reported in pituitary and gastric smooth muscle cells [658, 2054]. Additional galanin
receptor subtypes are also suggested from studies with chimeric peptides
(e.g. M15, M35 and M40), which act as antagonists
in functional assays in the cardiovascular system [1924], spinal cord [2024], locus coeruleus,
hippocampus [100] and hypothalamus
[101, 1078], but exhibit agonist
activity at some peripheral sites [101, 658]. The chimeric peptides
M15, M32, M35, M40 and C7 are agonists at
GAL1 receptors expressed endogenously in Bowes human melanoma cells
[1433], and at heterologously
expressed recombinant GAL1, GAL2 and GAL3 receptors
[525, 1765, 1766]. Recent studies have
described the synthesis of a series of novel, systemically‐active, galanin analogues,
with modest preferential binding at the GAL2 receptor. Specific chemical
modifications to the galanin backbone increased brain levels of these peptides after
i.v. injection and several of these peptides exerted a potent
antidepressant‐like effect in mouse models of depression [1623].

Further Reading
Foord SM et al. (2005)
International Union of Pharmacology. XLVI. G protein‐coupled receptor list.
Pharmacol Rev
57: 279‐288 [PMID:15914470]


Lang R et al. (2015)
Physiology, signaling, and pharmacology of galanin peptides and receptors: three
decades of emerging diversity. Pharmacol. Rev.
67: 118‐75 [PMID:25428932]


Lang R et al. (2011) The
galanin peptide family in inflammation. Neuropeptides
45: 1‐8 [PMID:21087790]


Lawrence C et al. (2011)
Galanin‐like peptide (GALP) is a hypothalamic regulator of energy homeostasis and
reproduction. Front Neuroendocrinol
32: 1‐9 [PMID:20558195]


Webling KE et al. (2012)
Galanin receptors and ligands. Front Endocrinol (Lausanne)
3: 146 [PMID:23233848]



Ghrelin receptor

Overview
The ghrelin receptor (nomenclature as
agreed by the NC‐IUPHAR
Subcommittee for the Ghrelin receptor [
397
]) is activated by a 28 amino‐acid peptide originally isolated from rat
stomach, where it is cleaved from a 117 amino‐acid precursor (GHRL, Q9UBU3). The human gene
encoding the precursor peptide has 83% sequence homology to rat prepro‐ghrelin,
although the mature peptides from rat and human differ by only two amino acids
[1222]. Alternative splicing
results in the formation of a second peptide, [des‐Gln14]ghrelin(GHRL, Q9UBU3) with equipotent
biological activity [783]. A unique
post‐translational modification (octanoylation of Ser3, catalysed by
ghrelin O‐acyltransferase (MBOAT4, Q96T53) [2082] occurs in both peptides,
essential for full activity in binding to ghrelin receptors in the hypothalamus and
pituitary, and for the release of growth hormone from the pituitary [983]. Structure activity
studies showed the first five N‐terminal amino acids to be the minimum required for
binding [116], and receptor mutagenesis
has indicated overlap of the ghrelin binding site with those for small molecule
agonists and allosteric modulators of ghrelin(GHRL, Q9UBU3) function [776]. In cell systems, the
ghrelin receptor is constitutively active [777], but this is abolished by
a naturally occurring mutation (A204E) that results in decreased cell surface
receptor expression and is associated with familial short stature [1458].


Nomenclature	
ghrelin receptor
	
HGNC, UniProt	
GHSR, Q92847
	
Rank order of
potency	
ghrelin
(GHRL, Q9UBU3) =
[des‐Gln14]ghrelin (GHRL, Q9UBU3)
[115, 1222]	
Selective
antagonists	
GSK1614343
(pIC50 8.4) [1624], GSK1614343
(pK
B 8) [1487] – Rat	
Labelled
ligands	
[125I][His9]ghrelin (human)
(Agonist) (pK
d 9.4) [912], [125I][Tyr4]ghrelin (human)
(Agonist) (pK
d 9.4) [1339]	



Comments

[des‐octanoyl]ghrelin(GHRL, Q9UBU3) has been shown to bind
(as [125I]Tyr4‐des‐octanoyl‐ghrelin) and have
effects in the cardiovascular system [115], which raises the possible
existence of different receptor subtypes in peripheral tissues and the central
nervous system. A potent inverse agonist has been identified ([D‐Arg1,D‐Phe5,D‐Trp7,9,Leu11]substance
P, pD
2 8.3; [774]). Ulimorelin, described as a
ghrelin receptor agonist (pK
i 7.8 and pD
2 7.5 at human recombinant ghrelin receptors), has been shown to stimulate
ghrelin receptor mediated food intake and gastric emptying but not elicit release of
growth hormone, or modify ghrelin stimulated growth hormone release, thus
pharmacologically discriminating the orexigenic and gastrointestinal actions of
ghrelin(GHRL, Q9UBU3) from the release of
growth hormone [538]. A number of selective
antagonists have been reported, including peptidomimetic [1338] and non‐peptide small
molecules including GSK1614343[1487, 1624].

Further Reading
Andrews ZB. (2011) The extra‐hypothalamic
actions of ghrelin on neuronal function. Trends Neurosci.
34: 31‐40 [PMID:21035199]


Angelidis G et al. (2010)
Current and potential roles of ghrelin in clinical practice. J. Endocrinol.
Invest.
33: 823‐38 [PMID:21293171]


Briggs DI et al. (2011)
Metabolic status regulates ghrelin function on energy homeostasis.
Neuroendocrinology
93: 48‐57 [PMID:21124019]


Callaghan B et al. (2014)
Novel and conventional receptors for ghrelin, desacyl‐ghrelin, and pharmacologically
related compounds. Pharmacol. Rev.
66: 984‐1001 [PMID:25107984]


Davenport AP et al. (2005)
International Union of Pharmacology. LVI. Ghrelin receptor nomenclature,
distribution, and function. Pharmacol. Rev.
57: 541‐6 [PMID:16382107]


De Smet B et al. (2009)
Motilin and ghrelin as prokinetic drug targets. Pharmacol. Ther.
123: 207‐23 [PMID:19427331]


De Vriese C et al. (2007)
Influence of ghrelin on food intake and energy homeostasis. Curr Opin Clin
Nutr Metab Care
10: 615‐9 [PMID:17693746]


Dezaki K et al. (2008) Ghrelin
is a physiological regulator of insulin release in pancreatic islets and glucose
homeostasis. Pharmacol. Ther.
118: 239‐49 [PMID:18433874]


Granata R et al. (2010)
Unraveling the role of the ghrelin gene peptides in the endocrine pancreas.
J. Mol. Endocrinol.
45: 107‐18 [PMID:20595321]


Nikolopoulos D et al. (2010)
Ghrelin: a potential therapeutic target for cancer. Regul. Pept.
163: 7‐17 [PMID:20382189]



Glucagon receptor family

Overview
The glucagon family of receptors
(nomenclature as agreed by the NC‐IUPHAR Subcommittee on the Glucagon receptor family [
1234
]) are activated by the endogenous peptide (27‐44 aa) hormones glucagon(GCG, P01275), glucagon‐like peptide
1(GCG, P01275), glucagon‐like peptide 2
(GCG, P01275), glucose‐dependent
insulinotropic polypeptide (also known as gastric inhibitory
polypeptide(GIP, P09681)), GHRH(GHRH, P01286) and secretin(SCT, P09683). One common precursor
(GCG) generates glucagon(GCG, P01275), glucagon‐like peptide
1(GCG, P01275) and glucagon‐like peptide
2(GCG, P01275) peptides [827].


Nomenclature	
GHRH receptor
	
GIP receptor
	
GLP‐1 receptor
	
HGNC, UniProt	
GHRHR, Q02643
	
GIPR, P48546
	
GLP1R, P43220
	
Endogenous
agonists	–	
gastric inhibitory
polypeptide (GIP, P09681)
(Selective) (pK
d 8.7) [1961]	
glucagon‐like peptide
1‐(7‐36) amide (GCG, P01275)
(Selective) (pK
i 9.2) [885], glucagon‐like peptide
1‐(7‐37) (GCG, P01275)
(Selective) [425]	
Agonists	
JI‐38 [255], sermorelin
	–	
liraglutide
(pEC50 10.2) [972], lixisenatide
(pK
i 8.9) [2010], WB4‐24
(pA2 4.9) [502]	
Selective
agonists	
BIM28011
[379], tesamorelin
	–	
exendin‐4
(pIC50 9.2) [1290], exendin‐4
(pK
i 8.7–9) [885], exendin‐3
(P20394)
[1564]	
Selective
antagonists	
JV‐1‐36
(pK
i 10.1–10.4) [1662, 1947, 1948] – Rat,
JV‐1‐38
(pK
i 10.1) [1662, 1947, 1948] – Rat	
[Pro3]GIP [584] –
Mouse	
exendin‐(9‐39)
(pK
i 8.1) [885], GLP‐1‐(9‐36)
(pIC50 6.9) [1314] – Rat,
T‐0632
(pIC50 4.7) [1883]	
Labelled
ligands	
[125I]GHRH
(human) (Agonist) (pK
d 7.6) [192] – Rat	
[125I]GIP
(human) (Agonist) (pK
d 8.6) [562] – Rat	
[125I]GLP‐1‐(7‐36)‐amide (Agonist)
(pK
d 9.3) [885], [125I]exendin‐(9‐39) (Antagonist)
(pK
d 8.3) [885], [125I]GLP‐1‐(7‐37) (human) (Agonist)	




Nomenclature	
GLP‐2 receptor
	
glucagon
receptor
	
secretin
receptor
	
HGNC, UniProt	
GLP2R, O95838
	
GCGR, P47871
	
SCTR, P47872
	
Endogenous
agonists	
glucagon‐like peptide
2 (GCG, P01275)
(Selective) (pIC50 8.5) [1880]	
glucagon
(GCG, P01275)
(Selective) (pEC50 9) [1515]	
secretin
(SCT, P09683)
(Selective) (pEC50 9.7) [329]	
Agonists	
teduglutide
[1248]	–	–	
Selective
antagonists	–	
L‐168,049
(pIC50 8.4) [269], des‐His1‐[Glu9]glucagon‐NH2 (pA2 7.2) [1928, 1929] – Rat,
NNC 92‐1687
(pK
i 5) [1170], BAY27‐9955
[1496]	
[(CH2NH)4,5]secretin
(pK
i 5.3) [668]	
Labelled
ligands	–	
[125I]glucagon
(human, mouse, rat) (Agonist)	
[125I](Tyr10)secretin‐27 (rat)
(Agonist) [1925] – Rat	



Comments
The glucagon receptor has been reported to
interact with receptor activity modifying proteins (RAMPs), specifically RAMP2, in heterologous
expression systems [333], although the
physiological significance of this has yet to be established.

Further Reading
Ahrén B. (2015) Glucagon–Early breakthroughs
and recent discoveries. Peptides
67: 74‐81 [PMID:25814364]


Campbell JE et al. (2013)
Pharmacology, physiology, and mechanisms of incretin hormone action. Cell
Metab.
17: 819‐37 [PMID:23684623]


Cho YM et al. (2012) Targeting
the glucagon receptor family for diabetes and obesity therapy. Pharmacol.
Ther.
135: 247‐78 [PMID:22659620]


Corazzini V et al. (2013)
Molecular and clinical aspects of GHRH receptor mutations. Endocr
Dev
24: 106‐17 [PMID:23392099]


Donnelly D. (2012) The structure and function
of the glucagon‐like peptide‐1 receptor and its ligands. Br. J.
Pharmacol.
166: 27‐41 [PMID:21950636]


Drucker DJ et al. (2014)
Physiology and pharmacology of the enteroendocrine hormone glucagon‐like peptide‐2.
Annu. Rev. Physiol.
76: 561‐83 [PMID:24161075]


Jones BJ et al. (2012)
Minireview: Glucagon in stress and energy homeostasis. Endocrinology
153: 1049‐54 [PMID:22294753]


Mayo KE et al. (2003)
International Union of Pharmacology. XXXV. The glucagon receptor family.
Pharmacol. Rev.
55: 167‐94 [PMID:12615957]


Miller LJ et al. (2013) The
orthosteric agonist‐binding pocket in the prototypic class B G‐protein‐coupled
secretin receptor. Biochem. Soc. Trans.
41: 154‐8 [PMID:23356276]


Rowland KJ et al. (2011) The
~cryptic~ mechanism of action of glucagon‐like peptide‐2. Am. J. Physiol.
Gastrointest. Liver Physiol.
301: G1‐8 [PMID:21527727]


Trujillo JM et al. (2014)
GLP‐1 receptor agonists for type 2 diabetes mellitus: recent developments and
emerging agents. Pharmacotherapy
34: 1174‐86 [PMID:25382096]



Glycoprotein hormone receptors

Overview
Glycoprotein hormone receptors
(provisional nomenclature [
530
]) are activated by a non‐covalent heterodimeric glycoprotein made up of
a common α chain (glycoprotein hormone common alpha
subunit (CGA, P01215) CGA, P01215), with a unique
β chain that confers the biological specificity to FSH(CGA
FSHB, P01215
P01225), LH(CGA
LHB, P01215
P01229), hCG(CGA
CGB, P01215
P01233) or TSH(CGA
TSHB, P01215
P01222). There is binding cross‐reactivity across
the endogenous agonists for each of the glycoprotein hormone receptors. The
deglycosylated hormones appear to exhibit reduced efficacy at these receptors
[1626].


Nomenclature	
FSH receptor
	
LH receptor
	
TSH receptor
	
HGNC, UniProt	
FSHR, P23945
	
LHCGR, P22888
	
TSHR, P16473
	
Endogenous
agonists	–	
hCG (CGA
CGB, P01215
P01233)
(Selective) (pK
d 9.9–11.8) [864, 1353], LH (CGA
LHB, P01215
P01229)
(Selective) (pIC50 9.9–10.9) [864, 1353]	–	
Antagonists	
FSH deglycosylated
α/β (pK
d 10) [527, 921]	–	–	
Labelled
ligands	
[125I]FSH
(human) (Agonist)	
[125I]LH (Agonist), [125I]chorionic
gonadotropin (human) (Agonist)	
[125I]TSH
(human) (Agonist)	
Comments	Animal follitropins
are less potent than the human hormone as agonists at the human FSH
receptor. Gain‐ and loss‐of‐function mutations of the FSH receptor are
associated with human reproductive disorders [19, 109, 650, 1900]. The rat
FSH receptor also stimulates phosphoinositide turnover through an
unidentified G protein [1547].	Loss‐of‐function
mutations of the LH receptor are associated with Leydig cell
hypoplasia and gain‐of‐function mutations are associated with
male‐limited gonadotropin‐independent precocious puberty
(e.g. [1044, 1720]) and
Leydig cell tumours [1126].	Autoimmune
antibodies that act as agonists of the TSH receptor are found in
patients with Graves' disease (e.g. [1558]). Mutants
of the TSH receptor exhibiting constitutive activity underlie
hyperfunctioning thyroid adenomas [1464] and
congenital hyperthyroidism [993]. TSH
receptor loss‐of‐function mutations are associated with TSH resistance
[1824].	



Further Reading
Chiamolera MI et al. (2009)
Minireview: Thyrotropin‐releasing hormone and the thyroid hormone feedback mechanism.
Endocrinology
150: 1091‐6 [PMID:19179434]


George JW et al. (2011)
Current concepts of follicle‐stimulating hormone receptor gene regulation.
Biol. Reprod.
84: 7‐17 [PMID:20739665]


Gershengorn MC et al. (2012)
Update in TSH receptor agonists and antagonists. J. Clin. Endocrinol.
Metab.
97: 4287‐92 [PMID:23019348]


Melamed P et al. (2012)
Gonadotrophin‐releasing hormone signalling downstream of calmodulin. J.
Neuroendocrinol.
24: 1463‐75 [PMID:22775470]


Menon KM et al. (2012)
Structure, function and regulation of gonadotropin receptors ‐ a perspective.
Mol. Cell. Endocrinol.
356: 88‐97 [PMID:22342845]


Puett D et al. (2010) The
luteinizing hormone receptor: insights into structure‐function relationships and
hormone‐receptor‐mediated changes in gene expression in ovarian cancer cells.
Mol. Cell. Endocrinol.
329: 47‐55 [PMID:20444430]



Gonadotrophin‐releasing hormone
receptors

Overview
GnRH1 and GnRH2 receptors
(provisonal nomenclature [
530
], also called Type I and Type II GnRH receptor, respectively [1284]) have been cloned from
numerous species, most of which express two or three types of GnRH receptor
[1283, 1284, 1741]. GnRH I (GNRH1, P01148)
(p‐Glu‐His‐Trp‐Ser‐Tyr‐Gly‐Leu‐Arg‐Pro‐Gly‐NH2) is a hypothalamic decapeptide also
known as luteinizing hormone‐releasing hormone, gonadoliberin, luliberin, gonadorelin
or simply as GnRH. It is a member of a family of similar peptides found in many
species [1283, 1284, 1741] including GnRH II(GNRH2, O43555)
(pGlu‐His‐Trp‐Ser‐His‐Gly‐Trp‐Tyr‐Pro‐Gly‐NH2(which is also known as
chicken GnRH‐II). Receptors for three forms of GnRH exist in some species but only
GnRH I and GnRH II and their cognate receptors have been found in mammals [1283, 1284, 1741]. GnRH1
receptors are expressed primarily by pituitary gonadotrophs, and mediate central
control of mammalian reproduction. They are selectively activated by GnRH I and all
lack the COOH‐terminal tails found in other GPCRs. GnRH2 receptors do have
COOH‐terminal tails and (where tested) are selective for GnRH II over GnRH I.
GnRH2 receptors are expressed by some primates but are thought not to
be expressed by humans because the human GNRHR2 gene contains a
frame shift and an internal stop codon [1325]. An alternative
phylogenetic classification divides GnRH receptors into three classes and includes
both GnRH I‐selective mammalian and GnRH II‐selective non‐mammalian GnRH receptors as
GnRH1 receptors [1284]. A more recent
phylogenetic classification groups vertebrate GnRH receptors into five subfamilies
[2028] and highlights examples
of gene loss through evolution, with humans notably retaining only one ancient gene.
Although thousands of peptide analogues of GnRH I have been synthesized and several
(agonists and antagonists) are used therapeutically [934], the potency of most of
these peptides at GnRH2 receptors is unknown.


Nomenclature	
GnRH1
receptor
	
GnRH2
receptor
	
HGNC, UniProt	
GNRHR, P30968
	
GNRHR2, Q96P88
	
Rank order of
potency	
GnRH I
(GNRH1, P01148)
>GnRH II
(GNRH2, O43555)
[1284]	
GnRH II
(GNRH2, O43555)
>GnRH I
(GNRH1, P01148) (Monkey)
[1282]	
Endogenous
agonists	–	
GnRH II
(GNRH2, O43555)
(pIC50 9) [1282] – Monkey,
GnRH I
(GNRH1, P01148)
(pIC50 7.4) [1282] –
Monkey	
Selective
agonists	
triptorelin
(pK
i 9.3–9.5) [112], leuprolide
(pK
i 8.5–9.1) [1807], buserelin,
goserelin,
histrelin,
nafarelin
	–	
Antagonists	
iturelix
(pK
i 9.5) [1591]	–	
Selective
antagonists	
cetrorelix
(pK
i 9.3–10) [113, 114, 1807], abarelix
(pK
i 9.1–9.5) [1807], degarelix
(pK
i 8.8) [1938], ganirelix
	
trptorelix‐1
[1183] –
Monkey	
Labelled
ligands	
[125I]buserelin (Agonist)
(pK
d 7.4) [1024] – Rat,
[125I]GnRH I
(human, mouse, rat) (Agonist)	–	
Comments	–	Probable
transcribed pseudogene in man [1284].	



Comments
GnRH1 and GnRH2 receptors
couple primarily to Gq/11[653] but coupling to
Gs and Gi is evident in some systems [1009, 1024]. GnRH2
receptors may also mediate (heterotrimeric) G protein‐independent signalling to
protein kinases [276]. There is increasing
evidence for expression of GnRH receptors on hormone‐dependent cancer cells where
they can exert antiproliferative and/or proapoptotic effects and mediate effects of
cytotoxins conjugated to GnRH analogues [309, 706, 1108, 1661]. In some human cancer
cell models GnRH II(GNRH2, O43555) is more potent than
GnRH I (GNRH1, P01148), implying mediation by
GnRH2 receptors [657]. However, GnRH2
receptors that are expressed by some primates are probably not expressed in humans
because the human GNRHR2 gene contains a frame shift and internal stop
codon [1325]. The possibility remains
that this gene generates GnRH2 receptor‐related proteins (other than the
full‐length receptor) that mediate responses to GnRH II(GNRH2, O43555) (see [1372]). Alternatively, there is
evidence for multiple active GnRH receptor conformations [276, 277, 516, 1231, 1284] raising the possibility
that GnRH1 receptor‐mediated proliferation inhibition in hormone‐dependent
cancer cells is dependent upon different conformations (with different ligand
specificity and ligand biased signalling) than effects on Gq/11 in
pituitary cells [277, 1231]. Loss‐of‐function
mutations in the GnRH1 receptor and deficiency of GnRH I (GNRH1, P01148) are associated with
hypogonadotropic hypogonadism although some ‘loss of function’ mutations may actually
prevent trafficking of ‘functional’ GnRH1 receptors to the cell surface,
as evidenced by recovery of function by nonpeptide antagonists [1061]. Human GnRH1
receptors appear to be poorly expressed at the cell surface because of failure to
meet structural quality control criteria for endoplasmic reticulum exit [517, 1061]. This may increase
susceptibility to point mutations that further impair trafficking and also increase
effects of non‐peptide antagonists on GnRH1 receptor trafficking to the
plasma membrane [517, 1061]. GnRH receptor signalling
may be dependent upon receptor oligomerisation [363, 1007].

Further Reading
Bianco SD et al. (2009) The
genetic and molecular basis of idiopathic hypogonadotropic hypogonadism. Nat
Rev Endocrinol
5: 569‐76 [PMID:19707180]


Bliss SP et al. (2010) GnRH
signaling, the gonadotrope and endocrine control of fertility. Front
Neuroendocrinol
31: 322‐40 [PMID:20451543]


Limonta P et al. (2012) GnRH
receptors in cancer: from cell biology to novel targeted therapeutic strategies.
Endocr. Rev.
33: 784‐811 [PMID:22778172]


McArdle CA and Roberson MS.. (2015)
Gonadotropes and gonadotropin‐releasing hormone signaling. In Knobil and
Neill's Physiology of Reproduction (4th edition). Edited by Plant TM and
Zeleznik AJ.: Elsevier Inc.: [ISBN: 9780123971753]

Millar RP et al. (2004)
Gonadotropin‐releasing hormone receptors. Endocr Rev
25: 235‐275 [PMID:15082521]


Tao YX et al. (2014)
Chaperoning G protein‐coupled receptors: from cell biology to therapeutics.
Endocr. Rev.
35: 602‐47 [PMID:24661201]



GPR18, GPR55 and GPR119

Overview
GPR18, GPR55 and GPR119 (provisional
nomenclature), although showing little structural similarity to
CB1 and CB2 cannabinoid receptors, respond to endogenous
agents analogous to the endogenous cannabinoid ligands, as well as some
natural/synthetic cannabinoid receptor ligands [1494]. Although there are
multiple reports to indicate that GPR18, GPR55 and GPR119 can be activated in
vitro by N‐arachidonoylglycine,
lysophosphatidylinositol and
N‐oleoylethanolamide,
respectively, there is a lack of evidence for activation by these lipid messengers
in vivo. As such, therefore, these receptors retain their orphan
status.


Nomenclature	
GPR18
	
GPR55
	
GPR119
	
HGNC, UniProt	
GPR18, Q14330
	
GPR55, Q9Y2T6
	
GPR119, Q8TDV5
	
Rank order of
potency	–	–	
N‐oleoylethanolamide, N‐palmitoylethanolamine>SEA (anandamide is
ineffective) [1452]	
Endogenous
agonists	
N‐arachidonoylglycine [980]	
lysophosphatidylinositol (pEC50 5.5–7.3)
[738, 1435, 1785], 2‐arachidonoylglycerolphosphoinositol (Selective)
[1437]	
N‐oleoylethanolamide (pEC50 5.4–6.3)
[338, 1452, 1785], N‐palmitoylethanolamine, SEA
	
Selective
agonists	–	
AM251
(pEC50 5–7.4) [738, 905, 1620]	
AS1269574
(pEC50 5.6) [2100], PSN632408
(pEC50 5.3) [1452], PSN375963
(pEC50 5.1) [1452]	
Selective
antagonists	–	
CID16020046
(apparent pA2) (pA2 7.3) [906]	–	
Comments	The pairing of
N‐arachidonoylglycine with GPR18 was not replicated in
two studies based on arrestin assays [1785, 2093]. See
[396] for
discussion.	See reviews
[396] and
[1732].	In addition to
those shown above, further small molecule agonists have been reported
[687].	



Comments
GPR18 failed to respond to a variety of
lipid‐derived agents in an in vitro screen [2093], but has been reported to
be activated by Δ9‐tetrahydrocannabinol[1246]. GPR55 responds to
AM251 and rimonabant at micromolar
concentrations, compared to their nanomolar affinity as CB1 receptor
antagonists/inverse agonists [1494]. It has been reported
that lysophosphatidylinositol acts
at other sites in addition to GPR55 [2075]. N‐Arachidonoylserine has
been suggested to act as a low efficacy agonist/antagonist at GPR18 in
vitro[1244]. It has also been
suggested oleoyl‐lysophosphatidylcholine
acts, at least in part, through GPR119 [1400]. Although PSN375963 and PSN632408 produce
GPR119‐dependent responses in heterologous expression systems, comparison with
N‐oleoylethanolamide‐mediated
responses suggests additional mechanisms of action [1400].

Further Reading
Alexander SP. (2012) So what do we call GPR18
now? Br. J. Pharmacol.
165: 2411‐3 [PMID:22014123]


Davenport AP et al. (2013)
International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein‐coupled
receptor list: recommendations for new pairings with cognate ligands.
Pharmacol. Rev.
65: 967‐86 [PMID:23686350]


Hansen HS et al. (2012) GPR119
as a fat sensor. Trends Pharmacol. Sci.
33: 374‐81 [PMID:22560300]


McHugh D. (2012) GPR18 in Microglia:
implications for the CNS and endocannabinoid system signalling. Br J
Pharmacol
[PMID:22563843]


Pertwee RG et al. (2010)
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors
and their ligands: beyond CB_1 and CB_2. Pharmacol. Rev.
62: 588‐631 [PMID:21079038]


Ross RA. (2011)
L‐α‐lysophosphatidylinositol meets GPR55: a deadly relationship.
Trends Pharmacol. Sci.
32: 265‐9 [PMID:21367464]


Yamashita A et al. (2013) The
actions and metabolism of lysophosphatidylinositol, an endogenous agonist for GPR55.
Prostaglandins Other Lipid Mediat.
[PMID:23714700]


Zhao P et al. (2013) GPR55 and
GPR35 and their relationship to cannabinoid and lysophospholipid receptors.
Life Sci.
92: 453‐7 [PMID:22820167]



Histamine receptors

Overview
Histamine receptors (nomenclature as
agreed by the NC‐IUPHAR
Subcommittee on Histamine Receptors [
754
,
1459
]) are activated by the endogenous ligand histamine. Marked species
differences exist between histamine receptor orthologues [754].


Nomenclature	
H1
receptor
	
H2
receptor
	
H3
receptor
	
H4
receptor
	
HGNC, UniProt	
HRH1, P35367
	
HRH2, P25021
	
HRH3, Q9Y5N1
	
HRH4, Q9H3N8
	
Selective
agonists	
methylhistaprodifen (pK
i 6.4) [1695], histaprodifen
(pK
i 5.7) [1107]	
amthamine
(pEC50 6.4) [1003]	
immethridine
(pK
i 9.1) [963], methimepip
(pK
i 9) [962], MK‐0249 (Inverse
agonist) (pK
i 8.8) [1354]	
clobenpropit
(Partial agonist) (pK
i 7.4–8.3) [490, 1107, 1122, 1123, 1335], 4‐methylhistamine (pK
i 7.3–8.2) [586, 1107], VUF 8430
(pK
i 7.5) [1106]	
Antagonists	
cyproheptadine
(pK
i 10.2) [1298], promethazine
(pK
i 9.6) [601], pyrilamine
(Inverse agonist) (pK
i 8.7–9) [184, 1563], hydroxyzine
(pK
i 8.7) [608], ketotifen
(pK
i 8.6) [1014], cetirizine
(Inverse agonist) (pK
i 8.2) [1298], diphenhydramine
(pK
i 7.9) [184]	–	
iodophenpropit
(pK
i 8.2–8.7) [2022, 2051], thioperamide
(pK
i 7.1–7.7) [355, 489, 490, 1104, 1145, 2022, 2051]	–	
Selective
antagonists	
clemastine
(pK
i 10.3) [68], desloratadine
(pK
i 9) [1090], triprolidine
(pK
i 8.5–9) [184, 1298], azelastine
(pK
i 8.9) [1535], astemizole
(pK
i 8.5) [1480], cyclizine
(pK
i 8.4) [68], chlorpheniramine
(pK
i 8.1) [1535], fexofenadine
(pK
i 7.6) [64], loratadine
(pK
i 7.4) [850], terfenadine
(pK
i 7.4) [64], tripelennamine
(pIC50 7.4) [635]	
tiotidine
(pK
i 7.5) [145] – Rat,
ranitidine
(pK
i 7.1) [1086], cimetidine
(pK
i 6.8) [263]	
clobenpropit
(pK
i 8.4–9.4) [355, 490, 1104, 1122, 1145, 2022, 2051], A331440
(pK
i 8.5) [688]	
JNJ 7777120
(pK
i 7.8–8.3) [1107, 1771, 1881]	
Labelled
ligands	
[3H]pyrilamine (Antagonist, Inverse agonist)
(pK
d 8.4–9.1) [403, 1298, 1675, 1695], [11C]doxepin (Antagonist)
(pK
d 9) [830], [11C]pyrilamine (Antagonist, Inverse
agonist)	
[125I]iodoaminopotentidine (Antagonist)
(pK
d 8.7) [1029] – Rat,
[3H]tiotidine (Antagonist)
(pK
d 7.7–8.7) [1310]	
[123I]iodoproxyfan (Antagonist)
(pK
d 10.2) [1104], [125I]iodophenpropit (Antagonist)
(pK
d 9.2) [849] – Rat,
[3H](R)‐α‐methylhistamine
(Agonist) (pK
d 9.2) [1122], N‐[3H]α‐methylhistamine
(Agonist) (pK
d 9) [301] –
Mouse	
[3H]JNJ
7777120 (Antagonist) (pK
d 8.4) [1881]	



Comments

histaprodifen and methylhistaprodifen are reduced
efficacy agonists. The H4 receptor appears to exhibit broadly similar
pharmacology to the H3 receptor for imidazole‐containing ligands, although
(R)‐α‐methylhistamine and N‐α‐methylhistamine are less potent,
while clobenpropit acts as a reduced
efficacy agonist at the H4 receptor and an antagonist at the H3
receptor [1122, 1360, 1390, 1422, 2132]. Moreover, 4‐methylhistamine is identified
as a high affinity, full agonist for the human H4 receptor [1107]. [3H]histamine has
been used to label the H4 receptor in heterologous expression systems.

Further Reading
Berlin M et al. (2011)
Histamine H3 receptor as a drug discovery target. J. Med. Chem.
54: 26‐53 [PMID:21062081]


Hill SJ et al. (1997)
International Union of Pharmacology. XIII. Classification of histamine receptors.
Pharmacol. Rev.
49: 253‐278 [PMID:9311023]


Leurs R et al. (2011) En route
to new blockbuster anti‐histamines: surveying the offspring of the expanding
histamine receptor family. Trends Pharmacol. Sci.
32: 250‐7 [PMID:21414671]


Marson CM. (2011) Targeting the histamine H4
receptor. Chem. Rev.
111: 7121‐56 [PMID:21842846]


Passani MB et al. (2011)
Histamine receptors in the CNS as targets for therapeutic intervention.
Trends Pharmacol. Sci.
32: 242‐9 [PMID:21324537]


Schwartz JC. (2011) The histamine H3 receptor:
from discovery to clinical trials with pitolisant. Br. J. Pharmacol.
163: 713‐21 [PMID:21615387]



Hydroxycarboxylic acid receptors

Overview
The hydroxycarboxylic acid family of receptors
(ENSFM00500000271913,
nomenclature as agreed by the NC‐IUPHAR Subcommittee on Hydroxycarboxylic acid receptors
[
396
,
1424
]) respond to organic acids, including the endogenous hydroxy carboxylic
acids 3‐hydroxy butyric acid and L‐lactic acid, as well as the
lipid lowering agents nicotinic acid (niacin),
acipimox and acifran[1774, 1913, 2036]. These receptors were
provisionally described as nicotinic acid receptors, although nicotinic acid shows
submicromolar potency at HCA2receptors only and is unlikely to be the
natural ligand [1913, 2036].


Nomenclature	
HCA1
receptor
	
HCA2
receptor
	
HCA3
receptor
	
HGNC, UniProt	
HCAR1, Q9BXC0
	
HCAR2, Q8TDS4
	
HCAR3, P49019
	
Endogenous
agonists	
L‐lactic acid
(Selective) (pEC50 1.3–2.9) [14, 256, 1124, 1785]	
β‐D‐hydroxybutyric acid
(pEC50 3.1) [1838]	
3‐hydroxyoctanoic
acid (pEC50 5.1) [13]	
Agonists	
compound 2 [PMID:
24486398] (pEC50 7.2) [1630], 3,5‐dihydroxybenzoic
acid (pEC50 3.7) [1121]	
SCH 900271
(pEC50 8.7) [1454], GSK256073
(pEC50 7.5) [1790]	–	
Selective
agonists	–	
MK 6892
(pEC50 7.8) [1719], MK 1903
(pEC50 7.6) [163], nicotinic acid
(pEC50 6–7.2) [1774, 1913, 2036], acipimox
(pEC50 5.2–5.6) [1774, 2036], monomethylfumarate (pEC50 5) [1859]	
compound 6o [PMID:
19524438] (pEC50 8.5) [1751], IBC 293
(pEC50 6.4) [1697]	
Labelled
ligands	–	
[3H]nicotinic
acid (Agonist) (pK
d 7–7.3) [1774, 1913, 2036]	–	



Comments
Further closely‐related GPCRs include the
5‐oxoeicosanoid receptor
(OXER1, Q8TDS5) and GPR31(O00270).

Further Reading
Chapman MJ et al. (2010)
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce
cardiovascular risk. Pharmacol. Ther.
126: 314‐45 [PMID:20153365]


Digby JE et al. (2012) Niacin
in cardiovascular disease: recent preclinical and clinical developments.
Arterioscler. Thromb. Vasc. Biol.
32: 582‐8 [PMID:22207729]


Hanson J et al. (2012) Role of
HCA_2(GPR109A) in nicotinic acid and fumaric acid ester‐induced effects on the skin.
Pharmacol. Ther.
136: 1‐7 [PMID:22743741]


Kamanna VS et al. (2013)
Recent advances in niacin and lipid metabolism. Curr. Opin. Lipidol.
24: 239‐45 [PMID:23619367]


Offermanns S. (2014) Free fatty acid (FFA) and
hydroxy carboxylic acid (HCA) receptors. Annu. Rev. Pharmacol.
Toxicol.
54: 407‐34 [PMID:24160702]


Offermanns S et al. (2011)
International Union of Basic and Clinical Pharmacology. LXXXII: Nomenclature and
Classification of Hydroxy‐carboxylic Acid Receptors (GPR81, GPR109A, and GPR109B).
Pharmacol. Rev.
63: 269‐90 [PMID:21454438]


Offermanns S et al. (2015)
Nutritional or pharmacological activation of HCA(2) ameliorates neuroinflammation.
Trends Mol Med
21: 245‐55 [PMID:25766751]



Kisspeptin receptor

Overview
The kisspeptin receptor (nomenclature as
agreed by the NC‐IUPHAR
Subcommittee on the kisspeptin receptor [
958
]), like neuropeptide FF (NPFF), prolactin‐releasing peptide (PrP) and
QRFP receptors (provisional nomenclature) responds to endogenous peptides with an
arginine‐phenylalanine‐amide (RFamide) motif. Kisspeptin‐54(KISS1, Q15726) (KP54, originally named
metastin), kisspeptin‐13(KISS1, Q15726) (KP13) and kisspeptin‐10(KISS1) (KP10) are biologically‐active peptides cleaved from the KISS1(Q15726) gene product.


Nomenclature	
kisspeptin
receptor
	
HGNC, UniProt	
KISS1R, Q969F8
	
Endogenous
agonists	
kisspeptin‐10
(KISS1) (Selective) (pK
i 8.6–10.4) [996, 1434], kisspeptin‐54
(KISS1, Q15726)
(Selective) (pK
i 8.8–9.5) [996, 1434], kisspeptin‐14
(KISS1, Q15726)
(pK
i 8.8) [996], kisspeptin‐13
(KISS1, Q15726)
(Selective) (pK
i 8.4) [996]	
Selective
agonists	
4‐fluorobenzoyl‐FGLRW‐NH2 (pEC50 9.2)
[1894], [dY]1KP‐10 (pIC50 8.4) [385] –
Mouse	
Selective
antagonists	
peptide 234
[1600]	
Labelled
ligands	
[125I]Tyr45‐kisspeptin‐15
(Agonist) (pK
d 10) [1434], [125I]kisspeptin‐13 (human) (Agonist)
(pK
d 9.7) [1252], [125I]kisspeptin‐10 (human) (Agonist)
(pK
d 8.7) [996], [125I]kisspeptin‐14 (human) (Agonist)
[1252]	



Further Reading
Kanda S et al. (2013)
Structure, synthesis, and phylogeny of kisspeptin and its receptor. Adv. Exp.
Med. Biol.
784: 9‐26 [PMID:23550000]


Kirby HR et al. (2010)
International Union of Basic and Clinical Pharmacology. LXXVII. Kisspeptin receptor
nomenclature, distribution, and function. Pharmacol. Rev.
62: 565‐78 [PMID:21079036]


Millar RP et al. (2010)
Kisspeptin antagonists: unraveling the role of kisspeptin in reproductive physiology.
Brain Res.
1364: 81‐9 [PMID:20858467]


Pasquier J et al. (2014)
Molecular evolution of GPCRs: Kisspeptin/kisspeptin receptors. J. Mol.
Endocrinol.
52: T101‐17 [PMID:24577719]


Roseweir AK et al. (2013)
Kisspeptin antagonists. Adv. Exp. Med. Biol.
784: 159‐86 [PMID:23550006]



Leukotriene receptors

Overview
Leukotriene receptors (nomenclature as
agreed by the NC‐IUPHAR
subcommittee on Leukotriene Receptors [
249
,
250
]) is activated by the endogenous ligands leukotrienes (LT), synthesized
from lipoxygenase metabolism of arachidonic acid.

The human BLT1 receptor is the high
affinity LTB4 receptor whereas the BLT2 receptor in addition to
being a low‐affinity LTB4 receptor also binds several other
lipoxygenase‐products, such as 12S‐HETE, 12S‐HPETE, 15S‐HETE, and the thromboxane
synthase product 12‐hydroxyheptadecatrienoic
acid. The BLT receptors mediate chemotaxis and immunomodulation in
several leukocyte populations and are in addition expressed on non‐myeloid cells,
such as vascular smooth muscle and endothelial cells. In addition to BLT receptors,
LTB4 has been reported to bind to the peroxisome proliferator activated
receptor (PPAR) α[1112] and the vanilloid TRPV1
ligand‐gated nonselective cation channel [1245].

The receptors for the cysteinyl‐leukotrienes
(i.e.
LTC4, LTD4 and LTE4) are termed CysLT1 and CysLT2 and exhibit distinct
expression patterns in human tissues, mediating for example smooth muscle cell
contraction, regulation of vascular permeability, and leukocyte activation. There is
also evidence in the literature for additional CysLT receptor subtypes, derived from
functional in vitro studies, radioligand binding and in mice lacking both
CysLT1 and CysLT2 receptors [250]. Cysteinyl‐leukotrienes
have also been suggested to signal through the P2Y12 receptor [542, 1407, 1466], GPR17 [344] and GPR99 [900].


Nomenclature	
BLT1
receptor
	
BLT2
receptor
	
CysLT1
receptor
	
CysLT2
receptor
	
HGNC, UniProt	
LTB4R, Q15722
	
LTB4R2, Q9NPC1
	
CYSLTR1, Q9Y271
	
CYSLTR2, Q9NS75
	
Rank order of
potency	
LTB4>20‐hydroxy‐LTB4≫12R‐HETE
[2096]	
12‐hydroxyheptadecatrienoic
acid>LTB4>12S‐HETE =
12S‐HPETE>15S‐HETE>12R‐HETE>20‐hydroxy‐LTB4 [1442, 2096]	
LTD4>LTC4>LTE4 [1157, 1643]	
LTC4≥LTD4≫LTE4 [733, 1411, 1847]	
Endogenous
agonists	–	
12S‐HETE
(Partial agonist) (pEC50<7.5) [2096]	–	–	
Antagonists	–	–	
ICI198615 (‐
8.4–8.6)	
BAYu9773
(against LTC4 and LTD4 induced contraction in
smooth muscle preparation) (pA2 6.8–7.7) [1912] – Rat	
Selective
antagonists	
BIIL 260
(pK
i 8.8) [152, 457], CP105696
(pIC50 8.1) [1735], U75302
(pK
i 6.4) [172]	
LY255283
(pIC50 6–7.1) [744, 2096]	
zafirlukast
(against [3H]LTD4 in COS‐7 or HEK‐293 cells)
(pIC50 8.6–8.7) [1157, 1643], SR2640
(pK
i 8.7), montelukast
(against [3H]LTD4 in COS‐7 or HEK‐293 cells)
(pIC50 8.3–8.6) [1157, 1643], sulukast
(pK
i 8.3), pobilukast
(against [3H]LTD4 in HEK‐293) (pIC50
7.5) [1643]	
BayCysLT2 (against 30‐300nM LTD4
β‐arrestin assay in C2C12 myofibroblasts)
(pIC50 6.6–7.3) [1391]	
Labelled
ligands	
[3H]LTB4 (Agonist) (pK
d 9.8) [2095], [3H]CGS23131 (Antagonist)
(pK
d 7.9) [836]	
[3H]LTB4 (pK
d 7.6–9.7)	
[3H]LTD4 (Agonist) (pK
d 8–10.7), [3H]ICI‐198615 (Antagonist)
(pK
d 10.6) [1608]	
[3H]LTD4 (Agonist) (pK
d 7.3–9.4) [733]	




Nomenclature	
FPR2/ALX
	
OXE receptor
	
HGNC, UniProt	
FPR2, P25090
	
OXER1, Q8TDS5
	
Rank order of
potency	
LXA4=aspirin triggered lipoxin
A4=ATLa2>LTC4=LTD4≫15‐deoxy‐LXA4≫fMet‐Leu‐Phe
[352, 519, 521, 651, 1846]	
5‐oxo‐ETE,
5‐oxo‐C20:3,
5‐oxo‐ODE>5‐oxo‐15‐HETE>5S‐HPETE>5S‐HETE
[784, 877, 1472]	
Endogenous
agonists	
LXA4 (Selective) (pEC50∼12) [1006], resolvin D1
(Selective) (pEC50∼11.9) [1006], aspirin triggered lipoxin
A4 (Selective)	
5‐oxo‐ETE
(Selective) (pEC50 8.3–8.5) [638, 1417, 1472, 1525, 1681]	
Selective
agonists	
ATLa2 [662]	–	
Endogenous
antagonists	–	
5‐oxo‐12‐HETE
(Selective) (pIC50 6.3) [1524]	
Antagonists	–	–	
Selective
antagonists	–	–	
Labelled
ligands	
[3H]LXA4 (Agonist) (pK
d 9.2–9.3) [519, 520]	
[3H]5‐oxo‐ETE (Agonist) (pK
d 8.4) [1417]	
Comments	The agonist
activity of the lipid mediators described has been questioned
[697, 1513], which may
derive from batch‐to‐batch differences, partial agonism or biased
agonism. Recent results from Cooray et al. (2013)
[365] have
addressed this issue and the role of homodimers and heterodimers in
the intracellular signaling .	–	



Comments
The FPR2/ALX receptor (nomenclature as
agreed by the NC‐IUPHAR
subcommittee on Leukotriene and Lipoxin Receptors [
250
]) is activated by the endogenous lipid‐derived, anti‐inflammatory
ligands lipoxin A4(LXA4) and 15‐epi‐LXA4(aspirin triggered lipoxin A4,
ATL). The FPR2/ALX receptor also interacts with endogenous peptide and protein
ligands, such as MHC binding peptide [315] as well as annexin I (ANXA1, P04083) (ANXA1) and its
N‐terminal peptides [365, 1491]. In addition, a soluble
hydrolytic product of protease action on the urokinase‐type plasminogen activator
receptor has been reported to activate the FPR2/ALX receptor [1572]. Furthermore, FPR2/ALX
has been suggested to act as a receptor mediating the proinflammatory actions of the
acute‐phase reactant, serum amyloid A [1772, 1809]. A receptor selective for
LXB4 has been suggested from functional studies [53, 1168, 1596]. Note that the data for
FPR2/ALX are also reproduced on the Formylpeptide receptor
pages.

Oxoeicosanoid receptors (OXE,
nomenclature agreed by the NC‐IUPHAR subcommittee on Oxoeicosanoid Receptors [
214
]) are activated by endogenous chemotactic eicosanoid ligands oxidised
at the C‐5 position, with 5‐oxo‐ETE the most potent
agonist identified for this receptor. Initial characterization of the heterologously
expressed OXE receptor suggested that polyunsaturated fatty acids, such as docosahexaenoic acid and
EPA, acted as receptor
antagonists [784]

Further Reading
Bäck M et al. (2014) Update on
leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7. Br. J.
Pharmacol.
171: 3551‐74 [PMID:24588652]


Cooray SN et al. (2013)
Ligand‐specific conformational change of the G‐protein‐coupled receptor ALX/FPR2
determines proresolving functional responses. Proc. Natl. Acad. Sci.
U.S.A.
110: 18232‐7 [PMID:24108355]


Nelson JW et al. (2014)
ALX/FPR2 receptor for RvD1 is expressed and functional in salivary glands.
Am. J. Physiol., Cell Physiol.
306: C178‐85 [PMID:24259417]


Norling LV et al. (2012)
Resolvin D1 limits polymorphonuclear leukocyte recruitment to inflammatory loci:
receptor‐dependent actions. Arterioscler. Thromb. Vasc. Biol.
32: 1970‐8 [PMID:22499990]



Lysophospholipid (LPA) receptors

Overview
Lysophosphatidic acid (LPA) receptors
(nomenclature as agreed by the NC‐IUPHAR Subcommittee on Lysophospholipid Receptors [
396
,
936
]) are activated by the endogenous phospholipid metabolite LPA. The first receptor,
LPA1, was identified as ventricular zone gene‐1
(vzg‐1), leading to deorphanisation of members of the endothelial
differentiation gene (edg) family as other LPA receptors along with
sphingosine 1‐phosphate (S1P) receptors. Additional LPA receptor GPCRs were later
identified. Gene names have been codified as LPAR1, etc. to reflect
the receptor function of proteins. The crystal structure of LPA1 was
recently solved and demonstrates ligand access characteristics that allows for
extracellular LPA binding [331]; these studies have also
implicated cross‐talk with endocannabinoids via phosphorylated
intermediates that can activate this receptor. The identified receptors can account
for most, although not all, LPA‐induced phenomena in the literature, indicating that
a majority of LPA‐dependent phenomena are receptor‐mediated. Radioligand binding has
been conducted in heterologous expression systems using [3H]LPA(e.g. [556]). In native systems,
analysis of binding data is complicated by metabolism and high levels of nonspecific
binding, and therefore the relationship between recombinant and endogenously
expressed receptors is unclear. Targeted deletion of LPA receptors has clarified
signalling pathways and identified physiological and pathophysiological roles.
Independent validation by multiple groups has been reported in the peer‐reviewed
literature for all six LPA receptors described in the tables, including further
validation using a distinct read‐out via a novel TGFα“shedding”
assay [825]. LPA has also been described as
an agonist at other orphan GPCRs (PSP24, GPR87 and GPR35), as well as at the nuclear
hormone PPARγ receptors [1247, 1743], although the
physiological significance of these observations remain unclear.


Nomenclature	
LPA1
receptor
	
LPA2
receptor
	
LPA3
receptor
	
HGNC, UniProt	
LPAR1, Q92633
	
LPAR2, Q9HBW0
	
LPAR3, Q9UBY5
	
Selective
agonists	–	
dodecylphosphate
(pEC50 6.2) [1958], decyl dihydrogen
phosphate (pEC50 5.4) [1958], GRI977143
(pEC50 4.5) [959]	
OMPT
(pEC50 7.2) [709]	
Selective
antagonists	
AM966
(pIC50 6.7–7.8) [1832]	–	
dioctanoylglycerol
pyrophosphate (pK
i 5.5–7) [522, 1432]	
Comments	–	Virtual screening
experiments have shown H2L5186303 to be
a potent antagonist of LPA2 [510]. dodecylphosphate
is also an antagonist at LPA3 receptors [1958].	–	




Nomenclature	
LPA4
receptor
	
LPA5
receptor
	
LPA6
receptor
	
HGNC, UniProt	
LPAR4, Q99677
	
LPAR5, Q9H1C0
	
LPAR6, P43657
	



Comments

Ki16425[1432], VPC12249[735] and VPC32179[729] have antagonist activity
at LPA1 and LPA3 receptors. There is growing evidence for
in vivo efficacy of these chemical antagonists in several
disorders, including fetal hydrocephalus [2107], lung fibrosis [1429], and systemic sclerosis
[1429].

Further Reading
Chun J et al. (2010)
International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid
receptor nomenclature. Pharmacol. Rev.
62: 579‐87 [PMID:21079037]


Kihara Y et al. (2014)
Lysophospholipid receptor nomenclature review: IUPHAR Review 8. Br. J.
Pharmacol.
[PMID:24602016]


Mirendil H et al. (2015) LPA
signaling initiates schizophrenia‐like brain and behavioral changes in a mouse model
of prenatal brain hemorrhage. Transl Psychiatry
5: e541 [PMID:25849980]


Mutoh T et al. (2012) Insights
into the pharmacological relevance of lysophospholipid receptors. Br. J.
Pharmacol.
165: 829‐44 [PMID:21838759]


Schober A et al. (2012)
Lysophosphatidic acid in atherosclerotic diseases. Br. J. Pharmacol.
167: 465‐82 [PMID:22568609]


Sheng X et al. (2015)
Lysophosphatidic acid signalling in development. Development
142: 1390‐5 [PMID:25852197]


Yung YC et al. (2014) LPA
receptor signaling: pharmacology, physiology, and pathophysiology. J. Lipid
Res.
55: 1192‐1214 [PMID:24643338]


Yung YC et al. (2015)
Lysophosphatidic Acid signaling in the nervous system. Neuron
85: 669‐82 [PMID:25695267]



Lysophospholipid (S1P) receptors

Overview
Sphingosine 1‐phosphate (S1P) receptors
(nomenclature as agreed by the NC‐IUPHAR Subcommittee on Lysophospholipid receptors [
936
]) are activated by the endogenous lipid sphingosine 1‐phosphate (S1P)
and with lower apparent affinity, sphingosylphosphorylcholine(SPC). Originally cloned as orphan members of
the endothelial differentiation gene (edg) family, deorphanisation
as lysophospholipid receptors for S1P was based on sequence homology to LPA
receptors. Current gene names have been codified as S1PR1, etc. to reflect the
receptor function of these proteins. Most cellular phenomena ascribed to S1P can be
explained by receptor‐mediated mechanisms; S1P has also been described to act at
intracellular sites [1841], and awaits precise
definition. Previously‐proposed SPC (or lysophophosphatidylcholine) receptors‐ G2A,
TDAG8, OGR1 and GPR4 ‐ continue to lack confirmation of these roles [396]. The relationship between
recombinant and endogenously expressed receptors is unclear. Radioligand binding has
been conducted in heterologous expression systems using [32P]S1P(e.g [1438]). In native systems,
analysis of binding data is complicated by metabolism and high levels of nonspecific
binding. Targeted deletion of several S1P receptors and key enzymes involved in S1P
biosynthesis or degradation has clarified signalling pathways and physiological
roles. A crystal structure of an S1P1‐T4 fusion protein has been described
[698].

The S1P receptor modulator, fingolimod(FTY720, Gilenya),
has received world‐wide approval as the first oral therapy for relapsing forms of
multiple sclerosis. This drug has a novel mechanism of action involving modulation of
S1P receptors in both the immune and nervous systems [325, 356, 654], although the precise
nature of its interaction requires clarification.


Nomenclature	
S1P1
receptor
	
S1P2
receptor
	
S1P3
receptor
	
S1P4
receptor
	
S1P5
receptor
	
HGNC, UniProt	
S1PR1, P21453
	
S1PR2, O95136
	
S1PR3, Q99500
	
S1PR4, O95977
	
S1PR5, Q9H228
	
Rank order of
potency	
sphingosine
1‐phosphate>dihydrosphingosine‐1‐phosphate>sphingosylphosphorylcholine [45, 1438]	
sphingosine
1‐phosphate>dihydrosphingosine‐1‐phosphate>sphingosylphosphorylcholine [45, 1438]	
sphingosine
1‐phosphate>dihydrosphingosine‐1‐phosphate>sphingosylphosphorylcholine [1438]	
sphingosine
1‐phosphate>dihydrosphingosine‐1‐phosphate>sphingosylphosphorylcholine [1936]	
sphingosine
1‐phosphate>dihydrosphingosine‐1‐phosphate>sphingosylphosphorylcholine [821]	
Agonists	
SEW2871
(pK
i 5.5–7.7) [1640]	–	–	–	–	
Antagonists	
VPC44116
(pK
i 8.5) [533], VPC23019
(pK
i 7.9) [400]	–	
VPC44116
(pK
i 6.5) [533], VPC23019
(pK
i 5.9) [400]	–	–	
Selective
antagonists	
W146
(pK
i 7.1) [1641]	
JTE‐013
(pIC50 7.8) [1447]	–	–	–	
Selective
agonists	
AUY954
(pEC50 8.9) [1456]	–	–	–	–	



Comments
The approved immunomodulator drug fingolimod can be
phosphorylated in vivo [31] to generate a relatively
potent agonist with activity at S1P1, S1P3, S1P4 and
S1P5 receptors [215, 1198], although its biological
activity appears to involve an element of functional antagonism [339, 356, 1405].

Further Reading
Chi H. (2011) Sphingosine‐1‐phosphate and
immune regulation: trafficking and beyond. Trends Pharmacol. Sci.
32: 16‐24 [PMID:21159389]


Chun J et al. (2010)
International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid
receptor nomenclature. Pharmacol. Rev.
62: 579‐87 [PMID:21079037]


Kihara Y et al. (2015)
Lysophospholipid receptors in drug discovery. Exp. Cell Res.
333: 171‐7 [PMID:25499971]


Mutoh T et al. (2012) Insights
into the pharmacological relevance of lysophospholipid receptors. Br. J.
Pharmacol.
165: 829‐44 [PMID:21838759]


O'Sullivan C et al. (2013) The
structure and function of the S1P1 receptor. Trends Pharmacol. Sci.
34: 401‐12 [PMID:23763867]


Spiegel S et al. (2011) The
outs and the ins of sphingosine‐1‐phosphate in immunity. Nat. Rev.
Immunol.
11: 403‐15 [PMID:21546914]



Melanin‐concentrating hormone
receptors

Overview
Melanin‐concentrating hormone (MCH) receptors
(provisional nomenclature as recommended by NC‐IUPHAR [
530
]) are activated by an endogenous nonadecameric cyclic peptide identical
in humans and rats (DFDMLRCMLGRVYRPCWQV) generated from a precursor (PMCH, P20382), which also produces
neuropeptide EI(PMCH, P20382) and neuropeptide GE (PMCH, P20382).


Nomenclature	
MCH1
receptor
	
MCH2
receptor
	
HGNC, UniProt	
MCHR1, Q99705
	
MCHR2, Q969V1
	
Rank order of
potency	
melanin‐concentrating
hormone (PMCH, P20382)
>MCH (salmon)
	
melanin‐concentrating
hormone (PMCH, P20382) =
MCH (salmon)
[753]	
Selective
antagonists	
GW803430
(pIC50 9.3) [745], SNAP‐7941
(pA2 9.2) [186], T‐226296
(pIC50 8.3) [1853], ATC0175
(pIC50 7.9–8.1) [283]	–	
Labelled
ligands	
[125I]S36057 (Antagonist)
(pK
d 9.2–9.5) [66], [125I][Phe13,Tyr19]MCH
(Agonist) (pK
d 9.2) [242], [3H]MCH (human,
mouse, rat) (Agonist) [242]	–	



Comments
The MCH2 receptor appears to be a
non‐functional pseudogene in rodents [1857].

Further Reading
Boughton CK et al. (2012) Can
Neuropeptides Treat Obesity? A review of neuropeptides and their potential role in
the treatment of obesity. Br. J. Pharmacol.
[PMID:23121386]


Chung S et al. (2011) Recent
updates on the melanin‐concentrating hormone (MCH) and its receptor system: lessons
from MCH1R antagonists. J. Mol. Neurosci.
43: 115‐21 [PMID:20582487]


Eberle AN et al. (2010)
Cellular models for the study of the pharmacology and signaling of
melanin‐concentrating hormone receptors. J. Recept. Signal Transduct.
Res.
30: 385‐402 [PMID:21083507]


Foord SM et al. (2005)
International Union of Pharmacology. XLVI. G protein‐coupled receptor list.
Pharmacol Rev
57: 279‐288 [PMID:15914470]


Macneil DJ. (2013) The role of
melanin‐concentrating hormone and its receptors in energy homeostasis. Front
Endocrinol (Lausanne)
4: 49 [PMID:23626585]


Parker JA et al. (2012)
Hypothalamic neuropeptides and the regulation of appetite.
Neuropharmacology
63: 18‐30 [PMID:22369786]


Takase K et al. (2014)
Meta‐analysis of melanin‐concentrating hormone signaling‐deficient mice on behavioral
and metabolic phenotypes. PLoS ONE
9: e99961 [PMID:24924345]



Melanocortin receptors

Overview
Melanocortin receptors (provisional
nomenclature as recommended by NC‐IUPHAR[
530
]) are activated by members of the melanocortin family (α‐MSH(POMC, P01189), β‐MSH(POMC, P01189) and γ‐MSH(POMC, P01189) forms;
‐δ form is not found in mammals) and adrenocorticotrophin
(ACTH(POMC, P01189)). Endogenous
antagonists include agouti(ASIP, P42127) and agouti‐related protein
(AGRP, O00253).


Nomenclature	
MC1
receptor
	
MC2
receptor
	
MC3
receptor
	
MC4
receptor
	
MC5
receptor
	
HGNC, UniProt	
MC1R, Q01726
	
MC2R, Q01718
	
MC3R, P41968
	
MC4R, P32245
	
MC5R, P33032
	
Rank order of
potency	
α‐MSH (POMC, P01189)
>β‐MSH (POMC, P01189)
>ACTH (POMC, P01189),
γ‐MSH (POMC, P01189)	
ACTH (POMC, P01189)	
γ‐MSH (POMC, P01189),
β‐MSH (POMC, P01189)
>ACTH (POMC, P01189),
α‐MSH (POMC, P01189)	
β‐MSH (POMC, P01189)
>α‐MSH (POMC, P01189),
ACTH (POMC, P01189)
>γ‐MSH (POMC, P01189)	
α‐MSH (POMC, P01189)
>β‐MSH (POMC, P01189)
>ACTH (POMC, P01189)
>γ‐MSH (POMC, P01189)	
Selective
agonists	–	
corticotropin
zinchydroxide
	
[D‐Trp8]γ‐MSH
(pIC50 8.2) [645]	
THIQ
(pIC50 8.9) [1690]	–	
Antagonists	–	–	
PG‐106
(pIC50 6.7) [646]	–	–	
Selective
antagonists	–	–	–	
MBP10
(pIC50 10) [117], HS014
(pK
i 8.5) [1667]	–	
Labelled
ligands	
[125I]NDP‐MSH (Agonist) (pK
d 9.5) [991]	
[125I]ACTH‐(1‐24) (Agonist)	
[125I]NDP‐MSH (Agonist) (pK
d 9.7) [991], [125I]SHU9119 (Antagonist) [1392]	
[125I]SHU9119 (Antagonist)
(pK
d 9.2) [1392], [125I]NDP‐MSH (Agonist) (pK
d 8.4–8.9) [991, 1665]	
[125I]NDP‐MSH (Agonist) (pK
d 8.6) [991]	



Comments
Polymorphisms of the MC1 receptor have been
linked to variations in skin pigmentation. Defects of the MC2 receptor underlie
familial glucocorticoid deficiency. Polymorphisms of the MC4 receptor have been
linked to obesity [282, 505].

Further Reading
Beaumont KA et al. (2011)
Melanocortin MC_1 receptor in human genetics and model systems. Eur. J.
Pharmacol.
660: 103‐10 [PMID:21199646]


Cooray SN et al. (2011)
Melanocortin receptors and their accessory proteins. Mol. Cell.
Endocrinol.
331: 215‐21 [PMID:20654690]


Foord SM et al. (2005)
International Union of Pharmacology. XLVI. G protein‐coupled receptor list.
Pharmacol Rev
57: 279‐288 [PMID:15914470]


Holloway PM et al. (2011)
Targeting the melanocortin receptor system for anti‐stroke therapy. Trends
Pharmacol. Sci.
32: 90‐8 [PMID:21185610]


Hruby VJ et al. (2011) Design
of novel melanocortin receptor ligands: multiple receptors, complex pharmacology, the
challenge. Eur. J. Pharmacol.
660: 88‐93 [PMID:21208601]


Loos RJ. (2011) The genetic epidemiology of
melanocortin 4 receptor variants. Eur. J. Pharmacol.
660: 156‐64 [PMID:21295023]


Meimaridou E et al. (2013)
ACTH resistance: genes and mechanisms. Endocr Dev
24: 57‐66 [PMID:23392095]


Renquist BJ et al. (2011)
Physiological roles of the melanocortin MC_3 receptor. Eur. J.
Pharmacol.
660: 13‐20 [PMID:21211527]


Yang Y. (2011) Structure, function and
regulation of the melanocortin receptors. Eur. J. Pharmacol.
660: 125‐30 [PMID:21208602]



Melatonin receptors

Overview
Melatonin receptors (nomenclature as
agreed by the NC‐IUPHARSubcommittee on Melatonin Receptors [
446
]) are activated by the endogenous ligands melatonin and N‐acetylserotonin.


Nomenclature	
MT1
receptor
	
MT2
receptor
	
HGNC, UniProt	
MTNR1A, P48039
	
MTNR1B, P49286
	
Endogenous
agonists	
melatonin
(pK
i 9.1–9.7) [67, 445, 447]	
melatonin
(pK
i 9.4–9.8) [67, 445, 447]	
Agonists	
ramelteon
(pK
i 10.9) [909], agomelatine
(pK
i 10–10.4) [67, 132]	
agomelatine
(pK
i 9.9–10.5) [67, 132], ramelteon
(pK
i 10) [909, 1565]	
Selective
agonists	–	
IIK7
(pK
i 10.3) [506, 1814], 5‐methoxy‐luzindole (Partial agonist)
(pK
i 9.6) [447]	
Selective
antagonists	–	
4P‐PDOT
(pK
i 8.8–9.4) [67, 447, 448], K185
(pK
i 9.3) [506, 1814], DH97
(pK
i 8) [1865]	
Labelled
ligands	
[125I]SD6 (Agonist) (pK
d 10.9) [1074], 2‐[125I]melatonin (Agonist)
(pK
d 9.9–10.7) [67, 447], [3H]melatonin (Agonist) (pK
d 9.4–9.9) [230]	
[125I]SD6 (Agonist) (pK
d 10.2) [1074], 2‐[125I]melatonin (Agonist)
(pK
d 9.7–10) [67, 447], [125I]DIV880 (Agonist, Partial agonist)
(pK
d 9.7) [1074], [3H]melatonin (Agonist) (pK
d 9–9.6) [230]	



Comments

melatonin, 2‐iodo‐melatonin, agomelatine, GR 196429, LY 156735 and ramelteon[909] are nonselective agonists
for MT1 and MT2 receptors. (‐)‐AMMTC displays an ~400‐fold
greater agonist potency than (+)‐AMMTC at rat MT1 receptors (see AMMTC for structure) [1888]. Luzindole is an
MT1/MT2 melatonin receptor‐selective competitive antagonist
with some selectivity for the MT2 receptor [448].
MT1/MT2 heterodimers present different pharmacological
profiles from MT1 and MT2 receptors [72].

The MT3 binding site of hamster brain and peripheral tissues such as kidney and
testis, also termed the ML2 receptor, binds selectively 2‐iodo‐[125I]5MCA‐NAT[1302]. Pharmacological
investigations of MT3 binding sites have primarily been conducted in hamster tissues. At this
site, N‐acetylserotonin[467, 1149, 1302, 1516] and 5MCA‐NAT[1516] appear to function as
agonists, while prazosin[1149] functions as an
antagonist. The MT3 binding site of hamster kidney was also identified as the hamster homologue
of human quinone reductase 2 (NQO2, P16083[1408, 1409]). The
MT3 binding site activated by 5MCA‐NAT in eye ciliary body is
positively coupled to adenylyl cyclase and regulates chloride secretion [802]. Xenopus
melanophores and chick brain express a distinct receptor (x420, P49219; c346, P49288,
initially termed Mel1C) coupled to the Gi/o family of G
proteins, for which GPR50 has recently been suggested to be a mammalian counterpart
[451] although melatonin does not bind to
GPR50 receptors.

Further Reading
Cardinali DP et al. (2012)
Melatonin and its analogs in insomnia and depression. J. Pineal Res.
52: 365‐75 [PMID:21951153]


Dardente H. (2012) Melatonin‐dependent timing
of seasonal reproduction by the pars tuberalis: pivotal roles for long daylengths and
thyroid hormones. J. Neuroendocrinol.
24: 249‐66 [PMID:22070540]


Dubocovich ML et al. (2010)
International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature,
classification, and pharmacology of G protein‐coupled melatonin receptors.
Pharmacol. Rev.
62: 343‐80 [PMID:20605968]


Hickie IB et al. (2011) Novel
melatonin‐based therapies: potential advances in the treatment of major depression.
Lancet
378: 621‐31 [PMID:21596429]


Korkmaz A et al. (2012) Gene
regulation by melatonin linked to epigenetic phenomena. Gene
503: 1‐11 [PMID:22569208]


Slominski A et al. (2008)
Melatonin in the skin: synthesis, metabolism and functions. Trends
Endocrinol. Metab.
19: 17‐24 [PMID:18155917]



Metabotropic glutamate receptors

Overview
Metabotropic glutamate (mGlu) receptors
(nomenclature as agreed by the NC‐IUPHAR Subcommittee on Metabotropic Glutamate Receptors
[1672]) are activated by the endogenous ligands L‐glutamic acid, L‐serine‐O‐phosphate,
N‐acetylaspartylglutamate (NAAG) and L‐cysteine sulphinic acid.
Examples of agonists selective for mGlu receptors compared with ionotropic glutamate
receptors are (1S,3R)‐ACPD and L‐CCG‐I, which show limited
selectivity for Group‐II receptors. An example of an antagonist selective for mGlu
receptors is LY341495, which blocks
mGlu2 and mGlu3 at low nanomolar concentrations,
mGlu8 at high nanomolar concentrations, and mGlu4,
mGlu5, and mGlu7 in the micromolar range [955]. Three groups of native
receptors are distinguishable on the bases of similarities of agonist pharmacology,
primary sequence and G protein coupling to effector: Group‐I (mGlu1 and
mGlu5), Group‐II (mGlu2 and mGlu3) and Group‐III
(mGlu4, mGlu6, mGlu7 and mGlu8) (see
Further reading). Group‐I mGlu receptors may be activated by 3,5‐DHPG and (S)‐3HPG[198] and antagonized by
(S)‐hexylhomoibotenic
acid[1171]. Group‐II mGlu receptors
may be activated by LY389795[1311], LY379268[1311], eglumegad[1673, 2050], DCG‐IV and (2R,3R)‐APDC[1674], and antagonised by
eGlu(4.3, [848] and LY307452[491, 2009]. Group‐III mGlu receptors
may be activated by L‐AP4 and (R,S)‐4‐PPG[579].

In addition to orthosteric ligands that
directly interact with the glutamate recognition site directly, allosteric modulators
have been described. Negative allosteric modulators are listed separately. The
positive allosteric modulators most often act as ‘potentiators’ of an orthosteric
agonist response, without significantly activating the receptor in the absence of
agonist.

Although mGlu receptors have been thought to
only form homodimers, recent studies revealed the possible formation of heterodimers
between either group‐I receptors, or within and between group‐II and ‐III receptors
[441]. Although well
characterized in transfected cells, co‐localization and specific pharmacological
properties also suggest the existence of such heterodimers in the brain [2094].

The structure of the 7 transmembrane (TM)
domains of both mGlu1 and mGlu5 have been solved, and confirm a
general helical organization similar to that of other GPCRs, although the helices
appear more compacted [438, 2048].


Nomenclature r	
mGlu1
receptor
	
mGlu2
receptor
	
mGlu3
receptor
	
mGlu4
receptor
	
HGNC, UniProt	
GRM1, Q13255
	
GRM2, Q14416
	
GRM3, Q14832
	
GRM4, Q14833
	
Endogenous
agonists	–	–	
NAAG (Selective)
(pK
i 4.7) [1679]	–	
Agonists	–	–	–	
L‐AP4
(pEC50 6.5) [2050], L‐serine‐O‐phosphate (pEC50 5.9) [2050]	
Selective
agonists	–	–	–	
LSP4‐2022
(pEC50 7) [631]	
Antagonists	
LY367385
(pIC50 5.1) [349]	–	–	
MAP4
(pK
i 4.6) [686] – Rat	
Selective
antagonists	
3‐MATIDA
(pIC50 5.2) [1333] – Rat,
(S)‐(+)‐CBPG
(pIC50 4.2) [1200] – Rat,
(S)‐TBPG
(pIC50 4.2) [367] – Rat,
AIDA
(pA2 4.2) [1334]	
PCCG‐4
(pIC50 5.1) [1483] – Rat	–	–	
Allosteric
modulators	
YM298198
(Negative) (pIC50 7.8) [979] – Rat	
CBiPES
(Positive) (pEC50 7) [874], 4‐MPPTS
(Positive) (pIC50 5.8) [94, 873, 874, 1660]	–	
SIB‐1893
(Positive) (pEC50 6.3–6.8) [1217], MPEP (Positive)
(pEC50 6.3–6.6) [1217], PHCCC (Positive)
(pEC50 4.5) [1184]	
Selective
allosteric modulators	
BAY 367620
(Negative) (pK
i 9.5) [267] – Rat,
JNJ16259685
(Negative) (pIC50 8.9) [1047], A‐841720
(Negative) (pIC50 8) [2126], Ro67‐7476
(Positive) (pK
i 7.5–7.9) [971] – Rat,
3,5‐dimethyl PPP
(Negative) (pIC50 7.8) [1271] – Rat,
EM‐TBPC
(Negative) (pK
i 7.8) [1191] – Rat,
Ro01‐6128
(Positive) (pK
i 7.5–7.7) [971] – Rat,
LY456236
(Negative) (pIC50 6.9) [1094], CPCCOEt
(Negative) (pIC50 5.2–5.8) [1116], Ro67‐4853
(Positive) (pK
i 5.1) [971] – Rat,
PHCCC
(Positive)	
Ro64‐5229
(Negative) (pIC50 7) [985] – Rat,
biphenylindanone
A (Positive) (pEC50 7) [183]	–	
VU0361737
(Positive) (pEC50 6.6) [480], VU0155041
(Positive) (pEC50 6.1) [1402]	
Comments	–	–	–	pEC50 values for
MPEP and SIB‐1893 were obtained in the presence of L‐AP4 [1217].	




Nomenclature	
mGlu5
receptor
	
mGlu6
receptor
	
mGlu7
receptor
	
mGlu8
receptor
	
HGNC, UniProt	
GRM5, P41594
	
GRM6, O15303
	
GRM7, Q14831
	
GRM8, O00222
	
Endogenous
agonists	–	–	–	
L‐serine‐O‐phosphate (pIC50 6.2–7.2)
[1192, 2050]	
Agonists	–	–	
LSP4‐2022
(pEC50 4.9) [631], L‐serine‐O‐phosphate (pEC50 4.5) [2050], L‐AP4
(pEC50 3.8) [2050]	
(S)‐3,4‐DCPG (pEC50 7.5)
[1876], L‐AP4
(pIC50 7–7.2) [1192]	
Selective
agonists	
(S)‐(+)‐CBPG
(Partial agonist) (pEC50 4.3) [1200] – Rat,
CHPG
(pIC50 3.4) [1350]	
1‐benzyl‐APDC
(pEC50 4.7) [1911] – Rat, homo‐AMPA
(pEC50 4.1) [237]	–	–	
Antagonists	–	
MAP4
(pIC50 3.5) [1504] – Rat,
THPG [1879] –
Unknown	–	
MPPG
(pIC50 4.3) [2050]	
Selective
antagonists	
ACDPP
(pIC50 6.9) [182]	–	–	–	
Allosteric
modulators	
3,3'‐difluorobenzaldazine (Positive) (pIC50
5.6–8.5) [1415, 1416], alloswitch‐1
(Negative) (pIC50 8.1) [1511] – Rat,
CDPPB (Positive)
(pEC50 7.6–8) [956, 1114], MTEP (Negative)
(pK
i 7.8) [223], MPEP (Negative)
(pIC50 7.4–7.7) [578, 580], fenobam
(Negative) (pIC50 7.2) [1519], SIB‐1893
(Negative) (pIC50 5.9–6.5) [578, 1949], SIB‐1757
(Negative) (pIC50 6–6.4) [578, 1949], CPPHA (Positive)
(pIC50 6.3) [1416]	–	
MMPIP (Negative)
(pIC50 6.1–7.6) [1401, 1827] – Rat,
AMN082
(Positive) (pEC50 6.5–6.8) [1293], XAP044
(Negative) (pIC50 5.6) [587]	–	
Selective
allosteric modulators	
VU‐1545
(Positive) (pEC50 8) [2142]	–	–	–	



Comments
The activity of NAAG as an agonist at
mGlu3 receptors was questioned on the basis of contamination with
glutamate [327, 547], but this has been refuted
[1369].

Radioligand binding using a variety of
radioligands has been conducted on recombinant receptors (for example, [3H]R214127[1046] and [3H]YM298198[979] at mGlu1
receptors and [3H]M‐MPEP[578] and [3H]methoxymethyl‐MTEP[47] at mGlu5
receptors. Although a number of radioligands have been used to examine binding in
native tissues, correlation with individual subtypes is limited. Many pharmacological
agents have not been fully tested across all known subtypes of mGlu receptors.
Potential differences linked to the species (e.g. human
versus rat or mouse) of the receptors and the receptor splice
variants are generally not known. The influence of receptor expression level on
pharmacology and selectivity has not been controlled for in most studies,
particularly those involving functional assays of receptor coupling.


(S)‐(+)‐CBPG is an antagonist
at mGlu1, but is an agonist (albeit of reduced efficacy) at
mGlu5 receptors. DCG‐IV also exhibits agonist
activity at NMDA glutamate receptors [1931], and is an antagonist at
all group‐III mGluRs with an IC50 of 30μM. A potential
novel metabotropic glutamate receptor coupled to phosphoinositide turnover has been
observed in rat brain; it is activated by 4‐methylhomoibotenic acid
(ineffective as an agonist at recombinant Group I metabotropic glutamate receptors),
but resistant to LY341495[341]. There are also reports of
a distinct metabotropic glutamate receptor coupled to phospholipase D in rat brain,
which does not readily fit into the current classification [964, 1482]

A related class C receptor composed of two
distinct subunits, T1R1 + T1R3 is also activated by glutamate and is responsible for
umami taste detection.

All selective antagonists at metabotropic
glutamate receptors are competitive.

Further Reading
Conn PJ et al. (1997)
Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev.
Pharmacol. Toxicol.
37: 205‐237 [PMID:9131252]


Ferraguti F et al. (2006)
Metabotropic glutamate receptors. Cell Tissue Res.
326: 483‐504 [PMID:16847639]


Nicoletti F et al. (2011)
Metabotropic glutamate receptors: from the workbench to the bedside.
Neuropharmacology
60: 1017‐41 [PMID:21036182]


Niswender CM et al. (2010)
Metabotropic glutamate receptors: physiology, pharmacology, and disease.
Annu. Rev. Pharmacol. Toxicol.
50: 295‐322 [PMID:20055706]


Rondard P et al. (2011) The
complexity of their activation mechanism opens new possibilities for the modulation
of mGlu and GABAB class C G protein‐coupled receptors.
Neuropharmacology
60: 82‐92 [PMID:20713070]



Motilin receptor

Overview
Motilin receptors (provisional
nomenclature) are activated by a 22 amino‐acid peptide derived from a
precursor (MLN, P12872), which may also
generate a motilin‐associated peptide
(MLN, P12872). These receptors are
also suggested to be responsible for the gastrointestinal prokinetic effects of
certain macrolide antibiotics (often called motilides; e.g.
erythromycin), although for many of these molecules the evidence is sparse.


Nomenclature	
motilin receptor
	
HGNC, UniProt	
MLNR, O43193
	
Endogenous
agonists	
motilin
(MLN, P12872)
(pK
i 8.4–8.7) [372, 1223, 1224, 1225]	
Agonists	
alemcinal
(pIC50 7.2) [1872], erythromycin‐A
(pIC50 5.5–6.5) [507, 1872], azithromycin
(pEC50 5.5) [220]	
Selective
agonists	
camicinal
(pEC50 7.9) [99, 1639], mitemcinal
(pEC50 7.5–7.8) [977, 1845] –
Rabbit	
Selective
antagonists	
MA‐2029
(pA2 9.2) [1811], GM‐109
(pIC50 8) [701] – Pig	
Labelled
ligands	
[125I]motilin
(human) (Agonist) (pK
d 10) [507]	



Comments
In laboratory rodents, the gene encoding the
motilin percursor appears to be absent, while the receptor appears to be a pseudogene
[725, 1637]. Functions of motilin(MLN, P12872) are not usually
detected in rodents, although brain and other responses to motilin and the macrolide
alemcinal have been reported
and the mechanism of these actions are obscure [1249, 1396]. Marked differences in
ligand affinities for the motilin receptor in dogs and humans may be explained by
significant differences in receptor structure [1638]. Note that for the
complex macrolide structures, selectivity of action has often not been rigorously
examined and other actions are possible (e.g. P2X inhibition by
erythromycin; [2123]). Small molecule motilin
receptor agonists are now described [1093, 1639, 2013]. The motilin receptor
does not appear to have constitutive activity [774]. Although not proven, the
existence of biased agonism at the receptor has been suggested [1225, 1292, 1636]. A truncated
5‐transmembrane structure has been identified but this is without activity when
transfected into a host cell [507].

Further Reading
De Smet B et al. (2009)
Motilin and ghrelin as prokinetic drug targets. Pharmacol. Ther.
123: 207‐23 [PMID:19427331]


Foord SM et al. (2005)
International Union of Pharmacology. XLVI. G protein‐coupled receptor list.
Pharmacol Rev
57: 279‐288 [PMID:15914470]


Sanger GJ et al. (2012)
Motilin: Toward a new understanding of the gastrointestinal neuropharmacology and
therapeutic use of motilin receptor agonists. Br. J. Pharmacol.
[PMID:23189978]


Takeshita E et al. (2006)
Molecular characterization and distribution of motilin family receptors in the human
gastrointestinal tract. J Gastroenterol
41: 223‐230 [PMID:16699856]



Neuromedin U receptors

Overview
Neuromedin U receptors (provisional
nomenclature as recommended by NC‐IUPHAR[
530
]) are activated by the endogenous 25 amino acid peptide neuromedin U
(neuromedin U‐25 (NMU, P48645), NmU‐25), a peptide
originally isolated from pig spinal cord [1287]. In humans, NmU‐25
appears to be the sole product of a precursor gene (NMU, P48645) showing a broad tissue
distribution, but which is expressed at highest levels in the upper gastrointestinal
tract, CNS, bone marrow and fetal liver. Much shorter versions of NmU are found in
some species, but not in human, and are derived at least in some instances from the
proteolytic cleavage of the longer NmU. Despite species differences in NmU structure,
the C‐terminal region (particularly the C‐terminal pentapeptide) is highly conserved
and contains biological activity. Neuromedin S (neuromedin S‐33 (NMS, Q5H8A3)) has also been
identified as an endogenous agonist [1326]. NmS‐33 is, as its name
suggests, a 33 amino‐acid product of a precursor protein derived from a single gene
and contains an amidated C‐terminal heptapeptide identical to NmU. NmS‐33 appears to
activate NMU receptors with equivalent potency to NmU‐25.


Nomenclature	
NMU1 receptor
	
NMU2 receptor
	
HGNC, UniProt	
NMUR1, Q9HB89
	
NMUR2, Q9GZQ4
	
Antagonists	–	
R‐PSOP
(pK
B 7) [1128]	



Comments
NMU1 and NMU2 couple predominantly to
Gq/11 although there is evidence of good coupling to
Gi/o[213, 786, 794]. NMU1 and NMU2 can be
labelled with [125I]‐NmU and [125I]‐NmS (of various species,
e.g. [1259]), BODIPY®; TMR‐NMU or
Cy3B‐NMU‐8[213]. A range of radiolabelled
(125I‐), fluorescently labelled (e.g. Cy3, Cy5,
rhodamine and FAM) and biotin labelled versions of
neuromedin U‐25(NMU, P48645) and neuromedin S‐33 (NMS, Q5H8A3) are now commercially
available.

Further Reading
Brighton PJ et al. (2004)
Neuromedin U and its receptors: structure, function, and physiological roles.
Pharmacol. Rev.
56: 231‐48 [PMID:15169928]


Budhiraja S et al. (2009)
Neuromedin U: physiology, pharmacology and therapeutic potential. Fundam Clin
Pharmacol
23: 149‐57 [PMID:19645813]


Foord SM et al. (2005)
International Union of Pharmacology. XLVI. G protein‐coupled receptor list.
Pharmacol Rev
57: 279‐288 [PMID:15914470]


Mitchell JD et al. (2009)
Emerging pharmacology and physiology of neuromedin U and the structurally related
peptide neuromedin S. Br. J. Pharmacol.
158: 87‐103 [PMID:19519756]


Novak CM. (2009) Neuromedin S and U.
Endocrinology
150: 2985‐7 [PMID:19549882]



Neuropeptide FF/neuropeptide AF
receptors

Overview
The Neuropeptide FF receptor family contains
two subtypes, NPFF1 and NPFF2 (provisional nomenclature [
530
]), which exhibit high affinities for neuropeptide FF (NPFF, O15130) and RFamide related
peptides (RFRP: precursor gene symbol NPVF, Q9HCQ7). NPFF1 is broadly distributed in the
central nervous system with the highest levels found in the limbic system and the
hypothalamus. NPFF2 is present in high density in the superficial layers of the
mammalian spinal cord where it is involved in nociception and modulation of opioid
functions.


Nomenclature	
NPFF1 receptor
	
NPFF2 receptor
	
HGNC, UniProt	
NPFFR1, Q9GZQ6
	
NPFFR2, Q9Y5X5
	
Rank order of
potency	
RFRP‐1
(NPVF, Q9HCQ7)
>RFRP‐3
(NPVF, Q9HCQ7) >
FMRFneuropeptide FF
(NPFF, O15130)
>neuropeptide AF
(NPFF, O15130)
>neuropeptide SF
(NPFF, O15130),
QRFP43
(QRFP, P83859),
PrRP‐31
(PRLH, P81277)
[628]	
neuropeptide AF
(NPFF, O15130),
neuropeptide FF
(NPFF, O15130)
>PrRP‐31
(PRLH, P81277) >
FMRF, QRFP43
(QRFP, P83859)
>neuropeptide SF
(NPFF, O15130)
[628]	
Endogenous
agonists	
neuropeptide FF
(NPFF, O15130)
(Selective) (pK
i 8.5–9.9) [628, 629, 1306], RFRP‐3
(NPVF, Q9HCQ7)
(Selective) (pK
i 9.2–9.3) [629, 630, 1306]	
neuropeptide FF
(NPFF, O15130)
(Selective) (pK
i 9.7) [629, 1305]	
Selective
agonists	–	
dNPA
(pK
i 10.6) [1607], AC263093
(pEC50 5.2–5.9) [1036]	
Antagonists	
RF9
(pK
i 7.2) [1745]	–	
Selective
antagonists	
AC262620
(pK
i 7.7–8.1) [1036], AC262970
(pK
i 7.4–8.1) [1036]	–	
Labelled
ligands	
[125I]Y‐RFRP‐3 (Agonist)
(pK
d 9.7) [629], [3H]NPVF (Agonist) (pK
d 8.6) [1855], [125I]NPFF (Agonist) [628]	
[125I]EYF (Agonist) (pK
d 10.2) [1306], [3H]EYF (Agonist) (pK
d 9.3) [1855], [125I]NPFF (Agonist) [628]	



Comments
An orphan receptor GPR83(Q9NYM4) shows sequence
similarities with NPFF1, NPFF2, PrRP and QRFP receptors. The antagonist RF9 is selective for NPFF
receptors, but does not distinguish between the NPFF1 and NPFF2 subtypes
(pK
i 7.1 and 7.2, respectively, [1745]).

Further Reading
Moulédous L et al. (2010)
Opioid‐modulating properties of the neuropeptide FF system.
Biofactors
36: 423‐9 [PMID:20803521]


Vyas N et al. (2006)
Structure‐activity relationships of neuropeptide FF and related peptidic and
non‐peptidic derivatives. Peptides
27: 990‐6 [PMID:16490282]


Yang HY et al. (2008)
Modulatory role of neuropeptide FF system in nociception and opiate analgesia.
Neuropeptides
42: 1‐18 [PMID:17854890]



Neuropeptide S receptor

Overview
The neuropeptide S receptor (NPS,
provisional nomenclature [
530
]) responds to the 20 amino‐acid peptide neuropeptide S derived from the
precursor (NPS, P0C0P6).


Nomenclature	
NPS receptor
	
HGNC, UniProt	
NPSR1, Q6W5P4
	
Endogenous
agonists	
neuropeptide S
(NPS, P0C0P6)
(pEC50 8) [2070]	
Labelled
ligands	
[125I]Tyr10NPS (human)
(Agonist) (pK
d 9.5) [2070]	



Comments
Polymorphisms in the NPS receptor have been
suggested to be associated with asthma [1953] and irritable bowel
syndrome [386].

Further Reading
Cannella N et al. (2013) The
role of the neuropeptide S system in addiction: focus on its interaction with the CRF
and hypocretin/orexin neurotransmission. Prog. Neurobiol.
100: 48‐59 [PMID:23041581]


Dal Ben D et al. (2011)
Neuropeptide S receptor: recent updates on nonpeptide antagonist discovery.
ChemMedChem
6: 1163‐71 [PMID:21452188]


Foord SM et al. (2005)
International Union of Pharmacology. XLVI. G protein‐coupled receptor list.
Pharmacol Rev
57: 279‐288 [PMID:15914470]


Guerrini R et al. (2010)
Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its
receptor. Med Res Rev
30: 751‐77 [PMID:19824051]


Pape HC et al. (2010)
Neuropeptide S: a transmitter system in the brain regulating fear and anxiety.
Neuropharmacology
58: 29‐34 [PMID:19523478]


Reinscheid RK. (2008) Neuropeptide S: anatomy,
pharmacology, genetics and physiological functions. Results Probl Cell
Differ
46: 145‐58 [PMID:18204825]



Neuropeptide W/neuropeptide B
receptors

Overview
The neuropeptide BW receptor 1 (NPBW1,
provisional nomenclature [
530
]) is activated by two 23‐amino‐acid peptides, neuropeptide W (neuropeptide W‐23 (NPW, Q8N729)) and neuropeptide B
(neuropeptide B‐23 (NPB, Q8NG41)) [554, 1725]. C‐terminally extended
forms of the peptides (neuropeptide W‐30(NPW, Q8N729) and neuropeptide B‐29 (NPB, Q8NG41)) also activate NPBW1
[211]. Unique to both forms of
neuropeptide B is the N‐terminal bromination of the first tryptophan residue, and it
is from this post‐translational modification that the nomenclature NPB is derived.
These peptides were first identified from bovine hypothalamus and therefore are
classed as neuropeptides. Endogenous variants of the peptides without the N‐terminal
bromination, des‐Br‐neuropeptide
B‐23(NPB, Q8NG41) and des‐Br‐neuropeptide B‐29
(NPB, Q8NG41), were not found to be
major components of bovine hypothalamic tissue extracts. The NPBW2 receptor is
activated by the short and C‐terminal extended forms of neuropeptide W and
neuropeptide B [211].


Nomenclature	
NPBW1 receptor
	
NPBW2 receptor
	
HGNC, UniProt	
NPBWR1, P48145
	
NPBWR2, P48146
	
Rank order of
potency	
neuropeptide
B‐29 (NPB, Q8NG41)
>neuropeptide
B‐23 (NPB, Q8NG41)
>neuropeptide
W‐23 (NPW, Q8N729)
>neuropeptide
W‐30 (NPW, Q8N729)
[211]	
neuropeptide
W‐23 (NPW, Q8N729)
>neuropeptide
W‐30 (NPW, Q8N729)
>neuropeptide
B‐29 (NPB, Q8NG41)
>neuropeptide
B‐23 (NPB, Q8NG41)
[211]	
Selective
agonists	
Ava3
(pK
i 9.4–9.4) [902], Ava5
(pK
i 8.8–9) [902]	–	
Labelled
ligands	
[125I]NPW‐23
(human) (Agonist) (pK
d 9.4) [1747]	
[125I]NPW‐23
(human) (Agonist) (pK
d 7.7) [1725]	



Comments
Potency measurements were conducted with
heterologously‐expressed receptors with a range of 0.14‐0.57 nM (NPBW1) and 0.98‐21
nM (NPBW2).

NPBW1‐/‐ mice show changes in social
behavior, suggesting that the NPBW1 pathway may have an important role in the
emotional responses of social interaction [1355].

Further Reading
Date Y et al. (2010)
Neuropeptide W: an anorectic peptide regulated by leptin and metabolic state.
Endocrinology
151: 2200‐10 [PMID:20189998]


Hondo M et al. (2008) The
NPB/NPW neuropeptide system and its role in regulating energy homeostasis, pain, and
emotion. Results Probl Cell Differ
46: 239‐56 [PMID:18204824]


Sakurai T. (2013) NPBWR1 and NPBWR2:
Implications in Energy Homeostasis, Pain, and Emotion. Front Endocrinol
(Lausanne)
4: 23 [PMID:23515889]


Singh G et al. (2006)
Neuropeptide B and W: neurotransmitters in an emerging G‐protein‐coupled receptor
system. Br. J. Pharmacol.
148: 1033‐41 [PMID:16847439]



Neuropeptide Y receptors

Overview
Neuropeptide Y (NPY) receptors
(nomenclature as agreed by the NC‐IUPHAR Subcommittee on Neuropeptide Y Receptors [
1270
]) are activated by the endogenous peptides neuropeptide Y (NPY, P01303), neuropeptide Y‐(3‐36),
peptide YY(PYY, P10082), PYY‐(3‐36) and
pancreatic polypeptide
(PPY, P01298) (PP). The receptor
originally identified as the Y3 receptor has been identified as the CXCR4 chemokine recepter
(originally named LESTR, [1135]). The y6 receptor is a
functional gene product in mouse, absent in rat, but contains a frame‐shift mutation
in primates producing a truncated non‐functional gene [642]. Many of the agonists
exhibit differing degrees of selectivity dependent on the species examined. For
example, the potency of PP is greater at the rat Y4receptor than at the
human receptor [485]. In addition, many
agonists lack selectivity for individual subtypes, but can exhibit comparable potency
against pairs of NPY receptor subtypes, or have not been examined for activity at all
subtypes. [125I]‐PYY or [125I]‐NPY can be used to label
Y1, Y2, Y5 and y6 subtypes
non‐selectively, while [125I][cPP(1‐7), NPY(19‐23),
Ala31, Aib32, Gln34]hPP may be used
to label Y5 receptors preferentially (note that cPP denotes chicken
peptide sequence and hPP is the human sequence).


Nomenclature	
Y1
receptor
	
Y2
receptor
	
Y4
receptor
	
Y5
receptor
	
y6
receptor
	
HGNC, UniProt	
NPY1R, P25929
	
NPY2R, P49146
	
NPY4R, P50391
	
NPY5R, Q15761
	
NPY6R, Q99463
	
Rank order of
potency	neuropeptide Y >
peptide YY ≫ pancreatic polypeptide	neuropeptide Y >
peptide YY ≫ pancreatic polypeptide	pancreatic
polypeptide > neuropeptide Y = peptide YY	neuropeptide Y >
peptide YY > pancreatic polypeptide	neuropeptide Y =
peptide YY > pancreatic polypeptide	
Endogenous
agonists	
neuropeptide Y
(NPY, P01303),
peptide YY
(PYY, P10082)	
PYY‐(3‐36)
(PYY, P10082)
(pK
i 9.2–9.7) [588, 599], neuropeptide Y
(NPY, P01303),
neuropeptide
Y‐(3‐36) (NPY, P01303),
peptide YY
(PYY, P10082)	
pancreatic
polypeptide (PPY, P01298)
(pK
i 8.7–10.9) [92, 1152, 1899, 2076]	–	–	
Selective
agonists	
[Leu31,Pro34]NPY
(pEC50 7.1) [378], [Leu31,Pro34]PYY (human),
[Pro34]NPY, [Pro34]PYY
(human)
	–	–	
[Ala31,Aib32]NPY (pig)
(pIC50 8.2) [254]	–	
Selective
antagonists	
BIBO3304
(pIC50 9.5) [2020], BIBP3226
(pK
i 8.1–9.3) [436, 2021]	
BIIE0246
(pIC50 8.5) [434], JNJ‐5207787
(pIC50 6.9–7.1) [178]	–	
L‐152,804
(pK
i 7.6) [901]	–	
Labelled
ligands	
[3H]BIBP3226 (Antagonist)
(pK
d 8.7), [125I][Leu31,Pro34]NPY
(Agonist)	
[125I]PYY‐(3‐36)
(human) (Agonist)	
[125I]PP
(human) (Agonist)	
[125I][cPP(1‐7),
NPY(19‐23), Ala31, Aib32,
Gln34]hPP (Agonist) (pK
d 9.2–9.3) [453] – Rat	–	
Comments	Note that
Pro34‐containing NPY and PYY can also bind Y4
and Y5 receptors, so strictly speaking are not selective,
but are the 'preferred' agonists.	–	–	–	The y6
receptor is a pseudogene in humans, but is functional in mouse, rabbit
and some other mammals.	



Comments
The Y1 agonists indicated are
selective relative to Y2 receptors. BIBP3226 is selective relative
to Y2, Y4 and Y5 receptors [598]. NPY‐(13‐36) is Y2
selective relative to Y1 and Y5 receptors. PYY‐(3‐36) is
Y2 selective relative to Y1 receptors.

Further Reading
Bowers ME et al. (2012)
Neuropeptide regulation of fear and anxiety: Implications of cholecystokinin,
endogenous opioids, and neuropeptide Y. Physiol. Behav.
107: 699‐710 [PMID:22429904]


Decressac M et al. (2012)
Neuropeptide Y and its role in CNS disease and repair. Exp. Neurol.
238: 265‐72 [PMID:23022456]


Michel MC et al. (1998) XVI.
International Union of Pharmacology recommendations for the nomenclature of
neuropeptide Y, peptide YY and pancreatic polypeptide receptors. Pharmacol.
Rev.
50: 143‐150 [PMID:9549761]


Morales‐Medina JC et al.
(2010) A possible role of neuropeptide Y in depression and stress. Brain
Res.
1314: 194‐205 [PMID:19782662]


Zengin A et al. (2010)
Neuropeptide Y and sex hormone interactions in humoral and neuronal regulation of
bone and fat. Trends Endocrinol. Metab.
21: 411‐8 [PMID:20202858]


Zhang L et al. (2011) The
neuropeptide Y system: pathophysiological and therapeutic implications in obesity and
cancer. Pharmacol. Ther.
131: 91‐113 [PMID:21439311]



Neurotensin receptors

Overview
Neurotensin receptors (nomenclature as
recommended by NC‐IUPHAR[
530
]) are activated by the endogenous tridecapeptide neurotensin
(pGlu‐Leu‐Tyr‐Glu‐Asn‐Lys‐Pro‐Arg‐Arg‐Pro‐Tyr‐Ile‐Leu) derived from a precursor
(NTS, 30990), which also generates
neuromedin N, an agonist at the NTS2 receptor. A nonpeptide antagonist,
SR142948A, shows high affinity
(pKi~9) at both NTS1 and NTS2 receptors
[664]. [3H]neurotensin (human, mouse,
rat) and [125I]neurotensin (human,
mouse, rat) may be used to label NTS1 and NTS2
receptors at 0.1‐0.3 and 3‐5 nM concentrations respectively.


Nomenclature	
NTS1
receptor
	
NTS2
receptor
	
HGNC, UniProt	
NTSR1, P30989
	
NTSR2, O95665
	
Rank order of
potency	
neurotensin
(NTS, P30990)
>neuromedin N
{Mouse, Rat} [741]	
neurotensin
(NTS, P30990) =
neuromedin N
{Mouse, Rat} [1235]	
Selective
agonists	
JMV449
(pK
i 10) [1753] – Rat	
levocabastine
(pK
i 6.8) [1235, 1583]	
Antagonists	
meclinertant
(pIC50 7.5–8.2) [664]	–	
Labelled
ligands	
[3H]meclinertant (Antagonist)
(pK
d 8.5) [1030] – Rat	–	
Comments	–	A splice variant of
the NTS2 receptor bearing 5 transmembrane domains has been
identified in mouse [191] and later
in rat [1492].	



Comments

neurotensin(NTS, P30990) appears to be a
low‐efficacy agonist at the NTS2 receptor [1959], while the
NTS1 receptor antagonist meclinertant is an agonist at
NTS2 receptors [1959]. An additional protein,
provisionally termed NTS3 (also known as NTR3, gp95 and sortilin;
ENSG00000134243), has been
suggested to bind lipoprotein lipase and mediate its degradation [1395]. It has been reported to
interact with the NTS1 receptor [1211] and has been implicated
in hormone trafficking and/or neurotensin uptake.

Further Reading
Boules M et al. (2013) Diverse
roles of neurotensin agonists in the central nervous system. Front Endocrinol
(Lausanne)
4: 36 [PMID:23526754]


Dupouy S et al. (2011) The
potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer
progression and as a component of personalized medicine in selective cancers.
Biochimie
93: 1369‐78 [PMID:21605619]


Foord SM et al. (2005)
International Union of Pharmacology. XLVI. G protein‐coupled receptor list.
Pharmacol Rev
57: 279‐288 [PMID:15914470]


Kalafatakis K et al. (2011)
Contribution of neurotensin in the immune and neuroendocrine modulation of normal and
abnormal enteric function. Regul. Pept.
170: 7‐17 [PMID:21549161]


Mazella J et al. (2012)
Neurotensin and its receptors in the control of glucose homeostasis. Front
Endocrinol (Lausanne)
3: 143 [PMID:23230428]


Myers RM et al. (2009) Cancer,
chemistry, and the cell: molecules that interact with the neurotensin receptors.
ACS Chem. Biol.
4: 503‐25 [PMID:19462983]



Opioid receptors

Overview
Opioid and opioid‐like receptors are activated
by a variety of endogenous peptides including [Met]enkephalin(PENK, P01210) (met), [Leu]enkephalin(PENK, P01210) (leu), β‐endorphin(POMC, P01189)
(β‐end), α‐neodynorphin(PDYN, P01213), dynorphin A(PDYN, P01213) (dynA), dynorphin B(PDYN, P01213) (dynB), big dynorphin(PDYN, P01213) (Big dyn), nociceptin/orphanin
FQ(PNOC, Q13519) (N/OFQ); endomorphin‐1 and endomorphin‐2 are also
potential endogenous peptides. The Greek letter nomenclature for the opioid
receptors, μ, δ and κ, is well
established, and NC‐IUPHAR considers this nomenclature most appropriate [376, 417, 530]. The human N/OFQ receptor
is considered 'opioid‐related' rather than opioid because while it exhibits a high
degree of structural homology with the conventional opioid receptors [1308], it displays a distinct
pharmacology.


Nomenclature	
δ receptor
	
κ receptor
	
μ receptor
	
NOP receptor
	
HGNC, UniProt	
OPRD1, P41143
	
OPRK1, P41145
	
OPRM1, P35372
	
OPRL1, P41146
	
Principal
endogenous agonists	
β‐endorphin (POMC, P01189),
[Leu]enkephalin
(PENK, P01210),
[Met]enkephalin
(PENK, P01210)	
big dynorphin
(PDYN, P01213),
dynorphin A
(PDYN, P01213)	
β‐endorphin (POMC, P01189),
[Met]enkephalin
(PENK, P01210),
[Leu]enkephalin
(PENK, P01210),
endomorphin‐1,
endomorphin‐2
	–	
Endogenous
agonists	–	–	
endomorphin‐2
(Selective) (pK
i 8.5) [2109] – Rat,
endomorphin‐1
(Selective) (pK
i 8.3) [622, 2109]	
nociceptin/orphanin
FQ (PNOC, Q13519)
(Selective) (pK
i 9.7–10.4) [149, 1242, 1303, 1307, 1439]	
Agonists	–	–	
levorphanol
(pIC50 9.9) [692], hydromorphone
(pK
i 9.6) [2007], fentanyl
(pK
i 9.2) [1893], buprenorphine
(Partial agonist) (pK
i 8.8) [1893], methadone
(pIC50 8.4) [1523], codeine
(pK
i 6.9) [1893], tapentadol
(pK
i 6.8) [1916], meperidine
(pIC50 6.5) [1523]	–	
Selective
agonists	
[D‐Ala2]deltorphin I (pK
d 9.4) [487, 1795], DPDPE
(pK
i 8.8) [1337, 1893], [D‐Ala2]deltorphin II (pK
i 8.8) [488], SNC80
(pK
i 7.2) [258, 1549]	
U50488
(pK
i 7.8–9.7) [297, 1478,
1744, 1893, 1962, 2128, 2130], enadoline
(pK
i 9.6) [808, 1383], U69593
(pK
i 9.5) [1034, 1893], salvinorin A
(pK
i 7.8–8.7) [251, 1603]	
sufentanil
(pK
i 9.9) [1960], DAMGO
(pK
i 9.3) [691, 1893], loperamide
(pK
i 9.3) [308], morphine
(pK
i 9) [620, 1893], PL017
(pK
i 8.2) [290, 1893]	
N/OFQ‐(1‐13)‐NH2 (pK
i 10.1–10.4) [149, 661, 1242, 1439], Ro64‐6198
(pK
i 9.6) [855]	
Antagonists	
naltrexone
(pK
i 8) [1893], naloxone
(pK
i 7.2) [1893]	
buprenorphine
(pK
i 9.1–10.2) [1893, 2130], nalmefene
(pK
i 9.5) [1893], naltrexone
(pK
i 8.4–9.4) [1478, 1744, 1893], naloxone
(pK
i 7.6–8.6) [1478, 1744, 1893, 2128, 2130]	
naltrexone
(pK
i 9.7) [1893], nalmefene
(pK
i 9.5) [1893], nalorphine
(pK
i 8.9) [1893], methylnaltrexone
(pK
i 8.7) [2007]	–	
Selective
antagonists	
naltriben
(pK
i 10) [1773, 1893], naltrindole
(pK
i 9.7) [1521, 1893], TIPPψ (Inverse agonist) (pK
i 9) [1664, 1893]	
nor‐binaltorphimine (pK
i 8.9–11) [1478, 1520, 1744, 1893, 2128, 2130], 5'‐guanidinonaltrindole (pK
i 9.7–9.9) [882, 1478,
1797]	
alvimopan
(pK
i 9.3) [1056], levallorphan
(pK
i 8.8–9.3) [1187], CTAP
(pK
i 8.6) [290, 1893]	
UFP‐101
(pK
i 10.2) [259], Banyu
Compound‐24 (pK
i 9.6) [523], SB 612111
(pK
i 9.5) [2112], J‐113397
(pIC50 8.3) [919]	
Labelled
ligands	
[3H]naltrindole (Antagonist)
(pK
d 10.4) [2072] – Rat,
[3H]DPDPE (Agonist) [26], [3H]deltorphin
II (Agonist) [252], [3H]naltriben (Antagonist) [1088]	
[3H]U69593 (Agonist) (pK
d 8.7–8.8) [1034, 1478,
1744], [3H]enadoline (Agonist) [1746]	
[3H]DAMGO (Agonist) (pK
d 9.2) [1567] – Rat,
[3H]PL017 (Agonist) [717] – Rat	
[3H]N/OFQ (Agonist) (pK
d 10.2) [437, 1307]	



Comments
Three naloxone‐sensitive opioid receptor genes
have been identified in humans, and while the μ‐receptor in
particular may be subject to extensive alternative splicing [1468], these putative isoforms
have not been correlated with any of the subtypes of receptor proposed in years past.
Opioid receptors may heterodimerize with each other or with other 7TM receptors
[884], and give rise to
complexes with a unique pharmacology, however, evidence for such heterodimers in
native cells is equivocal and the consequences this heterodimerization for signalling
remains largely unknown. For μ‐opioid receptors at least,
dimerization does not seem to be required for signalling [1026]. A distinct
met‐enkephalin receptor lacking structural resemblance to the opioid receptors listed
has been identified (OGFR, 9NZT2) and termed an opioid growth factor
receptor [2110].


Endomorphin‐1 and endomorphin‐2 have been
identified as highly selective, putative endogenous agonists for the
μ‐opioid receptor. At present, however, the mechanisms for
endomorphin synthesis in vivo have not been established, and there
is no gene identified that encodes for either. Thus, the status of these peptides as
endogenous ligands remains unproven.

Two areas of increasing importance in defining
opioid receptor function are the presence of functionally relevant single nucleotide
polymorphisms in human μ‐receptors [1423] and the identification of
biased signalling by opioid receptor ligands, in particular, compounds previously
characterized as antagonists [231]. Pathway bias for agonists
makes general rank orders of potency and efficacy somewhat obsolete, so these do not
appear in the table. As ever, the mechanisms underlying the acute and long term
regulation of opiod receptor function are the subject of intense investigation and
debate.

The richness of opioid receptor pharmacology
has been enhanced with the recent discovery of allosteric modulators of MOPr and
DOPr, notably the positive allosteric modulators and silent allosteric "antagonists"
outlined in [240, 241]. Negative allosteric
modulation of opioid receptors has been previously suggested [908], whether all compounds are
acting at a similar site remains to be established.

Further Reading
Butelman ER et al. (2012)
κ‐opioid receptor/dynorphin system: genetic and
pharmacotherapeutic implications for addiction. Trends Neurosci.
35: 587‐96 [PMID:22709632]


Cox BM et al. (2015)
Challenges for opioid receptor nomenclature: IUPHAR Review 9. Br. J.
Pharmacol.
172: 317‐23 [PMID:24528283]


Kelly E. (2011) The subtleties of
μ‐opioid receptor phosphorylation. Br. J.
Pharmacol.
164: 294‐7 [PMID:21449916]


Pradhan AA et al. (2011) The
delta opioid receptor: an evolving target for the treatment of brain disorders.
Trends Pharmacol. Sci.
32: 581‐90 [PMID:21925742]


Schröder W et al. (2014)
Functional plasticity of the N/OFQ‐NOP receptor system determines analgesic
properties of NOP receptor agonists. Br. J. Pharmacol.
171: 3777‐800 [PMID:24762001]


Williams JT et al. (2013)
Regulation of μ‐opioid receptors: desensitization, phosphorylation,
internalization, and tolerance. Pharmacol. Rev.
65: 223‐54 [PMID:23321159]



Orexin receptors

Overview
Orexin receptors (nomenclature as agreed
by the NC‐IUPHAR Subcommittee on
Orexin receptors [
627
]) are activated by the endogenous polypeptides orexin‐A(HCRT, O43612) and orexin‐B(HCRT, O43612) (also known as
hypocretin‐1 and ‐2; 33 and 28 aa) derived from a common precursor, preproorexin or orexin
precursor, by proteolytic cleavage [1629]. Binding to both
receptors may be accomplished with [125I]orexin A (human, mouse,
rat) [773].


Nomenclature	
OX1
receptor
	
OX2
receptor
	
HGNC, UniProt	
HCRTR1, O43613
	
HCRTR2, O43614
	
Rank order of
potency	
orexin‐A
(HCRT, O43612)
>orexin‐B
(HCRT, O43612)	
orexin‐A
(HCRT, O43612) =
orexin‐B
(HCRT, O43612)	
Selective
agonists	–	
[Ala11,
D‐Leu15]orexin‐B (pEC50 9.9)
[62]	
(Sub)family‐selective antagonists	
suvorexant
(pK
i 9.3) [377], SB‐649868
(pK
i 9.1) [419], filorexant
(pK
i 8.6) [2035], almorexant
(pIC50 7.9) [216]	
filorexant
(pK
i 9.5) [2035], suvorexant
(pK
i 9.5) [377], SB‐649868
(pK
i 8.9) [419], almorexant
(pIC50 8.1) [216]	
Selective
antagonists	
SB‐408124
(pK
i 7.2–7.6) [1042, 1190], SB‐334867
(pK
i 7.4–7.5) [1190, 1518]	
EMPA
(pK
i 9) [1189], JNJ 10397049
(pK
i 7.9–8.6) [1238], TCS‐OX2‐29
(pK
i 7.4) [760]	
Labelled
ligands	
[3H]SB‐674042 (Antagonist)
(pK
d 8.3–9.1) [1042, 1190, 1193]	–	



Comments
The primary coupling of orexin receptors to
Gq/11 proteins is rather speculative and based on the strong activation
of phospholipase C. Coupling of both receptors to Gi/o and Gs
has also been reported [1019, 1555]; for most cellular
responses observed, the G protein pathway is unknown. The rank order of endogenous
agonist potency may depend on the cellular signal transduction machinery. The
synthetic [Ala11,
D‐Leu15]orexin‐B may show poor OX2 receptor
selectivity [1540].

Loss‐of‐function mutations in the gene encoding
the OX2 receptor underlie canine hereditary narcolepsy [1111].

Further Reading
Boss C. (2014) Orexin receptor antagonists–a
patent review (2010 to August 2014). Expert Opin Ther Pat
24: 1367‐81 [PMID:25407283]


Boss C et al. (2009)
Biomedical application of orexin/hypocretin receptor ligands in neuroscience.
J. Med. Chem.
52: 891‐903 [PMID:19199652]


Christopher JA. (2014) Small‐molecule
antagonists of the orexin receptors. Pharm Pat Anal
3: 625‐38 [PMID:25489915]


Gotter AL et al. (2012)
International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin receptor
function, nomenclature and pharmacology. Pharmacol. Rev.
64: 389‐420 [PMID:22759794]


Lebold TP et al. (2013)
Selective orexin receptor antagonists. Bioorg. Med. Chem. Lett.
23: 4761‐9 [PMID:23891187]


Mieda M et al. (2013) Orexin
(hypocretin) receptor agonists and antagonists for treatment of sleep disorders.
Rationale for development and current status. CNS Drugs
27: 83‐90 [PMID:23359095]



Oxoglutarate receptor

Overview

Nomenclature as recommended by NC‐IUPHAR[
396
].


Nomenclature	
oxoglutarate
receptor
	
HGNC, UniProt	
OXGR1, Q96P68
	
Endogenous
agonists	
α‐ketoglutaric acid (pEC50
3.3–4.5) [728, 1785]	




P2Y receptors

Overview
P2Y receptors (nomenclature as agreed by
the NC‐IUPHAR Subcommittee on P2Y
Receptors [
1
,
2
]) are activated by the endogenous ligands ATP, adenosine diphosphate,
uridine triphosphate, uridine diphosphate and
UDP‐glucose. The relationship
of many of the cloned receptors to endogenously expressed receptors is not yet
established and so it might be appropriate to use wording such as ‘uridine triphosphate‐preferring
(or ATP‐, etc.)
P2Y receptor’ or ‘P2Y1‐like’, etc., until further, as yet
undefined, corroborative criteria can be applied [244, 486, 837, 2003, 2146].


Nomenclature	
P2Y1
receptor
	
P2Y2
receptor
	
P2Y4
receptor
	
P2Y6
receptor
	
HGNC, UniProt	
P2RY1, P47900
	
P2RY2, P41231
	
P2RY4, P51582
	
P2RY6, Q15077
	
Rank order of
potency	
adenosine
diphosphate>ATP
	
uridine
triphosphate=ATP
	
uridine
triphosphate>ATP (at rat
recombinant receptors, UTP = ATP)	
uridine
diphosphate≫uridine
triphosphate>ATP
	
Endogenous
agonists	–	–	–	
uridine
diphosphate (Selective) (pEC50 6.5)
[359]	
Agonists	
ADPβS (pEC50 7.3)
[1848], 2MeSADP
(pIC50 5.4–7) [1658, 1970]	–	–	
Rp‐5‐OMe‐UDPαB (pEC50
8.1) [611, 666]	
Selective
agonists	
MRS2365
(pEC50 9.4) [314], 2‐Cl‐ADP(α‐BH3)
(pEC50 8.1) [73]	
2‐thioUTP
(pEC50 7.3) [470], PSB1114
(EC50 value determined using an IP3
functional assay) (pEC50 6.9) [471], Ap4A
(pEC50 6.1) [270, 1471], UTPγS (pEC50 5.8)
[1054], MRS2768
(EC50 value determined using an IP3
functional assay) (pEC50 5.7) [973]	
MRS4062
(pEC50 7.6) [1213], UTPγS [1055] –
Unknown	
MRS2957
(pEC50 7.9) [1212], MRS2693
(pEC50 7.8) [143], 3‐phenacyl‐UDP
(pEC50 7.2) [470]	
Antagonists	–	–	
ATP
(pK
d 6.2) [925]	–	
Selective
antagonists	
MRS2500
(pK
i 8.8–9.1) [274, 942], BMS compound 16
[PMID:23368907] (pK
i 8.2) [295, 2115], MRS2279
(pK
i 7.9) [1970], MRS2179
(pK
i 7–7.1) [197, 1970], 2,2'‐pyridylisatogen
tosylate (pK
i 6.8) [570]	
AR‐C118925XX
(pIC50∼6) [924]	–	
MRS2578
(pIC50 7.4) [1196]	
Labelled
ligands	
[3H]MRS2279 (Antagonist)
(pK
d 8.1) [1970], [3H]2MeSADP (Agonist) (pK
d 7.3) [1848], [35S]ADPβS (Agonist) –
Unknown	–	–	–	




Nomenclature	
P2Y11
receptor
	
P2Y12
receptor
	
P2Y13
receptor
	
P2Y14
receptor
	
HGNC, UniProt	
P2RY11, Q96G91
	
P2RY12, Q9H244
	
P2RY13, Q9BPV8
	
P2RY14, Q15391
	
Rank order of
potency	
ATP>uridine
triphosphate
	–	
adenosine
diphosphate≫ATP
	–	
Rank order of
potency Human	–	–	–	
uridine
diphosphate≥UDP‐glucose
	
Endogenous
agonists	–	
adenosine
diphosphate (Selective) (pK
i 5.9) [740]	–	–	
Agonists	–	
2MeSADP
(pK
i 9.2) [740]	–	
MRS2690
(pEC50 6.6–7.3) [571, 974]	
Selective
agonists	
AR‐C67085
(pEC50 8.5) [88, 360], NF546
(pEC50 6.3) [1255], NAADP [1322], NAD [1323]	–	–	–	
Antagonists	
NF340
(pIC50 6.4–7.1) [1255]	
PSB‐0739
(pK
i 7.6) [91]	–	–	
Selective
antagonists	
NF157
(pK
i 7.3) [1923]	
AZD1283
(pK
i 8) [76, 2116], ARL66096
(pIC50 7.9) [806, 807], ticagrelor
(pK
i 7.8) [2113]	
MRS2211
(pIC50 6) [950]	
PPTN
(pK
i 10.1) [96]	
Labelled
ligands	–	
[3H]2MeSADP (Agonist) (pIC50
7.5–9.6) [1848], [3H]PSB‐0413 (Antagonist)
(pK
d 8.3–8.5) [469, 1431]	–	–	



Comments

cangrelor shows selectivity for
P2Y12 and P2Y13 receptors compared with other P2Y receptors
[1209, 1848]. NF157 also has antagonist
activity at P2X1 receptors [1923]. Uridine diphosphate has been
reported to be an antagonist at the P2Y14 receptor [548]. [35S]ATPαS has been used to label P2Y
receptors in rat synaptosomal membranes [1682, 1683].

An orphan GPCR suggested to be a
‘P2Y15’ receptor [823] appears not to be a
genuine nucleotide receptor [2], but rather responds to
dicarboxylic acids [728]. Further P2Y‐like
receptors have been cloned from non‐mammalian sources; a clone from chick brain,
termed a p2y3 receptor (ENSGALG00000017327), couples to
the Gq/11 family of G proteins and shows the rank order of potency
adenosine
diphosphate>uridine
triphosphate>ATP = uridine diphosphate [1998]. In addition, human
sources have yielded a clone with a preliminary identification of p2y5 (LPAR6, P43657) and contradictory
evidence of responses to ATP[954, 1999]. This protein is now
classified as LPA6, a receptor for lysophosphatidic acid (LPA) [1467, 2079]. The clone termed p2y9
(LPAR4, Q99677) is also a receptor for
lysophosphatidic acid, LPA4[1406]. The clone p2y7
(NOP9, Q86U38), originally suggested
to be a P2Y receptor [22], has been shown to encode a
leukotriene receptor [2095]. A P2Y receptor that was
initially termed a p2y8 receptor (P79928) has been cloned from Xenopus
laevis; it shows the rank order of potency ADPβS>ATP = uridine triphosphate =
guanosine‐5'‐triphosphate=
CTP = TTP = ITP>ATPγS and
elicits a Ca2+‐dependent Cl‐ current in
Xenopus oocytes [169]. The p2y10 clone
(P2RY10, O00398) lacks functional data.
Diadenosine polyphosphates also have effects on as yet uncloned P2Y‐like receptors
with the rank order of potency of Ap4A>Ap5a>Ap3a, coupling via
Gq/11[270]. P2Y‐like receptors have
recently been described on mitochondria [126]. CysLT1 and CysLT2
leukotriene receptors respond to nanomolar concentrations of uridine diphosphate, although
they are activated principally by leukotrienes LTC4 and LTD4[1257, 1258]. Human GPR17 (13304) and rat GPR17, which are structurally
related to CysLT and P2Y receptors, are also activated by leukotrienes [1542] as well as uridine diphosphate and
UDP‐glucose[344, 540]. Activity at the rat GPR17
is inhibited by submicromolar concentrations of MRS2179 and cangrelor[344].

Further Reading
Abbracchio MP et al. (2006)
International Union of Pharmacology LVIII: update on the P2Y G protein‐coupled
nucleotide receptors: from molecular mechanisms and pathophysiology to therapy.
Pharmacol. Rev.
58: 281‐341 [PMID:16968944]


Burnstock G. (2007) Purine and pyrimidine
receptors. Cell. Mol. Life Sci.
64: 1471‐83 [PMID:17375261]


Burnstock G et al. (2012)
Purinergic signalling and the nervous system. Springer: 1‐715

Erlinge D. (2011) P2Y receptors in health and
disease. Adv. Pharmacol.
61: 417‐39 [PMID:21586366]


Jacobson KA. (2013) Structure‐based approaches
to ligands for G‐protein‐coupled adenosine and P2Y receptors, from small molecules to
nanoconjugates. J. Med. Chem.
56: 3749‐67 [PMID:23597047]


Jacobson KA et al. (2009)
Development of selective agonists and antagonists of P2Y receptors.
Purinergic Signalling
5: 75‐89 [PMID:18600475]


Weisman GA et al. (2012) P2Y
receptors in the mammalian nervous system: pharmacology, ligands and therapeutic
potential. CNS Neurol Disord Drug Targets
11: 722‐38 [PMID:22963441]


von Kügelgen I et al. (2011)
Molecular pharmacology, physiology, and structure of the P2Y receptors. Adv.
Pharmacol.
61: 373‐415 [PMID:21586365]



Parathyroid hormone receptors

Overview
The parathyroid hormone receptors
(nomenclature as agreed by the NC‐IUPHAR Subcommittee on Parathyroid Hormone Receptors [
575
]) are family B G protein‐coupled receptors. The parathyroid hormone
(PTH)/parathyroid hormone‐related peptide (PTHrP) receptor (PTH1 receptor) is
activated by precursor‐derived peptides: PTH(PTH, P01270) (84 amino acids), and
PTHrP(PTHLH, P12272) (141 amino‐acids) and
related peptides (PTH‐(1‐34), PTHrP‐(1‐36)(PTHLH, P12272)). The parathyroid
hormone 2 receptor (PTH2 receptor) is activated by the precursor‐derived peptide
TIP39(PTH2, Q96A98) (39 amino acids).
[125I]PTH may be used to label both PTH1 and PTH2 receptors.


Nomenclature	
PTH1 receptor
	
PTH2 receptor
	
HGNC, UniProt	
PTH1R, Q03431
	
PTH2R, P49190
	
Rank order of
potency	
PTH (PTH, P01270) =
PTHrP (PTHLH, P12272)	
TIP39 (PTH2, Q96A98),
PTH (PTH, P01270)
≫PTHrP (PTHLH, P12272)	
Endogenous
agonists	–	
TIP39 (PTH2, Q96A98)
(pIC50 7.6–9.2) [626, 766]	
Agonists	
teriparatide
(pIC50 7.4) [573]	–	
Selective
agonists	
PTHrP‐(1‐34)
(human) (pIC50 7.8–8.1) [574] – Rat	–	



Comments
Although PTH(PTH, P01270) is an agonist at human
PTH2 receptors, it fails to activate the rodent orthologues. TIP39(PTH2, Q96A98) is a weak antagonist at
PTH1 receptors [883].

Further Reading
Cheloha RW et al. (2015)
Signal transduction at type‐1 parathyroid hormone receptor. Nat Rev
Endo.


Datta NS et al. (2009) PTH and
PTHrP signaling in osteoblasts. Cell. Signal.
21: 1245‐54 [PMID:19249350]


Gardella TJ et al. (2015)
International Union of Basic and Clinical Pharmacology. XCIII. The Parathyroid
Hormone Receptors‐Family B G Protein‐Coupled Receptors. Pharmacol.
Rev.
67: 310‐37 [PMID:25713287]


Kraenzlin ME et al. (2011)
Parathyroid hormone analogues in the treatment of osteoporosis. Nat Rev
Endocrinol
[PMID:21750510]


Vilardaga JP et al. (2014)
Endosomal generation of cAMP in GPCR signaling. Nat. Chem. Biol.
10: 700‐6 [PMID:25271346]



Platelet‐activating factor
receptor

Overview
Platelet‐activating factor (PAF,
1‐O‐alkyl‐2‐acetyl‐sn‐glycero‐3‐phosphocholine) is an ether
phospholipid mediator associated with platelet coagulation, but also subserves
inflammatory roles. The PAF receptor (provisional nomenclature recommended by
NC‐IUPHAR [
530
]) is activated by PAF and other suggested
endogenous ligands are oxidized phosphatidylcholine [1204] and lysophosphatidylcholine[1425]. It may also be activated
by bacterial lipopolysaccharide [1358].


Nomenclature	
PAF receptor
	
HGNC, UniProt	
PTAFR, P25105
	
Selective
agonists	
methylcarbamyl
PAF – Unknown	
Selective
antagonists	
foropafant
(pK
i 10.3) [739], ABT‐491
(pK
i 9.2) [30], CV‐6209
(pIC50 8.1–8.3) [619, 1357], L659989
(pK
i 7.8) [811], apafant
(pK
i 5.2–7.5) [1460, 1831]	
Labelled
ligands	
[3H]PAF (Agonist) (pK
d 8.8–8.9) [555, 1357]	



Comments
Note that a previously recommended radioligand
([3H]apafant;
Kd44.6 nM) is currently unavailable.

Further Reading
Foord SM et al. (2005)
International Union of Pharmacology. XLVI. G protein‐coupled receptor list.
Pharmacol Rev
57: 279‐288 [PMID:15914470]


Ishii S et al. (2000)
Platelet‐activating factor (PAF) receptor and genetically engineered PAF receptor
mutant mice. Prog. Lipid Res.
39: 41‐82 [PMID:10729607]


Montrucchio G et al. (2000)
Role of platelet‐activating factor in cardiovascular pathophysiology.
Physiol. Rev.
80: 1669‐99 [PMID:11015622]


Prescott SM et al. (2000)
Platelet‐activating factor and related lipid mediators. Annu. Rev.
Biochem.
69: 419‐45 [PMID:10966465]


Shimizu T. (2009) Lipid mediators in health and
disease: enzymes and receptors as therapeutic targets for the regulation of immunity
and inflammation. Annu. Rev. Pharmacol. Toxicol.
49: 123‐50 [PMID:18834304]


Summers JB et al. (1995)
Platelet activating factor antagonists. Adv Pharmacol
32: 67‐168 [PMID:7748804]



Prokineticin receptors

Overview
Prokineticin receptors, PKR1 and
PKR2(provisional nomenclature as recommended by NC‐IUPHAR[
530
]) respond to the cysteine‐rich 81‐86 amino‐acid peptides prokineticin‐1(PROK1, Q9HC23) (also known as
endocrine gland‐derived vascular endothelial growth factor, mambakine) and prokineticin‐2(PROK2, Q9HC23) (protein Bv8
homologue). An orthologue of PROK1 from black mamba (Dendroaspis
polylepis) venom, mamba intestinal toxin 1 (MIT1, [1678]) is a potent,
non‐selective agonist at prokineticin receptors [1215], while Bv8, an orthologue of PROK2
from amphibians (Bombina sp., [1304]), is equipotent at
recombinant PKR1 and PKR2[1371], and has high potency in
macrophage chemotaxis assays, which are lost in PKR1‐null mice.


Nomenclature	
PKR1
	
PKR2
	
HGNC, UniProt	
PROKR1, Q8TCW9
	
PROKR2, Q8NFJ6
	
Rank order of
potency	
prokineticin‐2
(PROK2, Q9HC23)
>prokineticin‐1
(PROK1, Q9HC23)
>prokineticin‐2β (PROK2) [1109, 1215, 1775]	
prokineticin‐2
(PROK2, Q9HC23)
>prokineticin‐1
(PROK1, Q9HC23)
>prokineticin‐2β (PROK2) [1109, 1215, 1775]	
Endogenous
agonists	
prokineticin‐2
(PROK2, Q9HC23)
(pIC50 8.2–8.4) [300, 1215], prokineticin‐1
(PROK1, Q9HC23)
(pIC50 6.6–7.6) [300, 1215], prokineticin‐2β (PROK2) (pIC50 7.5) [300]	
prokineticin‐2
(PROK2, Q9HC23)
(pIC50 8.1–8.2) [300, 1215], prokineticin‐1
(PROK1, Q9HC23)
(pIC50 7.1–7.3) [300, 1215], prokineticin‐2β (PROK2) (pIC50<6) [300]	
Agonists	
MIT1
(pIC50 8.4) [1215]	
MIT1
(pIC50 9.2) [1215]	
Selective
agonists	
IS20
(pEC50 7.4) [581], IS1
(pEC50 5.6) [581]	–	
Selective
antagonists	
triazine compound
PC1 (pK
i 7.7) [87], triazine compound
PC7 (pIC50 7.5) [842, 1552], triazine compound
PC10 (pIC50 7) [842]	
PKR‐A
(pIC50 7.3–7.4) [312]	
Labelled
ligands	
[125I]BH‐MIT1 (Agonist) (pIC50
8.4) [1215]	
[125I]BH‐MIT1 (Agonist) (pIC50
9.2) [1215]	



Comments
Genetic mutations in PROKR1
are associated with Hirschsprung's disease [1614], while genetic mutations
in PROKR2 are associated with hypogonadotropic hypogonadism with
anosmia [430], hypopituitarism with
pituitary stalk interruption [1575] and Hirschsprung's
disease [1614].

Further Reading
Boulberdaa M et al. (2011)
Prokineticin receptor 1 (PKR1) signalling in cardiovascular and kidney functions.
Cardiovasc. Res.
92: 191‐8 [PMID:21856786]


Martin C et al. (2011) The
role of the prokineticin 2 pathway in human reproduction: evidence from the study of
human and murine gene mutations. Endocr. Rev.
32: 225‐46 [PMID:21037178]


Monnier J et al. (2010)
Prokineticins in angiogenesis and cancer. Cancer Lett.
296: 144‐9 [PMID:20633984]


Negri L et al. (2012) Bv8/PK2
and prokineticin receptors: a druggable pronociceptive system. Curr Opin
Pharmacol
12: 62‐6 [PMID:22136937]


Negri L et al. (2007)
Bv8/Prokineticin proteins and their receptors. Life Sci.
81: 1103‐16 [PMID:17881008]


Ngan ES et al. (2008)
Prokineticin‐signaling pathway. Int. J. Biochem. Cell Biol.
40: 1679‐84 [PMID:18440852]



Prolactin‐releasing peptide
receptor

Overview
The precursor (PRLH, P81277) for PrRP generates 31
and 20‐amino‐acid versions. QRFP43(QRFP, P83859) (named after a
pyroglutamylated arginine‐phenylalanine‐amide peptide) is a 43 amino acid peptide
derived from QRFP(P83859) and is also known as P518 or 26RFa. RFRP is
an RF amide‐related peptide [756] derived from a
FMRFamide‐related peptide precursor (NPVF, Q9HCQ7), which is cleaved to
generate neuropeptide SF(NPFF, O15130), neuropeptide RFRP‐1(NPVF, Q9HCQ7), neuropeptide RFRP‐2(NPVF, Q9HCQ7) and neuropeptide
RFRP‐3(NPVF, Q9HCQ7) (neuropeptide
NPVF).


Nomenclature	
PrRP receptor
	
HGNC, UniProt	
PRLHR, P49683
	
Rank order of
potency	
PrRP‐20
(PRLH, P81277),
PrRP‐31
(PRLH, P81277)
[1043]	
Endogenous
agonists	
PrRP‐20
(PRLH, P81277)
(Selective) (pK
i 9–9.6) [481, 1043], PrRP‐31
(PRLH, P81277)
(Selective) (pK
i 9–9.2) [481, 1043]	
Endogenous
antagonists	
neuropeptide Y
(NPY, P01303)
(Selective) (pK
i 5.4) [1032]	
Labelled
ligands	
[125I]PrRP‐20
(human) (Agonist) (pK
d 9.2–10.6) [1043], [125I]PrRP31 (Agonist) [473]	



Comments
The orphan receptor GPR83(Q9NYM4) shows sequence
similarities with NPFF1, NPFF2, PrRP and QRFP receptors.

Further Reading
Samson WK et al. (2006)
Prolactin releasing peptide (PrRP): an endogenous regulator of cell growth.
Peptides
27: 1099‐103 [PMID:16500730]


Takayanagi Y et al. (2010)
Roles of prolactin‐releasing peptide and RFamide related peptides in the control of
stress and food intake. FEBS J.
277: 4998‐5005 [PMID:21126313]



Prostanoid receptors

Overview
Prostanoid receptors (nomenclature as
agreed by the NC‐IUPHAR
Subcommittee on Prostanoid Receptors [
2043
]) are activated by the endogenous ligands prostaglandins PGD2, PGE2 , PGF2α, PGH2, prostacyclin [PGI2] and thromboxane A2. Measurement of the potency of PGI2 and thromboxane A2 is hampered by their instability in physiological salt solution; they are
often replaced by cicaprost and U46619, respectively, in
receptor characterization studies.


Nomenclature	
DP1
receptor
	
DP2
receptor
	
IP receptor
	
FP receptor
	
TP receptor
	
HGNC, UniProt	
PTGDR, Q13258
	
PTGDR2, Q9Y5Y4
	
PTGIR, P43119
	
PTGFR, P43088
	
TBXA2R, P21731
	
Rank order of
potency	
PGD2≫PGE2>PGF2α>PGI2, thromboxane A2
	–	
PGI2≫PGD2, PGE2, PGF2α>thromboxane A2
	
PGF2α>PGD2>PGE2>PGI2, thromboxane A2
	
thromboxane A2 = PGH2≫PGD2, PGE2, PGF2α, PGI2
	
Rank order of
potency	–	
PGD2≫PGF2α, PGE2>PGI2, thromboxane A2
				
Agonists	–	
13,14‐dihydro‐15‐keto‐PGD2 (pK
i 7.4–8.5) [712, 1656, 1815]	
iloprost
(pK
i 7.5–8) [7, 2030], treprostinil
(pK
i 7.5) [2019]	
bimatoprost
(pIC50 5.3) [2044]	–	
Selective
agonists	
BW 245C
(pK
i 8.4–9.4) [171, 2045, 2046], L‐644,698
(pK
i 9–9.3) [2045, 2046], SQ‐27986
(pK
i 8) [1712], RS 93520
(Partial agonist) (pK
i 7.5) [1712], ZK118182
(pK
i 7.3) [1712]	
15(R)‐15‐methyl‐PGD2 (pK
i 8.9) [712, 1312, 1815]	
AFP‐07
(pIC50 8.5) [288], BMY 45778
(pIC50 8) [881], esuberaprost
(pK
d 7.9) [892], cicaprost
(pK
i 7.8) [7]	
fluprostenol
(pK
i 8.6) [7], latanoprost (free acid
form) (pK
i 8.6) [7], AL12180
(pEC50 7.7–7.9) [1714], tafluprost
[1843]	
I‐BOP
(pK
d 8.9–9.3) [1233], U46619
(pK
i 7.5) [7], STA2 (pIC50 6.4–7.1) [59]	
Antagonists	–	
ramatroban
(pK
i 7.4) [1815]	–	–	
ramatroban
(pK
i 8) [1869]	
Selective
antagonists	
laropiprant
(pK
i 10.1) [1808] – Unknown,
BWA868C
(pK
i 8.6–9.3) [171, 606, 2045], S‐5751
(pK
i 8.8) [54], ONO‐AE3‐237
(pK
i 7.7) [758, 1895, 1897]	
CAY 10471
(pIC50 8.9) [1610, 1927], AZD1981
(pIC50 8.4) [1150]	
RO1138452
(pK
i 8.7) [158], RO3244794
(pA2 8.5) [158]	
AS604872
(pK
i 7.5) [346]	
ifetroban
(pK
i 8.4–10) [1426], vapiprost
(pK
i 8.3–9.4) [59, 1151], SQ‐29548
(pK
i 8.1–9.1) [7, 1834, 2030], ONO‐3708
(pK
i 7.4–8.9) [910]	
Labelled
ligands	
[3H]PGD2 (Agonist) (pK
d 7.9–9.5) [2030, 2045]	
[3H]PGD2 (Agonist) (pK
d 7.8–8.2) [1216, 1723]	
[3H]iloprost (Agonist) (pK
d 7.7–9) [7, 170, 2030]	
[3H]PGF2α (Agonist) (pK
d 8.1–9) [7, 8, 2030], [3H](+)‐fluprostenol (Agonist)
(pK
d 7.5) – Unknown	
[125I]SAP (Antagonist) (pK
d 7.7–9.3) [1356], [125I]BOP (Agonist) (pK
d 8.7) [1328], [3H]SQ‐29548 (Antagonist)
(pK
d 7.4–8.2) [7, 2030]	




Nomenclature	
EP1
receptor
	
EP2
receptor
	
EP3
receptor
	
EP4
receptor
	
HGNC, UniProt	
PTGER1, P34995
	
PTGER2, P43116
	
PTGER3, P43115
	
PTGER4, P35408
	
Rank order of
potency	
PGE2>PGF2α, PGI2>PGD2, thromboxane A2
	
PGE2>PGF2α, PGI2>PGD2, thromboxane A2
	
PGE2>PGF2α, PGI2>PGD2, thromboxane A2
	
PGE2>PGF2α, PGI2>PGD2, thromboxane A2
	
Endogenous
agonists	
PGE1 (pK
i 6.8) [1713], PGI2 (pK
i 4.8) [1713]	
PGE2 (pK
i 7.5–8.3) [7, 1799, 2030]	–		
Agonists	
17‐phenyl‐ω‐trinor‐PGE2 (pK
i 8.1) [1713]	
evatanepag
(pIC50 7.3) [260] – Rat	
misoprostol (methyl
ester) (EP3‐III isoform) (pK
i 6.5) [7]	–	
Selective
agonists	
ONO‐DI‐004
(pK
i 6.8) [1826] –
Mouse	
ONO‐AE1‐259
(pK
i 8.5) [1826] – Mouse,
butaprost (free acid
form) (pK
i 5.9–7) [7, 1799]	
SC46275
(pEC50 10.4) [1655] – Guinea
pig, MB‐28767
(EP3‐III isoform) (pK
i 9.9) [7], ONO‐AE‐248
(pEC50 5.6–6.7) [534, 1140]	
L902688
(pEC50 8.1–10.3) [535, 1064], ONO‐AE1‐437
(pK
i 9.1) [1294] – Mouse,
CP734432
(pIC50 8.7) [1529], ONO‐AE1‐329
(pEC50 7.7–7.8) [534, 535]	
Antagonists	–	–	–	
evatanepag
(pK
i 8.6) [1345],	
Selective
antagonists	
ONO‐8711
(pK
i 9.2) [1992], GW848687X
(pIC50 8.6) [605], SC‐51322
(pK
i 7.9) [7]	
TG4‐155 (TG4‐155
also has affinity for the human DP1 receptor (pK
b = 7.8)) (pK
B 8.6) [865], TG7‐171
(pK
B 8.6) [567], PF‐04852946
(pK
B 8.4–8.5) [920], PF‐04418948
(PF‐04418948 has weaker affinity at the EP2‐receptor in guinea‐pigs)
(pK
B 8.3) [153, 2136]	
L‐798,106
(EP3‐III isoform) (pK
i 7.8–9.7) [888, 890, 1810], L‐826266
(EP3‐III isoform (pKi=8.04 in the presence of
HSA)) (pK
i 9.1) [890], ONO‐AE3‐240
(pIC50 8.8) [38] – Mouse,
DG‐041
(pK
i 8.4) [888]	
MK‐2894
(pK
i 9.2) [7, 161, 350], ONO‐AE3‐208
(pK
i 8.5), BGC201531
(pK
i 7.9) [1230], ER819762
(pIC50 7.2) [304], GW 627368
(pK
i 7–7.1) [2030, 2031]	
Labelled
ligands	
[3H]PGE2 (Agonist) (pK
d 7.6–7.9) [7, 1713, 2030]	
[3H]PGE2 (Agonist) (pK
d 7.7–7.9) [7, 2030]	
[3H]PGE2 (Agonist) (pK
d 8.2–9.5) [7, 2030]	
[3H]PGE2 (Agonist) (pK
d 7.6–9.5) [7, 401, 2019, 2030]	



Comments

ramatroban is an antagonist at
both DP2 and TP receptors. Whilst cicaprost is selective for IP
receptors, it does exhibit moderate agonist potency at EP4 receptors
[7]. Apart from IP receptors,
iloprost also binds to other
prostanoid receptors such as EP1 receptors. The TP receptor exists in
α and β isoforms due to alternative splicing of
the cytoplasmic tail [1566]. The IP receptor agonist
treprostinil binds also to
human EP2 and DP1 receptors with high affinity
(pK
i 8.44 and 8.36, respectively).

The EP1 agonist 17‐phenyl‐ω‐trinor‐PGE2 also shows agonist activity at EP3 receptors. Butaprost and SC46275 may require
de‐esterification within tissues to attain full agonist potency. There is evidence
for subtypes of FP [1105], IP [1851, 2037] and TP [1005] receptors. mRNA for the
EP1 and EP3 receptors undergo alternative splicing to
produce two [1441] and at least six
variants, respectively, which can interfere with signalling [1441] or generate complex
patterns of G‐protein (Gi/o, Gq/11, Gs and
G12,13) coupling (e.g. [997, 1370]). The number of
EP3 receptor (protein) variants are variable depending on species, with
five in human, three in rat and three in mouse. The possibility of additional
receptors for the isoprostanes has been suggested [1531]. Putative receptor(s) for
prostamide F (which as yet lack molecular correlates) and which preferentially
recognize PGF2‐1‐ethanolamide and its
analogues (e.g. Bimatoprost) have been
identified, together with moderate‐potency antagonists (e.g.
AGN 211334) [2042].

The free acid form of AL‐12182, AL12180, used in in
vitro studies, has a EC50 value of 15nM which is the
concentration of the compound giving half‐maximal stimulation of inositol phosphate
turnover in HEK‐293 cells expressing the human FP receptor [1714].

References given alongside the TP receptor
agonists I‐BOP [1233] and
STA2[59] use human platelets as the
source of TP receptors for competition radio‐ligand binding assays to determine the
indicated activity values.

Pharmacological evidence for a second IP
receptor, denoted IP2, in the central nervous system [1851, 1994] and in the BEAS‐2B human
airway epithelial cell line [2033] is available. This
receptor is selectively activated by
15R‐17,18,19,20‐tetranor‐16‐m‐tolyl‐isocarbacyclin (15R‐TIC) and 15R‐Deoxy
17,18,19,20‐tetranor‐16‐m‐tolyl‐isocarbacyclin (15‐deoxy‐TIC). However,
molecular biological evidence for the IP2 subtype is currently
lacking.

Further Reading
Billot X et al. (2003)
Discovery of a potent and selective agonist of the prostaglandin EP4 receptor.
Bioorg. Med. Chem. Lett.
13: 1129‐32 [PMID:12643927]


Félétou M et al. (2010)
Vasoconstrictor prostanoids. Pflugers Arch.
459: 941‐50 [PMID:20333529]


Félétou M et al. (2010) The
thromboxane/endoperoxide receptor (TP): the common villain. J. Cardiovasc.
Pharmacol.
55: 317‐32 [PMID:20422736]


Schuligoi R et al. (2010)
CRTH2 and D‐type prostanoid receptor antagonists as novel therapeutic agents for
inflammatory diseases. Pharmacology
85: 372‐82 [PMID:20559016]


Woodward DF et al. (2011)
International union of basic and clinical pharmacology. LXXXIII: classification of
prostanoid receptors, updating 15 years of progress. Pharmacol. Rev.
63: 471‐538 [PMID:21752876]


Yang C et al. (2011)
Prostaglandin E receptors as inflammatory therapeutic targets for atherosclerosis.
Life Sci.
88: 201‐5 [PMID:21112342]


af Forselles KJ et al. (2011)
In vitro and in vivo characterization of PF‐04418948, a novel, potent and selective
prostaglandin EP_2 receptor antagonist. Br. J. Pharmacol.
164: 1847‐56 [PMID:21595651]



Proteinase‐activated receptors

Overview
Proteinase‐activated receptors (PARs,
nomenclature as agreed by the NC‐IUPHAR Subcommittee on Proteinase‐activated Receptors [
770
]) are unique members of the GPCR superfamily activated by proteolytic
cleavage of their amino terminal exodomains. Agonist proteinase‐induced hydrolysis
unmasks a tethered ligand (TL) at the exposed amino terminus, which acts
intramolecularly at the binding site in the body of the receptor to effect
transmembrane signalling. TL sequences at human PAR1‐4 are SFLLRN‐NH2, SLIGKV‐NH2, TFRGAP‐NH2 and GYPGQV‐NH2, respectively. With the exception of PAR3, these synthetic peptide
sequences (as carboxyl terminal amides) are able to act as agonists at their
respective receptors. Several proteinases, including neutrophil elastase, cathepsin G
and chymotrypsin can have inhibitory effects at PAR1 and PAR2 such that they cleave
the exodomain of the receptor without inducing activation of
Gαq‐coupled calcium signalling, thereby preventing activation by
activating proteinases but not by agonist peptides. Neutrophil elastase cleavage of
PAR2 can however activate MAP kinase signaling by exposing a TL that is different
from the one revealed by trypsin [1553]. The role of such an
action in vivo is unclear.


Nomenclature	
PAR1
	
PAR2
	
PAR3
	
PAR4
	
HGNC, UniProt	
F2R, P25116
	
F2RL1, P55085
	
F2RL2, O00254
	
F2RL3, Q96RI0
	
Agonist
proteases	
thrombin
(F2, P00734),
activated protein C
(PROC, P04070),
matrix metalloproteinase
1 (MMP1, P45452),
matrix metalloproteinase
13 (MMP13, P45452)
[70]	Trypsin, tryptase,
TF/VIIa, Xa	
thrombin
(F2, P00734)	
thrombin
(F2, P00734),
trypsin, cathepsin G
(CTSG, P08311)	
Selective
agonists	
TFLLR‐NH2 (pEC50 5.4) [340]	
GB110
(pEC50 6.5) [98], 2‐furoyl‐LIGRLO‐amide (pK
i 5.4) [1243], SLIGKV‐NH2 [1069], SLIGRL‐NH2 [1069]	–	
AYPGKF‐NH2,
GYPGKF‐NH2,
GYPGQV‐NH2
	
Selective
antagonists	
vorapaxar
(pK
i 8.1) [281], atopaxar
(pIC50 7.7) [978], RWJ‐56110
(pIC50 6.4) [48]	
GB88
(pIC50 5.7) [1813], P2pal18s
[1705]	–	–	
Labelled
ligands	
[3H]haTRAP (Agonist) (pK
d 7.8) [15]	
2‐furoyl‐LIGRL[N‐(Alexa
Fluor 594)‐O]‐NH2 (Agonist) [771], 2‐furoyl‐LIGRL[N[3H]propionyl]‐O‐NH2 (Agonist) [771], [3H]2‐furoyl‐LIGRL‐NH2 (Selective Agonist) [903], trans‐cinnamoyl‐LIGRLO
[N‐[3H]propionyl]‐NH2 (Agonist) [28]	–	–	
Comments	
TFLLR‐NH2 is selective relative to the PAR2 receptor
[155, 915].	2‐Furoyl‐LIGRLO‐NH2 activity was measured via calcium
mobilisation in HEK 293 cells which constitutively coexpress human
PAR1 and PAR2.	–	–	



Comments

thrombin(F2, P00734) is inactive at the
PAR2 receptor.

Endogenous serine proteases (EC 3.4.21.) active
at the proteinase‐activated receptors include: thrombin(F2, P00734), generated by the
action of Factor X (F10, P00742) on liver‐derived
prothrombin (F2, P00734); trypsin, generated by
the action of enterokinase (TMPRSS15, P98073) on pancreatic‐derived
trypsinogen (PRSS1, P07477); tryptase, a family of
enzymes (α/β1 TPSAB1, Q15661 ; γ1
TPSG1, Q9NRR2; δ1
TPSD1, Q9BZJ3) secreted from mast
cells; cathepsin G (CTSG, P08311) generated from
leukocytes; liver‐derived protein C (PROC, P04070) generated in plasma by
thrombin(F2, P00734) and matrix metalloproteinase 1
(MMP1, P45452).

Further Reading
Adams MN et al. (2011)
Structure, function and pathophysiology of protease activated receptors.
Pharmacol. Ther.
130: 248‐82 [PMID:21277892]


Canto I et al. (2012)
Allosteric modulation of protease‐activated receptor signaling. Mini Rev Med
Chem
12: 804‐11 [PMID:22681248]


García PS et al. (2010) The
role of thrombin and protease‐activated receptors in pain mechanisms. Thromb.
Haemost.
103: 1145‐51 [PMID:20431855]


Hollenberg MD et al. (2002)
International Union of Pharmacology. XXVIII. Proteinase‐activated receptors.
Pharmacol. Rev.
54: 203‐17 [PMID:12037136]


Ramachandran R et al. (2012)
Targeting proteinase‐activated receptors: therapeutic potential and challenges.
Nat Rev Drug Discov
11: 69‐86 [PMID:22212680]


Soh UJ et al. (2010) Signal
transduction by protease‐activated receptors. Br. J. Pharmacol.
160: 191‐203 [PMID:20423334]


Vergnolle N. (2009) Protease‐activated
receptors as drug targets in inflammation and pain. Pharmacol. Ther.
123: 292‐309 [PMID:19481569]



QRFP receptor

Overview
The human gene encoding the QRFP receptor
(QRFPR, also known as the peptide P518 receptor), previously designated as an orphan
GPCR receptor was identified in 2001 by Lee et al. from a
hypothalamus cDNA library [1066]. However, the reported
cDNA (AF411117) is a chimera with bases 1‐127 derived from chromosome 1 and bases
155‐1368 derived from chromosome 4. When corrected, QRFPR (also referred to as SP9155
or AQ27) encodes a 431 amino acid protein that shares sequence similarities in the
transmembrane spanning regions with other peptide receptors. These include
neuropeptide FF2 (38%), neuropeptide Y2 (37%) and galanin GalR1 (35%) receptors.


Nomenclature	
QRFP receptor
	
HGNC, UniProt	
QRFPR, Q96P65
	
Endogenous
agonists	
QRFP43
(QRFP, P83859)
(pIC50 7.8–9.3) [557, 1850] – Rat,
QRFP26
(QRFP) (pEC50 8.2) [867]	
Labelled
ligands	
[125I]QRFP43
(human) (Agonist) (pK
d 7.8–10.3) [557, 1017,
1850]	



Comments
The orphan receptor GPR83(9NYM4) shows sequence
similarities with the QRFP receptor, as well as with the NPFF1, NPFF2, and PrRP
receptors.

Further Reading
Fukusumi S et al. (2006)
Recent advances in mammalian RFamide peptides: the discovery and functional analyses
of PrRP, RFRPs and QRFP. Peptides
27: 1073‐86 [PMID:16500002]



Relaxin family peptide receptors

Overview
Relaxin family peptide receptors (RXFP,
nomenclature as agreed by the NC‐IUPHAR Subcommittee on Relaxin family peptide receptors
[
105
,
677
]) may be divided into two pairs, RXFP1/2 and RXFP3/4. Endogenous
agonists at these receptors are a number of heterodimeric peptide hormones analogous
to insulin: relaxin‐1(RLN1, P04808), relaxin(RLN2, P04090), relaxin‐3(RLN3, Q8WXF3) (also known as INSL7),
insulin‐like peptide 3 (INSL3(INSL3, P51460)) and INSL5(INSL5, Q9Y5Q6).

Species homologues of relaxin have distinct
pharmacology ‐ relaxin(RLN2, P04090) interacts with RXFP1,
RXFP2 and RXFP3, whereas mouse and rat relaxin selectively bind to and activate RXFP1
[1686] and porcine relaxin may have a higher
efficacy than human relaxin(RLN2, P04090) [678]. Relaxin‐3(RLN3, Q8WXF3) has differential
affinity for RXFP2 receptors between species; mouse and rat RXFP2 have a higher
affinity for relaxin‐3(RLN3, Q8WXF3) [1685]. At least two binding
sites have been identified on the RXFP1 and RXFP2 receptors: a high‐affinity site in
the leucine‐rich repeat region of the ectodomain and a somewhat lower‐affinity site
located in the surface loops of the transmembrane domain [678, 1812]. The unique N‐terminal
LDLa module of RXFP1 and RXFP2 is essential for receptor signalling [1687].


Nomenclature	
RXFP1 receptor
	
RXFP2 receptor
	
RXFP3 receptor
	
RXFP4 receptor
	
HGNC, UniProt	
RXFP1, Q9HBX9
	
RXFP2, Q8WXD0
	
RXFP3, Q9NSD7
	
RXFP4, Q8TDU9
	
Rank order of
potency	
relaxin
(RLN2, P04090) =
relaxin‐1
(RLN1, P04808)
>relaxin‐3
(RLN3, Q8WXF3)
[1812]	
INSL3 (INSL3, P51460)
>relaxin
(RLN2, P04090)
≫relaxin‐3
(RLN3, Q8WXF3)
[1022, 1812]	
relaxin‐3
(RLN3, Q8WXF3)
>relaxin‐3 (B
chain) (RLN3, Q8WXF3)
>relaxin
(RLN2, P04090)
[1119]	
INSL5 (INSL5, Q9Y5Q6) =
relaxin‐3
(RLN3, Q8WXF3)
>relaxin‐3 (B
chain) (RLN3, Q8WXF3)
[1117, 1118]	
Endogenous
antagonists	–	–	
INSL5 (INSL5, Q9Y5Q6)
(pK
i 7) [2129]	–	
Antagonists	
B‐R13/17K H2
relaxin (pEC50 5.7–6.7) [788, 1382], LGR7‐truncate
[1687]	–	
R3(BΔ23‐27)R/I5 chimeric peptide
(pIC50 9.2) [1018]	
R3(BΔ23‐27)R/I5 chimeric peptide
(pIC50 8–8.6) [714, 1018]	
Selective
antagonists	–	
A(9‐26)INSL3
(pK
i 9.1) [787], A(10‐24)INSL3
(pK
i 8.7) [787], A(C10/15S)INSL3
(pK
i 8.6) [2118], INSL3 B chain dimer
analogue 8 (pK
i 8.5) [1710], A(Δ10/15C)INSL3 (pK
i 8.3) [2118], cyclic INSL3 B‐chain
analogue 6 (pK
i 6.7) [1708], INSL3 B‐chain
analogue (pK
i 5.1) [411], (des 1‐8) A‐chain INSL3
analogue [253]	
minimised relaxin‐3
analogue 3 (pK
i 7.6) [1706], R3‐B1‐22R
(pIC50 7.4) [714]	
minimised relaxin‐3
analogue 3 (pIC50 6.6) [1706]	
Selective
allosteric modulators	
ML290 (Agonist)
(pEC50 7) [2057, 2060]	–	–	–	
Labelled
ligands	
[33P]relaxin
(human) (Agonist) (pK
d 9.3–9.7) [678, 1812], [125I]relaxin
(human) (Agonist)	
[125I]INSL3
(human) (Agonist) (pK
d 10) [1340], [33P]relaxin
(human) (Agonist) (pK
d 9–9.2) [678, 1812]	
[125I]relaxin‐3
(human) (Agonist) (pK
d 9.5) [1119], [125I]relaxin‐3‐B/INSL5 A chimera (Agonist)
(pK
d 9.3) [1117]	
[125I]relaxin‐3
(human) (Agonist) (pK
d 8.7–9.7) [1118], [125I]relaxin‐3‐B/INSL5 A chimera (Agonist)
(pK
d 8.9) [1117], europium‐labelled
INSL5 (pK
d 8.3) [714]	
Comments	
europium‐labelled
relaxin is a fluorescent ligand for this receptor
(K
d=0.5nM) [1707].	
europium‐labelled
INSL3 is a fluorescent ligand for this receptor
(K
d=1nM) [1709].	
europium‐labelled
relaxin‐3‐B/INSL5 A chimera and R3‐B1‐22R are
fluorescent ligands for this receptor (K
d=5nM and 28nM) [714, 715].	
europium‐labelled
relaxin‐3‐B/INSL5 A chimera is a fluorescent probe at
this receptor (K
d=5nM) [714]. europium‐labelled mouse
INSL5 is a fluorescent ligand at this receptor
(K
d=5nM) [120].	



Comments
Relaxin has recently successfully completed a
Phase III clinical trial for the treatment of acute heart failure. 48 hr infusion of
relaxin reduced dyspnoea and 180 day mortality [1262]. Small molecule agonists
active at RXFP1 receptors have been developed [1718, 2060], and one of these
(ML290) is an allosteric agonist
at RXFP1 [2060]. The antifibrotic actions
of relaxin are dependent on the angiotensin receptor AT2, are absent in
AT2 knockout mice, and are associated with heterodimer formation
between RXFP1 and AT2[330]. Mutations in
INSL3 and LGR8 (RXFP2) have been reported in
populations of patients with cryptorchidism [512]. Numerous splice variants
of the human RXFP1 and RXFP2 receptors have been identified, most of which do not
bind relaxin family peptides [1340]. Splice variants of RXFP1
encoding the N‐terminal LDLa module act as antagonists of RXFP1 signalling [1685, 1687]. cAMP elevation appears
to be a major signalling pathway for RXFP1 and RXFP2 [795, 796], but RXFP1 also activates
MAP kinases, nitric oxide signalling, tyrosine kinase phosphorylation and relaxin can
interact with glucocorticoid receptors [681]. RXFP1 signalling involves
lipid rafts, residues in the C‐terminus of the receptor and activation of
phosphatidylinositol‐3‐kinase [682]. More recent studies
provide evidence that RXFP1 is pre‐assembled in signalosomes with other signalling
proteins including Gα
s, Gβ
γ and adenylyl cyclase 2 that display constitutive activity and are
exquisitely sensitive to sub‐picomolar concentrations of relaxin [679]. The cyclic AMP signalling pattern
is highly dependent on the cell type in which RXFP1 is expressed [680].

The receptor expression profiles suggested that
RXFP3 was a neuropeptide receptor and RXFP4 a gut hormone receptor. Studies in rats
and mice (including wildtype, and relaxin‐3 and RXFP3 gene‐deletion strains
[671, 782, 1759, 1971] have revealed putative
roles for the relaxin‐3/RXFP3 system in the modulation of feeding [564, 566, 714, 1706, 1760], anxiety [1618, 2114], and reward and
motivated, goal‐directed behaviours [782, 1619, 1971], particularly in relation
to the integration of stress and corticotrophin‐releasing factor signalling
[1162], with implications for
the therapeutic treatment of clinical anxiety, depression, eating disorders and
addiction (see [565, 1761] for review). Relaxin‐3(RLN3, Q8WXF3) acts as an agonist at
both RXFP3 and RXFP4 whereas INSL5(INSL5, Q9Y5Q6) is an agonist at RXFP4
and a weak antagonist at RXFP3. Unlike RXFP1 and RXFP2 both RXFP3 and RXFP4 are
encoded by a single exon and therefore no splice variants exist. The rat RXFP3
sequence has two potential start codons that encode RXFP3L and RXFP3S with the longer
variant having an additional 7 amino‐acids at the N‐terminus. It is not known which
variant is expressed. Rat and dog RXFP4 sequences are pseudogenes [2027]. Recent studies suggest
that INSL5 is an incretin secreted from enteroendocrine L cells and that the
INSL5/RXFP4 system has roles in controlling food intake and glucose homeostasis
[652]. RXFP3 couples to
Gi/o and inhibits adenylyl cyclase [1119, 2144], and also causes Erk1/2
phosphorylation [2144]. Relatively little is
known about RXFP4 signalling but like RXFP3 it couples to inhibitory Gi/o
G‐proteins [1120]. Recent studies suggest
that relaxin(RLN2, P04090) also interacts with
RXFP3 to cause a pattern of activation of signalling pathways that are a subset of
those activated by relaxin‐3(RLN3, Q8WXF3). The two patterns of
signaling observed in several cell types expressing RXFP3 are strong inhibition of
forskolin‐stimulated cyclic AMP accumulation, ERK1/2
activation and nuclear factor NFκ‐B reporter gene activation with
relaxin‐3(RLN3, Q8WXF3), and weaker activity
with relaxin(RLN2, P04090), porcine relaxin, or insulin‐like
peptide 3 (INSL3(INSL3, P51460)) and a strong
stimulation of activator protein (AP)‐1 reporter genes with relaxin(RLN2, P04090), and weaker activation
with relaxin‐3(RLN3, Q8WXF3) or porcine relaxin[2144]. Thus at RXFP3, relaxin(RLN2, P04090) is a biased ligand
compared to the cognate ligand relaxin‐3(RLN3, Q8WXF3). Two pharmacologically
distinct ligand binding sites were also identified on RXFP3‐expressing cells using
[125I]relaxin‐3‐B/INSL5 A
chimera which binds with high affinity and displays competition by
relaxin‐3(RLN3, Q8WXF3) or a relaxin‐3 (B chain) (RLN3, Q8WXF3) peptide, and [125I]relaxin
(human) which displays competition by relaxin(RLN2, P04090), relaxin‐3(RLN3, Q8WXF3), or INSL3(INSL3, P51460) and weakly by porcine
relaxin.

Further Reading
Bathgate RA et al. (2013)
Relaxin family peptides and their receptors. Physiol. Rev.
93: 405‐80 [PMID:23303914]


Bathgate RA et al. (2006)
International Union of Pharmacology LVII: recommendations for the nomenclature of
receptors for relaxin family peptides. Pharmacol Rev
58: 7‐31 [PMID:16507880]


Callander GE et al. (2010)
Relaxin family peptide systems and the central nervous system. Cell. Mol.
Life Sci.
67: 2327‐41 [PMID:20213277]


Du XJ et al. (2010)
Cardiovascular effects of relaxin: from basic science to clinical therapy.
Nat Rev Cardiol
7: 48‐58 [PMID:19935741]


Halls ML et al. (2015)
International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the
understanding of the pharmacology and biological roles of relaxin family peptide
receptors 1‐4, the receptors for relaxin family peptides. Pharmacol.
Rev.
67: 389‐440 [PMID:25761609]


Ivell R et al. (2011) Relaxin
family peptides in the male reproductive system–a critical appraisal. Mol.
Hum. Reprod.
17: 71‐84 [PMID:20952422]


Kong RC et al. (2010) Membrane
receptors: structure and function of the relaxin family peptide receptors.
Mol. Cell. Endocrinol.
320: 1‐15 [PMID:20138959]


van der Westhuizen ET et al.
(2008) Relaxin family peptide receptors–from orphans to therapeutic targets.
Drug Discov. Today
13: 640‐51 [PMID:18675759]



Somatostatin receptors

Overview
Somatostatin (somatotropin release inhibiting
factor) is an abundant neuropeptide, which acts on five subtypes of somatostatin
receptor (sst1‐sst5; nomenclature as agreed by the
NC‐IUPHAR Subcommittee on
Somatostatin Receptors [790]). Activation of these receptors produces a
wide range of physiological effects throughout the body including the inhibition of
secretion of many hormones. The relationship of the cloned receptors to endogenously
expressed receptors is not yet well established in some cases. Endogenous ligands for
these receptors are somatostatin‐14 (SRIF‐14(SST, P61278)) and somatostatin‐28
(SRIF‐28(SST, P61278)). Cortistatin‐14{Mouse, Rat} has
also been suggested to be an endogenous ligand for somatostatin receptors [404].


Nomenclature	
sst1
receptor
	
sst2
receptor
	
sst3
receptor
	
sst4
receptor
	
sst5
receptor
	
HGNC, UniProt	
SSTR1, P30872
	
SSTR2, P30874
	
SSTR3, P32745
	
SSTR4, P31391
	
SSTR5, P35346
	
Agonists	
pasireotide
(pIC50 8) [1669]	
vapreotide
(pK
i 8.3–10.1) [233, 1474], pasireotide
(pIC50 9) [1669]	
pasireotide
(pIC50 8.8) [1669], vapreotide
(pK
i 7.4–7.9) [233, 1474, 1738]	
NNC269100
(pK
i 8.2) [1132]	
pasireotide
(pIC50 9.8) [1669], vapreotide
(pK
i 7.3–9.2) [233, 1265, 1474, 1736, 1737, 1738]	
Selective
agonists	
L‐797,591
(pK
i 8.8) [1595], Des‐Ala1,2,5‐[D‐Trp8,IAmp9]SRIF
(pIC50 7.5) [484]	
L‐054,522
(pK
i 11) [2084], BIM 23027
(pIC50 10.9) [271], seglitide
(pK
i 8.8–10.3) [233, 1474, 1736, 1737, 1738, 2084], octreotide
(pK
i 8.7–9.9) [233, 1474, 1736, 1737, 1738, 2084]	
L‐796,778
(pK
i 7.6) [1595]	
L‐803,087
(pK
i 9.2) [1595]	
BIM 23052
(pK
i 7.4–9.6) [1265, 1736, 1737, 1738], L‐817,818
(pK
i 9.4) [1595], BIM 23268
(pK
i 8.7) [1265]	
Selective
antagonists	
SRA880
(pK
d 8–8.1) [792]	
[D‐Tyr8]CYN
154806 (pK
d 8.1–8.9) [1412]	
NVP ACQ090
(pK
i 7.9) [793]	–	–	
Labelled
ligands	–	
[125I]Tyr3 SMS 201‐995
(Agonist) (pK
d 9.9) [1736, 1737], [125I]BIM23027 (Agonist) (pIC50
9.7) [772] – Rat	–	–	
[125I]Tyr3 SMS 201‐995
(Agonist) (pK
d 9.6) [1736, 1737]	
Comments	–	–	Troxler et
al. (2010) describe the identification of non‐peptidic,
subtype‐selective sst3 receptor antagonists [1907].	–	–	



Comments

[125I]Tyr11‐SRIF‐14, [125I]LTT‐SRIF‐28,
[125I]CGP 23996 and
[125I]Tyr10‐CST14 may be used to label
somatostatin receptors nonselectively. A number of nonpeptide subtype‐selective
agonists have been synthesised [1595]. A novel peptide
somatostatin analogue, somatoprim, has affinity for
sst2, sst4 and sst5 receptors and is a potent
inhibitor of GH secretion [1514, 1726].

Further Reading
Ben‐Shlomo A et al. (2010)
Pituitary somatostatin receptor signaling. Trends Endocrinol. Metab.
21: 123‐33 [PMID:20149677]


Colao A et al. (2011)
Resistance to somatostatin analogs in acromegaly. Endocr. Rev.
32: 247‐71 [PMID:21123741]


Csaba Z et al. (2012)
Molecular mechanisms of somatostatin receptor trafficking. J. Mol.
Endocrinol.
48: R1‐12 [PMID:22159161]


Hoyer D et al. (2000)
Somatostatin receptors. In The IUPHAR Compendium of Receptor Characterization
and Classification, 2nd edn. Edited by Watson SP, Girdlestone D: IUPHAR
Media: 354‐364

Schulz S et al. (2014)
Fine‐tuning somatostatin receptor signalling by agonist‐selective phosphorylation and
dephosphorylation: IUPHAR Review 5. Br. J. Pharmacol.
171: 1591‐9 [PMID:24328848]


Zatelli MC et al. (2009) The
significance of new somatostatin analogs as therapeutic agents. Curr Opin
Investig Drugs
10: 1025‐31 [PMID:19777390]



Succinate receptor

Overview

Nomenclature as recommended by NC‐IUPHAR[
396
].


Nomenclature	
succinate
receptor
	
HGNC, UniProt	
SUCNR1, Q9BXA5
	
Endogenous
agonists	
succinic acid
(pEC50 3.1–4.7) [728, 1785]	




Tachykinin receptors

Overview
Tachykinin receptors (provisional
nomenclature as recommended by NC‐IUPHAR[
530
]) are activated by the endogenous peptides substance P(TAC1, P20366) (SP), neurokinin A (TAC1, P20366) (NKA; previously known
as substance K, neurokinin α, neuromedin L), neurokinin B (TAC3, Q9UHF0) (NKB; previously known
as neurokinin β, neuromedin K), neuropeptide K(TAC1, P20366) and neuropeptide γ(TAC1, P20366) (N‐terminally extended
forms of neurokinin A). The neurokinins (A and B) are mammalian members of the
tachykinin family, which includes peptides of mammalian and nonmammalian origin
containing the consensus sequence: Phe‐x‐Gly‐Leu‐Met. Marked species differences in
in vitro pharmacology exist for all three receptors, in the
context of nonpeptide ligands.


Nomenclature	
NK1
receptor
	
NK2
receptor
	
NK3
receptor
	
HGNC, UniProt	
TACR1, P25103
	
TACR2, P21452
	
TACR3, P29371
	
Rank order of
potency	
substance P
(TAC1, P20366)
>neurokinin A
(TAC1, P20366)
>neurokinin B
(TAC3, Q9UHF0)	
neurokinin A
(TAC1, P20366)
>neurokinin B
(TAC3, Q9UHF0)
≫substance P
(TAC1, P20366)	
neurokinin B
(TAC3, Q9UHF0)
>neurokinin A
(TAC1, P20366)
>substance P
(TAC1, P20366)	
Agonists	
substance P‐OMe
(pIC50 7.4–7.5) [1882]	–	–	
Selective
agonists	
[Sar9,Met(O2)11]SP
(pIC50 9.7–9.9) [1882], septide
(pK
i 7–9.3) [125, 711], [Pro9]SP (pIC50 8.6) [1896] – Rat	
[Lys5,Me‐Leu9,Nle10]NKA‐(4‐10)
(pIC50 8.8–9.4) [1229] – Rat,
GR64349
(pEC50 8.4) [407] – Rat,
[βAla8]neurokinin
A‐(4‐10) (pK
d 6) [477]	
[Phe(Me)7]neurokinin B (pK
i 8.7–9.6) [1644, 1645], senktide
(pK
i 7.1–8.6) [1644, 1645, 1882]	
Selective
antagonists	
aprepitant
(pK
i 10.1) [673, 674], lanepitant
(pK
i 9.8–10) [613], lanepitant
(pIC50 9.8) [798], CP 99994
(pK
i 9.3–9.7) [50, 1645], casopitant
(pK
i 9.4) [798, 1905], vestipitant
(pK
i 9.4) [221, 418], nolpitantium
(pIC50 8.9–9) [1882], RP67580
(pIC50 7.7) [528]	
GR94800
(pK
i 9.8) [200], saredutant
(pK
i 9.4–9.7) [50, 477, 1645], GR 159897
(pK
d 7.8–9.5) [133, 477, 1770], MEN10627
(pK
i 9.2) [603], nepadutant
(pK
i 8.5–8.7) [272, 343]	
osanetant
(pK
i 8.4–9.7) [50, 110, 342, 476, 898, 1450, 1644, 1645, 1882], talnetant
(pK
i 7.4–9) [129, 604, 1644, 1645], PD157672
(pIC50 7.8–7.9) [165, 1882]	
Labelled
ligands	
[125I]L703,606 (Antagonist)
(pK
d 9.5) [537], [125I]BH‐[Sar9,Met(O2)11]SP
(Agonist) (pK
d 9) [1901] – Rat,
[3H]BH‐[Sar9,Met(O2)11]SP
(Agonist) (pK
d 8.7) [1902] – Rat,
[3H]SP (human,
mouse, rat) (Agonist) (pK
d 8.6) [80], [125I]SP (human,
mouse, rat) (Agonist), [18F]SPA‐RQ (Antagonist) [317]	
[3H]saredutant (Antagonist)
(pK
d 9.7) [649] – Rat,
[125I]NKA
(human, mouse, rat) (Agonist) (pK
d 9.3) [1990], [3H]GR100679 (Antagonist)
(pK
d 9.2) [669]	
[3H]osanetant (Antagonist)
(pK
d 9.9), [3H]senktide (Agonist) (pK
d 8.1–8.7) [660] – Guinea
pig, [125I][MePhe7]NKB
(Agonist)	



Comments
The NK1 receptor has also been
described to couple to other G proteins [1606]. The hexapeptide agonist
septide appears to bind to an overlapping but non‐identical site to substance P(TAC1, P20366) on the NK1
receptor. There are suggestions for additional subtypes of tachykinin receptor; an
orphan receptor (SwissProt P30098) with structural similarities to the
NK3 receptor was found to respond to NKB when expressed in
Xenopus oocytes or Chinese hamster ovary cells [433, 1004].

Further Reading
Commons KG. (2010) Neuronal pathways linking
substance P to drug addiction and stress. Brain Res.
1314: 175‐82 [PMID:19913520]


Douglas SD et al. (2011)
Neurokinin‐1 receptor: functional significance in the immune system in reference to
selected infections and inflammation. Ann. N. Y. Acad. Sci.
1217: 83‐95 [PMID:21091716]


Foord SM et al. (2005)
International Union of Pharmacology. XLVI. G protein‐coupled receptor list.
Pharmacol Rev
57: 279‐288 [PMID:15914470]


Pantaleo N et al. (2010) The
mammalian tachykinin ligand‐receptor system: an emerging target for central
neurological disorders. CNS Neurol Disord Drug Targets
9: 627‐35 [PMID:20632965]


Rance NE et al. (2010)
Neurokinin B and the hypothalamic regulation of reproduction. Brain
Res.
1364: 116‐28 [PMID:20800582]


Rojas C et al. (2012)
Pharmacological mechanisms of 5‐HT_3 and tachykinin NK_1 receptor antagonism to
prevent chemotherapy‐induced nausea and vomiting. Eur. J. Pharmacol.
684: 1‐7 [PMID:22425650]


Tuluc F et al. (2009)
Neurokinin 1 receptor isoforms and the control of innate immunity. Trends
Immunol.
30: 271‐6 [PMID:19427266]



Thyrotropin‐releasing hormone
receptors

Overview
Thyrotropin‐releasing hormone (TRH) receptors
(provisional nomenclature as recommended by NC‐IUPHAR[
530
]) are activated by the endogenous tripeptide TRH(TRH, P20396) (pGlu‐His‐ProNH2).
TRH(TRH, P20396) and TRH analogues fail
to distinguish TRH1 and TRH2 receptors [1822]. [3H]TRH (human, mouse,
rat) is able to label both TRH1 and TRH2
receptors with Kd values of 13 and 9 nM respectively.


Nomenclature	
TRH1
receptor
	
TRH2
receptor
	
HGNC, UniProt	
TRHR, P34981
	–	
Antagonists	
diazepam
(pK
i 5.2) [444] – Rat	–	
Selective
antagonists	
midazolam
(pK
i 5.5) [444] – Rat,
chlordiazepoxide
(pK
i 4.8) [444] – Rat,
chlordiazepoxide
(pK
i 4.7) [1804] –
Mouse	–	
Comments	–	A class A G
protein‐coupled receptor: not present in man	



Further Reading
Bílek R et al. (2011) TRH‐like
peptides. Physiol Res
60: 207‐15 [PMID:21114375]


Foord SM et al. (2005)
International Union of Pharmacology. XLVI. G protein‐coupled receptor list.
Pharmacol Rev
57: 279‐288 [PMID:15914470]


Nillni EA. (2010) Regulation of the
hypothalamic thyrotropin releasing hormone (TRH) neuron by neuronal and peripheral
inputs. Front Neuroendocrinol
31: 134‐56 [PMID:20074584]



Trace amine receptor

Overview
Trace amine‐associated receptors were initially
discovered as a result of a search for novel 5‐HT receptors [185], where 15 mammalian
orthologues were identified and divided into two families. The TA1
receptor (nomenclature as agreed by the NC‐IUPHAR Subcommittee for the Trace amine receptor [
1181
]) has been shown to have affinity for the endogenous trace amines
tyramine, β‐phenylethylamine and octopamine in addition to the
classical amine dopamine[185]. Emerging evidence
suggests that TA1 is a modulator of monoaminergic activity in the brain
[2062] with TA1 and
dopamine D2 receptors shown to form constitutive heterodimers when
co‐expressed [492]. In addition to trace
amines, receptors can be activated by amphetamine‐like psychostimulants, and
endogenous thyronamines such as thyronamine and 3‐iodothyronamine.


Nomenclature	
TA1
receptor
	
HGNC, UniProt	
TAAR1, Q96RJ0
	
Rank order of
potency	
tyramine>β‐phenylethylamine>octopamine =
dopamine
[185]	
Agonists	
RO5166017
(pEC50 7.3) [1574]	
Antagonists	
EPPTB (Inverse
agonist) (pIC50 5.1) [199]	
Labelled
ligands	
[3H]tyramine (Agonist) (pK
d 7.7) [185]	



Comments
In addition to TA1, analysis has
shown that in man there are up to 5 functional TAAR genes (TAAR2,5,6,8,9). See
[185] for detailed discussion.
The product of the gene TAAR2 (also known as GPR58) appears to respond to β‐phenylethylamine>tyramine and to couple through
Gs[185].


TAAR3, in some individuals, and TAAR4 are pseudogenes in man, although functional in rodents. The signalling
characteristics and pharmacology of TAA5(PNR, Putative Neurotransmitter Receptor: TAAR5, O14804), TAA6(Trace amine receptor 4, TaR‐4: TAAR6, 96RI8), TAA8(Trace amine receptor 5, GPR102: TAAR8, Q969N4) and TAA9(trace amine associated receptor 9: TAAR9, 96RI9) are lacking. The thyronamines, endogenous
derivatives of thyroid hormone, have been shown to have affinity for rodent cloned
trace amine receptors, including TA1[1657]. An antagonist EPPTB has recently been
described that has a pKi of 9.1 at the mouse
TA1 but less than 5.3 for human TA1[1792].

Further Reading
Jing L et al. (2015) Trace
amine‐associated receptor 1: A promising target for the treatment of psychostimulant
addiction. Eur. J. Pharmacol.
[PMID:26092759]


Liberles SD. (2015) Trace amine‐associated
receptors: ligands, neural circuits, and behaviors. Curr. Opin.
Neurobiol.
34C: 1‐7 [PMID:25616211]


Maguire JJ et al. (2009)
International Union of Pharmacology. LXXII. Recommendations for trace amine receptor
nomenclature. Pharmacol. Rev.
61: 1‐8 [PMID:19325074]


Miller GM. (2011) The emerging role of trace
amine‐associated receptor 1 in the functional regulation of monoamine transporters
and dopaminergic activity. J. Neurochem.
116: 164‐76 [PMID:21073468]


Sotnikova TD et al. (2009)
Trace amine‐associated receptors as emerging therapeutic targets. Mol.
Pharmacol.
76: 229‐35 [PMID:19389919]


Zucchi R et al. (2006) Trace
amine‐associated receptors and their ligands. Br J Pharmacol
149: 967‐978 [PMID:17088868]



Urotensin receptor

Overview
The urotensin‐II (U‐II) receptor (UT,
nomenclature as agreed by the NC‐IUPHAR Subcommittee on the Urotensin receptor [439,
530
,
1952
]) is activated by the endogenous dodecapeptide urotensin‐II(UTS2, O95399), originally isolated
from the urophysis, the endocrine organ of the caudal neurosecretory system of
teleost fish [134]. Several structural forms
of U‐II exist in fish and amphibians. The Goby orthologue was used to identify U‐II
as the cognate ligand for the predicted receptor encoded by the rat gene
gpr14 [375, 1130, 1327, 1410]. Human urotensin‐II(UTS2, O95399), an 11‐amino‐acid
peptide [375], retains the
cyclohexapeptide sequence of goby U‐II that is thought to be important in ligand
binding [219, 957]. This sequence is also
conserved in the deduced amino‐acid sequence of rat urotensin‐II {Rat} (14
amino‐acids) and mouse urotensin‐II{Mouse} (14
amino‐acids), although the N‐terminal is more divergent from the human sequence
[374]. A second endogenous
ligand for UT has been discovered in rat [1816]. This is the urotensin II‐related peptide
(UTS2B, Q765I0), an octapeptide that is
derived from a different gene, but shares the C‐terminal sequence (CFWKYCV) common to
U‐II from other species. Identical sequences to rat urotensin II‐related peptide
(UTS2B, Q765I0) are predicted for the
mature mouse and human peptides.


Nomenclature	
UT receptor
	
HGNC, UniProt	
UTS2R, Q9UKP6
	
Endogenous
agonists	
urotensin II‐related
peptide (UTS2B, Q765I0)
(pK
d 9.6) [1179], urotensin‐II
(UTS2, O95399)
(pK
i 8.6) [440, 475, 647]	
Selective
agonists	
[Pen5]‐U (4‐11)
(human) (pK
i 9.7) [647], U‐II‐(4‐11)
(human) (pK
i 9.6) [647], FL104
(pEC50 5.8–7.5) [1075, 1077], AC‐7954
(pK
i 6.6) [382, 1076]	
Selective
antagonists	
urantide
(pK
i 8.3) [1469], SB‐706375
(pK
i 8) [440], palosuran
(pIC50 7.1) [353], SB‐611812
(pK
i 6.6) [1550]	
Labelled
ligands	
[125I]U‐II
(human) (Agonist) (pK
d 9.4–9.6) [42, 1179]	



Comments
In human vasculature, human urotensin‐II(UTS2, O95399) elicits both
vasoconstrictor (pD
2 9.3‐10.1, [1179]) and vasodilator
(pIC50 10.3‐10.4, [1800]) responses.

Further Reading
Douglas SA Ohlstein EH. (2000) Urotensin
receptors. In The IUPHAR Receptor Compendium of Receptor Characterization and
Classification. Edited by Girdlestone D: IUPHAR Media Ltd: 365‐372

Foord SM et al. (2005)
International Union of Pharmacology. XLVI. G protein‐coupled receptor list.
Pharmacol Rev
57: 279‐288 [PMID:15914470]


Guidolin D et al. (2010)
Urotensin‐II as an angiogenic factor. Peptides
31: 1219‐24 [PMID:20346384]


Hunt BD et al. (2010) A rat
brain atlas of urotensin‐II receptor expression and a review of central urotensin‐II
effects. Naunyn Schmiedebergs Arch. Pharmacol.
382: 1‐31 [PMID:20422157]


Maryanoff BE et al. (2010)
Urotensin‐II receptor modulators as potential drugs. J. Med. Chem.
53: 2695‐708 [PMID:20043680]


Ross B et al. (2010) Role of
urotensin II in health and disease. Am. J. Physiol. Regul. Integr. Comp.
Physiol.
298: R1156‐72 [PMID:20421634]



Vasopressin and oxytocin receptors

Overview
Vasopressin (AVP) and oxytocin (OT) receptors
(nomenclature as recommended by NC‐IUPHAR[
530
]) are activated by the endogenous cyclic nonapeptides vasopressin(AVP, P01185) and oxytocin(OXT, P01178). These peptides are
derived from precursors which also produce neurophysins (neurophysin I for oxytocin;
neurophysin II for vasopressin).


Nomenclature	
V1A
receptor
	
V1B
receptor
	
V2
receptor
	
OT receptor
	
HGNC, UniProt	
AVPR1A, P37288
	
AVPR1B, P47901
	
AVPR2, P30518
	
OXTR, P30559
	
Rank order of
potency	
vasopressin
(AVP, P01185)
>oxytocin
(OXT, P01178)	
vasopressin
(AVP, P01185)
>oxytocin
(OXT, P01178)	
vasopressin
(AVP, P01185)
>oxytocin
(OXT, P01178)	
oxytocin
(OXT, P01178)
>vasopressin
(AVP, P01185)	
Endogenous
agonists	
vasopressin
(AVP, P01185)
(pK
i 8.5–9.3) [24, 311, 369, 415, 1359, 1501, 1627, 1839, 1840, 1870, 1871, 2073]	
vasopressin
(AVP, P01185)
(pK
i 9–9.5) [24, 311, 415, 648, 1359, 1627, 1839, 1840, 1871, 2073]	
vasopressin
(AVP, P01185)
(pK
i 7.9–9.1) [24, 311, 319, 415, 1359, 1627, 1700, 1839, 1840, 1871, 2073]	
oxytocin
(OXT, P01178)
(pK
i 8.2–9.6) [24, 319, 320, 345, 648, 853]	
Selective
agonists	
F180
(pK
d 7.9–8.3) [49, 369]	
d[Leu4]LVP (pK
i 9.8) [1485], d[Cha4]AVP (pK
i 9–9.7) [415, 648]	
VNA932
(pIC50 7.1) [501], OPC‐51803
(pK
i 7) [1359], d[Val4,DArg8]VP
	
[Thr4,Gly7]OT
(pK
i 8.2–8.4) [320, 472, 853]	
Antagonists	
conivaptan
(pK
i 8.2–8.4) [1839, 1840]	
nelivaptan
(pK
i 8.4–9.3) [644, 648, 1702]	–	
L‐371,257
(pK
i 8.8) [648]	
Selective
antagonists	
relcovaptan
(pK
i 8.1–9.3) [24, 369, 648, 1501, 1700, 1839, 1870, 1871, 1910], d(CH2)5[Tyr(Me)2,Arg8]VP
(pK
i 9)	–	
conivaptan
(pK
i 9.4) [381], tolvaptan
(pK
i 9.4) [2073], satavaptan
(pK
i 8.4–9.3) [24, 369, 370, 1699, 1700, 1839, 1910], lixivaptan
(Inverse agonist) (pK
i 8.9–9.2) [33, 1700], d(CH2)5[D‐Ile2,Ile4]AVP
(pK
i 6.9–8.4) [1700], mozavaptan
(Inverse agonist) (pK
i 7.4–8.1) [370, 1700, 1839, 1871, 2073, 2074]	
SSR126768A
(pK
i 8.8–9.1) [1701], desGlyNH2‐d(CH2)5[Tyr(Me)2,Thr4,Orn8]OT
(pK
i 8.5), L‐372662
(pK
i 8.4) [121]	
Labelled
ligands	
[125I]OH‐LVA (Antagonist)
(pK
d 10.3–10.4) [319, 369, 1501], [3H]AVP (human,
mouse, rat) (Agonist) (pK
d 8.6–10.2) [208, 319, 369, 370, 1359, 1501, 1627, 1839, 1840, 1870, 1871, 1910, 2073], [3H]d(CH2)5[Tyr(Me)2]AVP
(Antagonist) (pK
d 9)	
[3H]AVP (human,
mouse, rat) (Agonist) (pK
d 8.6–9.6) [208, 319, 369, 370, 1359, 1501, 1627, 1839, 1840, 1870, 1871, 1910, 2073]	
[3H]AVP (human,
mouse, rat) (Agonist) (pK
d 8.4–9.4) [319, 369, 370, 1359, 1627, 1839, 1840, 1871, 1910, 2073], [3H]dDAVP (Agonist) (pK
d 7.2–9.1) [319, 370, 1871], [3H]desGly‐NH2[D‐Ile2,Ile4]VP
(pK
d 8.6)	
[125I]d(CH2)5[Tyr(Me)2,Thr4,Orn8,Tyr‐NH29]OVT (Antagonist) (pK
d 10), [3H]OT (human,
mouse, rat) (Agonist) (pK
d 8.2–9.5) [319, 553, 853, 952], [111In]DOTA‐dLVT (pK
d 8.3) [318]	



Comments
The V2 receptor exhibits marked
species differences, such that many ligands (d(CH2)5[D‐Ile2,Ile4]AVP
and [3H]desGly‐NH2[D‐Ile2,Ile4]VP)
exhibit low affinity at human V2 receptors [29]. Similarly, [3H]d[D‐Arg8]VP is V2 selective in
the rat, not in the human [1627]. The gene encoding the
V2 receptor is polymorphic in man, underlying nephrogenic diabetes
insipidus [148]. D[Cha4]AVP is
selective only for the human and bovine V1b receptors [415], while d[Leu4]LVP has high
affinity for the rat V1b receptor [1485].

Further Reading
Bartz JA et al. (2011) Social
effects of oxytocin in humans: context and person matter. Trends Cogn. Sci.
(Regul. Ed.)
15: 301‐9 [PMID:21696997]


Knepper MA. (2012) Systems biology in
physiology: the vasopressin signaling network in kidney. Am. J. Physiol.,
Cell Physiol.
303: C1115‐24 [PMID:22932685]


Koshimizu TA et al. (2012)
Vasopressin V1a and V1b receptors: from molecules to physiological systems.
Physiol. Rev.
92: 1813‐64 [PMID:23073632]


Manning M et al. (2012)
Oxytocin and vasopressin agonists and antagonists as research tools and potential
therapeutics. J. Neuroendocrinol.
24: 609‐28 [PMID:22375852]


Meyer‐Lindenberg A et al.
(2011) Oxytocin and vasopressin in the human brain: social neuropeptides for
translational medicine. Nat. Rev. Neurosci.
12: 524‐38 [PMID:21852800]


Neumann ID et al. (2012)
Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and
social behaviors. Trends Neurosci.
35: 649‐59 [PMID:22974560]



VIP and PACAP receptors

Overview
Vasoactive intestinal peptide (VIP) and
pituitary adenylate cyclase‐activating peptide (PACAP) receptors (nomenclature
as agreed by the NC‐IUPHAR
Subcommittee on Vasoactive Intestinal Peptide Receptors [
704
,
705
]) are activated by the endogenous peptides VIP(VIP, P01282), PACAP‐38(ADCYAP1, P18509), PACAP‐27(ADCYAP1, P18509), peptide histidine
isoleucineamide (PHI {Mouse, Rat}), peptide
histidine methionineamide (PHM(VIP, P01282)) and peptide histidine
valine (PHV(VIP, P01282)). VPAC1 and
VPAC2 receptors display comparable affinity for the PACAP peptides,
PACAP‐27(ADCYAP1, P18509) and PACAP‐38(ADCYAP1, P18509), and VIP(VIP, P01282), whereas PACAP‐27(ADCYAP1, P18509) and PACAP‐38(ADCYAP1, P18509) are >100 fold more
potent than VIP(VIP, P01282) as agonists of most
isoforms of the PAC1 receptor. However, one splice variant of the human
PAC1 receptor has been reported to respond to PACAP‐38(ADCYAP1, P18509), PACAP‐27(ADCYAP1, P18509) and VIP(VIP, P01282) with comparable
affinity [393]. PG 99‐465[1320] has been used as a
selective VPAC2receptor antagonist in a number of physiological studies,
but has been reported to have significant activity at VPAC1 and
PAC1 receptors [422]. The selective
PAC1 receptor agonist maxadilan, was extracted from
the salivary glands of sand flies (Lutzomyia longipalpis) and has no
sequence homology to VIP(VIP, P01282) or the PACAP peptides
[1330]. Two deletion variants of
maxadilan, M65[1918] and Max.d.4[1331] have been reported to be
PAC1 receptor antagonists, but these peptides have not been extensively
characterised.


Nomenclature	
PAC1
receptor
	
VPAC1
receptor
	
VPAC2
receptor
	
HGNC, UniProt	
ADCYAP1R1, P41586
	
VIPR1, P32241
	
VIPR2, P41587
	
Rank order of
potency	
PACAP‐27
(ADCYAP1, P18509),
PACAP‐38
(ADCYAP1, P18509)
≫VIP (VIP, P01282)	
VIP (VIP, P01282),
PACAP‐27
(ADCYAP1, P18509),
PACAP‐38
(ADCYAP1, P18509)
≫GHRH (GHRH, P01286),
PHI {Pig},
secretin
(SCT, P09683)	
VIP (VIP, P01282),
PACAP‐38
(ADCYAP1, P18509),
PACAP‐27
(ADCYAP1, P18509)
>PHI {Pig}
≫GHRH (GHRH, P01286),
secretin
(SCT, P09683)	
Selective
agonists	
maxadilan
(pEC50 10.3) [422], maxadilan
(pEC50 6.2) [422]	
[Lys15,Arg16,Leu27]VIP‐(1‐7)/GRF‐(8‐27)‐NH2 (pEC50 8.3) [1315], [Ala11,22,28]VIP (pK
i 8.1) [1393]	
Ro 25‐1553
(pIC50 7.8–9.5) [634, 887, 1315], Ro 25‐1392
(pK
i 8) [2056]	
Selective
antagonists	–	
PG 97‐269
(pIC50 8.7) [633, 887]	–	
Labelled
ligands	
[125I]PACAP‐27 (Agonist)
(pK
d 9.1) [1509]	
[125I]VIP
(human, mouse, rat) (Agonist) (pK
d 9.4) [1393], [125I]PACAP‐27 (Agonist)	
[125I]VIP
(human, mouse, rat) (Agonist) (pK
d 9.2) [1393], [125I]PACAP‐27 (Agonist)	



Comments
Subtypes of PAC1 receptors have been
proposed based on tissue differences in the potencies of PACAP‐27(ADCYAP1, P18509) and PACAP‐38(ADCYAP1, P18509); these might result
from differences in G protein coupling and second messenger mechanisms [1939], or from alternative
splicing of PAC1 receptor mRNA [1788].

Further Reading
Harmar AJ et al. (1998)
International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive
intestinal peptide and pituitary adenylate cyclase‐activating polypeptide.
Pharmacol Rev
50: 265‐270 [PMID:9647867]


Harmar AJ et al. (2012)
Pharmacology and functions of receptors for vasoactive intestinal peptide and
pituitary adenylate cyclase‐activating polypeptide: IUPHAR review 1. Br. J.
Pharmacol.
166: 4‐17 [PMID:22289055]


Reglodi D et al. (2012)
Effects of pituitary adenylate cyclase activating polypeptide in the urinary system,
with special emphasis on its protective effects in the kidney.
Neuropeptides
46: 61‐70 [PMID:21621841]


Smith CB et al. (2012) Is
PACAP the major neurotransmitter for stress transduction at the adrenomedullary
synapse? J. Mol. Neurosci.
48: 403‐12 [PMID:22610912]
==== Refs
References
1 

Abbracchio 
MP 

et al (2003 ) [12559763]

2 

Abbracchio 
MP 

et al (2006 ) [16968944]

3 

AbdAlla 
S 

et al (2000 ) [10993080]

4 

Abdul-Ridha 
A 

et al (2014 ) [25326383]

5 

Abdul-Ridha 
A 

et al (2014 ) [24443568]

6 

Abo-Salem 
OM 

et al (2004 ) [14563788]

7 

Abramovitz 
M 

et al (2000 ) [10634944]

8 

Abramovitz 
M 

et al (1994 ) [8300593]

9 

Adams 
CL 

et al (2007 ) [17894647]

10 

Adams 
JW 

et al (2008 ) [18539757]

11 

Adham 
N 

et al (1997 ) [9225282]

12 

Adham 
N 

et al (1993 ) [8380639]

13 

Ahmed 
K 

et al (2009 ) [19561068]

14 

Ahmed 
K 

et al (2010 ) [20374963]

15 

Ahn 
HS 

et al (1997 ) [9203642]

16 

Ahuja 
SK 

et al (1996 ) [8702798]

17 

Ahumada 
A 

et al (2002 ) [12471263]

18 

Ai 
LS 

et al (2002 ) [12081481]

19 

Aittomäki 
K 

et al (1995 ) [7553856]

20 

Aiyar 
N 

et al (2001 ) [11693189]

21 

Aiyar 
N 

et al (1993 ) [8463997]

22 

Akbar 
GK 

et al (1996 ) [8702478]

23 

Akbulut 
H 

et al (1999 ) [10323493]

24 

Akerlund 
M 

et al (1999 ) [10519430]

25 

Akgün 
E 

et al (2009 ) [19271701]

26 

Akiyama 
K 

et al (1985 ) [2986120]

27 

Akunne 
HC 

et al (1995 ) [7674830]

28 

Al-Ani 
B 

et al (1999 ) [10411588]

29 

Ala 
Y 

et al (1998 ) [9773787]

30 

Albert 
DH 

et al (1997 ) [9151941]

31 

Albert 
R 

et al (2005 ) [16078855]

32 

Albrandt 
K 

et al (1995 ) [7588285]

33 

Albright 
JD 

et al (1998 ) [9651149]

34 

Alexander 
SP 

et al (1996 ) [8937736]

35 

Alexander 
SP 

et al (2007 ) [17876303]

36 

Alexander 
SP 

et al (2001 ) [11164377]

37 

Alikhani 
V 

et al (2004 ) [15324892]

38 

Amano 
H 

et al (2003 ) [12538661]

39 

Amblard 
M 

et al (1999 ) [10514288]

40 

Ames 
RS 

et al (2001 ) [11342658]

41 

Ames 
RS 

et al (1996 ) [8898085]

42 

Ames 
RS 

et al (1999 ) [10499587]

43 

Ames 
RS 

et al (1997 ) [9476119]

44 

Amlaiky 
N 

et al (1992 ) [1328180]

45 

Ancellin 
N 

et al (1999 ) [10383399]

46 

Andersen 
PH 

et al (1990 ) [1973652]

47 

Anderson 
JJ 

et al (2002 ) [12438526]

48 

Andrade-Gordon 
P 

et al (1999 ) [10535908]

49 

Andres 
M 

et al (2002 ) [11934825]

50 

Anthes 
JC 

et al (2002 ) [12206858]

51 

Antoniu 
SA 
. (2010 ) [21154168]

52 

Antony 
J 

et al (2009 ) [18842964]

53 

Ariel 
A 

et al (2003 ) [12794159]

54 

Arimura 
A 

et al (2001 ) [11454901]

55 

Aristotelous 
T 

et al (2013 ) [24454993]

56 

Arita 
M 

et al (2005 ) [15753205]

57 

Arita 
M 

et al (2007 ) [17339491]

58 

Armour 
SL 

et al (1999 ) [11033437]

59 

Armstrong 
RA 

et al (1993 ) [8242228]

60 

Arnt 
J 

et al (1998 ) [9430133]

61 

Aronica 
SM 

et al (1994 ) [8078914]

62 

Asahi 
S 

et al (2003 ) [12467628]

63 

Asin 
KE 

et al (1992 ) [1636779]

64 

Aslanian 
R 

et al (2009 ) [19660947]

65 

Auchampach 
JA 

et al (2009 ) [19141710]

66 

Audinot 
V 

et al (2001 ) [11375253]

67 

Audinot 
V 

et al (2003 ) [12764576]

68 

Auerbach 
SS 

et al National Toxicology Program: Dept of Health and Human
Services. Accessed on 02/05/2014. DrugMatrix.
69 

Austin 
CE 

et al (1997 ) [9111052]

70 

Austin 
KM 

et al (2013 ) [23086754]

71 

Avlani 
VA 

et al (2010 ) [20413650]

72 

Ayoub 
MA 

et al (2004 ) [15266022]

73 

Azran 
S 

et al (2013 ) [23751098]

74 

Baba 
M 

et al (1997 ) [9169459]

75 

Baba 
M 

et al (1999 ) [10318947]

76 

Bach 
P 

et al (2013 ) [24215345]

77 

Bach 
T 

et al (2001 ) [11218067]

78 

Bachelerie 
F 

et al (2014 ) [24218476]

79 

Bachelerie 
F 

et al (2015 ) [25958743]

80 

Bahouth 
SW 

et al (1985 ) [2410593]

81 

Baker 
JG 
. (2010 ) [20590599]

82 

Baker 
JG 
. (2010 ) [21152092]

83 

Baker 
JG 
. (2005 ) [15655528]

84 

Baker 
JG 

et al (2003 ) [12770928]

85 

Baker 
JG 

et al (2003 ) [14645666]

86 

Baker 
JG 

et al (2003 ) [12920204]

87 

Balboni 
G 

et al (2008 ) [19006379]

88 

Balogh 
J 

et al (2005 ) [15893764]

89 

Bamberg 
CE 

et al (2010 ) [20044484]

90 

Bang-Andersen 
B 

et al (2011 ) [21486038]

91 

Baqi 
Y 

et al (2009 ) [19463000]

92 

Bard 
JA 

et al (1995 ) [7592911]

93 

Bard 
JA 

et al (1993 ) [8226867]

94 

Barda 
DA 

et al (2004 ) [15149652]

95 

Barnea 
G 

et al (2008 ) [18165312]

96 

Barrett 
MO 

et al (2013 ) [23592514]

97 

Barroso 
R 

et al (2012 ) [22913878]

98 

Barry 
GD 

et al (2010 ) [20873792]

99 

Barshop 
K 

et al (2015 ) [25341626]

100 

Bartfai 
T 

et al (1991 ) [1720557]

101 

Bartfai 
T 

et al (1993 ) [7504301]

102 

Bartoi 
T 

et al (2010 ) [20406808]

103 

Bassi 
MT 

et al (1995 ) [7647783]

104 

Bastian 
S 

et al (1997 ) [9313952]

105 

Bathgate 
RA 

et al (2006 ) [16507880]

106 

Bayewitch 
M 

et al (1996 ) [8626625]

107 

Beattie 
D 

et al (2012 ) [22932315]

108 

Beattie 
DT 

et al (2004 ) [15466450]

109 

Beau 
I 

et al (1998 ) [9769327]

110 

Beaujouan 
JC 

et al (1997 ) [9042606]

111 

Bechtold 
DA 

et al (2012 ) [22197240]

112 

Beckers 
T 

et al (2001 ) [11726197]

113 

Beckers 
T 

et al (1995 ) [7649152]

114 

Beckers 
T 

et al (1997 ) [9300077]

115 

Bedendi 
I 

et al (2003 ) [12969753]

116 

Bednarek 
MA 

et al (2000 ) [11087562]

117 

Bednarek 
MA 

et al (2001 ) [11606131]

118 

Beech 
JS 

et al (2007 ) [17289163]

119 

Behrens 
M 

et al (2004 ) [15178431]

120 

Belgi 
A 

et al (2011 ) [21866895]

121 

Bell 
IM 

et al (1998 ) [9622556]

122 

Belley 
M 

et al (1999 ) [10658574]

123 

Bellier 
B 

et al (2004 ) [14698161]

124 

Bellows-Peterson 
ML 

et al (2012 ) [22500977]

125 

Bellucci 
F 

et al (2002 ) [11786503]

126 

Belous 
A 

et al (2004 ) [15258927]

127 

Ben-Baruch 
A 

et al (1995 ) [7545673]

128 

Bender 
E 

et al (2000 ) [10646498]

129 

Bennacef 
I 

et al (2004 ) [15265501]

130 

Benned-Jensen 
T 

et al (2010 ) [20148890]

131 

Benya 
RV 

et al (1995 ) [7838118]

132 

Beresford 
IJ 

et al (1998 ) [9618428]

133 

Beresford 
IJ 

et al (1995 ) [7713168]

134 

Bern 
HA 

et al (1985 ) [2864726]

135 

Bernotas 
RC 

et al (2009 ) [19523834]

136 

Berque-Bestel 
I 

et al (2003 ) [12801225]

137 

Berrie 
CP 

et al (1984 ) [6478115]

138 

Berry 
CB 

et al (2014 ) [25221667]

139 

Bersani 
M 

et al (1991 ) [1710578]

140 

Bersani 
M 

et al (1991 ) [1718731]

141 

Bertarelli 
DC 

et al (2006 ) [18404493]

142 

Bertini 
R 

et al (2004 ) [15282370]

143 

Besada 
P 

et al (2006 ) [16942026]

144 

Bettler 
B 

et al (2004 ) [15269338]

145 

Beukers 
MW 

et al (1997 ) [9384502]

146 

Beukers 
MW 

et al (2000 ) [11093773]

147 

Bi 
Y 

et al (2015 ) [25754495]

148 

Bichet 
DG 

et al (1998 ) [9756088]

149 

Bigoni 
R 

et al (2002 ) [12070757]

150 

Binet 
V 

et al (2004 ) [15126507]

151 

Birdsall 
NJ 

et al (1979 ) [497538]

152 

Birke 
FW 

et al (2001 ) [11259574]

153 

Birrell 
MA 

et al (2013 ) [22747912]

154 

Bjursell 
M 

et al (2006 ) [16887097]

155 

Blackhart 
BD 

et al (1996 ) [8663335]

156 

Blair 
JB 

et al (2000 ) [11101361]

157 

Blanpain 
C 

et al (1999 ) [10477718]

158 

Bley 
KR 

et al (2006 ) [16331286]

159 

Blin 
N 

et al (1993 ) [7903415]

160 

Blondel 
O 

et al (1998 ) [9603189]

161 

Blouin 
M 

et al (2010 ) [20163116]

162 

Blue 
DR 

et al (2004 ) [14678390]

163 

Boatman 
PD 

et al (2012 ) [22435740]

164 

Bockaert 
J 

et al (2006 ) [16896947]

165 

Boden 
P 

et al (1996 ) [8648606]

166 

Boehm 
M 

et al (2013 ) [24900608]

167 

Boess 
FG 

et al (1997 ) [9284367]

168 

Boess 
FG 

et al (1998 ) [9730917]

169 

Bogdanov 
YD 

et al (1997 ) [9139711]

170 

Boie 
Y 

et al (1994 ) [7512962]

171 

Boie 
Y 

et al (1995 ) [7642548]

172 

Boie 
Y 

et al (1999 ) [10513580]

173 

Bolden 
C 

et al (1992 ) [1346637]

174 

Bolli 
MH 

et al (2012 ) [22862294]

175 

Bolli 
MH 

et al (2004 ) [15139756]

176 

Bologa 
CG 

et al (2006 ) [16520733]

177 

Bonaventure 
P 

et al (2012 ) [22570363]

178 

Bonaventure 
P 

et al (2004 ) [14617685]

179 

Bonhaus 
DW 

et al (1997 ) [9225293]

180 

Bonhaus 
DW 

et al (1999 ) [10455251]

181 

Bonhaus 
DW 

et al (1977 ) [9225287]

182 

Bonnefous 
C 

et al (2005 ) [15686941]

183 

Bonnefous 
C 

et al (2005 ) [16046122]

184 

Booth 
RG 

et al (2002 ) [12065734]

185 

Borowsky 
B 

et al (2001 ) [11459929]

186 

Borowsky 
B 

et al (2002 ) [12118247]

187 

Borowsky 
B 

et al (1998 ) [9880084]

188 

Borrmann 
T 

et al (2009 ) [19569717]

189 

Bosch 
MP 

et al (2004 ) [15267242]

190 

Bosnyak 
S 

et al (2011 ) [21542804]

191 

Botto 
JM 

et al (1997 ) [9001400]

192 

Boulanger 
L 

et al (2002 ) [11814616]

193 

Boulenguez 
P 

et al (1992 ) [1738002]

194 

Bowery 
NG 

et al (2002 ) [12037141]

195 

Bowery 
NG 

et al (2000 ) [10604925]

196 

Boyce 
M 

et al (2012 ) [22607579]

197 

Boyer 
JL 

et al (1996 ) [8913364]

198 

Brabet 
I 

et al (1995 ) [8532171]

199 

Bradaia 
A 

et al (2009 ) [19892733]

200 

Bradshaw 
CG 

et al (1994 ) [8027981]

201 

Brady 
AE 

et al (2008 ) [18772318]

202 

Brambilla 
R 

et al (2000 ) [10731034]

203 

Brame 
AL 

et al (2015 ) [25712721]

204 

Branchek 
T 

et al (1990 ) [2233697]

205 

Breivogel 
CS 

et al (1997 ) [9316881]

206 

Brenchat 
A 

et al (2009 ) [19118950]

207 
Brennan
et al (2007 ) Transgenic mice containing GPCR5-1 gene
disruptions. Patent number: US2007/0074299. Assignee:
Deltagen. Priority date: 28/08/1999. Publication date: 29/03/2007.
208 

Breton 
C 

et al (2001 ) [11337500]

209 

Breu 
V 

et al (1996 ) [8612786]

210 
Breu
et al (2003 ) Heterocyclic sulfonamides. Patent number:
US6521631. Assignee: Hoffmann-La Roche. Priority
date: 13/03/2015. Publication date: 18/02/2003.
211 

Brezillon 
S 

et al (2003 ) [12401809]

212 

Briddon 
SJ 

et al (2004 ) [15070776]

213 

Brighton 
PJ 

et al (2004 ) [15331768]

214 

Brink 
C 

et al (2004 ) [15001665]

215 

Brinkmann 
V 

et al (2002 ) [11967257]

216 

Brisbare-Roch 
C 

et al (2007 ) [17259994]

217 

Briscoe 
CP 

et al (2006 ) [16702987]

218 

Briscoe 
CP 

et al (2003 ) [12496284]

219 

Brkovic 
A 

et al (2003 ) [12807997]

220 

Broad 
J 

et al (2013 ) [23190027]

221 

Brocco 
M 

et al (2008 ) [18657401]

222 

Brodfuehrer 
J 

et al (2014 ) [24190631]

223 

Brodkin 
J 

et al (2002 ) [12473093]

224 

Bromidge 
SM 

et al (1999 ) [9925723]

225 

Bromidge 
SM 

et al (2001 ) [11140733]

226 

Brown 
AJ 

et al (2003 ) [12496283]

227 

Brown 
AM 

et al (1998 ) BRL 54443, a potent agonist with
selectivity for human cloned 5-HT1E and 5-HT1F receptors. British Journal of
Pharmacology
123 : 233
228 

Brown 
AM 

et al (1993 ) [125I]-SB 207710, A potent,
slective radioligand for 5-HT4 receptors. Br J Pharmacol
110 : 10
229 

Brown 
EM 

et al (1993 ) [8255296]

230 

Browning 
C 

et al (2000 ) [10696085]

231 

Bruchas 
MR 

et al (2007 ) [17702750]

232 

Bruinvels 
AT 

et al (1993 ) [8361548]

233 

Bruns 
C 

et al (1996 ) [8769372]

234 

Bryant 
HU 

et al (1996 ) [8845011]

235 

Bryja 
V 

et al (2007 ) [17426148]

236 

Bryja 
V 

et al (2008 ) [18953287]

237 

Bräuner-Osborne 
H 

et al (1996 ) [8759641]

238 

Buckley 
NJ 

et al (1989 ) [2704370]

239 

Bunzow 
JR 

et al (1988 ) [2974511]

240 

Burford 
NT 

et al (2013 ) [23754417]

241 

Burford 
NT 

et al (2015 ) [25901762]

242 

Burgaud 
JL 

et al (1997 ) [9434758]

243 

Burmakina 
S 

et al (2014 ) [24778228]

244 

Burnstock 
G 

et al (2012 ) Purinergic signalling and the nervous
system. Springer: 1-715
245 

Burris 
KD 

et al (1995 ) [7576010]

246 

Burstein 
ES 

et al (2005 ) [16135699]

247 

Bylund 
DB 

et al (1992 ) [1353247]

248 

Bylund 
DB 

et al (1994 ) [7938162]

249 

Bäck 
M 

et al (2011 ) [21771892]

250 

Bäck 
M 

et al (2014 ) [24588652]

251 

Béguin 
C 

et al (2005 ) [15869877]

252 

Búzás 
B 

et al (1992 ) [1313131]

253 

Büllesbach 
EE 

et al (2005 ) [15708846]

254 

Cabrele 
C 

et al (2002 ) [12069595]

255 

Cai 
R 

et al (2014 ) [24373935]

256 

Cai 
TQ 

et al (2008 ) [18952058]

257 

Cain 
SA 

et al (2002 ) [11773063]

258 

Calderon 
SN 

et al (1994 ) [8035418]

259 

Calo 
G 

et al (2002 ) [12010780]

260 

Cameron 
KO 

et al (2009 ) [19250823]

261 

Canals 
M 

et al (2012 ) [22086918]

262 

Candelore 
MR 

et al (1999 ) [10411574]

263 

Cappelli 
A 

et al (2013 ) [23466604]

264 

Cappelli 
A 

et al (2004 ) [15115399]

265 

Carmeci 
C 

et al (1997 ) [9367686]

266 

Carmon 
KS 

et al (2011 ) [21693646]

267 

Carroll 
FY 

et al (2001 ) [11306677]

268 

Carroll 
WA 

et al (2001 ) [11354357]

269 

Cascieri 
MA 

et al (1999 ) [10085108]

270 

Castro 
E 

et al (1992 ) [1393282]

271 

Castro 
SW 

et al (1996 ) [8646408]

272 

Catalioto 
RM 

et al (1998 ) [9484857]

273 

Catalán 
V 

et al (2007 ) [17371481]

274 

Cattaneo 
M 

et al (2004 ) [15476670]

275 

Caulfield 
MP 

et al (1998 ) [9647869]

276 

Caunt 
CJ 

et al (2004 ) [15059960]

277 

Caunt 
CJ 

et al (2012 ) [22808094]

278 

Cavanaugh 
DJ 

et al (2009 ) [19451647]

279 

Cayabyab 
M 

et al (2000 ) [11090199]

280 

Cembala 
TM 

et al (1998 ) [9846649]

281 

Chackalamannil 
S 

et al (2008 ) [18447380]

282 

Chagnon 
YC 

et al (1997 ) [9392003]

283 

Chaki 
S 

et al (2005 ) [15677346]

284 

Chaki 
S 

et al (1999 ) [10357258]

285 

Chan 
SD 

et al (1992 ) [1334084]

286 

Chan 
WY 

et al (2008 ) [18678919]

287 

Chandrashekar 
J 

et al (2000 ) [10761935]

288 

Chang 
CS 

et al (1997 ) [9112287]

289 

Chang 
DJ 

et al (1998 ) [9490024]

290 

Chang 
KJ 

et al (1983 ) [6313901]

291 

Chang 
RS 

et al (1990 ) [2314387]

292 

Chang 
RS 

et al (1986 ) [3018478]

293 

Chang 
W 

et al (2008 ) [18765830]

294 

Chansel 
D 

et al (1993 ) [8282008]

295 

Chao 
H 

et al (2013 ) [23368907]

296 

Chao 
TH 

et al (1999 ) [10092660]

297 

Chavkin 
C 

et al (2004 ) [14718611]

298 

Chen 
C 

et al (1996 ) [8893829]

299 

Chen 
H 

et al (2004 ) [15163697]

300 

Chen 
J 

et al (2005 ) [15772293]

301 

Chen 
J 

et al (2003 ) [12706455]

302 

Chen 
LH 

et al (2014 ) [25050158]

303 

Chen 
Q 

et al (2012 ) [22697179]

304 

Chen 
Q 

et al (2010 ) [20423341]

305 

Chen 
TB 

et al (1992 ) [1480133]

306 

Chen 
W 

et al (2003 ) [12958365]

307 

Chen 
YL 

et al (2008 ) [18288792]

308 

Chen 
Z 

et al (2004 ) [15454210]

309 

Cheng 
CK 

et al (2005 ) [15561800]

310 

Cheng 
K 

et al (2002 ) [12235229]

311 

Cheng 
LL 

et al (2004 ) [15084136]

312 

Cheng 
MY 

et al (2012 ) [22431614]

313 

Cherezov 
V 

et al (2007 ) [17962520]

314 

Chhatriwala 
M 

et al (2004 ) [15345752]

315 

Chiang 
N 

et al (2000 ) [10748237]

316 

Chiang 
N 

et al (2012 ) [22538616]

317 

Chin 
FT 

et al (2006 ) Automated radiosynthesis of [18F]SPA-RQ.
J Labeled Compounds Radiopharm 17-31
318 

Chini 
B 

et al (2003 ) [12942128]

319 

Chini 
B 

et al (1995 ) [7774575]

320 

Chini 
B 

et al (1996 ) [8955347]

321 

Chiu 
AT 

et al (1989 ) [2590220]

322 

Chiu 
AT 

et al (1992 ) [1445340]

323 

Chng 
SC 

et al (2013 ) [24316148]

324 

Chobanian 
HR 

et al (2012 ) [24900461]

325 

Choi 
JW 

et al (2011 ) [21177428]

326 

Choi 
S 

et al (2004 ) [15357957]

327 

Chopra 
M 

et al (2009 ) [19389924]

328 

Chou 
CC 

et al (2002 ) [12381680]

329 

Chow 
BK 
. (1995 ) [7612008]

330 

Chow 
BS 

et al (2014 ) [24429402]

331 

Chrencik 
JE 

et al (2015 ) [26091040]

332 

Christiansen 
E 

et al (2013 ) [23687558]

333 

Christopoulos 
A 

et al (2003 ) [12446722]

334 

Christopoulos 
A 

et al (1998 ) [9614217]

335 

Christopoulos 
A 

et al (1999 ) [9890565]

336 

Christopoulos 
A 

et al (2001 ) [11578621]

337 

Christopoulos 
G 

et al (1999 ) [10385705]

338 

Chu 
ZL 

et al (2010 ) [19901198]

339 

Chun 
J 

et al (2011 ) [21955849]

340 

Chung 
AW 

et al (2002 ) [11877318]

341 

Chung 
DS 

et al (1997 ) [9353394]

342 

Chung 
FZ 

et al (1995 ) [7476898]

343 

Cialdai 
C 

et al (2006 ) [16979621]

344 

Ciana 
P 

et al (2006 ) [16990797]

345 

Cirillo 
R 

et al (2003 ) [12660315]

346 

Cirillo 
R 

et al (2007 ) [17618756]

347 

Claeysen 
S 

et al (1997 ) [9351641]

348 

Clark 
AL 

et al (1976 ) [990587]

349 

Clark 
BP 

et al (1997 ) Bioorg Med Chem Letts
7 : 2777-2780
350 

Clark 
P 

et al (2008 ) [18287210]

351 

Clarke 
C 

et al (2011 ) [21254176]

352 

Clish 
CB 

et al (1999 ) [10393980]

353 

Clozel 
M 

et al (2004 ) [15146030]

354 

Clozel 
M 

et al (1994 ) [8035319]

355 

Cogé 
F 

et al (2001 ) [11284713]

356 

Cohen 
JA 

et al (2011 ) [21520239]

357 

Combadiere 
C 

et al (1995 ) [8530354]

358 

Commery 
TA 
. (2010 ) SAM-531,
N,N-dimethyl-3-[3-(1-naphthylsulfonyl)-1H-indazol-5-yl]oxy propan-1-amine, a novel
serotonin-6 receptor antagonist with preclinical pro-cognitive efficacy.
Alzheimer's &Dementia
6 : S548-S549
359 

Communi 
D 

et al (1996 ) [8670200]

360 

Communi 
D 

et al (1999 ) [10578132]

361 

Comps-Agrar 
L 

et al (2011 ) [21552208]

362 

Conigrave 
AD 

et al (2000 ) [10781086]

363 

Conn 
PM 

et al (1982 ) [6282571]

364 

Conroy 
JL 

et al (2015 ) [25660762]

365 

Cooray 
SN 

et al (2013 ) [24108355]

366 

Corbett 
DF 

et al (2005 ) [16002289]

367 

Costantino 
G 

et al (2001 ) [11249114]

368 

Costes 
N 

et al (2005 ) [16330560]

369 

Cotte 
N 

et al (2000 ) [10866830]

370 

Cotte 
N 

et al (1998 ) [9792651]

371 

Cottingham 
C 

et al (2011 ) [21859713]

372 

Coulie 
B 

et al (2001 ) [11461914]

373 

Coulin 
F 

et al (1997 ) [9346309]

374 

Coulouarn 
Y 

et al (1999 ) [10486557]

375 

Coulouarn 
Y 

et al (1998 ) [9861051]

376 

Cox 
BM 

et al (2015 ) [24528283]

377 

Cox 
CD 

et al (2010 ) [20565075]

378 

Cox 
HM 

et al (1995 ) [8590988]

379 

Coy 
DH 

et al (1996 ) [8993400]

380 

Croker 
DE 

et al (2013 ) [24060963]

381 

Crombie 
AL 

et al (2010 ) [20471258]

382 

Croston 
GE 

et al (2002 ) [12408704]

383 

Croy 
CH 

et al (2014 ) [24807965]

384 

Cunha 
RA 

et al (1996 ) [8692280]

385 

Curtis 
AE 

et al (2010 ) [19934405]

386 

D'Amato 
M 

et al (2007 ) [17854592]

387 

Dairaghi 
DJ 

et al (1999 ) [10419462]

388 

Dalpiaz 
A 

et al (1998 ) [9827575]

389 

Daniels 
DV 

et al (1999 ) [10334511]

390 

Dardonville 
C 

et al (2004 ) [15224384]

391 

Daugherty 
BL 

et al (1996 ) [8642344]

392 

Dautzenberg 
FM 

et al (2004 ) [15450949]

393 

Dautzenberg 
FM 

et al (1999 ) [10583729]

394 

Dautzenberg 
FM 

et al (2001 ) [11123370]

395 

Davenport 
AP 
. (2002 ) [12037137]

396 

Davenport 
AP 

et al (2013 ) [23686350]

397 

Davenport 
AP 

et al (2005 ) [16382107]

398 

Davenport 
AP 

et al (1998 ) [9489609]

399 

Davenport 
AP 

et al (1994 ) [8012722]

400 

Davis 
MD 

et al (2005 ) [15590668]

401 

Davis 
TL 

et al (2000 ) [10952683]

402 

Dawson 
LA 

et al (2009 ) [19499624]

403 

De Backer 
MD 

et al (1998 ) [9794809]

404 

De Lecea 
L 

et al (1996 ) [8622767]

405 

De Ponti 
F 

et al (1996 ) [8730727]

406 

De Vry 
J 

et al (1998 ) [9495870]

407 

Deal 
MJ 

et al (1992 ) [1331460]

408 

Dearry 
A 

et al (1990 ) [2144334]

409 

Deckert 
J 

et al (1993 ) [8469419]

410 

Del Bello 
F 

et al (2012 ) [22243489]

411 

Del Borgo 
MP 

et al (2006 ) [16547350]

412 

Deng 
C 

et al (2015 ) [25995451]

413 

Dennis 
MK 

et al (2009 ) [19430488]

414 

Dennis 
MK 

et al (2011 ) [21782022]

415 

Derick 
S 

et al (2002 ) [12446593]

416 

Devedjian 
JC 

et al (1994 ) [7908642]

417 

Dhawan 
BN 

et al (1996 ) [8981566]

418 

Di Fabio 
R 

et al (2009 ) [19388677]

419 

Di Fabio 
R 

et al (2011 ) [21831639]

420 

Di Marzo 
V 

et al (2001 ) [11181068]

421 

Di Salvo 
J 

et al (2000 ) [11104827]

422 

Dickson 
L 

et al (2006 ) [16930633]

423 

Dijksterhuis 
JP 

et al (2013 ) [24032637]

424 

Dijkstra 
D 

et al (2002 ) [12086487]

425 

Dillon 
JS 

et al (1993 ) [8404634]

426 

Dinter 
J 

et al (2015 ) [25706283]

427 

Dionisotti 
S 

et al (1997 ) [9179373]

428 

Disse 
B 

et al (1993 ) [8441333]

429 

Divorty 
N 

et al (2015 ) [25805994]

430 

Dodé 
C 

et al (2013 ) [23596439]

431 

Dolan 
JA 

et al (1994 ) [7912272]

432 

Domenech 
T 

et al (1997 ) [9303569]

433 

Donaldson 
LF 

et al (1996 ) [8947459]

434 

Doods 
H 

et al (1999 ) [10611450]

435 

Doods 
H 

et al (2000 ) [10711339]

436 

Doods 
HN 

et al (1995 ) [7562541]

437 

Dooley 
CT 

et al (1996 ) [8684262]

438 

Doré 
AS 

et al (2014 ) [25042998]

439 

Douglas 
SA 


Ohlstein 
EH 
. (2000 ) Urotensin receptors. In The IUPHAR
Receptor Compendium of Receptor Characterization and Classification.
Edited by Girdlestone D: IUPHAR Media Ltd: 365-372
440 

Douglas 
SA 

et al (2005 ) [15852036]

441 

Doumazane 
E 

et al (2011 ) [20826542]

442 

Dowling 
MR 

et al (2006 ) [16847442]

443 

Drake 
MT 

et al (2008 ) [18086673]

444 

Drummond 
AH 

et al (1989 ) [2566295]

445 

Dubocovich 
ML 
. (1985 ) [2991499]

446 

Dubocovich 
ML 

et al (2010 ) [20605968]

447 

Dubocovich 
ML 

et al (1997 ) [9089668]

448 

Dubocovich 
ML 

et al (1998 ) [9737724]

449 

Dudley 
DT 

et al (1990 ) [2402226]

450 

Dudley 
DT 

et al (1993 ) [8469774]

451 

Dufourny 
L 

et al (2008 ) [18400093]

452 

Duggal 
P 

et al (2003 ) [12761559]

453 

Dumont 
Y 

et al (2004 ) [15337369]

454 

Dunlop 
J 

et al (2005 ) [15705738]

455 

Dupuis 
DS 

et al (2006 ) [16966477]

456 

Dwyer 
MP 

et al (2006 ) [17181143]

457 

Díaz-González 
F 

et al (2007 ) [17170051]

458 

Dörje 
F 

et al (1991 ) [1994002]

459 

Eason 
MG 

et al (1995 ) [7559592]

460 

Eckle 
T 

et al (2007 ) [17353435]

461 

Edgar 
AJ 
. (2007 ) [17454009]

462 

Edinger 
AL 

et al (1997 ) [9405683]

463 

Edson 
MA 

et al (2010 ) [19887567]

464 

Edwards 
RM 

et al (1992 ) [1309870]

465 

Egan 
C 

et al (2000 ) [10611640]

466 

Eggerickx 
D 

et al (1995 ) [7639700]

467 

Eison 
AS 

et al (1993 ) [8246675]

468 

El Messari 
S 

et al (2004 ) [15341513]

469 

El-Tayeb 
A 

et al (2005 ) [16213725]

470 

El-Tayeb 
A 

et al (2006 ) [17125260]

471 

El-Tayeb 
A 

et al (2011 ) [21417463]

472 

Elands 
J 

et al (1988 ) [2827511]

473 

Ellacott 
KL 

et al (2005 ) [15752583]

474 

Elliott 
JD 

et al (1994 ) [8201588]

475 

Elshourbagy 
NA 

et al (2002 ) [11976263]

476 

Emonds-Alt 
X 

et al (1995 ) [7830490]

477 

Emonds-Alt 
X 

et al (1993 ) [7682062]

478 

Emson 
PC 
. (2007 ) [17499108]

479 

Engel 
KM 

et al (2011 ) [22216272]

480 

Engers 
DW 

et al (2009 ) [19469556]

481 

Engstrom 
M 

et al (2003 ) [12606605]

482 

Enna 
SJ 

et al (2004 ) [15451397]

483 

Ennis 
MD 

et al (1998 ) [9632349]

484 

Erchegyi 
J 

et al (2005 ) [15658864]

485 

Eriksson 
H 

et al (1998 ) [9802391]

486 

Erlinge 
D 
. (2011 ) [21586366]

487 

Erspamer 
V 
. (1988 ) [3071223]

488 

Erspamer 
V 

et al (1989 ) [2544892]

489 

Esbenshade 
TA 

et al (2004 ) [15294456]

490 

Esbenshade 
TA 

et al (2003 ) [12606603]

491 

Escribano 
A 

et al (1998 ) [9871538]

492 

Espinoza 
S 

et al (2011 ) [21670104]

493 

Esqueda 
EE 

et al (1996 ) [8759038]

494 

Evangelou 
E 

et al (2011 ) [21068099]

495 

Evans 
BA 

et al (2011 ) [20978120]

496 

Evans 
BA 

et al (1999 ) [10455305]

497 

Evans 
BA 

et al (2010 ) [20132209]

498 

Evans 
BN 

et al (2000 ) [10903324]

499 

Evans 
HF 

et al (1991 ) [1714839]

500 

Eveleigh 
P 

et al (1989 ) [2704371]

501 

Failli 
AA 

et al (2006 ) [16297621]

502 

Fan 
H 

et al (2015 ) [25176008]

503 

Fan 
X 

et al (2003 ) [12939143]

504 

Farde 
L 

et al (1996 ) [8835881]

505 

Farooqi 
IS 

et al (2008 ) [18779842]

506 

Faust 
R 

et al (2000 ) [10737738]

507 

Feighner 
SD 

et al (1999 ) [10381885]

508 

Felder 
CC 

et al (1998 ) [9435190]

509 

Felder 
CC 

et al (1995 ) [7565624]

510 

Fells 
JI 

et al (2008 ) [18467108]

511 

Feoktistov 
I 

et al (2001 ) [11705449]

512 

Ferlin 
A 

et al (2003 ) [12970298]

513 

Fernández 
J 

et al (2005 ) [15771415]

514 

Ferrari-Dileo 
G 

et al (1994 ) [7808421]

515 

Filardo 
EJ 

et al (2000 ) [11043579]

516 

Finch 
AR 

et al (2010 ) [20009083]

517 

Finch 
AR 

et al (2010 ) [19888967]

518 

Finnerup 
NB 

et al (2014 ) [24507378]

519 

Fiore 
S 

et al (1994 ) [8006586]

520 

Fiore 
S 

et al (1992 ) [1322894]

521 

Fiore 
S 

et al (1995 ) [8527441]

522 

Fischer 
DJ 

et al (2001 ) [11562440]

523 

Fischetti 
C 

et al (2009 ) [19445927]

524 

Fitzgerald 
LW 

et al (1999 ) [10217294]

525 

Fitzgerald 
LW 

et al (1998 ) [9808667]

526 

Flacco 
N 

et al (2013 ) [23373597]

527 

Flack 
MR 

et al (1994 ) [8188681]

528 

Fong 
TM 

et al (1992 ) [1281470]

529 

Foord 
APDW 

et al (1996 ) [8632751]

530 

Foord 
SM 

et al (2005 ) [15914470]

531 

Forbes 
IT 

et al (2002 ) [12392747]

532 

Ford 
APDW 

et al (1997 ) [9249248]

533 

Foss 
FW 

et al (2007 ) [17113298]

534 

Foudi 
N 

et al (2011 ) [21323896]

535 

Foudi 
N 

et al (2008 ) [18516068]

536 

Franchetti 
P 

et al (2009 ) [19317449]

537 

Francis 
BE 

et al (1994 ) [8287060]

538 

Fraser 
GL 

et al (2008 ) [18719021]

539 

Fraser 
NJ 

et al (1999 ) [10347248]

540 

Fratangeli 
A 

et al (2013 ) [23288840]

541 

Fredholm 
BB 

et al (2001 ) [11734617]

542 

Fredman 
G 

et al (2010 ) [20702811]

543 

Fredriksson 
R 

et al (2003 ) [12761335]

544 

Free 
RB 

et al (2014 ) [24755247]

545 

Freedman 
SB 

et al (1994 ) [8301582]

546 

Freer 
RJ 

et al (1980 ) [7387981]

547 

Fricker 
AC 

et al (2009 ) [19285517]

548 

Fricks 
IP 

et al (2008 ) [18252808]

549 

Frielle 
T 

et al (1988 ) [2849109]

550 

Froestl 
W 
. (2011 ) [21428811]

551 

Froestl 
W 

et al (1997 ) Chemistry of GABAB modulators.
In The GABA Receptors Edited by Enna SJ, Bowery NG: Humana Press:
271-296 [ISBN: 0896034585]
552 

Fruchart-Gaillard 
C 

et al (2006 ) [16439611]

553 

Fuchs 
AR 

et al (1982 ) [6278592]

554 

Fujii 
R 

et al (2002 ) [12118011]

555 

Fukunaga 
K 

et al (2001 ) [11560941]

556 

Fukushima 
N 

et al (1998 ) [9600933]

557 

Fukusumi 
S 

et al (2003 ) [12960173]

558 

Furman 
CA 

et al (2014 ) [25583363]

559 

Galandrin 
S 

et al (2006 ) [16901982]

560 

Galandrin 
S 

et al (2008 ) [18403719]

561 

Gallo-Rodriguez 
C 

et al (1994 ) [8126704]

562 

Gallwitz 
B 

et al (1996 ) [8795084]

563 

Galvez 
T 

et al (2000 ) [10692480]

564 

Ganella 
DE 

et al (2013 ) [23135160]

565 

Ganella 
DE 

et al (2013 ) [24065955]

566 

Ganella 
DE 

et al (2012 ) [22854307]

567 

Ganesh 
T 

et al (2014 ) [24937185]

568 

Gao 
H 

et al (2005 ) [15784721]

569 

Gao 
ZG 

et al (2000 ) [10927024]

570 

Gao 
ZG 

et al (2004 ) [15476669]

571 

Gao 
ZG 

et al (2013 ) [22825617]

572 

Gardell 
LR 

et al (2007 ) [17519387]

573 

Gardella 
TJ 

et al (1996 ) [8702701]

574 

Gardella 
TJ 

et al (1995 ) [7896796]

575 

Gardella 
TJ 

et al (2015 ) [25713287]

576 

Gareau 
Y 

et al (1996 ) Bioorg. Med. Chem. Lett.
6 : 189-194
577 

Garin 
A 

et al (2003 ) [14607932]

578 

Gasparini 
F 

et al (2002 ) [11814808]

579 

Gasparini 
F 

et al (1999 ) [10336568]

580 

Gasparini 
F 

et al (1999 ) [10530811]

581 

Gasser 
A 

et al (2015 ) [25831128]

582 

Gassmann 
M 

et al (2004 ) [15240800]

583 

Gaster 
LM 

et al (1998 ) [9548813]

584 

Gault 
VA 

et al (2003 ) [12627321]

585 

Gavrilyuk 
V 

et al (2005 ) [15715664]

586 

Gbahou 
F 

et al (2006 ) [16432504]

587 

Gee 
CE 

et al (2014 ) [24596089]

588 

Gehlert 
DR 

et al (1996 ) [8632753]

589 

Gembardt 
F 

et al (2008 ) [18636314]

590 

Genet 
C 

et al (2010 ) [19911773]

591 

Geng 
Y 

et al (2013 ) [24305054]

592 

Geng 
Y 

et al (2012 ) [22660477]

593 

Gentry 
PR 

et al (2014 ) [24692176]

594 

Gentry 
PR 

et al (2013 ) [24164599]

595 

Gentry 
PR 

et al (2014 ) [25147929]

596 

Gera 
L 

et al (2006 ) [16368899]

597 

Gerald 
C 

et al (1995 ) [7796807]

598 

Gerald 
C 

et al (1996 ) [8700207]

599 

Gerald 
C 

et al (1995 ) [7592910]

600 

Gershon 
MD 
. (1999 ) [10429737]

601 

Ghoneim 
OM 

et al (2006 ) [16782354]

602 

Giagulli 
C 

et al (2012 ) [22262769]

603 

Giannotti 
D 

et al (2000 ) [11063600]

604 

Giardina 
GA 

et al (1996 ) [8691422]

605 

Giblin 
GM 

et al (2007 ) [17084082]

606 

Giles 
H 

et al (1989 ) [2924081]

607 

Gilet 
M 

et al (2014 ) [25316608]

608 

Gillard 
M 

et al (2002 ) [11809864]

609 

Gillberg 
PG 

et al (1998 ) [9671109]

610 

Gingell 
JJ 

et al (2014 ) [24169554]

611 

Ginsburg-Shmuel 
T 

et al (2012 ) [22901672]

612 

Gironacci 
MM 

et al (2011 ) [21670420]

613 

Gitter 
BD 

et al (1995 ) [7473161]

614 

Gladue 
RP 

et al (2003 ) [12909630]

615 

Glennon 
RA 
. (2003 ) [12825922]

616 

Glennon 
RA 

et al (2000 ) [10715164]

617 

Gobeil 
F 

et al (1999 ) [10082494]

618 

Gobeil 
F 

et al (1996 ) [8901831]

619 

Goldring 
WP 

et al (2005 ) [15922596]

620 

Goldstein 
A 

et al (1989 ) [2549383]

621 

Gomes 
I 

et al (2013 ) [24043826]

622 

Gong 
J 

et al (1998 ) [9849897]

623 

Gong 
X 

et al (1997 ) [9115216]

624 

González 
N 

et al (2009 ) [19463875]

625 

González 
N 

et al (2015 ) [26066663]

626 

Goold 
CP 

et al (2001 ) [11602681]

627 

Gotter 
AL 

et al (2012 ) [22759794]

628 

Gouardères 
C 

et al (2007 ) [17011599]

629 

Gouardères 
C 

et al (2002 ) [12421602]

630 

Gouardères 
C 

et al (2007 ) [17337079]

631 

Goudet 
C 

et al (2012 ) [22223752]

632 

Gouldson 
P 

et al (2000 ) [10988332]

633 

Gourlet 
P 

et al (1997 ) [9437716]

634 

Gourlet 
P 

et al (1997 ) [9145428]

635 

Govoni 
M 

et al (2003 ) [14667234]

636 

Grailhe 
R 

et al (2001 ) [11343685]

637 

Granas 
C 

et al (1999 ) [10513577]

638 

Grant 
GE 

et al (2009 ) [19450703]

639 

Grant 
MK 

et al (2005 ) [16002459]

640 

Gravel 
S 

et al (2010 ) [20956518]

641 

Greaves 
DR 

et al (1997 ) [9294138]

642 

Gregor 
P 

et al (1996 ) [8641440]

643 

Gregori-Puigjané 
E 

et al (2012 ) [22711801]

644 

Griebel 
G 

et al (2002 ) [11959912]

645 

Grieco 
P 

et al (2000 ) [11150170]

646 

Grieco 
P 

et al (2007 ) [17482720]

647 

Grieco 
P 

et al (2002 ) [12238917]

648 

Griffante 
C 

et al (2005 ) [16158071]

649 

Grisshammer 
R 

et al (1994 ) [7719707]

650 

Gromoll 
J 

et al (1996 ) [8636335]

651 

Gronert 
K 

et al (2001 ) [11141472]

652 

Grosse 
J 

et al (2014 ) [25028498]

653 

Grosse 
R 

et al (2000 ) [10734055]

654 

Groves 
A 

et al (2013 ) [23518370]

655 

Grundt 
P 

et al (2007 ) [17095222]

656 

Grundt 
P 

et al (2007 ) [17672446]

657 

Gründker 
C 

et al (2002 ) [12237622]

658 

Gu 
ZF 

et al (1995 ) [7529309]

659 

Guan 
XM 

et al (2010 ) [20096642]

660 

Guard 
S 

et al (1990 ) [1694464]

661 

Guerrini 
R 

et al (1997 ) [9191955]

662 

Guilford 
WJ 

et al (2004 ) [15056011]

663 

Gully 
D 

et al (2002 ) [11907190]

664 

Gully 
D 

et al (1997 ) [9023294]

665 

Guo 
Y 

et al (2011 ) [21712392]

666 

Haas 
M 

et al (2014 ) [24970757]

667 

Habasque 
C 

et al (2002 ) [11994538]

668 

Haffar 
BM 

et al (1991 ) [1702423]

669 

Hagan 
RM 

et al (1993 ) [8210508]

670 

Hague 
C 

et al (2004 ) [14718583]

671 

Haidar 
M 

et al (2015 ) [26023064]

672 

Halai 
R 

et al (2014 ) [25446428]

673 

Hale 
JJ 

et al (2000 ) [10737756]

674 

Hale 
JJ 

et al (1998 ) [9804700]

675 

Hall 
DA 

et al (1999 ) [10188995]

676 

Hall 
H 

et al (2000 ) [11044889]

677 

Halls 
ML 

et al (2015 ) [25761609]

678 

Halls 
ML 

et al (2005 ) [15649866]

679 

Halls 
ML 

et al (2010 ) [20664520]

680 

Halls 
ML 

et al (2009 ) [19416169]

681 

Halls 
ML 

et al (2007 ) [17293890]

682 

Halls 
ML 

et al (2009 ) [19029286]

683 

Hamann 
J 

et al (2015 ) [25713288]

684 

Hamblin 
MW 

et al (1991 ) [1652050]

685 

Hameg 
A 

et al (2003 ) [12527336]

686 

Han 
G 

et al (1999 ) [10187777]

687 

Han 
S 

et al (2015 ) [26048791]

688 

Hancock 
AA 

et al (2004 ) [15033391]

689 

Hancock 
AA 

et al (1998 ) Drug Development
Research
44 : 140-162
690 

Hancock 
AA 

et al (1994 ) [8206129]

691 

Handa 
BK 

et al (1981 ) [6263640]

692 

Hanessian 
S 

et al (2003 ) [12502358]

693 

Hannan 
S 

et al (2011 ) [21724853]

694 

Hannedouche 
S 

et al (2011 ) [21796212]

695 

Hansen 
C 

et al (2009 ) [19651774]

696 

Hansen 
W 

et al (2010 ) [20200545]

697 

Hanson 
J 

et al (2013 ) [23643932]

698 

Hanson 
MA 

et al (2012 ) [22344443]

699 

Hanus 
L 

et al (1999 ) [10588688]

700 

Harada 
K 

et al (2006 ) [17074317]

701 

Haramura 
M 

et al (2002 ) [11806718]

702 

Harland 
SP 

et al (1995 ) [8587429]

703 

Harmar 
AJ 
. (2001 ) [11790261]

704 

Harmar 
AJ 

et al (1998 ) [9647867]

705 

Harmar 
AJ 

et al (2012 ) [22289055]

706 

Harrison 
GS 

et al (2004 ) [15613448]

707 

Hartig 
PR 

et al (1996 ) [8936345]

708 

Hase 
M 

et al (2008 ) [18347022]

709 

Hasegawa 
Y 

et al (2003 ) [12554733]

710 

Haskell 
CA 

et al (2006 ) [16221874]

711 

Hastrup 
H 

et al (1996 ) [8985159]

712 

Hata 
AN 

et al (2003 ) [12721327]

713 

Hatae 
N 

et al (2007 ) [17312275]

714 

Haugaard-Kedström 
LM 

et al (2011 ) [21384867]

715 

Haugaard-Kedström 
LM 

et al (2015 ) [25792111]

716 

Hauger 
RL 

et al (2003 ) [12615952]

717 

Hawkins 
KN 

et al (1987 ) [3030778]

718 

Hay 
DL 

et al (2005 ) [15692146]

719 

Hay 
DL 

et al (2006 ) [16959943]

720 

Hay 
DL 

et al (2003 ) [12970090]

721 

Hay 
DL 

et al (2008 ) [18552275]

722 

Hay 
DL 

et al (2011 ) [21051558]

723 

Hayallah 
AM 

et al (2002 ) [11906291]

724 

He 
HQ 

et al (2013 ) [23160941]

725 

He 
J 

et al (2010 ) [19696113]

726 

He 
L 

et al (2000 ) [10669572]

727 

He 
S 

et al (2010 ) [20167483]

728 

He 
W 

et al (2004 ) [15141213]

729 

Heasley 
BH 

et al (2004 ) [15125924]

730 

Hegde 
SS 

et al (1997 ) [9113359]

731 

Hegde 
SS 

et al (1996 ) [8903510]

732 

Heier 
RF 

et al (1997 ) [9057850]

733 

Heise 
CE 

et al (2000 ) [10851239]

734 

Heise 
CE 

et al (2005 ) [15761110]

735 

Heise 
CE 

et al (2001 ) [11723223]

736 

Heitman 
LH 

et al (2006 ) [16444290]

737 

Henke 
BR 

et al (1997 ) [9276016]

738 

Henstridge 
CM 

et al (2010 ) [20136841]

739 

Herbert 
JM 

et al (1993 ) [8395255]

740 

Herbert 
JM 

et al (2003 ) [15199474]

741 

Hermans 
E 

et al (1997 ) [9283723]

742 

Hern 
JA 

et al (2010 ) [20133736]

743 

Herrick-Davis 
K 

et al (2000 ) [10991983]

744 

Herron 
DK 

et al (1992 ) [1316967]

745 

Hertzog 
DL 

et al (2006 ) [16870432]

746 

Hesselgesser 
J 

et al (1998 ) [9551924]

747 

Hesselgesser 
J 

et al (1998 ) [9624164]

748 

Heusler 
P 

et al (2010 ) [20799027]

749 

Hidaka 
K 

et al (1995 ) [7777184]

750 

Hieble 
JP 
. (2000 ) [10812954]

751 

Hieble 
JP 

et al (1995 ) [7658428]

752 

Hieble 
JP 

et al (1995 ) [7568329]

753 

Hill 
J 

et al (2001 ) [11274220]

754 

Hill 
SJ 

et al (1997 ) [9311023]

755 

Hillard 
CJ 

et al (1999 ) [10336536]

756 

Hinuma 
S 

et al (2000 ) [11025660]

757 

Hirasawa 
A 

et al (2005 ) [15619630]

758 

Hirata 
T 

et al (2011 ) [21819041]

759 

Hirose 
H 

et al (2001 ) [11303071]

760 

Hirose 
M 

et al (2003 ) [14643355]

761 

Hirst 
RA 

et al (1996 ) [8981483]

762 

Hirst 
WD 

et al (2003 ) [12663046]

763 

Hirst 
WD 

et al (2006 ) [17069795]

764 

Hisatsune 
C 

et al (2007 ) [17925404]

765 

Ho 
C 

et al (1995 ) [7493018]

766 

Hoare 
SR 

et al (2000 ) [10854439]

767 

Hoare 
SR 

et al (2000 ) [10882389]

768 

Hoffmann 
C 

et al (2004 ) [14730417]

769 

Holenz 
J 

et al (2005 ) [15771424]

770 

Hollenberg 
MD 

et al (2002 ) [12037136]

771 

Hollenberg 
MD 

et al (2008 ) [18477767]

772 

Holloway 
S 

et al (1996 ) [9121614]

773 

Holmqvist 
T 

et al (2001 ) [11403934]

774 

Holst 
B 

et al (2003 ) [12907757]

775 

Holst 
B 

et al (2007 ) [16959833]

776 

Holst 
B 

et al (2009 ) [18923064]

777 

Holst 
B 

et al (2004 ) [15383539]

778 

Honczarenko 
M 

et al (2005 ) [15990859]

779 

Hong 
Y 

et al (2011 ) [21658025]

780 

Horie 
K 

et al (1995 ) [8564227]

781 

Horwell 
DC 

et al (1995 ) Bioorg Med Chem Letts
5 : 2501-2506
782 

Hosken 
IT 

et al (2015 ) [25257104]

783 

Hosoda 
H 

et al (2000 ) [10801861]

784 

Hosoi 
T 

et al (2002 ) [12065583]

785 

Hosoya 
M 

et al (2000 ) [10777510]

786 

Hosoya 
M 

et al (2000 ) [10887190]

787 

Hossain 
MA 

et al (2008 ) [18434306]

788 

Hossain 
MA 

et al (2010 ) [20043231]

789 

Hoyer 
D 

et al (1994 ) [7938165]

790 

Hoyer 
D 

et al (2000 ) Somatostatin receptors. In The
IUPHAR Compendium of Receptor Characterization and Classification, 2nd
edn. Edited by Watson SP, Girdlestone D: IUPHAR Media:
354-364
791 

Hoyer 
D 

et al (2002 ) [11888546]

792 

Hoyer 
D 

et al (2004 ) [15135911]

793 

Hoyer 
D 

et al (2004 ) Functional characterization of NVP
ACQ090, a somatostatin sst3 receptor antagonist. Soc Neuroscience
Abs -
794 

Hsu 
SH 

et al (2007 ) [17652154]

795 

Hsu 
SY 

et al (2000 ) [10935549]

796 

Hsu 
SY 

et al (2002 ) [11809971]

797 

Huang 
F 

et al (2001 ) [12049493]

798 

Huang 
SC 

et al (2010 ) [20533894]

799 

Hudson 
BD 

et al (2014 ) [24870406]

800 

Hudson 
BD 

et al (2013 ) [23589301]

801 

Hudson 
BD 

et al (2012 ) [23066016]

802 

Huete-Toral 
F 

et al (2015 ) [25344385]

803 

Huey 
R 

et al (1985 ) [4020139]

804 

Huffman 
JW 

et al (1999 ) [10658595]

805 

Hughes 
J 

et al (1990 ) [1975695]

806 

Humphries 
RG 

et al (1995 ) [7582510]

807 

Humphries 
RG 

et al (1994 ) [7858849]

808 

Hunter 
JC 

et al (1990 ) [2178014]

809 

Hunter 
JC 

et al (1993 ) [8474432]

810 

Hutchinson 
DS 

et al (2002 ) [11959793]

811 

Hwang 
SB 

et al (1988 ) [2841449]

812 

Ichimura 
A 

et al (2012 ) [22343897]

813 

Ignatov 
A 

et al (2004 ) [15111018]

814 

Ignatov 
A 

et al (2003 ) [12574419]

815 

Ignatov 
A 

et al (2003 ) [14592418]

816 

Ignatov 
A 

et al (2006 ) [17001303]

817 

Ihara 
M 

et al (1995 ) [7768260]

818 

Ikeda 
K 

et al (2002 ) [12122494]

819 

Ikubo 
M 

et al (2015 ) [25970039]

820 

Ilien 
B 

et al (2009 ) [19451648]

821 

Im 
DS 

et al (2000 ) [10799507]

822 

Imai 
T 

et al (1998 ) [9430724]

823 

Inbe 
H 

et al (2004 ) [15001573]

824 

Inngjerdingen 
M 

et al (2001 ) [11154210]

825 

Inoue 
A 

et al (2012 ) [22983457]

826 

Iredale 
PA 

et al (1994 ) [8032613]

827 

Irwin 
DM 
. (2001 ) [11179772]

828 

Isberg 
V 

et al (2014 ) [24826842]

829 

Ishibashi 
T 

et al (2010 ) [20404009]

830 

Ishiwata 
K 

et al (2004 ) [15093820]

831 

Isogaya 
M 

et al (1999 ) [10531390]

832 

Ito 
M 

et al (1993 ) [8349705]

833 

Itoh 
Y 

et al (2003 ) [12629551]

834 

Iwamoto 
Y 

et al (1987 ) [2437574]

835 

Jaakola 
VP 

et al (2008 ) [18832607]

836 

Jackson 
RH 

et al (1992 ) [1320692]

837 

Jacobson 
KA 
. (2013 ) [23597047]

838 

Jacobson 
KA 


IJzerman 
AP 

et al (1999 ) Drug Dev Res
45-53
839 

Jacobson 
KA 

et al (2006 ) [16518376]

840 

Jacobson 
KA 

et al (1997 ) [9364471]

841 

Jacobson 
MA 

et al (1995 ) [7558011]

842 

Jacobson 
O 

et al (2011 ) [21421710]

843 

Jacobson 
SG 

et al (2008 ) [18463160]

844 

Jagerschmidt 
A 

et al (1996 ) [8720482]

845 

Jagoda 
EM 

et al (2003 ) [12668051]

846 

Jakubik 
J 

et al (1997 ) [9224827]

847 

Jakubik 
J 

et al (2006 ) [16675658]

848 

Jane 
DE 

et al (1996 ) [9121605]

849 

Jansen 
FP 

et al (1994 ) [7834183]

850 

Janssens 
F 

et al (2005 ) [15771458]

851 

January 
B 

et al (1997 ) [9295336]

852 

Jarvis 
MF 

et al (1989 ) [2600819]

853 

Jasper 
JR 

et al (1995 ) [7475979]

854 

Jasper 
JR 

et al (1998 ) [9605427]

855 

Jenck 
F 

et al (2000 ) [10758169]

856 

Jenh 
CH 

et al (1999 ) [10201891]

857 

Jensen 
RT 

et al (2008 ) [18055507]

858 

Jensen 
RT 

et al (2013 ) Bombesin-Related Peptides. In
Handbook of Biologically Active Peptides Edited by Kastin AJ: Elsevier:
118-96 [ISBN: 9780123850959]
859 

Jensen 
RT 

et al (2013 ) Bombesin Peptides (Cancer). In
Handbook of Biologically Active Peptides Edited by Kastin AJ: Elsevier:
506-11 [ISBN: 9780123850959]
860 

Jensen 
T 

et al (2014 ) [25442311]

861 

Jerning 
E 

et al (1998 ) [9851589]

862 

Ji 
X 

et al (2001 ) [11266650]

863 

Ji 
XD 

et al (1999 ) [10624567]

864 

Jia 
XC 

et al (1991 ) [1922095]

865 

Jiang 
J 

et al (2012 ) [22323596]

866 

Jiang 
JL 

et al (1996 ) [8917655]

867 

Jiang 
Y 

et al (2003 ) [12714592]

868 

Jin 
C 

et al (2014 ) [24793972]

869 

Jin 
C 

et al (2008 ) [18487371]

870 

Jockers 
R 

et al (1994 ) [7798201]

871 

Johansson 
B 

et al (1995 ) [7566470]

872 

Johansson 
L 

et al (1997 ) [9336327]

873 

Johnson 
MP 

et al (2003 ) [12852748]

874 

Johnson 
MP 

et al (2005 ) [15717213]

875 

Jolkkonen 
M 

et al (1994 ) [7925952]

876 

Jones 
C 

et al (1999 ) [10422787]

877 

Jones 
CE 

et al (2003 ) [12606753]

878 

Jones 
CK 

et al (2008 ) [18842902]

879 

Jones 
KA 

et al (1998 ) [9872315]

880 

Jones 
PG 

et al (2007 ) [17363172]

881 

Jones 
RL 

et al (1997 ) [9156364]

882 

Jones 
RM 

et al (2000 ) [10822054]

883 

Jonsson 
KB 

et al (2001 ) [11159842]

884 

Jordan 
BA 

et al (1999 ) [10385123]

885 

Jorgensen 
R 

et al (2005 ) [15528268]

886 

Joseph 
SS 

et al (2004 ) [15060759]

887 

Juarranz 
MG 

et al (1999 ) [10570056]

888 

Jugus 
MJ 

et al (2009 ) [19486006]

889 

Jung 
M 

et al (1997 ) [8978752]

890 

Juteau 
H 

et al (2001 ) [11504634]

891 

Kabarowski 
JH 

et al (2001 ) [11474113]

892 

Kajikawa 
N 

et al (1989 ) [2665758]

893 

Kaku 
K 

et al (2015 ) [25787200]

894 

Kalant 
D 

et al (2003 ) [12540846]

895 

Kalant 
D 

et al (2005 ) [15833747]

896 

Kalipatnapu 
S 

et al (2004 ) [15628665]

897 

Kalk 
P 

et al (2007 ) [17558436]

898 

Kamali 
F 
. (2001 ) [11757797]

899 

Kamohara 
M 

et al (2005 ) [15823563]

900 

Kanaoka 
Y 

et al (2013 ) [23504326]

901 

Kanatani 
A 

et al (2000 ) [10872822]

902 

Kanesaka 
M 

et al (2007 ) [17486669]

903 

Kanke 
T 

et al (2005 ) [15765104]

904 

Kapas 
S 

et al (1995 ) [7592696]

905 

Kapur 
A 

et al (2009 ) [19723626]

906 

Kargl 
J 

et al (2013 ) [23639801]

907 

Katafuchi 
T 

et al (2003 ) [12556539]

908 

Kathmann 
M 

et al (2006 ) [16489449]

909 

Kato 
K 

et al (2005 ) [15695169]

910 

Kattelman 
EJ 

et al (1986 ) [3008368]

911 

Katugampola 
SD 

et al (2001 ) [11250876]

912 

Katugampola 
SD 

et al (2001 ) [11522606]

913 

Kaumann 
AJ 

et al (1996 ) [8864547]

914 

Kaupmann 
K 

et al (1997 ) [9069281]

915 

Kawabata 
A 

et al (1999 ) [9862790]

916 

Kawai 
M 

et al (1992 ) [1732540]

917 

Kawamata 
Y 

et al (2003 ) [12524422]

918 

Kawamata 
Y 

et al (2001 ) [11336787]

919 

Kawamoto 
H 

et al (1999 ) [10602690]

920 

Kay 
LJ 

et al (2013 ) [23786281]

921 

Keene 
JL 

et al (1994 ) Endocrinol J
2 : 175-179
922 

Keir 
MJ 

et al (1999 ) [10521582]

923 

Kelly 
LM 

et al (2011 ) [21844396]

924 

Kemp 
PA 

et al (2004 ) [15231488]

925 

Kennedy 
C 

et al (2000 ) [10779375]

926 

Kennedy 
K 

et al (1995 ) [7654246]

927 

Kennedy 
SP 

et al (1998 ) [9535752]

928 

Kennett 
GA 

et al (1997 ) [9225286]

929 

Kerkhof 
HJ 

et al (2010 ) [20112360]

930 

Kessler 
A 

et al (2004 ) [15149704]

931 

Khanolkar 
AD 

et al (1996 ) [8893848]

932 

Khattar 
SK 

et al (2006 ) [16369696]

933 

Khawaja 
X 

et al (1997 ) [9048968]

934 

Kiesel 
LA 

et al (2002 ) [12072036]

935 

Kiesewetter 
DO 

et al (1997 ) [9313861]

936 

Kihara 
Y 

et al (2014 ) [24602016]

937 

Kikuchi 
A 

et al (2009 ) [19208479]

938 

Kikuchi 
C 

et al (1999 ) [10052959]

939 

Kilander 
MB 

et al (2011 ) [21070854]

940 

Kim 
GH 

et al (2007 ) [17476309]

941 

Kim 
HO 

et al (1994 ) [7932588]

942 

Kim 
HS 

et al (2003 ) [14584948]

943 

Kim 
J 

et al (1995 ) [7775460]

944 

Kim 
SA 

et al (2002 ) [12014951]

945 

Kim 
SV 

et al (2013 ) [23661644]

946 

Kim 
TH 

et al (2013 ) [23721409]

947 

Kim 
Y 

et al (2013 ) [23541835]

948 

Kim 
YC 

et al (2000 ) [10737749]

949 

Kim 
YC 

et al (1996 ) [8863790]

950 

Kim 
YC 

et al (2005 ) [15913566]

951 

Kimura 
I 

et al (2011 ) [21518883]

952 

Kimura 
T 

et al (1994 ) [7921228]

953 

Kimura 
Y 

et al (2004 ) [14709324]

954 

King 
BF 

et al (2000 ) [10869716]

955 

Kingston 
AE 

et al (1998 ) [9680254]

956 

Kinney 
GG 

et al (2005 ) [15608073]

957 

Kinney 
WA 

et al (2002 ) [12203418]

958 

Kirby 
HR 

et al (2010 ) [21079036]

959 

Kiss 
GN 

et al (2012 ) [22968304]

960 

Kitamura 
H 

et al (2012 ) [22343749]

961 

Kitaura 
M 

et al (1999 ) [10488147]

962 

Kitbunnadaj 
R 

et al (2005 ) [15771452]

963 

Kitbunnadaj 
R 

et al (2004 ) [15115383]

964 

Klein 
J 

et al (1997 ) [9175608]

965 

Klein 
KR 

et al (2014 ) [25203207]

966 

Klein 
MT 

et al (2011 ) [21422162]

967 

Klos 
A 

et al (2013 ) [23383423]

968 
Klotz K-N
et al (1998 ) [9459566]

969 

Knepper 
SM 

et al (1995 ) [7616455]

970 

Knight 
AR 

et al (2004 ) [15322733]

971 

Knoflach 
F 

et al (2001 ) [11606768]

972 

Knudsen 
LB 

et al (2000 ) [10794683]

973 

Ko 
H 

et al (2008 ) [18514530]

974 

Ko 
H 

et al (2007 ) [17407275]

975 

Kobilka 
B 
. (2013 ) [23650120]

976 

Koe 
BK 

et al (1992 ) Drug Dev Res
26 : 241-250
977 

Koga 
H 

et al (1994 ) Bioorg Med Chem Letts
4 : 1347-1352
978 

Kogushi 
M 

et al (2011 ) [21300059]

979 

Kohara 
A 

et al (2005 ) [15976016]

980 

Kohno 
M 

et al (2006 ) [16844083]

981 

Koike 
H 

et al (2001 ) [11451212]

982 

Kojima 
D 

et al (2011 ) [22043319]

983 

Kojima 
M 

et al (1999 ) [10604470]

984 

Kolakowski Jr 
LF 
 (1994 ) [8081729]

985 

Kolczewski 
S 

et al (1999 ) [10465539]

986 

Kongsamut 
S 

et al (2002 ) [12176106]

987 

Konkel 
MJ 

et al (2006 ) [16789730]

988 

Konkel 
MJ 

et al (2006 ) [16730981]

989 

Konteatis 
ZD 

et al (1994 ) [7930622]

990 

Koo 
C 

et al (1982 ) [6285921]

991 

Kopanchuk 
S 

et al (2005 ) [15840392]

992 

Kopin 
AS 

et al (1992 ) [1373504]

993 

Kopp 
P 

et al (1995 ) [7800007]

994 

Korstanje 
R 

et al (2008 ) [18796533]

995 

Kortagere 
S 

et al (2004 ) [15448188]

996 

Kotani 
M 

et al (2001 ) [11457843]

997 

Kotani 
M 

et al (1995 ) [7476918]

998 

Kotarsky 
K 

et al (2003 ) [12565875]

999 

Kotarsky 
K 

et al (2003 ) [14675457]

1000 

Kottyan 
LC 

et al (2009 ) [19641187]

1001 

Kovacs 
A 

et al (2003 ) [15107597]

1002 

Kovacs 
I 

et al (1998 ) [9454790]

1003 

Kraus 
A 

et al (2009 ) [19072936]

1004 

Krause 
JE 

et al (1997 ) [8990205]

1005 

Krauss 
AH 

et al (1996 ) [8882612]

1006 

Krishnamoorthy 
S 

et al (2010 ) [20080636]

1007 

Kroeger 
KM 

et al (2001 ) [11278883]

1008 

Kroeze 
WK 

et al (2003 ) [12629531]

1009 

Krsmanovic 
LZ 

et al (2003 ) [12591945]

1010 

Kruse 
AC 

et al (2013 ) [24256733]

1011 

Krushinski Jr 
JH 

et al (2007 ) [17804228]

1012 

Ku 
GM 

et al (2012 ) [22253604]

1013 

Kubo 
Y 

et al (2005 ) [15922585]

1014 

Kubota 
K 

et al (2011 ) [21470866]

1015 

Kuc 
D 

et al (2008 ) [18235993]

1016 

Kuc 
RE 

et al (1995 ) [8587419]

1017 

Kuc 
RE 

et al (2006 ) The novel ligand [125I]-QRFP43 reveals a
remarkably discrete distribution of the orphan receptor GPR103 in human adrenal.
Proceedings of the British Pharmacological Society
4 : abst186
1018 

Kuei 
C 

et al (2007 ) [17606621]

1019 

Kukkonen 
JP 

et al (2005 ) Intracellular Signal Pathways Utilized by
the Hypocretin/Orexin Receptors. In Hypocretins. Integrators of Physiological
Signals Edited by de Lecea L, Sutcliffe JG: Verlag: Springer: 221-231
[ISBN: 9780387254463]
1020 

Kulagowski 
JJ 

et al (1996 ) [8642550]

1021 

Kull 
B 

et al (1999 ) [9920286]

1022 

Kumagai 
J 

et al (2002 ) [12114498]

1023 

Kumar 
S 

et al (2003 ) [12604693]

1024 

Kuphal 
D 

et al (1994 ) [8013367]

1025 

Kursar 
JD 

et al (1994 ) [8078486]

1026 

Kuszak 
AJ 

et al (2009 ) [19542234]

1027 

Kuwasako 
K 

et al (2003 ) [12565884]

1028 

Köhler 
C 

et al (1985 ) [4015674]

1029 

Kühn 
B 

et al (1996 ) [8961278]

1030 

Labbé-Jullié 
C 

et al (1995 ) [7746272]

1031 

Laeremans 
H 

et al (2011 ) [21931076]

1032 

Lagerström 
MC 

et al (2005 ) [15885496]

1033 

Lahti 
RA 

et al (1993 ) [8102973]

1034 

Lahti 
RA 

et al (1985 ) [2986999]

1035 

Lainé 
DI 

et al (2009 ) [19317446]

1036 

Lameh 
J 

et al (2010 ) [20354177]

1037 

Lan 
R 

et al (1999 ) [11741201]

1038 

Lan 
R 

et al (1999 ) [10052983]

1039 

Lang 
R 

et al (2005 ) [15944009]

1040 

Langmead 
CJ 

et al (2008 ) [18454168]

1041 

Langmead 
CJ 

et al (2006 ) [16207821]

1042 

Langmead 
CJ 

et al (2004 ) [14691055]

1043 

Langmead 
CJ 

et al (2000 ) [11030716]

1044 

Latronico 
AC 

et al (1999 ) [10486313]

1045 

Lautner 
RQ 

et al (2013 ) [23446738]

1046 

Lavreysen 
H 

et al (2003 ) [12695537]

1047 

Lavreysen 
H 

et al (2004 ) [15555631]

1048 

Lawrence 
AJ 

et al (2002 ) [12110614]

1049 

Lazareno 
S 

et al (1995 ) [7651370]

1050 

Lazareno 
S 

et al (2004 ) [14722259]

1051 

Lazareno 
S 

et al (1998 ) [9495826]

1052 

Lazareno 
S 

et al (2000 ) [10860942]

1053 

Lazareno 
S 

et al (2002 ) [12435818]

1054 

Lazarowski 
ER 

et al (1995 ) [8564228]

1055 

Lazarowski 
ER 

et al (1996 ) [8825364]

1056 

Le Bourdonnec 
B 

et al (2008 ) [18313920]

1057 

Le Poul 
E 

et al (2003 ) [12711604]

1058 

Le 
Y 

et al (2002 ) [12401407]

1059 

Leach 
K 

et al (2011 ) [21300722]

1060 

Leach 
K 

et al (2010 ) [19940843]

1061 

Leaños-Miranda 
A 

et al (2003 ) [12843188]

1062 

Leban 
JJ 

et al (1993 ) [8446610]

1063 

Ledent 
C 

et al (2005 ) [15956199]

1064 

Leduc 
M 

et al (2009 ) [19584306]

1065 

Lee 
C 

et al (2010 ) [21124972]

1066 

Lee 
DK 

et al (2001 ) [11574155]

1067 

Lee 
DK 

et al (2005 ) [15486224]

1068 

Lee 
J 

et al (1992 ) [1379593]

1069 

Lee 
MC 

et al (2008 ) [18179608]

1070 

Lee 
T 

et al (2008 ) [18818303]

1071 

Lee 
YM 

et al (1993 ) [7681836]

1072 

Leeb-Lundberg 
LM 

et al (2005 ) [15734727]

1073 

Lefkowitz 
RJ 
. (2013 ) [23650015]

1074 

Legros 
C 

et al (2013 ) [23698757]

1075 

Lehmann 
F 

et al (2009 ) [19481466]

1076 

Lehmann 
F 

et al (2005 ) [15781415]

1077 

Lehmann 
F 

et al (2007 ) [17112638]

1078 

Leibowitz 
SF 

et al (1992 ) [1283559]

1079 

Lejeune 
F 

et al (1997 ) [9067310]

1080 

Lembo 
PM 

et al (2002 ) [11850634]

1081 

Leonardi 
A 

et al (1997 ) [9190863]

1082 

Leopoldo 
M 

et al (2007 ) [17649988]

1083 

Leopoldo 
M 

et al (2008 ) [18800769]

1084 

Lesage 
AS 

et al (1998 ) [9605573]

1085 

Leung 
T 

et al (2008 ) [18755178]

1086 

Leurs 
R 

et al (1994 ) [7921611]

1087 

Leuthauser 
K 

et al (2000 ) [11023820]

1088 

Lever 
JR 

et al (1998 ) [9696425]

1089 

Levoye 
A 

et al (2006 ) [16778767]

1090 

Lewis 
TA 

et al (2004 ) [15482930]

1091 

Leysen 
JE 

et al (1996 ) [8967979]

1092 

Li 
AH 

et al (1998 ) [9703464]

1093 

Li 
JJ 

et al (2004 ) [15027861]

1094 

Li 
L 

et al (2002 ) Neuropharmacology
43 : 295
1095 

Li 
R 

et al (2013 ) [23239822]

1096 

Li 
X 

et al (2002 ) [12013525]

1097 

Liang BT Urso R Sambraski 
E 

et al (2010 ) Adenosine A3 receptors in
muscle protection. In Adenosine Receptors from Cell Biology to
Pharmacology Edited by Borea P: Springer: 257-280 [ISBN:
9789048131440]
1098 

Liang 
M 

et al (2000 ) [10748002]

1099 

Liang 
TS 

et al (2001 ) [11714831]

1100 

Liapakis 
G 

et al (2004 ) [15102946]

1101 

Liaw 
CW 

et al (2009 ) [19630535]

1102 

Liebscher 
I 

et al (2011 ) [21097509]

1103 

Liggett 
SB 
. (2003 ) [15090197]

1104 

Ligneau 
X 

et al (2000 ) [11090094]

1105 

Liljebris 
C 

et al (1995 ) [7830272]

1106 

Lim 
HD 

et al (2006 ) [17154494]

1107 

Lim 
HD 

et al (2005 ) [15947036]

1108 

Limonta 
P 

et al (2003 ) [14726258]

1109 

Lin 
DC 

et al (2002 ) [11886876]

1110 

Lin 
DC 

et al (2012 ) [22859723]

1111 

Lin 
L 

et al (1999 ) [10458611]

1112 

Lin 
Q 

et al (1999 ) [9890897]

1113 

Linden 
J 

et al (1999 ) [10496952]

1114 

Lindsley 
CW 

et al (2004 ) [15537338]

1115 

Lindström 
E 

et al (1999 ) [10385255]

1116 

Litschig 
S 

et al (1999 ) [10051528]

1117 

Liu 
C 

et al (2005 ) [15465925]

1118 

Liu 
C 

et al (2003 ) [14522967]

1119 

Liu 
C 

et al (2003 ) [14522968]

1120 

Liu 
C 

et al (2005 ) [15525639]

1121 

Liu 
C 

et al (2012 ) [22434674]

1122 

Liu 
C 

et al (2001 ) [11179434]

1123 

Liu 
C 

et al (2001 ) [11561071]

1124 

Liu 
C 

et al (2009 ) [19047060]

1125 

Liu 
C 

et al (2011 ) [21796211]

1126 

Liu 
G 

et al (1999 ) [10580072]

1127 

Liu 
JJ 

et al (2012 ) [22267580]

1128 

Liu 
JJ 

et al (2009 ) [19369576]

1129 

Liu 
P 

et al (2011 ) [24900283]

1130 

Liu 
Q 

et al (1999 ) [10581185]

1131 

Liu 
Q 

et al (2009 ) [20004959]

1132 

Liu 
S 

et al (1998 ) [9822540]

1133 

Llinares 
M 

et al (1999 ) [10231715]

1134 

Lobo 
MK 

et al (2007 ) [17934457]

1135 

Loetscher 
M 

et al (1994 ) [8276799]

1136 

Loetscher 
P 

et al (1998 ) [9712844]

1137 

Logue 
SF 

et al (2009 ) [19796684]

1138 

Londregan 
AT 

et al (2013 ) [23337601]

1139 

Long 
DD 

et al (2012 ) [22959244]

1140 

Longrois 
D 

et al (2012 ) [22342278]

1141 

Lopez 
VM 

et al (2008 ) [18828673]

1142 

Lopez-Gimenez 
JF 

et al (2001 ) [11562430]

1143 

Lorenzen 
A 

et al (1996 ) [8937447]

1144 

Louis 
SN 

et al (1999 ) [10079020]

1145 

Lovenberg 
TW 

et al (2000 ) [10869375]

1146 

Lu 
X 

et al (2005 ) [15944007]

1147 

Lu 
X 

et al (2010 ) [20660766]

1148 

Luangsay 
S 

et al (2009 ) [19841182]

1149 

Lucchelli 
A 

et al (1997 ) [9283717]

1150 

Luker 
T 

et al (2011 ) [21944852]

1151 

Lumley 
P 

et al (1989 ) [2527074]

1152 

Lundell 
I 

et al (1995 ) [7493937]

1153 

Lundkvist 
J 

et al (1996 ) [8874139]

1154 

Luo 
J 

et al (2009 ) [19605502]

1155 

Luo 
R 

et al (2011 ) [21768377]

1156 

Luttrell 
LM 

et al (2010 ) [20427692]

1157 

Lynch 
KR 

et al (1999 ) [10391245]

1158 

Lüttichau 
HR 
. (2010 ) [20044480]

1159 

Lüttichau 
HR 

et al (2003 ) [12554737]

1160 

Ma 
JN 

et al (2011 ) [21239511]

1161 

Ma 
L 

et al (2009 ) [19717450]

1162 

Ma 
S 

et al (2013 ) [23671163]

1163 

MacDonald 
E 

et al (1997 ) [9227000]

1164 

MacKenzie 
RG 

et al (1994 ) [7907989]

1165 

MacLennan 
SJ 

et al (1997 ) [9283709]

1166 

Macaluso 
NJ 

et al (2011 ) [21560248]

1167 

Machwate 
M 

et al (2001 ) [11408598]

1168 

Maddox 
JF 

et al (1996 ) [8551217]

1169 

Madsen 
K 

et al (2011 ) [21831646]

1170 

Madsen 
P 

et al (1998 ) [9857085]

1171 

Madsen 
U 

et al (2005 ) [15996690]

1172 

Maeda 
DY 

et al (2014 ) [25254640]

1173 

Maeda 
K 

et al (2006 ) [16476734]

1174 

Maeda 
K 

et al (2001 ) [11454872]

1175 

Maekawa 
A 

et al (2009 ) [19561298]

1176 

Maggio 
R 

et al (1994 ) [7805774]

1177 

Maggiolini 
M 

et al (2004 ) [15090535]

1178 

Maguire 
JJ 

et al (1995 ) [7647976]

1179 

Maguire 
JJ 

et al (2000 ) [11015293]

1180 

Maguire 
JJ 

et al (1997 ) [9023329]

1181 

Maguire 
JJ 

et al (2009 ) [19325074]

1182 

Maier 
DL 

et al (2009 ) [19401496]

1183 

Maiti 
K 

et al (2003 ) [14651258]

1184 

Maj 
M 

et al (2003 ) [14573382]

1185 

Majumdar 
ID 

et al (2011 ) [21042212]

1186 

Majumdar 
ID 

et al (2012 ) [22157398]

1187 

Majumdar 
S 

et al (2011 ) [21621410]

1188 

Malgouris 
C 

et al (1993 ) [8472747]

1189 

Malherbe 
P 

et al (2009 ) [19751316]

1190 

Malherbe 
P 

et al (2009 ) [19542319]

1191 

Malherbe 
P 

et al (2003 ) [12509432]

1192 

Malherbe 
P 

et al (1999 ) [10216218]

1193 

Malherbe 
P 

et al (2010 ) [20404073]

1194 

Mallee 
JJ 

et al (2002 ) [11847213]

1195 

Malmberg 
A 

et al (1993 ) [8099194]

1196 

Mamedova 
LK 

et al (2004 ) [15081875]

1197 

Manara 
L 

et al (1996 ) [8821531]

1198 

Mandala 
S 

et al (2002 ) [11923495]

1199 

Manglik 
A 

et al (2015 ) [25981665]

1200 

Mannaioni 
G 

et al (1999 ) [10428410]

1201 

Mantey 
S 

et al (1993 ) [7684815]

1202 

Mantey 
SA 

et al (2004 ) [15102928]

1203 

Mantey 
SA 

et al (1997 ) [9325344]

1204 

Marathe 
GK 

et al (1999 ) [10497200]

1205 

Marazziti 
D 

et al (2009 ) [19398891]

1206 

Marazziti 
D 

et al (2011 ) [21372109]

1207 

Marazziti 
D 

et al (2007 ) [17519329]

1208 

Marlo 
JE 

et al (2009 ) [19047481]

1209 

Marteau 
F 

et al (2003 ) [12815166]

1210 

Martin 
PL 

et al (1996 ) [8632314]

1211 

Martin 
S 

et al (2002 ) [12360476]

1212 

Maruoka 
H 

et al (2010 ) [20446735]

1213 

Maruoka 
H 

et al (2011 ) [21528910]

1214 

Maruyama 
T 

et al (2002 ) [12419312]

1215 

Masuda 
Y 

et al (2002 ) [12054613]

1216 

Mathiesen 
JM 

et al (2006 ) [16418339]

1217 

Mathiesen 
JM 

et al (2003 ) [12684257]

1218 

Mathieu 
MC 

et al (2005 ) [16154494]

1219 

Matsufuji 
T 

et al (2015 ) [25497965]

1220 

Matsufuji 
T 

et al (2014 ) [24412111]

1221 

Matsui 
A 

et al (1998 ) [9808703]

1222 

Matsumoto 
M 

et al (2001 ) [11549267]

1223 

Matsuura 
B 

et al (2005 ) [15677347]

1224 

Matsuura 
B 

et al (2002 ) [11781320]

1225 

Matsuura 
B 

et al (2006 ) [16531413]

1226 

Matteson 
PG 

et al (2008 ) [18250320]

1227 

Matthes 
H 

et al (1993 ) [8450829]

1228 

Mattsson 
C 

et al (2005 ) [16055331]

1229 

Matuszek 
MA 

et al (1998 ) [9718274]

1230 

Maubach 
KA 

et al (2009 ) [19154437]

1231 

Maudsley 
S 

et al (2004 ) [15492280]

1232 

May 
LT 

et al (2007 ) [17525129]

1233 

Mayeux 
PR 

et al (1991 ) [1830308]

1234 

Mayo 
KE 

et al (2003 ) [12615957]

1235 

Mazella 
J 

et al (1996 ) [8795617]

1236 

Maëga 
A 

et al (2013 ) [23935897]

1237 

McAllister 
G 

et al (1992 ) [1608964]

1238 

McAtee 
LC 

et al (2004 ) [15261275]

1239 

McCall 
RB 

et al (2005 ) [15980060]

1240 

McCall 
RB 

et al (1994 ) [7965808]

1241 

McClellan 
KJ 

et al (1998 ) [9878991]

1242 

McDonald 
J 

et al (2003 ) [12967935]

1243 

McGuire 
JJ 

et al (2004 ) [14976230]

1244 

McHugh 
D 

et al (2010 ) [20346144]

1245 

McHugh 
D 

et al (2006 ) [16207832]

1246 

McHugh 
D 

et al (2012 ) [21595653]

1247 

McIntyre 
TM 

et al (2003 ) [12502787]

1248 

McKeage 
K 
. (2015 ) [25859983]

1249 

McKee 
KK 

et al (1997 ) [9441746]

1250 

McKinnell 
RM 

et al (2013 ) [23756062]

1251 

McLatchie 
LM 

et al (1998 ) [9620797]

1252 

Mead 
EJ 

et al (2007 ) [17023533]

1253 

Meder 
W 

et al (2003 ) [14675762]

1254 

Medhurst 
AD 

et al (2003 ) [12603839]

1255 

Meis 
S 

et al (2010 ) [19815812]

1256 

Mejean 
A 

et al (1995 ) [8719421]

1257 

Mellor 
EA 

et al (2003 ) [13679572]

1258 

Mellor 
EA 

et al (2001 ) [11438743]

1259 

Meng 
T 

et al (2008 ) [18358099]

1260 

Methven 
L 

et al (2009 ) [19572943]

1261 

Methven 
L 

et al (2009 ) [19888965]

1262 

Metra 
M 

et al (2013 ) [23273292]

1263 

Meyer 
MD 

et al (1997 ) [9379432]

1264 

Meyer 
RC 

et al (2013 ) [23690594]

1265 

Meyerhof 
W 
. (1998 ) [9600011]

1266 

Mialet 
J 

et al (2000 ) [10683202]

1267 

Mialet 
J 

et al (2000 ) [11030734]

1268 

Mialet 
J 

et al (2000 ) [10821780]

1269 

Michel 
AD 

et al (1990 ) [1970500]

1270 

Michel 
MC 

et al (1998 ) [9549761]

1271 

Micheli 
F 

et al (2003 ) [12470711]

1272 

Middlemiss 
DN 

et al (1999 ) [10443589]

1273 

Mierau 
J 

et al (1995 ) [7664822]

1274 

Migeotte 
I 

et al (2005 ) [15623572]

1275 

Millan 
MJ 

et al (1994 ) [7988633]

1276 

Millan 
MJ 

et al (2003 ) [12750432]

1277 

Millan 
MJ 

et al (1998 ) [9732398]

1278 

Millan 
MJ 

et al (2000 ) [10869410]

1279 

Millan 
MJ 

et al (2002 ) [12388666]

1280 

Millan 
MJ 

et al (2000 ) [10611634]

1281 

Millan 
MJ 

et al (1995 ) [7473180]

1282 

Millar 
R 

et al (2001 ) [11493674]

1283 

Millar 
RP 
. (2005 ) [16140177]

1284 

Millar 
RP 

et al (2004 ) [15082521]

1285 

Miller 
BE 

et al (2015 ) [26092545]

1286 

Miller 
JH 

et al (1992 ) [1331410]

1287 

Minamino 
N 

et al (1985 ) [3839674]

1288 

Minarini 
A 

et al (2008 ) [18595721]

1289 

Minneman 
KP 

et al (1994 ) [7969082]

1290 

Miranda 
LP 

et al (2008 ) [18412318]

1291 

Mirzadegan 
T 

et al (2000 ) [10770925]

1292 

Mitselos 
A 

et al (2007 ) [17074305]

1293 

Mitsukawa 
K 

et al (2005 ) [16339898]

1294 

Miyamoto 
M 

et al (2003 ) [12954235]

1295 

Mizuguchi 
T 

et al (1997 ) [9113361]

1296 

Moeller 
I 

et al (1997 ) [9166749]

1297 

Moepps 
B 

et al (2006 ) [16084593]

1298 

Moguilevsky 
N 

et al (1994 ) [7925364]

1299 

Mohr 
M 

et al (2004 ) [15163212]

1300 

Molenaar 
P 

et al (1992 ) [1472961]

1301 

Molenaar 
P 

et al (1997 ) [9117106]

1302 

Molinari 
EJ 

et al (1996 ) [8773460]

1303 

Molinari 
S 

et al (2013 ) [22827708]

1304 

Mollay 
C 

et al (1999 ) [10422759]

1305 

Mollereau 
C 

et al (2001 ) [11325787]

1306 

Mollereau 
C 

et al (2002 ) [12242085]

1307 

Mollereau 
C 

et al (1996 ) [8849681]

1308 

Mollereau 
C 

et al (1994 ) [8137918]

1309 

Mombaerts 
P 
. (2004 ) [15034552]

1310 

Monczor 
F 

et al (2003 ) [12869657]

1311 

Monn 
JA 

et al (1999 ) [10090786]

1312 

Monneret 
G 

et al (2003 ) [12490611]

1313 

Monnier 
C 

et al (2011 ) [21063387]

1314 

Montrose-Rafizadeh 
C 

et al (1997 ) [9261127]

1315 

Moody 
TW 

et al (2002 ) [11931347]

1316 

Moody 
TW 

et al (2015 ) [25554218]

1317 

Moody 
TW 

et al (2004 ) [15134870]

1318 

Moore 
K 

et al (2009 ) [19723586]

1319 

Moreland 
RB 

et al (2005 ) [16153699]

1320 

Moreno 
D 

et al (2000 ) [11068102]

1321 

Moreno 
P 

et al (2013 ) [23892571]

1322 

Moreschi 
I 

et al (2008 ) [17707504]

1323 

Moreschi 
I 

et al (2006 ) [16926152]

1324 

Morfis 
M 

et al (2008 ) [18599553]

1325 

Morgan 
K 

et al (2003 ) [12538601]

1326 

Mori 
K 

et al (2005 ) [15635449]

1327 

Mori 
M 

et al (1999 ) [10548501]

1328 

Morinelli 
TA 

et al (1989 ) [2530338]

1329 

Morishima 
S 

et al (2007 ) [17162094]

1330 

Moro 
O 

et al (1997 ) [8995389]

1331 

Moro 
O 

et al (1999 ) [10438479]

1332 

Morokata 
T 

et al (2005 ) [16339911]

1333 

Moroni 
F 

et al (2002 ) [12015200]

1334 

Moroni 
F 

et al (1997 ) [9152378]

1335 

Morse 
KL 

et al (2001 ) [11181941]

1336 

Morton 
MF 

et al (2011 ) [21493750]

1337 

Mosberg 
HI 

et al (1983 ) [6310598]

1338 

Moulin 
A 

et al (2013 ) [22798076]

1339 

Muccioli 
G 

et al (2001 ) [11314756]

1340 

Muda 
M 

et al (2005 ) [16051677]

1341 

Muff 
R 

et al (1999 ) [10342886]

1342 

Munchhof 
MJ 

et al (2012 ) [24900436]

1343 

Munk 
SA 

et al (1996 ) [8784451]

1344 

Murakami 
M 

et al (2008 ) [18466763]

1345 

Murase 
A 

et al (2008 ) [18155068]

1346 

Murphy 
PM 
. (2002 ) [12037138]

1347 

Murphy 
PM 

et al (2000 ) [10699158]

1348 

Murphy 
PM 

et al (1992 ) [1373134]

1349 

Murugesan 
N 

et al (2003 ) [12502366]

1350 

Mutel 
V 

et al (2000 ) [11080213]

1351 

Müller 
A 

et al (2013 ) [23335960]

1352 

Müller 
A 

et al (2014 ) [25516095]

1353 

Müller 
T 

et al (2003 ) [12727981]

1354 

Nagase 
T 

et al (2008 ) [18598020]

1355 

Nagata-Kuroiwa 
R 

et al (2011 ) [21390312]

1356 

Naka 
M 

et al (1992 ) [1386885]

1357 

Nakamura 
M 

et al (1991 ) [1657923]

1358 

Nakamura 
M 

et al (1992 ) [1333988]

1359 

Nakamura 
S 

et al (2000 ) [10780976]

1360 

Nakamura 
T 

et al (2000 ) [11118334]

1361 

Nakane 
M 

et al (2005 ) [15992586]

1362 

Nambi 
P 

et al (1994 ) [8301559]

1363 

Nambu 
H 

et al (2011 ) [21971119]

1364 

Napier 
C 

et al (2005 ) [16298345]

1365 

Napier 
C 

et al (1999 ) [10193663]

1366 

Nawaratne 
V 

et al (2010 ) [20406819]

1367 

Nawaratne 
V 

et al (2008 ) [18628403]

1368 

Naya 
A 

et al (2003 ) [12614873]

1369 

Neale 
JH 
. (2011 ) [21740441]

1370 

Negishi 
M 

et al (1995 ) [7608175]

1371 

Negri 
L 

et al (2005 ) [16113687]

1372 

Neill 
JD 
. (2002 ) [11861490]

1373 

Nelson 
CP 

et al (2006 ) [16188951]

1374 

Nelson 
DL 

et al (1999 ) [9933142]

1375 

Nelson 
DL 

et al (2010 ) [20855361]

1376 

Nelson 
G 

et al (2001 ) [11509186]

1377 

Nemeth 
EF 

et al (2001 ) [11561095]

1378 

Nemeth 
EF 

et al (2004 ) [14593085]

1379 

Nemeth 
EF 

et al (1998 ) [9520489]

1380 

Nenasheva 
TA 

et al (2013 ) [23357106]

1381 

Nergårdh 
R 

et al (2005 ) [16318870]

1382 

Neschadim 
A 

et al (2014 ) [24812057]

1383 

Neumeyer 
JL 

et al (2003 ) [14613319]

1384 

Newman-Tancredi 
A 

et al (2000 ) [11040052]

1385 

Newman-Tancredi 
A 

et al (1999 ) [10431754]

1386 

Newman-Tancredi 
A 

et al (1998 ) [9760039]

1387 

Newman-Tancredi 
A 

et al (2009 ) [19154445]

1388 

Newman-Tancredi 
A 

et al (1998 ) [9550290]

1389 

Newman-Tancredi 
A 

et al (1992 ) [1386736]

1390 

Nguyen 
T 

et al (2001 ) [11179435]

1391 

Ni 
NC 

et al (2011 ) [21903747]

1392 

Nickolls 
SA 

et al (2003 ) [12604699]

1393 

Nicole 
P 

et al (2000 ) [10801840]

1394 

Niedernberg 
A 

et al (2003 ) [12618218]

1395 

Nielsen 
MS 

et al (1999 ) [10085125]

1396 

Nieuwenhuijs 
VB 

et al (1999 ) [10092986]

1397 

Nikaido 
Y 

et al (2015 ) [25425658]

1398 

Nilsson 
I 

et al (2002 ) [11738246]

1399 

Nilsson 
NE 

et al (2003 ) [12684041]

1400 

Ning 
Y 

et al (2008 ) [18724386]

1401 

Niswender 
CM 

et al (2010 ) [20026717]

1402 

Niswender 
CM 

et al (2008 ) [18664603]

1403 

Noble 
F 

et al (1999 ) [10581329]

1404 

Noda 
M 

et al (2003 ) [12558985]

1405 

Noguchi 
K 

et al (2011 ) [20979571]

1406 

Noguchi 
K 

et al (2003 ) [12724320]

1407 

Nonaka 
Y 

et al (2005 ) [16185654]

1408 

Nosjean 
O 

et al (2000 ) [10913150]

1409 

Nosjean 
O 

et al (2001 ) [11331072]

1410 
Nothacker H-P
et al (1999 ) [10559967]

1411 

Nothacker 
HP 

et al (2000 ) [11093801]

1412 

Nunn 
C 

et al (2003 ) [12616335]

1413 

Nygaard 
R 

et al (2013 ) [23374348]

1414 

Näsman 
J 

et al (2000 ) [10799315]

1415 

O'Brien 
JA 

et al (2003 ) [12920211]

1416 

O'Brien 
JA 

et al (2004 ) [14747613]

1417 

O'Flaherty 
JT 

et al (1998 ) [9829988]

1418 

O'Sullivan 
SE 
. (2007 ) [17704824]

1419 

Obiefuna 
PC 

et al (2005 ) [16020631]

1420 

Obika 
K 

et al (1995 ) [8719417]

1421 

Ochi 
T 

et al (2005 ) [15686911]

1422 

Oda 
T 

et al (2000 ) [10973974]

1423 

Oertel 
BG 

et al (2009 ) [19116204]

1424 

Offermanns 
S 

et al (2011 ) [21454438]

1425 

Ogita 
T 

et al (1997 ) [9038918]

1426 

Ogletree 
ML 

et al (1993 ) [8437108]

1427 

Oh 
DY 

et al (2010 ) [20813258]

1428 

Oh da 
Y 

et al (2014 ) [24997608]

1429 

Ohashi 
T 

et al (2015 ) [25959255]

1430 

Ohki-Hamazaki 
H 

et al (1997 ) [9367152]

1431 

Ohlmann 
P 

et al (2013 ) [22892887]

1432 

Ohta 
H 

et al (2003 ) [14500756]

1433 

Ohtaki 
T 

et al (1999 ) [10601261]

1434 

Ohtaki 
T 

et al (2001 ) [11385580]

1435 

Oka 
S 

et al (2007 ) [17765871]

1436 

Oka 
S 

et al (2010 ) [20361937]

1437 

Oka 
S 

et al (2009 ) [18845565]

1438 

Okamoto 
H 

et al (1998 ) [9765227]

1439 

Okawa 
H 

et al (1999 ) [10369464]

1440 

Okinaga 
S 

et al (2003 ) [12899627]

1441 

Okuda-Ashitaka 
E 

et al (1996 ) [8940129]

1442 

Okuno 
T 

et al (2008 ) [18378794]

1443 

Olender 
T 

et al (2008 ) [19129093]

1444 

Olianas 
MC 

et al (1999 ) [9862767]

1445 

Ongini 
E 

et al (1999 ) [9933143]

1446 

Opgenorth 
TJ 

et al (1996 ) [8632312]

1447 

Osada 
M 

et al (2002 ) [12445827]

1448 

Osborn 
O 

et al (2012 ) [22653059]

1449 

Ott 
TR 

et al (2006 ) [16904643]

1450 

Oury-Donat 
F 

et al (1995 ) [7616392]

1451 

Overington 
JP 

et al (2006 ) [17139284]

1452 

Overton 
HA 

et al (2006 ) [16517404]

1453 

Padmanabhan 
S 

et al (2009 ) [19059244]

1454 

Palani 
A 

et al (2012 ) [24900372]

1455 

Palani 
A 

et al (2001 ) [11585437]

1456 

Pan 
S 

et al (2006 ) [17114004]

1457 

Pang 
L 

et al (1998 ) [9832122]

1458 

Pantel 
J 

et al (2006 ) [16511605]

1459 

Panula 
P 

et al (2015 ) [26084539]

1460 

Parent 
JL 

et al (1996 ) [8798529]

1461 

Park 
D 

et al (2007 ) [17960134]

1462 

Parker 
CA 

et al (2012 ) [22223878]

1463 

Parker 
EM 

et al (1996 ) [8863519]

1464 

Parma 
J 

et al (1993 ) [8413627]

1465 

Parody 
TR 

et al (2004 ) [15207250]

1466 

Paruchuri 
S 

et al (2009 ) [19822647]

1467 

Pasternack 
SM 

et al (2008 ) [18297070]

1468 

Pasternak 
GW 

et al (2013 ) [24076545]

1469 

Patacchini 
R 

et al (2003 ) [14645137]

1470 

Patane 
MA 

et al (1998 ) [9548811]

1471 

Patel 
K 

et al (2001 ) [11711032]

1472 

Patel 
P 

et al (2008 ) [18292294]

1473 

Patel 
S 

et al (1996 ) [8967990]

1474 

Patel 
YC 

et al (1994 ) [7988476]

1475 

Pauli 
A 

et al (2014 ) [24407481]

1476 

Pauwels 
PJ 

et al (1988 ) [2462161]

1477 

Pauwels 
PJ 

et al (2003 ) [12649300]

1478 

Payza 
K 
. (2003 ) Binding and activity of opioid ligands at the
cloned human delta, mu and kappa receptors. In The Delta Receptor
Edited by Chang KJ: CRC Press: 261-275 [ISBN: 0824740319]
1479 

Pazos 
A 

et al (1984 ) [6519175]

1480 

Pearlstein 
R 

et al (2003 ) [12747773]

1481 

Peirce 
SM 

et al (2001 ) [11406470]

1482 

Pellegrini-Giampietro 
DE 

et al (1996 ) [8799579]

1483 

Pellicciari 
R 

et al (1996 ) [8667369]

1484 

Peltonen 
JM 

et al (1998 ) [9760042]

1485 

Pena 
A 

et al (2007 ) [17300166]

1486 

Peralta 
EG 

et al (1987 ) [3443095]

1487 

Perdonà 
E 

et al (2011 ) [21034740]

1488 

Pereira 
JP 

et al (2009 ) [19597478]

1489 

Perkins 
AV 

et al (1995 ) [7595134]

1490 

Perlman 
S 

et al (1995 ) [7829475]

1491 

Perretti 
M 

et al (2002 ) [12368905]

1492 

Perron 
A 

et al (2005 ) [15637074]

1493 

Pertwee 
RG 
. (2000 ) [11060760]

1494 

Pertwee 
RG 

et al (2010 ) [21079038]

1495 

Peter 
MG 

et al (1996 ) [7881728]

1496 

Petersen 
KF 

et al (2001 ) [11719833]

1497 

Petersen 
PS 

et al (2011 ) [21784784]

1498 

Petitet 
F 

et al (1996 ) [8733746]

1499 

Petrel 
C 

et al (2004 ) [14976203]

1500 

Petrel 
C 

et al (2003 ) [14506236]

1501 

Phalipou 
S 

et al (1997 ) [9334232]

1502 

Phebus 
LA 

et al (1997 ) [9395253]

1503 

Pihlavisto 
M 

et al (1998 ) [9824686]

1504 

Pin 
JP 

et al (2002 ) [12769621]

1505 

Pin 
JP 

et al (2009 ) [19723778]

1506 

Pin 
JP 

et al (2004 ) [15451400]

1507 

Pin 
JP 

et al (2007 ) [17329545]

1508 

Pinard 
A 

et al (2010 ) [20655485]

1509 

Pisegna 
JR 

et al (2000 ) [11193823]

1510 

Pitkin 
SL 

et al (2010 ) [20605969]

1511 

Pittolo 
S 

et al (2014 ) [25173999]

1512 

Pizzonero 
M 

et al (2014 ) [25380412]

1513 

Planagumà 
A 

et al (2013 ) [23607720]

1514 

Plöckinger 
U 

et al (2012 ) [22065857]

1515 

Pohl 
SL 

et al (1969 ) [4305077]

1516 

Popova 
JS 

et al (1995 ) [7798906]

1517 

Popp 
BD 

et al (2004 ) [14744619]

1518 

Porter 
RA 

et al (2001 ) [11459658]

1519 

Porter 
RH 

et al (2005 ) [16040814]

1520 

Portoghese 
PS 

et al (1987 ) [2444704]

1521 

Portoghese 
PS 

et al (1988 ) [2832195]

1522 

Postma 
B 

et al (2004 ) [15153520]

1523 

Poulain 
R 

et al (2001 ) [11585443]

1524 

Powell 
WS 

et al (1999 ) [9920859]

1525 

Powell 
WS 

et al (1992 ) [1326548]

1526 

Power 
CA 

et al (1997 ) [9294137]

1527 

Powers 
SP 

et al (1988 ) [3410633]

1528 

Poyner 
DR 

et al (2002 ) [12037140]

1529 

Prasanna 
G 

et al (2009 ) [19445930]

1530 

Prat 
M 

et al (2009 ) [19653626]

1531 

Pratico 
D 

et al (1996 ) [8663015]

1532 

Price 
MR 

et al (2005 ) [16113085]

1533 

Primus 
RJ 

et al (1997 ) [9262371]

1534 

Procopiou 
PA 

et al (2010 ) [20462258]

1535 

Procopiou 
PA 

et al (2011 ) [21381763]

1536 

Prossnitz 
ER 

et al (2015 ) [26023144]

1537 

Pruneau 
D 

et al (1999 ) [10596852]

1538 

Prömel 
S 

et al (2013 ) [23850273]

1539 

Pugsley 
TA 

et al (1995 ) [8531103]

1540 

Putula 
J 

et al (2011 ) [21362456]

1541 

Pérez-Garci 
E 

et al (2006 ) [16701210]

1542 

Qi 
AD 

et al (2013 ) [23908386]

1543 

Qi 
T 

et al (2013 ) [22946511]

1544 

Quinn 
SJ 

et al (2004 ) [15201280]

1545 

Quinn 
SJ 

et al (1998 ) [9677383]

1546 

Quinn 
SJ 

et al (1997 ) [9357776]

1547 

Quintana 
J 

et al (1994 ) [8132609]

1548 

Quinton 
L 

et al (2010 ) [20015090]

1549 

Quock 
RM 

et al (1997 ) [9178661]

1550 

Rakowski 
E 

et al (2005 ) [16171813]

1551 

Rakugi 
H 

et al (2014 ) [24742498]

1552 

Ralbovsky 
JL 

et al (2009 ) [19375913]

1553 

Ramachandran 
R 

et al (2012 ) [22212680]

1554 

Ramage 
AG 

et al (2008 ) [19086344]

1555 

Ramanjaneya 
M 

et al (2009 ) [19460850]

1556 

Ramos-álvarez 
I 

et al (2015 ) [25976083]

1557 

Ramsay 
D 

et al (2004 ) [15266013]

1558 

Rapoport 
B 

et al (1998 ) [9861544]

1559 

Rashid 
M 

et al (2003 ) [12738034]

1560 

Rask-Andersen 
M 

et al (2014 ) [24016212]

1561 

Rasmussen 
SG 

et al (2011 ) [21228869]

1562 

Rasmussen 
SG 

et al (2011 ) [21772288]

1563 

Ratnala 
VR 

et al (2004 ) [15206929]

1564 

Raufman 
JP 

et al (1991 ) [1704369]

1565 

Rawashdeh 
O 

et al (2011 ) [21182402]

1566 

Raychowdhury 
MK 

et al (1994 ) [8034687]

1567 

Raynor 
K 

et al (1994 ) [8114680]

1568 

Reavill 
C 

et al (1999 ) [10188965]

1569 

Reavill 
C 

et al (2000 ) [10945872]

1570 

Regoli 
D 

et al (1998 ) [9650825]

1571 

Reid 
RC 

et al (2014 ) [25259874]

1572 

Resnati 
M 

et al (2002 ) [11818541]

1573 

Revankar 
CM 

et al (2005 ) [15705806]

1574 

Revel 
FG 

et al (2011 ) [21525407]

1575 

Reynaud 
R 

et al (2012 ) [22466334]

1576 

Reynolds 
EE 

et al (1995 ) [7733918]

1577 

Reynolds 
GP 

et al (1995 ) [7780656]

1578 

Rezgaoui 
M 

et al (2006 ) [16443751]

1579 

Rhee 
MH 

et al (1997 ) [9379442]

1580 

Ricci 
A 

et al (1994 ) [8051291]

1581 

Ricci 
A 

et al (1995 ) [7759603]

1582 

Rice 
AS 

et al (2014 ) [24507377]

1583 

Richard 
F 

et al (2001 ) [11723247]

1584 

Richardson 
RM 

et al (2003 ) [12626541]

1585 

Richer 
M 

et al (2009 ) [19052921]

1586 

Rinaldi-Carmona 
M 

et al (1994 ) [8070571]

1587 

Rinaldi-Carmona 
M 

et al (1998 ) [9454810]

1588 

Rinaldi-Carmona 
M 

et al (1996 ) [8614277]

1589 

Rivail 
L 

et al (2004 ) [15351779]

1590 

Rives 
ML 

et al (2009 ) [19590495]

1591 

Rivier 
J 

et al (1991 ) [1850267]

1592 

Rivkees 
SA 

et al (1999 ) [9920910]

1593 

Rizzi 
A 

et al (1997 ) [9095082]

1594 

Robas 
N 

et al (2003 ) [12915402]

1595 

Rohrer 
SP 

et al (1998 ) [9784130]

1596 

Romano 
M 

et al (1996 ) [8757340]

1597 

Roos 
RS 

et al (1997 ) [9211859]

1598 

Rosenbaum 
DM 

et al (2011 ) [21228876]

1599 

Rosengren 
AH 

et al (2010 ) [19965390]

1600 

Roseweir 
AK 

et al (2009 ) [19321788]

1601 

Rosier 
A 

et al (1996 ) [9027929]

1602 

Ross 
RA 

et al (1999 ) [10188977]

1603 

Roth 
BL 

et al (2002 ) [12192085]

1604 

Roth 
BL 

et al (1994 ) [7908055]

1605 

Rothman 
RB 

et al (2000 ) [11104741]

1606 

Roush 
ED 

et al (1998 ) [9654151]

1607 

Roussin 
A 

et al (2005 ) [16129413]

1608 

Rovati 
GE 

et al (1992 ) [1329767]

1609 

Rowley 
M 

et al (1996 ) [8642551]

1610 

Royer 
JF 

et al (2007 ) [17714552]

1611 

Ruffing 
N 

et al (1998 ) [9790730]

1612 

Ruffner 
H 

et al (2012 ) [22815884]

1613 

Ruiu 
S 

et al (2003 ) [12663689]

1614 

Ruiz-Ferrer 
M 

et al (2011 ) [21858136]

1615 

Ruiz-Medina 
J 

et al (2011 ) [21352831]

1616 

Russell 
FD 

et al (1996 ) [8904635]

1617 

Russell 
JL 

et al (2012 ) [22462679]

1618 

Ryan 
PJ 

et al (2013 ) [23380674]

1619 

Ryan 
PJ 

et al (2013 ) [24297931]

1620 

Ryberg 
E 

et al (2007 ) [17876302]

1621 

Römpler 
H 

et al (2005 ) [15987686]

1622 

Rühmann 
A 

et al (2002 ) [11835994]

1623 

Saar 
I 

et al (2013 ) [23600864]

1624 

Sabbatini 
FM 

et al (2010 ) [20593439]

1625 

Sabroe 
I 

et al (2000 ) [10854442]

1626 

Sairam 
MR 
. (1989 ) [2542111]

1627 

Saito 
M 

et al (1997 ) [9264324]

1628 

Sakai 
N 

et al (2011 ) [21693308]

1629 

Sakurai 
T 

et al (1998 ) [9491897]

1630 

Sakurai 
T 

et al (2014 ) [24486398]

1631 

Sallinen 
J 

et al (2007 ) [17220913]

1632 

Salmon 
M 

et al (2013 ) [23435542]

1633 

Salvatore 
CA 

et al (2008 ) [18039958]

1634 

Salvatore 
CA 

et al (1993 ) [8234299]

1635 

Sams 
AG 

et al (2010 ) [20684563]

1636 

Sanger 
GJ 
. (2014 ) [24438586]

1637 

Sanger 
GJ 

et al (2011 ) [21531468]

1638 

Sanger 
GJ 

et al (2012 ) [23189978]

1639 

Sanger 
GJ 

et al (2009 ) [19374732]

1640 

Sanna 
MG 

et al (2004 ) [14732717]

1641 

Sanna 
MG 

et al (2006 ) [16829954]

1642 

Sano 
H 

et al (2004 ) [15203211]

1643 

Sarau 
HM 

et al (1999 ) [10462554]

1644 

Sarau 
HM 

et al (2001 ) [11226387]

1645 

Sarau 
HM 

et al (1997 ) [9190866]

1646 

Sarau 
HM 

et al (1997 ) [9336350]

1647 

Sasse 
BC 

et al (2007 ) [17826096]

1648 

Sato 
H 

et al (2007 ) [17825251]

1649 

Sato 
M 

et al (2007 ) [17717109]

1650 

Sato 
M 

et al (2008 ) [18684840]

1651 

Sato 
Y 

et al (1996 ) [8982677]

1652 
Saussy DL Jr
et al (1996 ) [8764344]

1653 

Sautel 
F 

et al (1995 ) [7756621]

1654 

Sautel 
F 

et al (1995 ) [8531087]

1655 

Savage MA Moummi 
C 

et al (1993 ) [8140121]

1656 

Sawyer 
N 

et al (2002 ) [12466225]

1657 

Scanlan 
TS 

et al (2004 ) [15146179]

1658 

Schachter 
JB 

et al (1997 ) [9154346]

1659 

Schaerlinger 
B 

et al (2003 ) [12970106]

1660 

Schaffhauser 
H 

et al (2003 ) [14500736]

1661 

Schally 
AV 

et al (2004 ) [15350601]

1662 

Schally 
AV 

et al (1999 ) [10542394]

1663 

Schechter 
LE 

et al (2008 ) [17625499]

1664 

Schiller 
PW 

et al (1993 ) [8230106]

1665 

Schioth 
HB 

et al (1995 ) [7774675]

1666 

Schiöth 
HB 

et al (2005 ) [15862553]

1667 

Schiöth 
HB 

et al (1998 ) [9630346]

1668 

Schlachter 
SK 

et al (1997 ) [9098699]

1669 

Schmid 
HA 

et al (2004 ) [15477717]

1670 

Schmidt 
J 

et al (2011 ) [21220428]

1671 

Schmitz 
B 

et al (2015 ) [25666387]

1672 

Schoepp 
DD 

et al (2000 ) Metabotropic glutamate receptors.
In IUPHAR Compendium of Receptor Characterization and
Classification Edited by Watson SP, Girdlestone D: IUPHAR Press:
195-208
1673 

Schoepp 
DD 

et al (1997 ) [9144636]

1674 

Schoepp 
DD 

et al (1996 ) [9076745]

1675 

Schotte 
A 

et al (1996 ) [8935801]

1676 

Schulte 
G 
. (2010 ) [21079039]

1677 

Schwartz 
C 


Carlsson 
A 


Caron 
M 


Scatton 
B 


Civelli 
O 


Kebabian 
JW 


Langer 
SZ 


Sedvall 
G 


Seeman 
P 


Spano 
PF 


Sokoloff 
P 


Van Tol 
H 
. (1998 ) Dopamine receptors. In The IUPHAR
Compendium of Receptor Characterization and Classification Edited by
Girdlestone D: IUPHAR media: 141-151
1678 

Schweitz 
H 

et al (1999 ) [10567694]

1679 

Schweitzer 
C 

et al (2000 ) [10884552]

1680 

Schwenk 
J 

et al (2010 ) [20400944]

1681 

Schwenk 
U 

et al (1995 ) [7797484]

1682 

Schäfer 
R 

et al (1997 ) [9222547]

1683 

Schäfer 
R 

et al (1999 ) [10372917]

1684 

Scola 
AM 

et al (2009 ) [19100624]

1685 

Scott 
DJ 

et al (2005 ) [15956681]

1686 

Scott 
DJ 

et al (2005 ) [15956680]

1687 

Scott 
DJ 

et al (2006 ) [16963451]

1688 

Scott 
MK 

et al (2000 ) [10896115]

1689 

Sebhat 
IK 

et al (2011 ) [24900253]

1690 

Sebhat 
IK 

et al (2002 ) [12361385]

1691 

Seeman 
P 
. (2001 ) Antipsychotic drugs, dopamine receptors, and
schizophrenia. Clinical Neuroscience Research
1 : 53-60
1692 

Seeman 
P 

et al (1975 ) [1060115]

1693 

Seeman 
P 

et al (1997 ) [9015795]

1694 

Seeman 
P 

et al (1998 ) [9577836]

1695 

Seifert 
R 

et al (2003 ) [12626648]

1696 

Selkirk 
JV 

et al (1998 ) [9776361]

1697 

Semple 
G 

et al (2006 ) [16480258]

1698 

Seo 
HJ 

et al (2011 ) [21823597]

1699 

Serradeil-Le Gal 
C 

et al (1996 ) [8981918]

1700 

Serradeil-Le Gal 
C 

et al (2000 ) [11012895]

1701 

Serradeil-Le Gal 
C 

et al (2004 ) [14722330]

1702 

Serradeil-Le Gal 
C 

et al (2002 ) [11861823]

1703 

Setoh 
M 

et al (2014 ) [24884590]

1704 

Seuwen 
K 

et al (2006 ) [17118800]

1705 

Sevigny 
LM 

et al (2011 ) [21536878]

1706 

Shabanpoor 
F 

et al (2012 ) [22257012]

1707 

Shabanpoor 
F 

et al (2012 ) [22425984]

1708 

Shabanpoor 
F 

et al (2007 ) [17120268]

1709 

Shabanpoor 
F 

et al (2008 ) [18529069]

1710 

Shabanpoor 
F 

et al (2011 ) [20560146]

1711 

Shahid 
M 

et al (2009 ) [18308814]

1712 

Sharif 
NA 

et al (2000 ) [10772998]

1713 

Sharif 
NA 

et al (2002 ) [11999132]

1714 

Sharif 
NA 

et al (2006 ) [17076623]

1715 

Sharif 
NA 

et al (2001 ) [11572462]

1716 

Sharpe 
IA 

et al (2003 ) [12824165]

1717 

Sheffler 
DJ 

et al (2009 ) [19407080]

1718 

Shemesh 
R 

et al (2008 ) [18854305]

1719 

Shen 
HC 

et al (2010 ) [20184326]

1720 

Shenker 
A 
. (2002 ) [12408104]

1721 

Shi 
F 

et al (2011 ) [24900311]

1722 

Shibata 
K 

et al (1995 ) [7651358]

1723 

Shichijo 
M 

et al (2003 ) [12975488]

1724 

Shimizu 
N 

et al (1999 ) [10233994]

1725 

Shimomura 
Y 

et al (2002 ) [12130646]

1726 

Shimon 
I 

et al (2004 ) [15636423]

1727 

Shimpukade 
B 

et al (2012 ) [22519963]

1728 

Shinkre 
BA 

et al (2010 ) [20801028]

1729 

Shinohara 
T 

et al (2004 ) [15037633]

1730 

Shire 
D 

et al (1996 ) [8679694]

1731 

Shitara 
K 

et al (2009 ) Monoclonal antibodies which
preferentially bind to chemokine receptors, used for immunotherapy, as
antiinflammatory, aniticarcinogenic agents and for prophylaxis of respiratory system
disorders or antiallergens. Patent number: US7504104. Assignee: Kyowa Hakko Kogyo Co., Ltd.
Priority date: 31/08/2001. Publication date: 17/01/2010.
1732 

Shore 
DM 

et al (2015 ) [25926795]

1733 

Showalter 
VM 

et al (1996 ) [8819477]

1734 

Showell 
HJ 

et al (1976 ) [1262785]

1735 

Showell 
HJ 

et al (1995 ) [7714764]

1736 

Siehler 
S 

et al (1998 ) [9652348]

1737 

Siehler 
S 

et al (1999 ) [10598788]

1738 

Siehler 
S 

et al (1998 ) [9650799]

1739 

Sikand 
P 

et al (2011 ) [21593341]

1740 

Sillard 
R 

et al (1992 ) [1283627]

1741 

Silver 
MR 

et al (2005 ) [15878963]

1742 

Sim 
LJ 

et al (1996 ) [8987831]

1743 

Simon 
MF 

et al (2005 ) [15710620]

1744 

Simonin 
F 

et al (1995 ) [7624359]

1745 

Simonin 
F 

et al (2006 ) [16407169]

1746 

Simonin 
F 

et al (2001 ) [11239918]

1747 

Singh 
G 

et al (2004 ) [15261118]

1748 

Singh 
L 

et al (1995 ) [8605955]

1749 

Sinha 
S 

et al (2010 ) [20590605]

1750 

Skerlj 
RT 

et al (2010 ) [20297846]

1751 

Skinner 
PJ 

et al (2009 ) [19524438]

1752 

Skofitsch 
G 

et al (1986 ) [2436195]

1753 

Skrzydelski 
D 

et al (2003 ) [12869647]

1754 

Sleight 
AJ 

et al (1998 ) [9647481]

1755 

Sleight 
AJ 

et al (1996 ) [8534270]

1756 

Slipetz 
DM 

et al (1995 ) [7651369]

1757 

Slusarski 
DC 

et al (1997 ) [9389482]

1758 

Small 
KM 

et al (2006 ) [16605244]

1759 

Smith 
CM 

et al (2014 ) [24681162]

1760 

Smith 
CM 

et al (2012 ) [21899720]

1761 

Smith 
CM 

et al (2014 ) [24711793]

1762 

Smith 
CM 

et al (1997 ) [9029489]

1763 

Smith 
JA 

et al (2008 ) [18415081]

1764 

Smith 
JP 

et al (2002 ) [12429993]

1765 

Smith 
KE 

et al (1997 ) [9305929]

1766 

Smith 
KE 

et al (1998 ) [9722565]

1767 

Smith 
MT 

et al (2013 ) [23489258]

1768 

Smith 
NJ 

et al (2009 ) [19398560]

1769 

Smith 
NJ 

et al (2011 ) [21498659]

1770 

Smith 
PW 

et al (1995 ) [7562907]

1771 

Smits 
RA 

et al (2006 ) [16854056]

1772 

Sodin-Semrl 
S 

et al (2004 ) [15171815]

1773 

Sofuoglu 
M 

et al (1991 ) [1851833]

1774 

Soga 
T 

et al (2003 ) [12646212]

1775 

Soga 
T 

et al (2002 ) [12427552]

1776 

Sokoloff 
P 

et al (1992 ) [1354163]

1777 

Sokoloff 
P 

et al (1992 ) [1586393]

1778 

Sokoloff 
P 

et al (1990 ) [1975644]

1779 

Solinski 
HJ 

et al (2014 ) [24867890]

1780 

Sollenberg 
UE 

et al (2006 ) Int J Pept Res Ther
12 : 115-119
1781 

Song 
H 

et al (2008 ) [18955481]

1782 

Song 
I 

et al (1993 ) [8415658]

1783 

Song 
ZH 

et al (1996 ) [8622639]

1784 

Soriano-Ursúa 
MA 

et al (2009 ) [19168263]

1785 

Southern 
C 

et al (2013 ) [23396314]

1786 

Spalding 
TA 

et al (2006 ) [16959945]

1787 

Spalding 
TA 

et al (2002 ) [12021390]

1788 

Spengler 
D 

et al (1993 ) [8396727]

1789 

Speth 
RC 

et al (1990 ) [2194459]

1790 

Sprecher 
D 

et al (2015 ) [25773497]

1791 

Srivastava 
A 

et al (2014 ) [25043059]

1792 

Stalder 
H 

et al (2011 ) [21237643]

1793 

Stam 
NJ 

et al (1997 ) [9303561]

1794 

Stearns 
TM 

et al (2012 ) [23026400]

1795 

Stefano 
GB 

et al (1992 ) [1329092]

1796 

Steinfeld 
T 

et al (2007 ) [17478612]

1797 

Stevens 
WC 

et al (2000 ) [10893314]

1798 

Stewart 
M 

et al (2004 ) [15194002]

1799 

Stillman 
BA 

et al (1999 ) [10462542]

1800 

Stirrat 
A 

et al (2001 ) [11158995]

1801 

Stocks 
MJ 

et al (2010 ) [21036043]

1802 

Stoddart 
LA 

et al (2007 ) [17200419]

1803 

Stoddart 
LA 

et al (2008 ) [19047536]

1804 

Straub 
RE 

et al (1990 ) [2175902]

1805 

Strizki 
JM 

et al (2005 ) [16304152]

1806 

Strosberg 
AD 
. (1997 ) [9131260]

1807 

Struthers 
RS 

et al (2007 ) [17095587]

1808 

Sturino 
CF 

et al (2007 ) [17300164]

1809 

Su 
SB 

et al (1999 ) [9892621]

1810 

Su 
X 

et al (2008 ) [18632791]

1811 

Sudo 
H 

et al (2008 ) [18164286]

1812 

Sudo 
S 

et al (2003 ) [12506116]

1813 

Suen 
JY 

et al (2012 ) [21806599]

1814 

Sugden 
D 

et al (1999 ) [10420436]

1815 

Sugimoto 
H 

et al (2005 ) [16256979]

1816 

Sugo 
T 

et al (2008 ) [17628210]

1817 

Sugo 
T 

et al (2006 ) [16460680]

1818 

Sullivan 
GW 

et al (2001 ) [11226132]

1819 

Sumichika 
H 

et al (2002 ) [12384495]

1820 

Sun 
Q 

et al (2010 ) [20685848]

1821 

Sun 
R 

et al (2004 ) [15210802]

1822 

Sun 
Y 

et al (2003 ) [12683933]

1823 

Sunahara 
RK 

et al (1991 ) [1826762]

1824 

Sunthornthepvarakui 
T 

et al (1995 ) [7528344]

1825 

Sur 
C 

et al (2003 ) [14595031]

1826 

Suzawa 
T 

et al (2000 ) [10746663]

1827 

Suzuki 
G 

et al (2007 ) [17609420]

1828 

Suzuki 
M 

et al (2013 ) [23449982]

1829 

Suzuki 
T 

et al (2008 ) [19007110]

1830 

Suzuki 
T 

et al (1993 ) [7902433]

1831 

Svetlov 
S 

et al (1993 ) [8380690]

1832 

Swaney 
JS 

et al (2010 ) [20649573]

1833 

Swanson 
CJ 

et al (2005 ) [16287967]

1834 

Swayne 
GT 

et al (1988 ) [2975605]

1835 

Säfholm 
A 

et al (2008 ) [18927296]

1836 

Tabata 
K 

et al (2007 ) [17905198]

1837 

Tabata 
T 

et al (2004 ) [15550547]

1838 

Taggart 
AK 

et al (2005 ) [15929991]

1839 

Tahara 
A 

et al (1998 ) [9884074]

1840 

Tahara 
A 

et al (1998 ) [9459574]

1841 

Takabe 
K 

et al (2008 ) [18552276]

1842 

Takada 
Y 

et al (2003 ) [12960358]

1843 

Takagi 
Y 

et al (2004 ) [15037111]

1844 

Takahara 
M 

et al (2014 ) [24739538]

1845 

Takanashi 
H 

et al (2007 ) [17183187]

1846 

Takano 
T 

et al (1997 ) [9151906]

1847 

Takasaki 
J 

et al (2000 ) [10913337]

1848 

Takasaki 
J 

et al (2001 ) [11502873]

1849 

Takasu 
T 

et al (2007 ) [17293563]

1850 

Takayasu 
S 

et al (2006 ) [16648250]

1851 

Takechi 
H 

et al (1996 ) [8621463]

1852 

Takeda 
S 

et al (2004 ) [15173198]

1853 

Takekawa 
S 

et al (2002 ) [11909603]

1854 

Takinami 
Y 

et al (1997 ) [9042983]

1855 

Talmont 
F 

et al (2009 ) [19682524]

1856 

Tamamura 
H 

et al (1998 ) [9918823]

1857 

Tan 
CP 

et al (2002 ) [12036292]

1858 

Tan 
M 

et al (2009 ) [19126537]

1859 

Tang 
H 

et al (2008 ) [18722346]

1860 

Tang 
L 

et al (1994 ) [8301592]

1861 

Taniguchi 
H 

et al (1996 ) [8813597]

1862 

Taniguchi 
T 

et al (1999 ) [10433504]

1863 

Taniguchi 
Y 

et al (2006 ) [16934253]

1864 

Tatemoto 
K 

et al (1998 ) [9792798]

1865 

Teh 
MT 

et al (1998 ) [9840420]

1866 

Terakita 
A 
. (2005 ) [15774036]

1867 

Testa 
R 

et al (1997 ) [9190864]

1868 

Thathiah 
A 

et al (2009 ) [19213921]

1869 

Theis 
JG 

et al (1992 ) [1387312]

1870 

Thibonnier 
M 

et al (1994 ) [8106369]

1871 

Thibonnier 
M 

et al (1997 ) [9322919]

1872 

Thielemans 
L 

et al (2005 ) [15764739]

1873 

Thomas 
BF 

et al (1998 ) [9536023]

1874 

Thomas 
DR 

et al (2000 ) [10807680]

1875 

Thomas 
DR 

et al (1998 ) [9720804]

1876 

Thomas 
NK 

et al (2001 ) [11166323]

1877 

Thomas 
P 

et al (2005 ) [15539556]

1878 

Thomsen 
WJ 

et al (2008 ) [18252809]

1879 

Thoreson 
WB 

et al (1997 ) [9144637]

1880 

Thulesen 
J 

et al (2002 ) [11738243]

1881 

Thurmond 
RL 

et al (2004 ) [14722321]

1882 

Tian 
Y 

et al (1996 ) [8702757]

1883 

Tibaduiza 
EC 

et al (2001 ) [11498540]

1884 

Tiberi 
M 

et al (1994 ) [7525564]

1885 

Tice 
MA 

et al (1994 ) [7862709]

1886 

Tilakaratne 
N 

et al (2000 ) [10871296]

1887 

Timmermans 
PBMWM 

et al (1993 ) [8372104]

1888 

Ting 
KN 

et al (1999 ) [10433507]

1889 

Tobo 
A 

et al (2015 ) [26070068]

1890 

Toda 
N 

et al (2013 ) [24900747]

1891 

Todde 
S 

et al (2000 ) [11087559]

1892 

Tokita 
K 

et al (2001 ) [11463790]

1893 

Toll 
L 

et al (1998 ) [9686407]

1894 

Tomita 
K 

et al (2008 ) [18302161]

1895 

Torisu 
K 

et al (2004 ) [15388164]

1896 

Torrens 
Y 

et al (1997 ) [9243521]

1897 

Torres 
D 

et al (2008 ) [18178816]

1898 

Tosh 
DK 

et al (2012 ) [22559880]

1899 

Tough 
IR 

et al (2006 ) [16807358]

1900 

Touraine 
P 

et al (1999 ) [10551778]

1901 

Tousignant 
C 

et al (1990 ) [1705465]

1902 

Tousignant 
C 

et al (1991 ) [1722129]

1903 

Townsend-Nicholson 
A 

et al (1994 ) [8300561]

1904 

Tremblay 
MR 

et al (2009 ) [19522463]

1905 

Trist 
DG 

et al (2013 ) [24106886]

1906 

Trivellin 
G 

et al (2014 ) [25470569]

1907 

Troxler 
T 

et al (2010 ) [20137944]

1908 

Tränkle 
C 

et al (2003 ) [12815174]

1909 

Tsujihata 
Y 

et al (2011 ) [21752941]

1910 

Tsukada 
J 

et al (2001 ) [11429400]

1911 

Tuckmantel 
W 

et al (1997 ) Bioorg Med Chem Lett.
7 : 601-606
1912 

Tudhope 
SR 

et al (1994 ) [7698171]

1913 

Tunaru 
S 

et al (2003 ) [12563315]

1914 

Turecek 
R 

et al (2014 ) [24836506]

1915 

Turner 
MR 

et al (2005 ) [15689356]

1916 

Tzschentke 
TM 

et al (2007 ) [17656655]

1917 

Uberti 
MA 

et al (2005 ) [15615865]

1918 

Uchida 
D 

et al (1998 ) [9928019]

1919 

Uehara 
H 

et al (2011 ) [21729729]

1920 

Uguccioni 
M 

et al (1997 ) [9276730]

1921 

Uhlenbrock 
K 

et al (2002 ) [12220620]

1922 

Uhlén 
S 

et al (1994 ) [7996470]

1923 

Ullmann 
H 

et al (2005 ) [16250663]

1924 

Ulman 
LG 

et al (1993 ) [7693918]

1925 

Ulrich 2nd 
CD 

et al (1998 ) [9843782]

1926 

Ulrich 
D 

et al (2007 ) [17433877]

1927 

Ulven 
T 

et al (2005 ) [15715457]

1928 

Unson 
C 

et al (1987 ) [3035568]

1929 

Unson 
CG 

et al (1989 ) [2560175]

1930 

Ursini 
A 

et al (2000 ) [11020274]

1931 

Uyama 
Y 

et al (1997 ) [9106476]

1932 

Vacher 
CM 

et al (2006 ) [16606363]

1933 

Valant 
C 

et al (2012 ) [21989256]

1934 

Valant 
C 

et al (2008 ) [18723515]

1935 

Valdes 
AM 

et al (2010 ) [20090528]

1936 

Van Brocklyn 
JR 

et al (2000 ) [10753843]

1937 

Van Lith 
LH 

et al (2009 ) [19641221]

1938 

Van Poppel 
H 
. (2010 ) [21188095]

1939 

Van Rampelbergh 
J 

et al (1996 ) [8967982]

1940 

Van Tol 
HHM 

et al (1991 ) [1840645]

1941 

Van den Wyngaert 
I 

et al (1997 ) [9349523]

1942 

Vanderheyden 
PML 

et al (1999 ) [10193788]

1943 

Vanover 
KE 

et al (2004 ) [15102927]

1944 

Vanti 
WB 

et al (2003 ) [14559210]

1945 

Varani 
K 

et al (2005 ) [16219300]

1946 

Varani 
K 

et al (2000 ) [10779381]

1947 

Varga 
JL 

et al (1999 ) [9892695]

1948 

Varga 
JL 

et al (2004 ) [14755056]

1949 

Varney 
MA 

et al (1999 ) [10381773]

1950 

Varnäs 
K 

et al (2011 ) [20424633]

1951 

Vassileva 
G 

et al (2006 ) [16724960]

1952 

Vaudry 
H 

et al (2015 ) [25535277]

1953 

Vendelin 
J 

et al (2005 ) [15947423]

1954 

Verheijen 
I 

et al (2000 ) [11206708]

1955 

Vigot 
R 

et al (2006 ) [16701209]

1956 

Vilardaga 
JP 

et al (2008 ) [18193048]

1957 

Villalón 
CM 

et al (2007 ) [17703282]

1958 

Virag 
T 

et al (2003 ) [12695531]

1959 

Vita 
N 

et al (1998 ) [9851594]

1960 

Volpe 
DA 

et al (2011 ) [21215785]

1961 

Volz 
A 

et al (1995 ) [7589426]

1962 

Vonvoigtlander 
PF 

et al (1983 ) [6129321]

1963 

Wacker 
D 

et al (2013 ) [23519215]

1964 

Wacker 
DA 

et al (2002 ) [12067561]

1965 

Waeber 
C 

et al (1998 ) [9928243]

1966 

Waelbroeck 
M 

et al (1996 ) [8813552]

1967 

Wainscott 
DB 

et al (1993 ) [8450835]

1968 

Wainscott 
DB 

et al (2005 ) [15900510]

1969 

Wainscott 
DB 

et al (1998 ) [9459568]

1970 

Waldo 
GL 

et al (2002 ) [12391289]

1971 

Walker 
AW 

et al (2015 ) [25849482]

1972 

Walker 
CS 

et al (2010 ) [20633935]

1973 

Walker 
CS 

et al (2015 ) [26125036]

1974 

Wallrabenstein 
I 

et al (2013 ) [23393561]

1975 

Walter 
S 

et al (2013 ) [23674604]

1976 

Wan 
W 

et al (1990 ) [2213023]

1977 

Wan 
Y 

et al (2002 ) [12450563]

1978 

Wang 
C 

et al (2013 ) [23519210]

1979 

Wang 
J 

et al (2012 ) [23063522]

1980 

Wang 
J 

et al (2006 ) [16754668]

1981 

Wang 
J 

et al (2006 ) [16966319]

1982 

Wang 
S 

et al (1998 ) [9742938]

1983 

Wang 
S 

et al (1997 ) [9281594]

1984 

Wang 
S 

et al (1997 ) [9405385]

1985 

Wang 
SZ 

et al (1993 ) [7687290]

1986 

Wank 
SA 

et al (1992 ) [1313582]

1987 

Ward 
SE 

et al (2005 ) [15887956]

1988 

Warne 
T 

et al (2011 ) [21228877]

1989 

Warne 
T 

et al (2008 ) [18594507]

1990 

Warner 
FJ 

et al (1999 ) [10455255]

1991 

Watakabe 
T 

et al (1992 ) [1320877]

1992 

Watanabe 
K 

et al (1999 ) [10537280]

1993 

Watanabe 
T 

et al (1995 ) [7780649]

1994 

Watanabe 
Y 

et al (1999 ) [10349870]

1995 

Watson 
M 

et al (1984 ) [6546354]

1996 

Watson 
SJ 

et al (2012 ) [22282525]

1997 

Watts 
AO 

et al (2013 ) [23341447]

1998 

Webb 
TE 

et al (1996 ) [8700132]

1999 

Webb 
TE 

et al (1996 ) [8619790]

2000 

Weber 
AE 

et al (1998 ) [9873496]

2001 

Webster 
EL 

et al (1996 ) [8940412]

2002 

Weinshank 
RL 

et al (1991 ) [1834671]

2003 

Weisman 
GA 

et al (2012 ) [22963441]

2004 

Wellendorph 
P 

et al (2005 ) [15576628]

2005 

Weng 
J 

et al (2008 ) [18424556]

2006 

Weng 
Y 

et al (1998 ) [9660793]

2007 

Wentland 
MP 

et al (2009 ) [19282177]

2008 

Wenzel-Seifert 
K 

et al (1993 ) [8387097]

2009 

Wermuth 
CG 

et al (1996 ) [8632404]

2010 

Werner 
U 

et al (2010 ) [20570597]

2011 

Werry 
TD 

et al (2008 ) [18554725]

2012 

Wess 
J 

et al (1991 ) [2043926]

2013 

Westaway 
SM 

et al (2009 ) [21544957]

2014 

Wetzel 
JM 

et al (1995 ) [7752182]

2015 

Weyler 
S 

et al (2006 ) [16902942]

2016 

White 
JR 

et al (1998 ) [9553055]

2017 

Whitebread 
S 

et al (1989 ) [2775266]

2018 

Whitebread 
SE 

et al (1991 ) [1764088]

2019 

Whittle 
BJ 

et al (2012 ) [22480736]

2020 

Wieland 
HA 

et al (1998 ) [9806339]

2021 

Wieland 
HA 

et al (1995 ) [7562543]

2022 

Wieland 
K 

et al (2001 ) [11714875]

2023 

Wiener 
A 

et al (2012 ) [21940398]

2024 

Wiesenfeld-Hallin 
Z 

et al (1992 ) [1373497]

2025 

Wiest 
SA 

et al (1991 ) [1709220]

2026 

Wilbanks 
A 

et al (2001 ) [11290797]

2027 

Wilkinson 
TN 

et al (2005 ) [15707501]

2028 

Williams 
BL 

et al (2014 ) [25344287]

2029 

Williams 
TJ 

et al (1999 ) [10369480]

2030 

Wilson 
RJ 

et al (2006 ) [16604093]

2031 

Wilson 
RJ 

et al (2005 ) [15655509]

2032 

Wilson 
S 

et al (2005 ) [15946947]

2033 

Wilson 
SM 

et al (2011 ) [21173040]

2034 

Windischhofer 
W 

et al (1997 ) [9333122]

2035 

Winrow 
CJ 

et al (2012 ) [22019562]

2036 

Wise 
A 

et al (2003 ) [12522134]

2037 

Wise 
H 

et al (1995 ) [7589166]

2038 

Witte 
ON 

et al (2005 ) [15653487]

2039 

Wong 
AK 

et al (1998 ) [9719594]

2040 

Wood 
MD 

et al (1999 ) [10323594]

2041 

Wood 
MD 

et al (2000 ) [11082110]

2042 

Woodward 
DF 

et al (2008 ) [18700152]

2043 

Woodward 
DF 

et al (2011 ) [21752876]

2044 

Woodward 
DF 

et al (2003 ) [12606640]

2045 

Wright 
DH 

et al (1998 ) [9579725]

2046 

Wright 
DH 

et al (1999 ) [10448933]

2047 

Wu 
C 

et al (1997 ) [9171878]

2048 

Wu 
H 

et al (2014 ) [24603153]

2049 

Wu 
L 

et al (1996 ) [8940121]

2050 

Wu 
S 

et al (1998 ) [9473604]

2051 

Wulff 
BS 

et al (2002 ) [12393057]

2052 

Wurch 
T 

et al (1998 ) [9855638]

2053 

Wuyts 
A 

et al (1998 ) [9692902]

2054 

Wynick 
D 

et al (1993 ) [7683428]

2055 

Xi 
ZX 

et al (2007 ) [17627675]

2056 

Xia 
M 

et al (1997 ) [9152366]

2057 

Xiao 
J 

et al (2010 ) [23905199]

2058 

Xiao 
J 

et al (2010 ) [24260782]

2059 

Xiao 
J 

et al (2014 ) [24666157]

2060 

Xiao 
J 

et al (2013 ) [23764525]

2061 

Xie 
Z 

et al (1999 ) [10452531]

2062 

Xie 
Z 

et al (2009 ) [19482011]

2063 

Xiong 
Y 

et al (2004 ) [14722361]

2064 

Xiong 
Y 

et al (2013 ) [23403053]

2065 

Xu 
F 

et al (2011 ) [21393508]

2066 

Xu 
L 

et al (2006 ) [16757564]

2067 

Xu 
Y 

et al (2006 ) [16508674]

2068 

Xu 
Y 

et al (2000 ) [10806476]

2069 

Xu 
YC 

et al (1999 ) [9986723]

2070 

Xu 
YL 

et al (2004 ) [15312648]

2071 

Yamamoto 
T 
. (2000 ) [11107061]

2072 

Yamamura 
MS 

et al (1992 ) [1313133]

2073 

Yamamura 
Y 

et al (1998 ) [9864265]

2074 

Yamamura 
Y 

et al (1992 ) [1387020]

2075 

Yamashita 
A 

et al (2013 ) [23714700]

2076 

Yan 
H 

et al (1996 ) [8643460]

2077 

Yan 
L 

et al (2003 ) [14662005]

2078 

Yan 
P 

et al (2006 ) [17082621]

2079 

Yanagida 
K 

et al (2009 ) [19386608]

2080 

Yanagisawa 
T 

et al (2000 ) [11249148]

2081 

Yang 
D 

et al (1999 ) [10521347]

2082 

Yang 
J 

et al (2008 ) [18267071]

2083 

Yang 
J 

et al (2012 ) [22645144]

2084 

Yang 
L 

et al (1998 ) [9724791]

2085 

Yang 
LV 

et al (2007 ) [17145776]

2086 

Yang 
P 

et al ELABELA/Toddler, a critical regulator of cardiac development,
is expressed in the human cardiovascular system and binds the apelin receptor.
Accessed on 07/07/2015. http://circ.ahajournals.org/content/130/Suppl_2/A15352.
2087 

Yang 
W 

et al (2005 ) [15686947]

2088 

Yao 
BB 

et al (2006 ) [16894349]

2089 

Yasuda 
H 

et al (2007 ) [17214962]

2090 

Yates 
L 

et al (2006 ) [16553647]

2091 

Ye 
C 

et al (2014 ) [24633425]

2092 

Ye 
RD 

et al (2009 ) [19498085]

2093 

Yin 
H 

et al (2009 ) [19286662]

2094 

Yin 
S 

et al (2014 ) [24381270]

2095 

Yokomizo 
T 

et al (1997 ) [9177352]

2096 

Yokomizo 
T 

et al (2001 ) [11278893]

2097 

Yona 
S 

et al (2008 ) [18789697]

2098 

Yoshida 
R 

et al (1997 ) [9153236]

2099 

Yoshida 
R 

et al (1998 ) [9507024]

2100 

Yoshida 
S 

et al (2010 ) [20804735]

2101 

Yoshie 
O 

et al (2000 ) [10714678]

2102 

Yoshio 
R 

et al (2001 ) [11459121]

2103 

Yosten 
GL 

et al (2013 ) [23759446]

2104 

Young 
P 

et al (1989 ) [2573535]

2105 

Young 
RN 

et al (2004 ) Heterocycles
64 : 437-446
2106 

Yu 
M 

et al (2013 ) [24900757]

2107 

Yung 
YC 

et al (2011 ) [21900594]

2108 

Zabel 
BA 

et al (2005 ) [15611246]

2109 

Zadina 
JE 

et al (1997 ) [9087409]

2110 

Zagon 
IS 

et al (2002 ) [11890982]

2111 

Zajdel 
P 

et al (2013 ) [23279866]

2112 

Zaratin 
PF 

et al (2004 ) [14593080]

2113 

Zech 
G 

et al (2012 ) [22984835]

2114 

Zhang 
C 

et al (2015 ) [26057358]

2115 

Zhang 
D 

et al (2015 ) [25822790]

2116 

Zhang 
K 

et al (2014 ) [24670650]

2117 

Zhang 
LL 

et al (2011 ) [21924326]

2118 

Zhang 
S 

et al (2010 ) [20570702]

2119 

Zhang 
SP 

et al (1998 ) [9651119]

2120 

Zhang 
SP 

et al (2001 ) [11379050]

2121 

Zhang 
WB 

et al (2002 ) [11923301]

2122 

Zhang 
Y 

et al (2003 ) [12581520]

2123 

Zhao 
DM 

et al (2000 ) [10749750]

2124 

Zhao 
P 

et al (2010 ) [20826425]

2125 

Zhen 
J 

et al (2010 ) [20122961]

2126 

Zheng 
GZ 

et al (2005 ) [16279797]

2127 

Zhou 
QZ 

et al (1990 ) [2168520]

2128 

Zhu 
J 

et al (1995 ) [7869844]

2129 

Zhu 
J 

et al (2008 ) [18582868]

2130 

Zhu 
J 

et al (1997 ) [9262330]

2131 

Zhu 
K 

et al (2001 ) [11535583]

2132 

Zhu 
Y 

et al (2001 ) [11179436]

2133 

Zobel 
AW 

et al (2000 ) [10867111]

2134 

Zoffmann 
S 

et al (2001 ) [11170631]

2135 

Zygmunt 
PM 

et al (1999 ) [10440374]

2136 

af Forselles 
KJ 

et al (2011 ) [21595651]

2137 

de Gasparo 
M 

et al (2000 ) [10977869]

2138 

de Gasparo 
M 

et al (1995 ) [8577935]

2139 

de Gasparo 
M 

et al (1994 ) Heterogeneity of angiotensin receptor
subtypes. In
Medicinal Chemistry of the Renin-Angiotensin System. Edited by
Timmermanns PBMWM, Wexler RR: Elsevier: 269-294 [ISBN: 0444820531]
2140 

de Lau 
W 

et al (2011 ) [21727895]

2141 

de Ligt 
RA 

et al (2005 ) [15740718]

2142 

de Paulis 
T 

et al (2006 ) [16722652]

2143 

van Muijlwijk-Koezen 
JE 

et al (2000 ) [10841801]

2144 

van der Westhuizen 
ET 

et al (2010 ) [20159943]

2145 

von Geldern 
TW 

et al (1999 ) [10479298]

2146 

von Kügelgen 
I 

et al (2011 ) [21586365]

2147 (1988 ) [3071214]

